{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_community.document_loaders import PyPDFLoader\n",
    "\n",
    "path = \"../../dataset/pdfs/anesthesia/1.pdf\"\n",
    "\n",
    "loader = PyPDFLoader(path)\n",
    "\n",
    "pages = loader.load_and_split()\n",
    "\n",
    "page_texts = [page.page_content for page in pages]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "sample_list = [1,2,3,4,5,56]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "df\n",
    "\n",
    "df['context'] = sample_list"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 1}, page_content='P1: SBT0521759385pre CUNY1088/Sladen 0 521 75938 5 June 23, 2007 13:27\\nAnesthesia andCo-Existing Disease\\nEdited by\\nROBERT N. SLADEN, MD\\nProfessor and Vice-ChairDepartment of AnesthesiologyChief, Division of Critical CareDirector, Cardiothoracic and Surgical Intensive Care UnitsColumbia UniversityCollege of Physicians and SurgeonsNew York, NY\\nDOUGLAS B. COURSIN, MD\\nProfessorDepartments of Anesthesiology and Internal MedicineUniversity of Wisconsin Medical SchoolMadison, WI\\nJONATHAN T. KETZLER, MD\\nAssociate ProfessorDepartments of Anesthesiology and Critical Care ServicesUniversity of Wisconsin Medical SchoolMadison, WI\\nHUGH PLAYFORD, MD\\nAssistant ProfessorDepartment of AnesthesiologyAssociate Program DirectorCritical Care FellowshipColumbia UniversityCollege of Physicians and SurgeonsNew York, NY\\ni'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 2}, page_content='P1: SBT0521759385pre CUNY1088/Sladen 0 521 75938 5 June 23, 2007 13:27\\ncambridge university press\\nCambridge, New York, Melbourne, Madrid, Cape Town, Singapore, S ˜ao Paulo, Delhi\\nCambridge University Press\\n32 Avenue of the Americas, New York, NY10013-2473, USA\\nwww.cambridge.orgInformation on this title: www.cambridge.org/9780521709385\\nC⃝2007, 2005, Anesthesia and Co-Existing Disease by PocketMedicine.com, Inc.\\nThis publication is in copyright. Subject to statutory exceptionand to the provisions of relevant collective licensing agreements,no reproduction of any part may take place withoutthe written permission of Cambridge University Press.First published 2007\\nPrinted in the United States of America\\nAcatalog record for this publication is available from the British Library.\\nLibrary of Congress Cataloging in Publication DataAnesthesia and co-existing disease / Robert N. Sladen ...[et al.].\\np. ;cm.\\nISBN-13: 978-0-521-70938-5 (pbk.)ISBN-10: 0-521-70938-5 (pbk.)1. Anesthesia. 2. Anesthetics – Side effects. I. Sladen, Robert N.[DNLM: 1. Anesthesia – methods. 2. Anesthesia – adverse effects.3. Perioperative Care – methods. WO 200 A5775 2007]RD82.A6594 2007\\n617.9\\n′6–dc22 2007016739\\nISBN 978-0-521-70938-5 paperback\\nCambridge University Press has no responsibility for\\nthe persistence or accuracy of URL sfor external or\\nthird-party Internet Web sites referred to in this publicationand does not guarantee that any content on suchWebsites is, or will remain, accurate or appropriate.\\nEvery effort has been made in preparing this book to provide accurate and\\nup-to-date information that is in accord with accepted standards and practice atthe time of publication. Nevertheless, the authors, editors, and publisher can makeno warranties that the information contained herein is totally free from error, notleast because clinical standards are constantly changing through research andregulation. The authors, editors, and publisher therefore disclaim all liability for\\ndirect or consequential damages resulting from the use of material contained inthis book. Readers are strongly advised to pay careful attention to informationprovided by the manufacturer of any drugs or equipment that they plan to use.\\nii'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 3}, page_content='P1: SBT0521759385pre CUNY1088/Sladen 0 521 75938 5 June 23, 2007 13:27\\nNOTICE\\nBecause of the dynamic nature of medical practice and drug\\nselection and dosage, users are advised that decisions regardingdrug therapy must be based on the independent judgment of theclinician, changing information about a drug (e.g., as reﬂectedin the literature and manufacturer’s most current product infor-mation), and changing medical practices.While great care has been taken to ensure the accuracy of theinformation presented, users are advised that the authors, edi-tors, contributors, and publisher make no warranty, express orimplied, with respect to, and are not responsible for, the currency,completeness, or accuracy of the information contained in thispublication, nor for any errors, omissions, or the application ofthis information, nor for any consequences arising therefrom.Users are encouraged to conﬁrm the information contained\\nherein with other sources deemed authoritative. Ultimately, itis the responsibility of the treating physician, relying on expe-rience and knowledge of the patient, to determine dosages and\\nthe best treatment for the patient. Therefore, the author(s), edi-tors, contributors, and the publisher make no warranty, expressor implied, and shall have no liability to any person or entity withregard to claims, loss, or damage caused, or alleged to be caused,\\ndirectly or indirectly, by the use of information contained in thispublication.Further, the author(s), editors, contributors, and the publisher\\nare not responsible for misuse of any of the information pro-vided in this publication, for negligence by the user, or for anytypographical errors.\\niii'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 4}, page_content='P1: SBT0521759385pre CUNY1088/Sladen 0 521 75938 5 June 23, 2007 13:27\\niv'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 5}, page_content='P1: SBT0521759385pre CUNY1088/Sladen 0 521 75938 5 June 23, 2007 13:27\\nContents\\nPreface page xiii\\npart one. disease\\nAdrenal & Pituitary Disease ............................. 2\\nAdult Congenital Heart Disease .......................... 4\\nAlcohol Abuse ...................................... 12\\nAnemia .......................................... 15\\nAnkylosing Spondylitis ............................... 20\\nAnticoagulation Therapy .............................. 22\\nAortic Regurgitation ................................. 23\\nAortic Stenosis ..................................... 24\\nBronchospastic Disease .............................. 26\\nCarcinoid Syndrome ................................. 29\\nChemotherapeutic Agents ............................. 31\\nChronic Obstructive Pulmonary Disease (COPD) ............ 38\\nChronic Renal Failure ................................ 41\\nCocaine Toxicity .................................... 45\\nCongestive Heart Failure .............................. 47\\nCorPulmonale and RHF .............................. 50\\nDiabetes Mellitus and Diabetic Emergencies ............... 53\\nEpilepsy .......................................... 58\\nThe Geriatric Patient ................................. 59\\nGI Disease (Gastrointestinal Disease) ..................... 61\\nHemoglobinopathies ................................ 65\\nHemophilia A & Hemophilia B .......................... 70\\nv'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 6}, page_content='P1: SBT0521759385pre CUNY1088/Sladen 0 521 75938 5 June 23, 2007 13:27\\nvi Contents\\nHerbal Therapy ..................................... 71\\nHIV & AIDS ........................................ 72\\nHypertension ...................................... 74\\nICU Patient Scheduled for Intercurrent Surgery ............. 76\\nIdiopathic Hypertrophic Subaortic Stenosis (IHSS) ........... 89\\nIschemic Heart Disease ............................... 92\\nLatex Allergy ....................................... 94\\nLiver Disease ...................................... 96\\nMalignant Hyperthermia .............................. 99\\nMitral Regurgitation ................................ 101\\nMitral Stenosis .................................... 103\\nMorbid Obesity .................................... 105\\nMultiple Sclerosis .................................. 106\\nMuscular Dystrophy ................................ 108\\nMyasthenia Gravis ................................. 109\\nNeuroleptic Malignant Syndrome ...................... 111\\nObstetric Patient Having Intercurrent Surgery ............. 113\\nParkinson’s Disease ................................. 116\\nPatient with a Transplant ............................. 117\\nPheochromocytoma ................................ 120\\nPlatelet Disorders .................................. 122\\nPolycythemia ..................................... 124\\nPsychiatric Disorders ............................... 128\\nRestrictive Lung Disease ............................. 129\\nRheumatoid Arthritis ............................... 132\\nScleroderma ...................................... 133\\nSickle Cell Disease .................................. 136\\nSpinal Cord Injury .................................. 140\\nStroke ........................................... 146'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 7}, page_content='P1: SBT0521759385pre CUNY1088/Sladen 0 521 75938 5 June 23, 2007 13:27\\nContents vii\\nSubacute Bacterial Endocarditis Prophylaxis\\n(SBE Prophylaxis) .................................. 149\\nSystemic Lupus Erythematosus (SLE) .................... 150\\nThalassemia ...................................... 153\\nThyroid and Parathyroid Disease ....................... 155\\nTransfusion Therapy ................................ 160\\nvon Willebrand’s Disease ............................. 167\\npart two. p harmacology\\nAdrenal & Pituitary Disease ........................... 170\\nAdult Congenital Heart Disease ........................ 171\\nAlcohol Abuse ..................................... 171\\nAnemia .......................................... 172\\nAnkylosing Spondylitis .............................. 172\\nAnticoagulation Therapy ............................. 173\\nAortic Regurgitation ................................ 173\\nAortic Stenosis .................................... 174\\nBronchospastic Disease .............................. 175\\nCarcinoid Syndrome ................................ 175\\nChemotherapeutic Agents ............................ 176\\nChronic Obstructive Pulmonary Disease (COPD) ........... 176\\nChronic Renal Failure ............................... 177\\nCocaine Toxicity ................................... 179\\nCongestive Heart Failure ............................. 180\\nCorPulmonale and RHF ............................. 182\\nDiabetes Mellitus and Diabetic Emergencies .............. 183\\nEpilepsy ......................................... 184\\nThe Geriatric Patient ................................ 185\\nGI Disease (Gastrointestinal Disease) .................... 186\\nHemoglobinopathies ............................... 186'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 8}, page_content='P1: SBT0521759385pre CUNY1088/Sladen 0 521 75938 5 June 23, 2007 13:27\\nviii Contents\\nHemophilia A & Hemophilia B ......................... 186\\nHerbal Therapy .................................... 187\\nHIV & AIDS ....................................... 192\\nHypertension ..................................... 193\\nICU Patient Scheduled for Intercurrent Surgery ............ 193\\nIdiopathic Hypertrophic Subaortic Stenosis (IHSS) .......... 194\\nIschemic Heart Disease .............................. 195\\nLatex Allergy ...................................... 199\\nLiver Disease ..................................... 199\\nMalignant Hyperthermia ............................. 200\\nMitral Regurgitation ................................ 201\\nMitral Stenosis .................................... 201\\nMorbid Obesity .................................... 202\\nMultiple Sclerosis .................................. 203\\nMuscular Dystrophy ................................ 204\\nMyasthenia Gravis ................................. 205\\nNeuroleptic Malignant Syndrome ...................... 206\\nObstetric Patient Having Intercurrent Surgery ............. 206\\nParkinson’s Disease ................................. 207\\nPatient with a Transplant ............................. 208\\nPheochromocytoma ................................ 208\\nPlatelet Disorders .................................. 209\\nPolycythemia ..................................... 209\\nPsychiatric Disorders ............................... 210\\nRestrictive Lung Disease ............................. 211\\nRheumatoid Arthritis ............................... 211\\nScleroderma ...................................... 213\\nSickle Cell Disease .................................. 213\\nSpinal Cord Injury .................................. 214'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 9}, page_content='P1: SBT0521759385pre CUNY1088/Sladen 0 521 75938 5 June 23, 2007 13:27\\nContents ix\\nStroke ........................................... 214\\nSubacute Bacterial Endocarditis Prophylaxis\\n(SBE Prophylaxis) .................................. 214\\nSystemic Lupus Erythematosus (SLE) .................... 215\\nThalassemia ...................................... 216\\nThyroid and Parathyroid Disease ....................... 216\\nTransfusion Therapy ................................ 217\\nvon Willebrand’s Disease. ............................ 217\\npart three. clinical management\\nAdrenal & Pituitary Disease ........................... 220\\nAdult Congenital Heart Disease ........................ 224\\nAlcohol Abuse ..................................... 227\\nAnemia and Hemoglobinopathies ...................... 229\\nAnkylosing Spondylitis .............................. 231\\nAnticoagulation Therapy ............................. 233\\nAortic Regurgitation ................................ 242\\nAortic Stenosis .................................... 246\\nBronchospastic Disease .............................. 249\\nCarcinoid Syndrome ................................ 253\\nChemotherapeutic Agents ............................ 254\\nChronic Obstructive Pulmonary Disease (COPD) ........... 255\\nChronic Renal Failure ............................... 260\\nCocaine Toxicity ................................... 264\\nCongestive Heart Failure ............................. 266\\nCorPulmonale and RHF ............................. 269\\nDiabetes Mellitus and Diabetic Emergencies .............. 273\\nEpilepsy ......................................... 279\\nThe Geriatric Patient ................................ 282\\nGI Disease (Gastrointestinal Disease) .................... 282'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 10}, page_content='P1: SBT0521759385pre CUNY1088/Sladen 0 521 75938 5 June 23, 2007 13:27\\nx Contents\\nHemoglobinopathies ............................... 285\\nHemophilia A & Hemophilia B ......................... 287\\nHerbal Therapy .................................... 289\\nHIV & AIDS ....................................... 289\\nHypertension ..................................... 291\\nICU Patient Scheduled for Intercurrent Surgery ............ 295\\nIdiopathic Hypertrophic Subaortic Stenosis (IHSS) .......... 298\\nIschemic Heart Disease .............................. 302\\nLatex Allergy ...................................... 308\\nLiver Disease ..................................... 310\\nMalignant Hyperthermia ............................. 315\\nMitral Regurgitation ................................ 317\\nMitral Stenosis .................................... 321\\nMorbid Obesity .................................... 325\\nMultiple Sclerosis .................................. 328\\nMuscular Dystrophy ................................ 330\\nMyasthenia Gravis ................................. 331\\nNeuroleptic Malignant Syndrome ...................... 335\\nObstetric Patient Having Intercurrent Surgery ............. 336\\nParkinson’s Disease ................................. 338\\nPatient with a Transplant ............................. 341\\nPheochromocytoma ................................ 344\\nPlatelet Disorders .................................. 348\\nPolycythemia ..................................... 349\\nPsychiatric Disorders ............................... 350\\nRestrictive Lung Disease ............................. 352\\nRheumatoid Arthritis ............................... 356\\nScleroderma ...................................... 359\\nSickle Cell Disease .................................. 361'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 11}, page_content='P1: SBT0521759385pre CUNY1088/Sladen 0 521 75938 5 June 23, 2007 13:27\\nContents xi\\nSpinal Cord Injury .................................. 363\\nStroke ........................................... 366\\nSubacute Bacterial Endocarditis Prophylaxis\\n(SBE Prophylaxis) .................................. 369\\nSystemic Lupus Erythematosus (SLE) .................... 371\\nThalassemia ...................................... 372\\nThyroid and Parathyroid Disease ....................... 373\\nTransfusion Therapy ................................ 379\\nvon Willebrand’s Disease ............................. 380'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 12}, page_content='P1: SBT0521759385pre CUNY1088/Sladen 0 521 75938 5 June 23, 2007 13:27\\nxii'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 13}, page_content='P1: SBT0521759385pre CUNY1088/Sladen 0 521 75938 5 June 23, 2007 13:27\\nPreface\\nAnesthesia and Co-existing Disease provides a timely, rapid\\noverview of common and uncommon co-morbidities that are\\nencountered in the day-to-day practice of anesthesiology. It pro-vides a guide to the perioperative assessment and anestheticmanagement of patients with widely prevalent co-morbiditiessuch as hypertension, diabetes, obesity, myocardial ischemia,and kidney and liver disease. It concisely outlines priorities forpatients with special problems who are undergoing unrelatedoperative procedures, such as the obstetrical patient, the patientwith prior organ transplantation, the adult patient with con-genital heart disease, the spinal cord injured patient, the can-cer patient with prior chemotherapy, the critically ill patient, orthe patient with a psychiatric disorder. It also focuses on speciﬁcchallenges to the anesthesiologist, such as patients with latexallergy, a history of substance abuse, preoperative use of herbalmedications, or those who are at risk of malignant hyperthermia.\\nThis text consists of 57 individual chapters with a structured\\noutline format that starts with a description of the disease orcondition. Subsections address its impact on ﬂuid and elec-trolyte management, the cardiopulmonary system, hematologicreserve, gastrointestinal function, metabolism and nutrition,\\nneurologic and psychiatric function. Next, the pharmacologicimplications – pharmacokinetic and pharmacodynamic – enu-merated. In the third component, subsections tackle preoper-ative evaluation, risk stratiﬁcation, and preparation; intraoper-ative priorities, preparation, monitoring, and care; and ﬁnallypostoperative management, pain control, PACU issues, andintermediate care or ICU requirements and indications.\\nxiii'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 14}, page_content='P1: SBT0521759385pre CUNY1088/Sladen 0 521 75938 5 June 23, 2007 13:27\\nxiv Preface\\nAnesthesia and Co-Existing Disease is not intended to be an\\nexhaustive or referenced text. Instead, it is a uniquely portablehands-on guide that provides a logical approach to acute periop-erative care for adult patients with common or specialized needs.This multi-authored resource draws from a host of experts inidentifying important issues, establishing perioperative priori-ties, and providing management guidelines in a consistent andeasily accessible format.\\nRobert N. Sladen\\nDouglas B. Coursin\\nJonathan T. Ketzler\\nHugh Playford'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 15}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\nPART ONE\\nDisease\\n1'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 16}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\nADRENAL & PITUITARY DISEASE\\nGIUDITTA ANGELINI, MD\\noverview\\n■Pituitary adenomas represent 10–15% of intracranial neo-plasms.\\n■Prevalence is 200/1,000,000; post-mortem incidence is 10–27%.\\n■Signiﬁcant number are asymptomatic.\\n■Most pituitary tumors arise from anterior lobe (adenohy-pophysis)\\n➣ Majority are benign.\\n■75% of tumors secrete hormones inappropriately\\n➣ Prolactin\\n➣ Growth hormone (GH): acromegaly\\n➣ Premature puberty or resumption of menstrual bleedingin postmenopausal women\\n➣ Adrenocorticotrophic hormone (ACTH): Cushing’s syn-drome\\n■Presentation variable\\n➣ Hormonal hypersecretion syndrome (see above)\\n➣ Mass effect (non-secreting macroadenomas >1 cm):\\nvisual disturbance (bitemporal hemianopsia/third nervepalsy) or increased ICP\\n➣ Nonspeciﬁc symptoms, such as headache, infertility, pitu-itary hypofunction or epilepsy (compression from non-functioning adenoma, secondary hyperprolactinemia,apoplexy or infarction)\\n➣ Incidental ﬁnding\\nﬂuid & electrolytes\\n■Acromegaly\\n➣ Diabetes\\n2'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 17}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\nAdrenal & Pituitary Disease 3\\n■Cushing’s syndrome\\n➣ Diabetes\\n➣ Hypernatremia, hypokalemia & alkalosis\\n➣ Renal calculi\\n■Hypopituitarism\\n➣ Hyponatremia, hyperkalemia & acidosis\\ncardiopulmonary\\n■Acromegaly\\n➣ Hypertension\\n➣ Cardiomegaly, impaired LV function (interstitial ﬁbrosis)\\n➣ Obstructive sleep apnea (OSA): macroglossia, thickenedpharyngeal tissues\\n■Cushing’s syndrome\\n➣ Hypertension\\n➣ ECG: LVH, high-voltage QRS, inverted T waves; reversiblew/ pituitary removal\\nhematologic\\nN/A\\nmetabolic-nutritional\\n■5 distinct cell types plus null (functionally inert) cells\\n➣ 50% somatotrophs: secrete GH\\n➣ 10–25% lactotrophs: secrete prolactin\\n➣ 15% corticotrophs: secrete ACTH\\n➣ 10% gonadotrophs: secrete follicle-stimulating hormone(FSH) & luteinizing hormone (LH)\\n➣ 5–10% thyrotrophs: secrete thyroid-stimulating hormone\\n■Production & release of anterior pituitary (adenohypophysis)hormones under control of hypothalamus:\\n➣ Prolactin stimulated by prolactin-releasing hormone(PRH) & inhibited by dopamine\\n➣ GH stimulated by growth hormone-releasing hormone &inhibited by somatostatin'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 18}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\n4 Adrenal & Pituitary Disease Adult Congenital Heart Disease\\n➣ Thyroid-stimulating hormone (TSH) stimulated bythyroid-releasing hormone (TRH)\\n➣ ACTH stimulated by corticotrophin-releasing hormone(CRH)\\n■Anterior pituitary hormones are under feedback control.\\n➣ Insulin-like growth factor I directly inhibits GH but alsostimulates secretion of somatostatin.\\n➣ Thyroid hormones inhibit both TSH & TRH.\\n➣ FSH & LH have both inhibitory & stimulatory effects onthe pituitary & hypothalamus.\\n■Posterior (neurohypophysis) secretes oxytocin & argininevasopressin (AVP).\\ngastrointestinal\\n■Cushing’s syndrome is associated w/ gastroesophageal reﬂuxdisease (GERD).\\nneuropsychiatric\\n■Cushing’s syndrome is associated w/ mental disturbance.\\nADULT CONGENITAL HEART DISEASE\\nMARY E. McSWEENEY, MD\\noverview\\n■Adults w/ CHD may remain undiagnosed until adulthood.\\n■Adults may have had 1 or more corrective or palliative cardiacprocedures.\\n■Clinical picture: ranges from essentially normal physiology tocritically ill\\n■End-stage adult CHD: severe pulmonary hypertension (PHT)& Eisenmenger physiology\\nCongenital defects fall into 3 groups:\\n■Shunt lesions resulting in increased pulmonary blood ﬂow(PBF)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 19}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\nAdult Congenital Heart Disease 5\\n■Shunt lesions resulting in decreased PBF\\n■Obstructive lesions, resulting in increased cardiac work &impaired blood ﬂow distal to the obstruction\\nTwo major consequences of the abnormal anatomy:\\n■Cyanosis: decreased pulmonary artery (PA) blood ﬂow or mix-ing of systemic & pulmonary venous (PV) return\\n■CHF: increased PA blood ﬂow, from excessive PV return, orimpaired PV return from obstruction or impaired forward car-diac output (CO). Both lead to pulmonary vascular conges-tion.\\nClassiﬁcation of CHD also depends on surgical status:\\n■Anatomy may be unchanged or previously surgically alteredby a corrective or palliative procedure.\\n■Surgical correction of complex lesions (eg, single ventricles)is often staged.\\n■Corrective procedures can themselves induce heart block orimpair ventricular function.\\nAcyanotic lesions\\n■Ventricular septal defect (VSD)\\n➣ Chronic volume overload results in abnormal ventricularfunction. Pts repaired after 5 yrs of age are likely to haveresidual ventricular dysfunction.\\n➣ Nonrestrictive or moderately restrictive VSDs causepulmonary vascular pressure/volume overload & PHT.Ultimately, reversal of shunt results in Eisenmenger phys-iology.\\n■Atrial septal defect (ASD)\\n➣ Simple ostium secundum defect is the most commonshunt lesion in adults.\\n➣ May be asymptomatic & permit survival into late adult-hood'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 20}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\n6 Adult Congenital Heart Disease\\n➣ Most pts >60 yrs old are symptomatic: increased sys-\\ntemic arterial pressure & decreased ventricular compli-ance cause increased L-to-R shunt through the ASD.\\n➣ Atrial tachyarrhythmias are common >40 yrs.\\n➣ PHT develops >40 yrs.\\n➣ Pts w/ normal pulmonary pressures corrected surgicallybefore 24 yrs have normal survival.\\n➣ Paradoxical emboli (from atrium to cerebral vessels)may occur because of preferential streaming of bloodﬂow from IVC across foramen ovale (secundum ASD),especially during sudden increases in PVR (coughing,etc.).\\n■Partial anomalous pulmonary venous connection\\n➣ Partial pulmonary venous return to right atrium (RA)\\n➣ Wide variety of anomalous pulmonary venous connec-tions, usually w/ sinus venosus ASD\\n➣ Physiology & natural history similar to ASD for similardegree of L-to-R shunt\\n➣ SA node dysfunction possible if sinus venosus type\\n➣ Scimitar syndrome: anomalous connection of all right PVto IVC, associated w/ hypoplastic right lung (arterial cir-culation to right lung from descending thoracic aorta)\\n■Coarctation of the aorta\\n➣ Commonly associated w/ bicuspid aortic valve\\n➣ Severe coarctation presents w/ heart failure within ﬁrstwks of life.\\n➣ Milder coarctation: survive into adulthood\\n➣ Later repairs associated w/:\\nrHigh incidence of hypertension in pts repaired late\\nrIncreased incidence of premature coronary artery dis-ease\\n■Pulmonary valve stenosis\\n➣ Most stenosis is noncritical; survival into adulthood is therule.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 21}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\nAdult Congenital Heart Disease 7\\n➣ Associated w/ right ventricular (RV) hypertrophy & even-tual RV failure\\n➣ Commonly repaired w/ balloon valvuloplasty\\n■Congenitally corrected transposition of the great arteries (L-transposition, ventricular inversion)\\n➣ Blood ﬂow: RA →MV→LV→PA→lungs →LA→tri-\\ncuspid valve →RV→aorta\\n➣ Aorta located anterior & to the left of the main PA\\n➣ Anatomic RV serves as systemic ventricle.\\n➣ RV eventually vulnerable to failure\\n➣ High incidence of heart block\\n■Ebstein’s anomaly of the tricuspid valve\\n➣ Abnormal apical displacement of the tricuspid tissue →\\natrialized RV w/ tricuspid regurgitation\\n➣ Sometimes w/ pulmonic stenosis\\nCyanotic lesions\\n■Tetralogy of Fallot (TOF)\\n➣ Pulmonic stenosis, VSD, overriding aorta, RVH\\n➣ Most common cyanotic lesion encountered in older pts\\n➣ Uncorrected: 25% survival to adolescence; 3% >40 yrs\\n➣ After early repair, LV ok, RV usually impaired\\n➣ “Tet spell”: increased R-to-L shunt secondary to decreasedSVR; treated w/ phenylephrine to increase SVR (pul-monary resistance “ﬁxed” from stenotic pulmonic valve)\\n➣ “Tet spells” rare in older pts w/ uncorrected TOF\\n➣ After repair, right bundle branch block (RBBB) common,sometimes associated w/ left anterior hemiblock\\n■Palliated tetralogy of Fallot\\n➣ Palliative shunts (Blalock-Taussig, Waterston-Cooley,Potts or Gore-Tex central aortopulmonary) to increase PBF\\n➣ PBF dependent on relative PVR vs. SVR\\n■Complete transposition of the great arteries (D-transposition)\\n➣ Incompatible w/ life unless adequate mixing'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 22}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\n8 Adult Congenital Heart Disease\\n➣ 4 types of repair\\nrMustard or Senning (atrial repair): systemic venousreturn →LV→PA & pulmonary venous return →RV→\\naorta\\nrArterial switch: aorta & coronary arteries transposed toarise from LV & PA moved to arise from RV; most com-mon repair now\\nrRastelli: LV outﬂow channeled through the VSD to aorta& RV connected to PA by external conduit\\nrPalliative atrial repair in presence of a VSD & pulmonicvalve disease (least common)\\n➣ Post-repair physiology depends on repair type:\\nrAn RV that must function as a systemic ventricle is vul-nerable to failure.\\nrAtrial repair is associated w/ high incidence of electro-physiologic problems (SA node dysfunction, AV block,SVT, etc.).\\n■Single ventricle physiology\\n➣ Include those w/ tricuspid atresia or a single, double inletventricle, usually a morphologic left ventricle\\n➣ Survival to adulthood depends on the anatomy: pul-monary stenosis (protects pulmonary vascular bed) &competent atrioventricular valve(s) increase survival.\\n➣ Generally pts w/ single LV do better than pts w/ single RV(morphologic).\\n➣ Pts w/ unrestricted PBF typically develop pulmonary vas-cular disease.\\n➣ Pts w/ restricted PBF may have required palliative shuntsto increase PBF (to treat hypoxia).\\n➣ Aortopulmonary shunts result in volume overload ofthe single ventricle; over time this results in ventricularfailure.\\n➣ Cavopulmonary shunts (Glenn) increase PBF w/out vol-ume overload of the single ventricle.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 23}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\nAdult Congenital Heart Disease 9\\n■Fontan procedure\\n➣ RA to PA connection for “correction” of single-ventriclehearts\\n➣ Two-stage procedure\\n➣ Step 1: anastomosis of SVC to undivided right PA =bidi-\\nrectional Glenn shunt\\n➣ Step 2: IVC connected to PA via Gore-Tex graft through RA\\n➣ Graft usually bafﬂed into LA so that some R-to-L shunt per-sists as safety valve in cases of high pulmonary resistance\\nrFluid retention (effusions, ascites)\\nrForward ﬂow depends on CVP exceeding LAP to providedriving force for PA blood ﬂow.\\nrMust have adequate intravascular volume & avoidincreased PVR (see above)\\n■Truncus arteriosus\\n➣ Truncus arteriosus w/ unobstructed PA origin from theascending aorta rapidly results in fatal CHF w/out correc-tion.\\n➣ Survival is permitted by pulmonary vascular inﬂow steno-sis/disease sufﬁcient to limit L-to-R shunt (but cyanosis isincreased).\\n➣ Truncal valve often malformed & incompetent; regurgita-tion is biventricular & can be severe\\n➣ Adult survivors: repair by closure of VSD & interpositionof valved conduit between RV & PA\\nrThe truncal valve remains as the aortic valve & incom-petence should be treated like aortic insufﬁciency.\\nrThe valved RV to PA conduit is prone to stenosis & insuf-ﬁciency RV failure.\\nrThe conduit lies just beneath the sternum & is vulnera-ble to sternotomy.\\n■Total anomalous pulmonary venous connection\\n➣ Obligatory R-to-L shunt resulting from pulmonary veinsemptying into RA'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 24}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\n10 Adult Congenital Heart Disease\\n➣ Pts w/ supradiaphragmatic PV connection, low PVR & alarge ASD have natural history similar to that of isolatednonrestrictive ASD but w/ systemic arterial saturations inthe low 90s.\\n■Eisenmenger physiology/pulmonary vascular disease\\n➣ PVR at or above SVR w/ resultant R-to-L shunt\\n➣ Anatomy: nonrestrictive communications at great arterial,ventricular or atrial level, by heart w/ single ventricle ortwo ventricles w/ or w/out ventricular inversion\\n➣ Excessive PBF & pressure result in changes in PA vascula-ture & ultimately ﬁxed high PVR.\\n➣ Confers high perioperative risk:\\nrRepresents most of unoperated adults w/ CHD who arereferred for preop anesthetic evaluation\\nrFixed PVR precludes rapid adaptation to intraoperativehemodynamic changes.\\nrVariations in SVR produce changes in the magnitudeof R-to-L shunting (decreased SVR leads to increasedR-to-L shunt).\\nrHypovolemia, hypotension, vasodilators & regionalanesthesia are poorly tolerated & exacerbate R-to-Lshunt.\\nrDistorted cardiac anatomy & R-to-L shunt obviate PAcatheters (hazardous placement, inaccurate CO). Rel-ative resistance of PVR vs. SVR can be monitored bychanges in systemic arterial pulse oximetry (SpO\\n2).\\nrFixed high PVR is unresponsive to pharmacologic treat-ment but exacerbated by cold, acidosis, hypercarbia,hypoxia, endogenous or exogenous catecholamines w/alpha-adrenergic effects.\\n■Aortopulmonary shunts\\n➣ Used in any defect associated w/ low PBF\\n➣ May be palliative until reparative procedure or deﬁnitiveprocedure can be done'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 25}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\nAdult Congenital Heart Disease 11\\n➣ Ventricular function determined by cardiac abnormality& amount of volume overload produced by shunt\\n➣ Systemic arterial oxygen saturation depends on PBF,which depends on maintenance of high SVR vs. PVR. R-to-L shunt is exacerbated by any fall in SVR or increase inPVR.\\n➣ Types\\nrBlalock-Taussig (BT): subclavian artery to pulmonaryartery; subclavian artery usually ligated for use\\nrPotts: PA to aorta; higher pressure, higher ﬂow than BTshunt, results in development of pulmonary vasculardisease\\nrCentral: main PA to aorta; similar hemodynamically toPotts\\nﬂuid & electrolytes\\nN/A\\ncardiopulmonary\\n■Shunt lesions: pts are dependent on relative PVR vs. SVR fordirection of blood ﬂow.\\n■Pts w/ long-standing increased pressure and/or volume loadto the pulmonary vasculature ultimately develop PHT. Thiscan lead to R-to-L shunting in pts w/ previous L-to-R shunts.\\n■Blood ﬂow across the non-shunt lesion is dependent on ven-tricular pumping against high resistance. Myocardial depres-sion may cause decompensation.\\n■Lesions w/ increased PBF cause decreased pulmonary com-pliance, which increases the work of breathing.\\nhematologic\\nPolycythemia\\n■Cyanotic lesions & attendant hypoxemia result in increa-sed renal erythropoietin, high hematocrit & hyperviscosity(if Hct >65%).'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 26}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\n12 Adult Congenital Heart Disease Alcohol Abuse\\n■Dehydration increases thrombotic risk (especially in upperlobes of lungs when PVR is elevated). A bleeding diathesisalso exists, not reliably related to thrombocytopenia.\\n➣ Artifactually elevated PT & PTT: erythrocytosis, lessplasma in sample to interact w/ citrate in blood tubes.\\nmetabolic/nutritional\\nN/A\\ngastrointestinal\\nN/A\\nneuropsychiatric\\n■Paradoxical emboli to CNS are a risk in any pt w/ lesions w/R-to-L shunt.\\n■Lower extremity or pelvic veins: source of thrombotic emboli\\n■Hospitalized pts are at risk for air or particle emboli enteringfrom peripheral or central venous catheters.\\n■Prior surgical nerve injury can cause deﬁcits in recurrentlaryngeal, phrenic or sympathetic chain function.\\nALCOHOL ABUSE\\nJONATHAN T. KETZLER, MD\\noverview\\n■Lifetime prevalence of alcohol (ETOH) abuse: 14–36%\\n■Alcohol abuse is common in surgical & trauma pts.\\n■In one study, 43% of surgical pts who had ETOH levels checkedwere positive.\\n■ETOH abuse is more common in surgical population thangeneral public.\\n■At-risk drinking: >16 standard drinks per wk for men & >10\\ndrinks per wk for women'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 27}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\nAlcohol Abuse 13\\n■WHO deﬁnes “harmful drinking” as ETOH consumption thatresults in physical or psychological harm.\\nﬂuid & electrolytes\\n■May have very poor nutritional status\\ncardiopulmonary\\n■3 possible mechanisms for myocardial damage\\n➣ An acute & transient toxic effect on cardiac performance,resulting in impaired myocardial contractility. This effecton myocardial function can become permanent w/ chro-nic alcohol consumption.\\n➣ Nutritional deﬁciency, particularly of thiamine, which canlead to beriberi heart disease\\n➣ Additives to an alcoholic beverage (eg, cobalt) may rarelyexert a toxic effect on the myocardium.\\n■The prevalence of alcoholic cardiomyopathy is similar in men& women w/ no signiﬁcant differences in age or nutritional,clinical & radiologic parameters of heart failure.\\n■Alcohol can produce asymptomatic cardiac dysfunction evenwhen ingested by healthy individuals in smaller quantities, asduring social drinking.\\n■The risk of developing left ventricular dysfunction & alco-holic cardiomyopathy is related to both the mean daily alcoholintake & the duration of drinking.\\n■Most pts in whom alcoholic cardiomyopathy develops havebeen drinking >80 g ethanol per day for >5 yrs.\\n■The pt w/ alcoholic cardiomyopathy presents w/ symptoms& physical ﬁndings that are similar to those in pts w/ a dilatedcardiomyopathy of any etiology.\\nhematologic\\n■Macrocytosis w/ or w/out anemia, leukopenia and/or throm-bocytopenia'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 28}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\n14 Alcohol Abuse\\n■Mechanism unknown but may be related to utilization of folicacid, direct toxic effect on hematopoietic cells or abnormali-ties in membrane phospholipids\\n■With abstinence & reasonable diet, pt may have reboundthrombocytosis w/ platelet counts of >900,000/microliter at\\n1–2 wks. Return to normal levels at 7–10 days.\\nmetabolic/nutritional\\nN/A\\ngastrointestinal\\n■Prone to hepatic insufﬁciency w/ attendant esophagealvarices\\n■Common to have chronic gastropathy\\n■Hepatic toxicity: acute alcoholic hepatitis, liver dysfunction,synthetic dysfunction, etc.\\n■Risk of pancreatitis\\nneuropsychiatric\\n■May have axonal degeneration of peripheral nerves\\n■CNS symptoms include memory loss, irritability & dementia.\\n■Withdrawal-associated seizures are generalized tonic-clonic& usually occur within 48 hrs of last drink.\\n■Usually single episodes & require no treatment\\n■5% of pts who undergo withdrawal experience delirium tre-mens (DTs).\\n■DTs typically occur 48–96 hrs after last drink.\\n■Wernicke’s encephalopathy secondary to thiamine deﬁciency\\n➣ Cognitive dysfunction, especially memory disorders\\n➣ Classic triad\\nrEncephalopathy\\nrProfound disorientation, indifference & inattentive-ness\\nrOculomotor dysfunction'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 29}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\nAlcohol Abuse Anemia 15\\nrNystagmus, lateral rectus palsy & conjugate gazepalsies\\nrSecondary to lesions of the oculomotor, abducens &vestibular nuclei\\nrGait ataxia\\nrDue to combination of polyneuropathy, cerebellarinvolvement & vestibular paresis\\nrWide-based gait w/ short steps\\n■Korsakoff’s amnestic syndrome is a late manifestation of Wer-nicke’s.\\nANEMIA\\nDOUGLAS B. COURSIN, MD, AND KARL WILLMANN, MD\\noverview\\n■Red blood cell (RBC) production normally matches red celldestruction.\\n➣ Normal life of an RBC is 110–120 days.\\n■RBCs are generated in the bone marrow under the control oferythropoietin (EPO) & various cytokines.\\n➣ EPO is a trophic hormone produced in the macula densaof the kidney.\\nrModulated by the adequacy of tissue O\\n2delivery\\nrTherefore, it should increase w/ anemia, hypoxemia& decreased O\\n2delivery to the kidney.\\nrVarious cytokines may alter normal EPO responsive-ness.\\nrMay be cause of some anemias of chronic disease& ICU illnesses\\n■Reticulocytes are young RBCs & normally represent 1.5% ofcirculating RBCs.\\n■Reticulocyte count normally increases as response to anemia.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 30}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\n16 Anemia\\n■Anemia is deﬁned as a reduction below the normal limits ofRBCs in the circulation.\\n➣ Iron deﬁciency is most common nutrient deﬁciency.\\n➣ Incidence of anemia increases w/ age.\\n➣ About 2.5% of the population has a physiologic anemia.\\n■Determine etiology, degree of anemia, physiologic effect &need, if any, to treat immediately or treat during OR/ICUcare.\\n➣ Signs & symptoms of anemia depend on the degree of ane-mia, speed with which the anemia developed & individualphysiologic reserve.\\n➣ Symptoms are related to decreased O 2delivery & if actively\\nbleeding or inadequately compensated, degree of hypov-olemia.\\n■Hemoglobin (Hgb): concentration of the oxygen-carrying pig-ment in whole blood\\n➣ Normal Hgb for male: 15.7 +/– 1.7 mg/dL; anemic if Hgb\\n<13.5 mg/dL\\n➣ Normal Hgb for female: 13.8 +/– 1.5; anemic if Hgb\\n<12 mg/dL\\nrPts living at altitude frequently have higher normal val-ues secondary to hypoxia-induced increased erythro-poiesis.\\nrSmokers & those exposed to some environmental pollu-tants may have higher Hgb, which may approach poly-cythemic levels.\\nrSome athletes may have higher baseline Hgb.\\nrAs pts age, some develop a physiologic anemia; how-ever, need to rule out underlying pathology such ascolon cancer, GI blood loss or other.\\n■Hematocrit (Hct) is the percent of a volume of whole bloodthat is occupied by intact RBCs.\\n■Red cell count: number of RBCs in a volume of whole blood,millions of RBCs/microliter'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 31}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\nAnemia 17\\n■When measuring Hgb, Hct & red cell volume, take into accountclinical scenario, speed of onset of anemia, presence of bleed-ing & overall volume status.\\n■Most important physiologic effect of anemia is decrease intissue oxygen delivery\\n➣ Can compensate as long as there is adequate intravascu-lar volume, good cardiac function, reﬂex production of2,3-DPG & decreased blood viscosity\\n➣ Hgb disassociation curve shifts to the right in anemia,which facilitates O\\n2release & delivery.\\nﬂuid and electrolytes\\n■RBCs circulate in plasma, which is essentially a non-cellularbalanced salt solution w/ plasma proteins & coagulation fac-tors.\\n■Exogenous RBCs should be administered in normal saline-based solutions to avoid hemolysis, crenation or chelation ofpreservative-based anticoagulants.\\ncardiopulmonary\\n■Primary effect on cardiovascular system depends on whetheranemia is normovolemic (well tolerated) or hypovolemic(poorly tolerated).\\n■Effects depend on rapidity & severity of anemia & pt reserve.\\n■Acute anemia has high potential for inducing myocardialischemia in susceptible pts.\\n■Chronic anemia may induce a nutritional cardiomyopathy:transfusion may not improve cardiac function but simplyinduce CHF & pulmonary congestion.\\nhematologic\\n■Etiology of anemia\\n➣ Morphology (based on CBC-based indices or red cell size)\\nrMicrocytic: low MCV, MCHC, RBC index'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 32}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\n18 Anemia\\nrIron deﬁciency anemia, sickle cell anemia, tha-lassemia, others\\nrMacrocytic: high MCV\\nrVitamin B\\n12or folate deﬁciency\\nrMixed: combination of micro & macrocytic anemia\\nrNormocytic: anemia of chronic disease\\n➣ Mechanism (applied below)\\nrBlood loss\\nrMost commonly encountered etiology\\nrMay be obvious during surgery, trauma\\nrOccult: GI, GU, retroperitoneal, internal, soft tissue,etc.\\nrIatrogenic\\nrExcessive phlebotomy\\nrDecreased RBC production\\nrNutrient-mediated\\nrIron deﬁciency\\nrB\\n12deﬁciency (pernicious anemia)\\nrAssociated w/ degeneration of lateral & posteriorwhite columns of spinal cord\\nrParesthesias, loss of proprioception & vibratorysense\\nrAssociated w/ hypothyroidism\\nrFolate deﬁciency\\nrMost common in alcoholic & postpartum pts\\nrBone marrow compromise\\nrAplastic anemia: absolute failure of marrow to makered cells\\nrMarrow replacement w/ tumor, infection, other\\nrMarrow ﬁbrosis such as myelodysplasia\\nrDrug- or irradiation-induced suppression\\nrHormonal deﬁciency\\nrErythropoietin (EPO)\\nrAcute or chronic renal impairment'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 33}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\nAnemia 19\\nrAnemia of chronic disease\\nrAnemia of critical illness\\nrRarely, autonomic dysfunction syndromes\\nrHypothyroidism\\nrAndrogen deﬁciency\\nrRBC destruction\\nrAbnormal RBCs\\nrHemolytic anemia\\nrOccurs when RBCs live <100 days\\nrMay be antibody-mediated\\nrInherited\\nrSickle cell anemia\\nrThalassemia\\nrSpherocytosis\\nrAcquired\\nrCoombs-positive, drug-induced hemolysis\\nrThrombotic thrombocytopenic purpura (TTP)\\nrHemolytic-uremic syndrome (HUS)\\nmetabolic-nutritional\\n■See “Nutrient-Induced Anemia” under “Hematologic” sec-tion.\\ngastrointestinal\\n■GI losses are a common cause of occult anemia.\\n■Upper or lower GI blood loss\\n➣ Upper\\nrDrug-related: NSAIDs, ASA\\nrETOH-induced\\nrGastritis\\nrGastric ulcer\\nrVarices\\nrPeptic ulcer disease\\nrTumor'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 34}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\n20 Anemia Ankylosing Spondylitis\\nrVascular\\nrOther\\n➣ Lower\\nrDiverticula\\nrVascular\\nrTumor\\nrInfectious\\nrOther\\nRenal\\n■EPO secreted by kidney is responsible for RBC production inthe marrow.\\n■Normally make more RBC precursors than needed, so pro-erythrocytes are recycled.\\n■EPO stimulation, say from anemia or hypoxemia, stimulatesnormal maturation of RBCs as well as increased production.\\n■Pts w/ acute or chronic renal failure are usually anemic &treated w/ EPO.\\n➣ Subcutaneous or IV treatment, usually 3x weekly\\n➣ Avoid excessive administration.\\n➣ Side effects: seizures, DVT, stroke, hypertension\\nneuropsychiatric\\n■Pts w/ pernicious anemia may have symptoms from vitaminB12 deﬁciency.\\nANKYLOSING SPONDYLITIS\\nHUGH R. PLAYFORD, MD\\noverview\\nN/A\\nﬂuids and electrolytes\\nN/A'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 35}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\nAnkylosing Spondylitis 21\\ncardiopulmonary\\n■TMJ arthritis\\n■Cricoarytenoid arthritis\\n■Pleuritic inﬂammation\\n■Chest rigidity w/ restrictive pulmonary disease\\n➣ Compensation by increased diaphragmatic contribution,thorax ﬁxed at higher lung volumes, chest wall symmetryretained\\n■Upper lobe cavitation (rare)\\n■Cardiomyopathy\\n■Conduction defects\\n■Aortitis & aortic insufﬁciency\\nhematologic\\nN/A\\nmetabolic-nutritional\\nN/A\\ngastrointestinal\\n■Irritable bowel syndrome\\nneuropsychiatric\\n■Radiculopathy\\n■Atlantoaxial subluxation\\n■Vertebrobasilar insufﬁciency\\n■Occult spinal fracture\\n■Sacroiliitis\\n■Joint ankylosis\\n■“Bamboo spine”\\n■Spondylodiscitis\\n■Chronic back pain\\n■Cauda equina syndrome (rare)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 36}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\n22 Anticoagulation Therapy\\nANTICOAGULATION THERAPY\\nJONATHAN T. KETZLER, MD\\noverview\\n■In April 2002 the American Society of Regional Anesthesia &Pain Medicine convened its Second Consensus Conferenceon Neuraxial Anesthesia & Anticoagulation.\\n■Although the statements are based on a thorough evaluationof the evidence, data are sparse.\\n■The ﬁnal decision about the use of regional anesthesia in anti-coagulated pts is left to the judgment of the responsible anes-thesiologist.\\n■The consensus focuses on neuraxial blocks, leaving the risk ofplexus & peripheral blocks undeﬁned.\\nﬂuid and electrolytes\\nN/A\\ncardiopulmonary\\nN/A\\nhematologic\\nN/A\\nmetabolic/nutritional\\nN/A\\ngastrointestinal\\nN/A\\nneuropsychiatric\\nN/A'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 37}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\nAortic Regurgitation 23\\nAORTIC REGURGITATION\\nROBERT N. SLADEN, MD\\noverview\\n■Etiology\\n➣ Rheumatic fever\\n➣ Congenital disease (Marfan’s syndrome, Ehler-Danlossyndrome, etc.)\\n➣ Acquired disease (syphilis, aortic dissection)\\n■Variable onset, slow progression, manifests in third to sixthdecade\\n■Cardinal\\n➣ Dyspnea\\n➣ Syncope\\n➣ Congestive heart failure\\nﬂuid/electrolyte\\nN/A\\ncardiopulmonary\\n■Hemodynamic proﬁle: hyperdynamic\\n■Left ventricle (LV) undergoes eccentric hypertrophy & dilation(volume overload)\\n➣ EF is increased >0.6 while compensated\\n➣ Restricted forward cardiac output: impaired circulatoryreserve, effort intolerance, dyspnea\\n■Diagnosis\\n➣ Wide pulse pressure (“water hammer” or “collapsing”pulse)\\n➣ Harsh systolic +early diastolic murmur (“to & fro”) at left\\nsternal border\\n➣ Cardiomegaly on chest x-ray\\n➣ Left ventricular hypertrophy (LVH) on ECG\\n➣ Increasing aortic regurgitation (TTE, TEE)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 38}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\n24 Aortic Regurgitation Aortic Stenosis\\n■Acute decompensation (low cardiac output syndrome)\\n➣ Acute atrial ﬁbrillation, tachyarrhythmias (loss of atrialkick)\\n■Late manifestations\\n➣ Congestive heart failure\\n➣ Sudden death\\n■Increased risk of perioperative myocardial ischemia\\n➣ Very low diastolic perfusion pressure (may be closeto 0)\\n➣ Increased cardiac output requires increased heart rate(ﬁxed stroke volume).\\nhematologic\\nN/A\\nmetabolic/nutritional\\nN/A\\ngastrointestinal\\nN/A\\nneuropsychiatric\\nN/A\\nAORTIC STENOSIS\\nROBERT N. SLADEN, MD\\noverview\\n■Etiology\\n➣ Rheumatic fever (rarely)\\n➣ Bicuspid aortic valve\\n➣ Calciﬁc aortic sclerosis\\n■Variable onset, slow progression, manifests in third to sixthdecade'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 39}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\nAortic Stenosis 25\\n■Cardinal symptoms & life expectancy after onset (w/out treat-ment)\\n➣ Angina (3 yrs)\\n➣ Syncope (2 yrs)\\n➣ Congestive heart failure (1 yr)\\nﬂuid & electrolytes\\nN/A\\ncardiopulmonary\\n■Hemodynamic proﬁle: hypodynamic\\n■Left ventricle (LV) undergoes concentric hypertrophy (pres-sure overload)\\n➣ Ejection fraction (EF) is increased >0.7 (end-systolic col-\\nlapse).\\n➣ Restricted forward cardiac output: impaired circulatoryreserve, effort intolerance, dyspnea\\n➣ Syncope or sudden death may occur w/ LV outﬂow tract(LVOT) obstruction.\\n■Impaired myocardial oxygen balance (MVO 2)\\n➣ Increased demand (increased afterload, contractility)\\n➣ Decreased supply (decreased aortic diastolic pressure,thickened myocardium)\\n➣ Angina may occur w/out coronary artery disease (CAD).\\n➣ Earlier-onset angina w/ concomitant CAD\\n■Diagnosis\\n➣ Narrow pulse pressure\\n➣ Harsh “diamond-shaped” systolic murmur radiating toneck\\n➣ Cardiomegaly on chest x-ray\\n➣ Left ventricular hypertrophy (LVH) on ECG\\n➣ Increasing gradient across aortic valve (critical: peak >70\\nmm Hg, mean >50 mm Hg)\\n➣ Decreasing aortic valve area (normal, 2–4 cm2, critical <\\n1.0 cm2)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 40}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\n26 Aortic Stenosis Bronchospastic Disease\\n■Acute decompensation (low cardiac output syndrome)\\n➣ Acute atrial ﬁbrillation, tachyarrhythmias (loss of atrialkick)\\n➣ Late manifestations\\n➣ Congestive heart failure\\n➣ Sudden death\\n■Increased risk of perioperative myocardial ischemia\\n➣ Acute ischemia w/ relatively mild perturbations\\n➣ Low cardiac output syndrome (unable to respond topostop demands)\\n➣ Cardiac arrest: CPR may be unsuccessful in overcomingLVOT obstruction\\nhematologic\\nN/A\\nmetabolic/nutritional\\nN/A\\ngastrointestinal\\nN/A\\nneuropsychiatric\\nN/A\\nBRONCHOSPASTIC DISEASE\\nHUGH PLAYFORD, MD\\noverview\\nN/A\\nﬂuids and electrolytes\\n■Usually normal\\n■Chronic systemic steroid use may lead to ﬂuid retention,hypernatremia, hypokalemia.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 41}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\nBronchospastic Disease 27\\n■Severe asthma\\n➣ May be dehydrated (high insensible respiratory loss w/hyperventilation, poor intake)\\n➣ Hypokalemia related to beta-2 agonists\\ncardiopulmonary\\n■Typically related to:\\n➣ Bronchospasm of bronchial smooth muscle\\n➣ Mucus hypersecretion\\n➣ Airway inﬂammation\\n■Symptoms & signs\\n➣ May have no symptoms or signs during periods of normalto near-normal pulmonary function\\n➣ Wheezing: turbulent gas ﬂow during expiration. Absenceof wheeze in severe acute asthma may reﬂect absence ofairﬂow.\\n➣ Cough: may range from nonproductive to copious tena-cious mucoid sputum\\n➣ Dyspnea often parallels the severity of the expiratory air-ﬂow obstruction & may be associated w/ tachypnea &hyperventilation.\\n➣ Chest discomfort frequent\\n■Investigations\\n➣ FEV1 & maximal mid-expiratory ﬂow rate reﬂect the sever-ity of the expiratory airﬂow obstruction.\\n➣ Pts often present to hospital w/ FEV1 <35% of normal, or\\nmaximal mid-expiratory ﬂow rate <20% of normal. When\\nFEV1 returns to about 50%, symptoms decrease markedly.\\n➣ Flow-volume loop: downward scooping of the expiratorylimb of the loop\\n➣ Between asthma attacks, FRC may be increased by 1–2 L,but TLC remains normal.\\n➣ DLCO usually unchanged\\n➣ ABG (between attacks): often normal'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 42}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\n28 Bronchospastic Disease\\n➣ ABG (mild asthma attacks): decreased PaCO 2& respiratory\\nalkalosis\\n➣ ABG (worsening airﬂow limitation): decreased PaO 2(from\\nincreasing ventilation-perfusion mismatch) & increasedPaCO\\n2(fatigue w/ increased work of breathing)\\n➣ Chest x-ray: important in excluding other causes ofrespiratory failure; often normal but may have hyper-inﬂation\\n➣ ECG: may have right axis deviation & ventricular irritability(beta-2 agonists, acidemia)\\n■Related to therapy\\n➣ Beta-2 agonists: sympathetic stimulation, tachycardia,cardiac dysrhythmias\\n➣ Methylxanthines (eg, theophylline): cardiac dysrhythmias\\nhematologic\\n■Usually normal\\n■May be associated w/ an eosinophilia\\n➣ Eosinophilia may parallel the degree of airway inﬂamma-tion & airway hyperreactivity.\\nmetabolic-nutritional\\n■Usually normal\\n■May have chronic changes related to long-term systemicsteroid use\\ngastrointestinal\\n■Usually normal\\n■May have chronic changes related to long-term systemicsteroid use (gastritis, peptic ulcer disease)\\nneuropsychiatric\\n■Usually normal'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 43}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\nBronchospastic Disease Carcinoid Syndrome 29\\n■In severe acute asthma\\n➣ Generalized myopathy may be present (related tobeta agonists, steroids, non-depolarizing neuromuscularblockers)\\n➣ Anxiety common (beta agonists, hypoxemia, dyspnea)\\nCARCINOID SYNDROME\\nGIUDITTA ANGELINI, MD\\noverview\\n■Incidence 1–2/100,000 in North America\\n■Most commonly seen in fourth or ﬁfth decade of life\\n■At diagnosis of carcinoid tumors, 10–20% of pts are found tohave noncarcinoid malignancies.\\n■10% have MEN-I\\n➣ Evaluate for pancreatic, pituitary & parathyroid disease.\\n■Most common presentation w/out syndrome is GI bleeding,intestinal obstruction or appendicitis.\\n■Mostly GI & lung but can also be found in breasts & ovaries\\n■Metastases usually from tumors >2 cm in diameter\\n■35% of pts w/ metastases have symptoms of syndrome; only2–5% w/out metastases have syndrome.\\n■Histamine, serotonin & bradykinin are main hormonesinvolved, but also kallikrein, substance P , prostaglandins, gas-trin, corticotropin, neuron-speciﬁc enolase\\nﬂuid and electrolytes\\n■Hypoalbuminemia\\n■Hyperglycemia\\ncardiopulmonary\\n■20% of tumors occur in lung.\\n■Histamine'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 44}, page_content='P1: SBT0521759385p2-A CUNY1088/Sladen 0 521 75938 5 May 28, 2007 8:52\\n30 Carcinoid Syndrome\\n➣ Vasodilation\\n➣ Extravascular smooth muscle contraction\\n■Serotonin\\n➣ Vasodilation\\n■Bradykinin\\n➣ Vasodilation\\n➣ Histamine release\\n➣ Bronchoconstriction\\n■Hypertension, hypotension, bronchospasm are all symptomsof carcinoid syndrome.\\n■One third of pts w/ carcinoid syndrome have cardiac disease\\n➣ Right ventricular wall ﬁbrinous plaques\\n➣ Tricuspid regurgitation\\n➣ Pulmonic stenosis\\nhematologic\\n■Nonmetastatic tumors secrete hormones that reach the liverby the portal vein & are usually inactivated.\\n■Cutaneous erythematous ﬂushing is characteristic of carci-noid syndrome.\\nmetabolic-nutritional\\n■Tryptophan depletion is associated w/ serotonin release.\\n■Pellagra can result from carcinoid syndrome.\\ngastrointestinal\\n■Most tumors are GI\\n➣ 50% appendix\\n➣ 25% ileum (usually source of metastases)\\n➣ 20% rectum\\n■Liver metastases have direct access to systemic circulation torelease hormones & produce syndrome.\\n■Serotonin causes increased motility.\\n■Abdominal pain, vomiting, diarrhea & hepatomegaly are allsymptoms of carcinoid syndrome.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 45}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\nCarcinoid Syndrome Chemotherapeutic Agents 31\\nneuropsychiatric\\nN/A\\nCHEMOTHERAPEUTIC AGENTS\\nJONATHAN T. KETZLER, MD\\noverview\\n■Various combinations of chemotherapeutic agents are usedto treat neoplasms.\\n■Anesthesiologists must deal with pts whose organ systemshave been impaired.\\n■Categories of chemotherapeutic agents\\n➣ Alkylating agents\\nrNitrogen mustard\\nrCyclophosphamide\\n➣ Antimetabolites\\nrMethotrexate\\n➣ Vinca alkaloids\\nrVincristine\\n➣ Antibiotics\\nrAnthracyclines: doxorubicin (Adriamycin), daunoru-bicin, others\\nrBleomycin\\n➣ Enzymes\\nrAsparaginase\\n➣ Synthetics\\nrCisplatin\\n➣ Hormones\\nrCorticosteroids\\nﬂuids/electrolytes\\nN/A\\ncardiopulmonary\\n■Cardiac toxicity'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 46}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\n32 Chemotherapeutic Agents\\n➣ Shock\\nrCardiogenic shock\\nrCongestive heart failure\\nrAnthracyclines; doxorubicin, daunorubicin, idaru-bicin, epirubicin, mitoxantrone\\nrCHF that is refractory to cardiac glycosides is thehallmark.\\nrToxicity is related to cumulative dose; threatincreases after cumulative dose reaches 400 mg/m\\n2.\\nrFactors that exacerbate effects\\nrRadiation to mediastinum\\nrExposure to cyclophosphamide, vincristine, ﬂu-orouracil or another anthracycline\\nrCalcium channel blockers\\nrAcute myocarditis uncommon\\nrEarly ST-segment & T-wave changes not signiﬁcant\\nrDiscontinue anthracycline if left ventricular ejec-tion fraction is <35% or absolute decrease of >10%.\\nrMyocardial ischemia & necrosis\\nrCisplatin, vinblastine, vincristine\\nrCyclophosphamide\\nrAfter high dose used for bone marrow transplant\\nrECG changes, heart failure & pericardial effusionscan occur days to wks after dosing.\\nr5-Fluorouracil\\nrMay induce coronary artery spasm within min-utes to hrs after dosing\\nrPericarditis\\nrAnthracyclines (rare)\\nrRadiation\\nrApprox. 50% of cases of thoracic radiation\\nrTypically occurs 6 months to 2 yrs after treatment\\nrCan also cause cardiac ischemia, ﬁbrosis & tam-ponade'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 47}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\nChemotherapeutic Agents 33\\nrCardiac dysrhythmias\\nrCyclophosphamide, 5-ﬂuorouracil, ifosfamide,amsacrine, Taxol, doxorubicin, interleukin-2\\nrDistributive shock\\nrPancreatitis\\nrL-asparaginase\\nrTreat w/ glucocorticoids.\\nrAddisonian crisis\\nrGlucocorticoid withdrawal\\nrSeptic shock\\nrBusulfan, carboplatin, carmustine (BCNU), cyclo-phosphamide, cytarabine, etoposide, ﬂudarabine,idarubicin, ifosfamide, melphalan, mercaptop-urine, methotrexate, mitomycin, procarbazine,thiotepa, topotecan, doxorubicin\\nrDue to prolonged myelosuppression\\nrAnaphylaxis\\nrCarboplatin, cisplatin, cytarabine, etoposide, L-asparaginase, melphalan, methotrexate, mitomy-cin, pentostatin, procarbazine, teniposide\\nrHypovolemic shock\\nrCyclophosphamide, ifosfamide\\nrHemorrhagic cystitis\\n■Pulmonary toxicity\\n➣ Chronic pneumonitis, pulmonary ﬁbrosis\\nrOffending drugs\\nrAzathioprine, bleomycin, busulfan, carmustine,chlorambucil, cyclophosphamide, melphalan,methotrexate, mitomycin C\\nrClinical ﬁndings\\nrBibasilar “Velcro-like” rales\\nrHypoxemia, respiratory alkalosis. Pulmonary func-tion tests show restrictive process w/ decreased dif-fusion of CO.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 48}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\n34 Chemotherapeutic Agents\\nrChest x-ray: bibasilar reticulonodular inﬁltrates\\nrLung biopsy: interstitial inﬂammation & thickening,cellular atypia, ﬁbrosis\\nrTreatment\\nrStop offending drug.\\nrCorticosteroids 1 mg/kg/day prednisone equivalent\\nrAvoid excessive supplemental oxygen.\\n➣ Hypersensitivity pneumonitis\\nrOffending drugs\\nrBleomycin, methotrexate, procarbazine\\nrClinical ﬁndings\\nrSubacute onset of dyspnea\\nrNonproductive cough\\nrHeadache, chills, rash\\nrChest x-ray: diffuse interstitial inﬁltrates, often acinarpattern\\nrLung biopsy: interstitial eosinophilic inﬁltrates w/histocytic cells\\nrTreatment\\n➣ Acute respiratory distress syndrome\\nrOffending drugs\\nrCyclophosphamide, cytarabine, interleukin-2, me-thotrexate, mitomycin, teniposide, all trans-retinoicacids\\nrClinical ﬁndings\\nrAcute onset\\nrRales, respiratory failure\\nrPulmonary artery occlusion pressure not elevated\\nrChest x-ray: pulmonary edema due to increased cap-illary permeability\\nrLung biopsy: pulmonary edema, focal hemorrhage &thrombi & hyaline membranes\\nrTreatment\\nrSupportive'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 49}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\nChemotherapeutic Agents 35\\nrHigh-dose corticosteroids in ﬁbroproliferative phasecontroversial\\n➣ Acute chest syndrome\\nrOffending drugs\\nrBleomycin, methotrexate\\nrClinical ﬁndings\\nrPleuritic or retrosternal pain\\nrPleural rubs uncommon\\nrChest x-ray: normal\\nrTreatment\\nrAnalgesia\\n➣ Bronchiolitis obliterans\\nrOffending drugs\\nrBone marrow transplant\\nrOccurs most commonly after lung transplantation\\nrClinical ﬁndings\\nrInsidious onset cough & dyspnea on exertion w/ orw/out wheezing\\nrExam similar to emphysema\\nrPulmonary function tests: obstructive pattern\\nrChest x-ray: patchy inﬁltrates\\nrLung biopsy: lymphocytic or mixed inﬂammatoryinﬁltrates w/ granulation tissue or ﬁbrosis obstruct-ing bronchiolar lumina\\nrTreatment\\nrBronchodilators\\nrHigh-dose corticosteroids\\nrImmunosuppression controversial\\n➣ Radiation-induced pulmonary toxicity\\nrClinical ﬁndings\\nrDose-related toxicity\\nrDyspnea, cough, fever\\nrTypically occurs 2–3 months after irradiation\\nrTreatment'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 50}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\n36 Chemotherapeutic Agents\\nrCorticosteroids for acute toxicity but not recom-mended for ﬁbrosis\\nhematologic\\nN/A\\nmetabolic/nutritional\\nN/A\\ngastrointestinal\\n■Nausea & vomiting\\n➣ Offending drugs\\nrCisplatin, cyclophosphamide, cytarabine, hydroxyurea,doxorubicin, 5-ﬂuorouracil, nitrosourea\\n■Mucositis\\n➣ Offending drugs\\nrCytarabine, doxorubicin, 5-ﬂuorouracil, hydroxyurea,methotrexate\\n➣ Clinical ﬁndings\\nrGrade 0: none\\nrGrade 1: mild soreness, erythema, painless ulcers\\nrGrade 2: painful erythema, edema or ulcers; able to eat\\nrGrade 3: painful erythema, edema or ulcers; unable toeat\\nrGrade 4: requires enteral or parenteral nutritional sup-port\\n➣ Treatment\\nrMouth care\\nrChlorhexidine gluconate rinse to reduce microbialcolonization\\nrDyclonine hydrochloride rinse for topical analgesia\\nrIV hydration\\nrSucralfate for cytoprotection\\nrNutritional support if necessary\\n■Diarrhea\\n➣ Offending drugs'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 51}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\nChemotherapeutic Agents 37\\nrCytarabine, doxorubicin, 5-ﬂuorouracil, hydroxyurea,methotrexate\\n■Veno-occlusive disease\\n➣ Offending drugs\\nrMitomycin C, carmustine, busulfan, cyclophospha-mide, dactinomycin, bone marrow transplant, radia-tion therapy\\n➣ Clinical ﬁndings\\nrAcute onset upper abdominal pain\\nrJaundice, hepatomegaly, ascites, oliguria\\nrHyperbilirubinemia, elevated serum transaminaseactivity\\nrHepatic biopsy: centrilobular cholestasis, hemorrhagicnecrosis, central luminal obliteration\\n➣ Treatment\\nrSupportive therapy\\nr35% mortality in bone marrow transplantation\\n■Hepatotoxicity\\n➣ Increased transaminase activity, alkaline phosphataseactivity & bilirubin concentrations\\nrOffending drugs\\nrCytarabine, hydroxyurea, L-asparaginase, 6-mercap-topurine, methotrexate, nitrosourea, pentostatin, pli-camycin\\n➣ Cirrhosis\\nrOffending drugs\\nrMethotrexate\\n➣ Hepatic vein thrombosis\\nrOffending drugs\\nrDacarbazine\\n➣ Coagulopathy (decreased factors II, V, VII, X)\\nrOffending drugs\\nrL-asparaginase\\n➣ Treatment\\nrSupportive'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 52}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\n38 Chemotherapeutic Agents Chronic Obstructive Pulmonary Disease\\nneuropsychiatric\\nN/A\\nCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)\\nHUGH R. PLAYFORD, MBBS\\noverview\\nN/A\\nﬂuids & electrolytes\\n■May be mildly to moderately dehydrated by pt’s high minuteventilation, diuretics\\n■Presence of hypokalemia may be related to beta-2-agonistsand/or diuretics.\\ncardiopulmonary\\n■Risk factors\\n➣ External\\nrSmoking (cigarette, cigar/pipe, passive), occupationalexposure (miners, grain millers, etc.), environmentalpollution\\n➣ Internal\\nrGenetic (alpha-1-antitrypsin deﬁciency), gender(male >female), socioeconomic status (poor), bron-\\nchial hyperresponsiveness, atopy & asthma, childhoodillnesses (low birthweight, respiratory disease), dietaryinﬂuences (vitamin C & E deﬁciency)\\n■Pathologic changes\\n➣ Early stages: changes in large & small airways & lungparenchyma\\n➣ Later stages: involvement of pulmonary circulation(medial hypertrophy of vascular smooth muscle & inti-mal hyperplasia, pulmonary hypertension), heart (rightventricular hypertrophy & failure, cor pulmonale) & res-piratory muscles (atrophy)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 53}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\nChronic Obstructive Pulmonary Disease 39\\n■Clinically often separated as chronic bronchitis, emphysema\\n➣ Chronic bronchitis\\nrMucus hypersecretion, decreased airway lumen due tomucus & inﬂammation, productive cough, normal dif-fusing capacity\\nrDecreased FEV1, marked decrease PaO\\n2(“blue\\nbloater”), increased PaCO 2, DLCO normal, Hct incr-\\neased, marked cor pulmonale\\n➣ Emphysema\\nrDestructive loss of lung parenchyma, loss of elasticrecoil, possibly increased collagen deposition & ﬁbro-sis, airway collapse in exhalation, increased airwayresistance, bullae formation w/ compression of adja-cent lung tissue, increased work of breathing fromreduced elastic recoil, decreased diffusing capacity, maybe linked to alpha-1-antitrypsin deﬁciency (0.1% pop-ulation, 5–10% of these also have hepatic disease)\\nrDecreased FEV1, modest decrease PaO\\n2(“pink puffer”),\\nnormal to decreased PaCO 2, decreased DLCO, normal\\nHct, mild cor pulmonale\\n■Physiologic changes\\n➣ Permanent & minimally reversible obstruction to airﬂowduring exhalation but w/ relatively preserved inspiratoryﬂow\\n➣ Characterized by progressive expiratory airﬂow limitationw/ FEV1 <65% predicted, FEV1/FVC <80%\\n➣ Maximal inspiratory ﬂow rate normal or near normal\\n➣ Increased RV, increased FRC, increased work of breathing\\n■Symptoms & signs\\n➣ Symptoms may not be present until relatively late; cough,dyspnea (often limiting exercise), ankle swelling, hepaticcongestion\\n➣ Slow & prolonged expiration, hyperinﬂation of thorax,distant breath sounds, may have wheeze, coarse earlyinspiratory crackles, use of accessory muscles of'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 54}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\n40 Chronic Obstructive Pulmonary Disease\\nrespiration, signs of pulmonary hypertension, right heartenlargement and/or failure\\n➣ With extremis, asterixis & cyanosis\\n■Investigations\\n➣ Chest x-ray: hyperlucency, hyperinﬂation, bullae\\n➣ ABGs: hypoxemia w/ advanced disease, hypercapnia &compensatory metabolic alkalosis w/ advanced disease\\n➣ PFTs: as above\\n➣ ECG: right heart strain (right axis deviation, RBBB, p pul-monale)\\n➣ Flow volume loops: early changes: scooped-out lower partof expiratory limb (abnormal ﬂow at low lung volumes);later changes: scooping at all lung volumes\\n■Implications\\n➣ High risk acute-on-chronic respiratory failure (upper &lower respiratory tract infections, surgery)\\n■Therapies\\n➣ Bronchodilators (beta-2 agonists, hypokalemia, cardiacarrhythmias, tremor), mucolytics, anticholinergics (mildAE, dry mouth), steroids (inhaled & systemic, cataracts,osteoporosis, secondary infection, diabetes), methylx-anthines (eg, theophylline, nausea/diarrhea/headache/seizures/cardiac arrhythmias), supplemental oxygen,intermittent antibiotics\\nhematologic\\nPolycythemia secondary to chronic hypoxemia\\nmetabolic-nutritional\\n■High work of breathing increases metabolic load, elevatedresting energy expenditure.\\n■Malnutrition occurs in 25–33% of pts w/ moderate to severeCOPD.\\n■Depletion of fat mass & skeletal muscle mass'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 55}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\nChronic Obstructive Pulmonary Disease Chronic Renal Failure 41\\n■Dyspnea, smoking may interfere w/ adequacy & style of nutri-tion.\\n■Signiﬁcant deconditioning, particularly of respiratory mus-cles\\ngastrointestinal\\nMinimal change\\nneuropsychiatric\\nMinimal change\\nCHRONIC RENAL FAILURE\\nROBERT N. SLADEN, MD\\noverview\\n■Chronic renal disease\\n➣ Chronic renal insufﬁciency (CRI)\\n➣ End-stage renal disease (ESRD) (dialysis-dependent)\\n■Etiology\\n➣ Primary (nephropathy)\\n➣ Secondary (diabetes, hypertension, SLE, vasculitides)\\n■Dialysis\\n➣ Hemodialysis (HD) (about 85% of pts)\\n➣ Chronic ambulatory peritoneal dialysis (CAPD)\\nﬂuid and electrolytes\\n■Metabolic acidosis, hyperkalemia & congestive heart failure(CHF)\\n➣ Well controlled by dialysis\\n■Anuric pts\\n➣ Fluid loss is insensible only, about 500 mL/d.\\n■Polyuric chronic renal failure (CRF)\\n➣ Urine output “normal” , but concentrating ability absent\\n➣ Fluid loss quickly results in hypovolemia.\\n■Moderate compensated anion gap acidosis'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 56}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\n42 Chronic Renal Failure\\n➣ Buffer base is depleted; bicarbonate (HCO 3–) 15–18\\nmEq/L\\n■Shock, diarrhea, hypercatabolism\\n➣ Rapid onset of metabolic acidosis\\n■Potassium (K), magnesium (Mg) & phosphate accumulate inCRF\\n➣ pH decrease of 0.1 can increase potassium by 0.5 mEq/L.\\n■Acute hyperkalemia\\n➣ Catabolic stress, acidosis\\n➣ K-sparing diuretics\\n➣ Red blood cell (RBC) transfusion\\n➣ K replacement\\n■Hyperkalemia\\n➣ Asystolic arrest (may occur w/out ECG prodrome)\\n■Hypermagnesemia\\n➣ Muscle weakness\\n➣ Increased susceptibility to muscle relaxants\\n■Hyperphosphatemia\\n➣ Renal osteodystrophy\\n■Excessive dialysis can result in K, Mg & phosphate depletion.\\n■Hypokalemia\\n➣ Supraventricular, ventricular arrhythmias\\n➣ Muscle weakness\\n■Hypomagnesemia\\n➣ Supraventricular, ventricular arrhythmias\\n■Hypophosphatemia\\n➣ Muscle weakness\\n➣ Increased susceptibility to muscle relaxants\\n➣ Difﬁcult ventilatory weaning\\n➣ CNS dysfunction\\ncardiopulmonary\\n■Pericarditis, hemorrhagic pericardial effusion\\n➣ Rare, well controlled by regular dialysis'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 57}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\nChronic Renal Failure 43\\n■Systemic hypertension\\n➣ Left ventricular hypertrophy (LVH) (may be asymmetric)\\n■Accelerated atherosclerosis, coronary artery disease (CAD)\\n➣ Hypertension +hyperlipidemia +hyperglycemia\\n■Hyperdynamic circulation w/ ﬁxed low systemic vascularresistance (SVR)\\n➣ Anemia, arteriovenous shunts\\n➣ Impaired circulatory reserve\\n➣ Poor tolerance of myocardial ischemia or sepsis\\n■Increased risk of postop pulmonary edema, atelectasis &pneumonia\\n➣ Hypoalbuminemia, low oncotic pressure, immune com-promise\\n➣ Abdominal distention (CAPD)\\nhematologic\\n■Normochromic, normocytic anemia (Hct 25–28%)\\n➣ Decreased erythropoietin, red cell survival & chronicblood loss (GI tract, labs)\\n➣ Increased cardiac output (CO)\\n➣ Increased 2,3-diphosphoglycerate (2,3-DPG) (impaired byhypophosphatemia)\\n■Uremic coagulopathy (BUN >60–80 mg/dL)\\n➣ Defective endothelial release of von Willebrand’s factor &factor VIII\\n➣ Platelet function is abnormal.\\n➣ Ivy bleeding time (BT) is prolonged >15 min (normal 3–8\\nmin).\\nmetabolic-nutritional\\n■Disordered metabolism\\n➣ Hyperglycemia (glucose intolerance)\\n➣ Hypertriglyceridemia\\n➣ Increased risk of atherosclerosis'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 58}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\n44 Chronic Renal Failure\\n■Protein malnutrition (kwashiorkor, hypoalbuminemic mal-nutrition)\\n➣ Albuminuria\\n➣ Dietary protein restriction\\n➣ Losses via CAPD (10–40 g/d protein)\\n■Depleted lean body mass\\n➣ Catabolic effects of uremia\\n➣ Hypoalbuminemia, low colloid oncotic pressure (COP),interstitial & pulmonary edema\\n➣ Decreased functional residual capacity (FRC), ventilatoryreserve\\n➣ Nosocomial & opportunistic infections (shunt or peri-toneal catheter sites)\\n➣ Wound dehiscence, ﬁstulas, bedsores\\ngastrointestinal\\n■Anorexia, hiccups, nausea & vomiting (hallmarks of acute ure-mia)\\n➣ Delayed gastric emptying\\n➣ Increased risk of regurgitation & aspiration\\n■Mucosal inﬂammation, ulceration, bleeding (throughout GItract)\\n■Peptic ulcer disease (25% of pts despite regular dialysis)\\n➣ High incidence of hepatitis B and C\\n➣ Anicteric carrier state in pts on chronic hemodialysis\\nneuropsychiatric\\n■Wide range of CNS manifestations\\n➣ Subtle personality changes\\n➣ Drowsiness, asterixis, myoclonus, seizures\\n■Acute encephalopathy\\n➣ Major surgery, GI bleeding or infection\\n■Distal sensorimotor neuropathy\\n➣ Concomitant autonomic neuropathy likely (see below)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 59}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\nChronic Renal Failure Cocaine Toxicity 45\\n➣ Important indication for dialysis\\n■Autonomic neuropathy\\n➣ Delayed gastric emptying\\n➣ Silent myocardial ischemia\\n➣ Orthostatic hypotension\\n➣ Impaired circulatory response to anesthesia\\nCOCAINE TOXICITY\\nMARY E. McSWEENEY, MD\\noverview\\n■Cocaine is the second most commonly used illegal drug in theUS, after marijuana.\\n■Current users represent about 0.7% of the population; use ismost common in males, age 18–25.\\n■Cocaine is an alkaloid made from the leaves of Erythroxylon\\ncoca, a shrub native to Central & South America, Indonesia &the West Indies.\\n■Cocaine is the only known naturally occurring local anes-thetic.\\n■Consumption may be IV, intranasal or inhaled.\\n■First isolated in 1859, it was used in many products, includingCoca-Cola, until banned in 1906 for nonprescription use.\\n■Most pts w/ a history of drug abuse deny it.\\n■Polysubstance abuse is common; consider toxicology screen-ing.\\nﬂuid and electrolytes\\n■Rhabdomyolysis can lead to acute renal failure.\\ncardiopulmonary\\n■Myocardial ischemia/infarction: acute coronary syndrome isthe most common cardiac pathology associated w/ cocaine'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 60}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\n46 Cocaine Toxicity\\nabuse. Up to 25% of nonfatal MIs in age group 18–45 areattributable to frequent cocaine abuse. Most MIs occur within3 hrs of cocaine use, but this is variable. Anterior wall is themost frequent site of infarction. Pts often have normal coro-naries. Ischemia mechanisms:\\n➣ Increased myocardial oxygen demand: sympathomimeticaction increases myocardial inotropy, heart rate & sys-temic BP\\n➣ Coronary artery vasoconstriction/spasm: mediated byalpha-adrenergic receptors\\n➣ Coronary artery thrombosis: cocaine can activateplatelets, increase platelet aggregability & potentiate thr-omboxane production\\n■Arrhythmias & conduction abnormalities: arrhythmogenicpotential is poorly understood: sinus tachycardia & brady-cardia, bundle branch block, sudden death (ventricular ﬁb-rillation or asystole), ventricular tachycardia & acceleratedidioventricular rhythm, heart block, torsades de pointes, avariety of supraventricular arrhythmias & an ECG pattern typ-ical of Brugada syndrome (pseudo-right bundle branch block& persistent ST-segment elevation in V1-V3) have all beenobserved; arrhythmias disappear when drug is metabolizedunless MI occurs\\n■Myocarditis: mechanism unclear (infection, hypersensitivityreaction, etc.)\\n■Cardiomyopathy: dilated cardiomyopathy secondary tounclear mechanism (direct toxic effect leading to destructionof myoﬁbrils, interstitial ﬁbrosis, myocardial dilation &heartfailure suggested)\\n■Acute aortic dissection\\n■Left ventricular hypertrophy\\n■Infective endocarditis (among IV users)\\n■Pulmonary: pulmonary edema, infarction & hemoptysis, dif-fuse alveolar damage & bronchiolitis obliterans w/ organizing'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 61}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\nCocaine Toxicity Congestive Heart Failure 47\\npneumonia (BOOP); crack cocaine is associated w/ “cracklung”: diffuse alveolar inﬁltrates, eosinophilia & fever\\nhematologic\\nN/A\\nmetabolic/nutritional\\nN/A\\ngastrointestinal\\n■Mesenteric ischemia & infarction\\nneuropsychiatric\\n■Stroke: increased risk secondary to vasospasm, thrombus for-mation, vasculitis\\n■Combative behavior\\n■Altered pain perception\\nCONGESTIVE HEART FAILURE\\nMUHAMMED ITANI, MD, AND JONATHAN T. KETZLER, MD\\noverview\\n■Affects 1% of adults in the USA\\n■Mortality rate is about 40% during ﬁrst 4 years after diagnosis.\\n■Causes\\n➣ Cardiac valvular abnormalities\\n➣ Impaired myocardial contractility secondary to ischemiaor cardiomyopathy\\n➣ Systemic hypertension\\n➣ Pulmonary hypertension\\nﬂuids and electrolytes\\n■Hyponatremia may occur.\\n■Hypokalemia is common in diuretic-treated pts.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 62}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\n48 Congestive Heart Failure\\n■Salt restriction & diuretics often administered\\n■ACE inhibitors & aldosterone inhibitors such as spironolac-tone may induce hyperkalemia.\\ncardiopulmonary\\n■Systolic dysfunction\\n➣ Systolic wall motion abnormalities, localized w/ CAD,global w/ cardiomyopathy\\n➣ Ventricular dysrhythmias common\\n➣ Chronic hypertension produces pressure overload; valvu-lar regurgitation may produce volume overload.\\n➣ Hallmark: reduced LV EF (reﬂects severity of disease; mea-sured w/ echocardiography, ventriculogram or radionu-clide scanning)\\n➣ LV dysfunction implies EF <45% w/ or w/out symptoms\\n■Diastolic dysfunction\\n➣ Age-dependent (<15% of pts <45 yrs, 35% of pts >65 yrs)\\n➣ Hallmark: impaired ventricular relaxation\\n➣ May have symptoms w/ normal systolic function\\n➣ Higher ﬁlling pressures are required, which reﬂect back onthe pulmonary system, causing pulmonary congestion &pulmonary edema depending on severity.\\n➣ Most common causes: ischemic heart disease, aortic valvestenosis, chronic essential hypertension\\n➣ Affects women >men\\n■Resting cardiac output may be normal but may not increase w/exercise; eventually resting cardiac output becomes abnormaltoo (<2.5 L/min/m\\n2).\\n■Increased arteriovenous O 2content difference due to inc-\\nreased O 2extraction\\n■Pts may have concentric LV hypertrophy (w/ pressure over-load) or eccentric LV hypertrophy (w/ volume overload); even-tually LV will dilate & both systolic & diastolic dysfunction maycoexist.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 63}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\nCongestive Heart Failure 49\\n■Beta-receptor density is decreased in cardiac muscles in CHF& there is a decrease in response to beta agonists.\\n■Catecholamines are depleted in cardiac muscles & contractil-ity is reduced.\\n■Stroke volume is relatively ﬁxed; cardiac output can beincreased only by increasing heart rate.\\n■Sympathetic nervous system overactivation causes arteriolar& venous constriction; therefore, BP is maintained & volumeis shifted centrally toward the heart & brain.\\n■LV end-diastolic pressure (LVEDP) is elevated (normal: 12 mmHg) due to increased LV stiffness & LV end-diastolic volume.\\n■LVEDP can be approximated from LA pressure in absence ofmitral valve disease & from pulmonary artery diastolic pres-sure in absence of pulmonary artery disease.\\n■Increased LA pressure can be seen on EKG as P wave >0.1 sec\\n& M-shaped conﬁguration lead II\\n■Pulmonary edema is the ultimate manifestation of CHF.\\n➣ Signs & symptoms: tachycardia, hypertension\\n➣ PCWP >30 mm Hg\\n➣ Ratio of colloid osmotic pressure of edema ﬂuid/plasma<0.6\\nhematologic\\n■Anemia not uncommon in advanced CHF\\n■Correction of anemia associated w/ improved survival\\nmetabolic-nutritional\\n■Catecholamine depletion in the cardiac muscles w/ dec-reased contractility; urinary catecholamines are increasedin CHF\\n■Renal blood ﬂow is reduced, so renal tubular sodium & waterretention increases to increase blood volume & maintain anadequate cardiac output; this can cause worsening of CHF &should be treated w/ vasodilators & ACE inhibitors. Prerenalazotemia is seen as BUN/CR >20.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 64}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\n50 Congestive Heart Failure Cor Pulmonale and RHF\\n■Atrial natriuretic peptide production is reduced.\\n■Aldosterone release is suppressed & ADH release is increased.\\ngastrointestinal\\n■Liver congestion & enlargement w/ right heart failure\\n■Manifests as RUQ pain w/ rapid engorgement\\n■May have moderate to severe liver function test changesdepending on severity\\n■Ascites: late ﬁnding, may happen secondary to liver dysfunc-tion, constrictive pericarditis or tricuspid stenosis\\nneuropsychiatric\\n■Decreased cerebral blood ﬂow w/ severe CHF leads to confu-sion & somnolence.\\n■In the setting of atrial ﬁbrillation, LA clotting & cerebralembolization w/ ischemic stroke may occur.\\n■Overactivation of sympathetic nervous system to maintainsystemic BP\\nCOR PULMONALE AND RHF\\nMUHAMMED ITANI, MD, AND JONATHAN T. KETZLER, MD\\noverview\\n■Cor pulmonale: right ventricular (RV) enlargement secondaryto pulmonary hypertension\\n■Third most common cardiac disorder in persons >50 yrs\\n■Male:female =5:1\\n■Exhibited in 10–30% of hospitalized pts w/ CHF\\n■COPD is the most common cause.\\n■COPD causes pulmonary capillary loss & arterial hypoxemialeading to pulmonary vasoconstriction. If hypoxemia is sus-tained, pulmonary medial hypertrophy occurs, leading to irre-versible pulmonary hypertension.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 65}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\nCor Pulmonale and RHF 51\\n■Systemic acidosis causes a synergistic effect w/ arterial hypox-emia on pulmonary vasoconstriction.\\n■Prognosis directly dependent on severity of pulmonary dis-ease\\n■Other cause of right heart failure: primary pulmonary hyper-tension\\nﬂuids and electrolytes\\n■RV overload is usually treated w/ diuretics.\\n■Electrolyte disturbances may occur secondary to diuretictherapy.\\n■Avoid excessive ﬂuid administration. If needed, measure RVpressures using central venous line.\\n■In case of biventricular failure, a PA catheter may be needed.\\n■With isolated RV failure, PCWP is usually in normal range.\\ncardiopulmonary\\n■RV impairment may be acute (eg, pulmonary embolism) orprogressive (eg, pulmonary hypertension w/ COPD).\\n■Criteria for pulmonary hypertension: mean PA pressure >\\n20 mm Hg (normal upper limit 16 mm Hg), w/ normal PCWP(normal upper limit 12 mm Hg)\\n■Severity of pulmonary hypertension indicated by gradientbtwn pulmonary artery diastolic pressure & PCWP\\n■Signs & symptoms\\n■Loud P component of S2 & diastolic murmur due to pul-monary valve incompetence\\n■Prominent A wave of RA pressure wave\\n■Tricuspid regurgitation on Doppler echo\\n■Jugular venous distention in overt RV failure\\n■May have LV dysfunction due to concurrent CAD\\n■Mean PA pressure >35 mm Hg is moderate pulmonary hyper-\\ntension.\\n■RV failure in COPD is exacerbated by pulmonary infection.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 66}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\n52 Cor Pulmonale and RHF\\n■Treatment goal is to return PaO 2, PaCO 2& pH toward normal.\\nCor pulmonale is more responsive to treatment w/ COPD &less responsive if the cause of pulmonary hypertension is irre-versible vascular smooth muscle hypertrophy.\\nhematologic\\n■Erythrocytosis (secondary to chronic hypoxemia) increasesblood viscosity.\\n■Erythrocytosis & thrombocytosis increase viscosity, potentialfor spontaneous clotting.\\n■Increased potential for spontaneous pulmonary thrombusformation & pulmonary embolism\\n■Diuretics may increase blood viscosity & worsen situation.\\n■Long-term anticoagulation essential w/ warfarin & similarmeds, in addition to antiplatelet meds\\nmetabolic-nutritional\\n■COPD: Respiratory acidosis due to CO 2retention\\n■COPD: Arterial hypoxemia due to pulmonary capillarydestruction\\n■Diuretics may produce metabolic alkalosis & aggravate ven-tilatory insufﬁciency by decreasing the efﬁcacy of CO\\n2as a\\nrespiratory stimulant.\\n■Electrolyte disturbances (especially K+) may occur due to\\ndiuretic therapy.\\n■10% of pts w/ pulmonary hypertension (usually females)report symptoms of Raynaud’s phenomenon.\\n■Low plasma proteins are seen in pts w/ liver failure.\\ngastrointestinal\\n■Congestive hepatopathy may develop due to elevated right-sided pressures.\\n■Portal hypertension may develop, leading to hypersplenism& thrombocytopenia.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 67}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\nCor Pulmonale and RHF Diabetes Mellitus and Diabetic Emergencies 53\\n■Esophageal varices & esophageal bleeding may develop as aconsequence.\\n■Liver failure: ascites & increased risk of spontaneous bacterialperitonitis\\nneuropsychiatric\\n■Medullary respiratory center becomes less sensitive to CO 2\\n(increased levels required to maintain ventilatory drive).\\n■Hepatic encephalopathy (w/ liver failure)\\n■Spontaneous thrombosis may occur in small terminal vessels& induce multiple infarcts.\\nDIABETES MELLITUS AND DIABETIC EMERGENCIES\\nDOUGLAS B. COURSIN, MD\\noverview\\n■Etiology\\n➣ Disease of dysregulation of glucose metabolism related toinsulin deﬁciency, resistance and/or abnormal gluconeo-genesis\\n■Most common endocrinopathy\\n■Type 1 DM affects 0.4% of population\\n➣ Most often autoimmune\\n➣ Usually develops in childhood or adolescence\\n➣ May ﬁrst present in diabetic ketoacidosis (DKA)\\n➣ Absolute deﬁciency of insulin, therefore obligate need forinsulin\\n■Type 2 DM affects 8–10% of population (25–35 million Amer-icans)\\n➣ Usually older, inactive & overweight\\nrIncreasingly developing in younger adults; some maybe active & ﬁt\\nrSome appear to be genetically linked'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 68}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\n54 Diabetes Mellitus and Diabetic Emergencies\\n➣ Produce insulin, so need for insulin supplementation isindividualized\\n➣ May be treated w/ diet, oral hypoglycemic agents, insulinor any combination of these\\nrStress hormone response may necessitate ﬁrst-timeneed for insulin.\\n➣ 1/3 to 1/2 of type 2 pts do not know they are diabetic atthe time of surgery.\\n➣ Major acute diabetic-related complications\\nrHypoglycemia\\nrHyperglycemia\\nrDKA\\nrNonketotic hyperosmolar state\\n➣ Major chronic diabetic-related complications\\nrVascular disease\\nrCerebrovascular\\nrCoronary\\nrHypertension\\nrPeripheral vascular\\nrCardiac compromise\\nrRenal insufﬁciency/failure\\nrAutonomic & peripheral neuropathy\\nrRetinopathy\\nrConnective tissue abnormalities\\nrStiff joint syndrome\\nrIncreased infectious risk\\nﬂuid and electrolytes\\n■Risk for hypovolemia secondary to glucosuria\\n➣ Key is to reduce serum glucose to less than renal thresholdfor reabsorption (<180 mg/dL).\\n➣ Marked hypovolemia in pts w/ DKA (type 1 diabetics) ornonketotic hyperosmolar state (type 2 diabetics)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 69}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\nDiabetes Mellitus and Diabetic Emergencies 55\\n■Infuse glucose judiciously to avoid hypoglycemia after insulinis administered & to avoid excessive hyperglycemia.\\n■Type 1 DM obligate need for insulin\\n➣ Lack of insulin leads to hyperglycemia w/ dehydration.\\n➣ Conversion to lipid metabolism results in ketogenesis &ketoacidosis.\\nrMetabolic acidosis results in movement of potassiumout of cell to correct acidosis & serum hyperkalemia.However, total body potassium is low because of urinarylosses.\\n➣ DKA frequently results in hypomagnesemia & hypophos-phatemia.\\n➣ Pts may become signiﬁcantly hypovolemic; volume resus-citation a key to initial treatment of DKA.\\n■Various electrolyte abnormalities are common in diabetics.These are related to volume status, acid-base & metabolicderangements & baseline or evolving renal dysfunction. Sincerenal insufﬁciency is so common in diabetes, seek hyper-kalemia.\\n➣ Magnesium wasting common in advanced diabeticnephropathy\\ncardiopulmonary\\n■Increased risk of coronary artery disease, hypertension, CHF,systolic & diastolic dysfunction\\n➣ Coronary disease is the most common cause of death indiabetics.\\n➣ Coronary disease may be asymptomatic because ofautonomic neuropathy; therefore, “silent ischemia” is arisk.\\n➣ Use of ACE inhibitors may slow progression of cardiac &renal disease in diabetics; therefore, they are increasinglyused chronically.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 70}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\n56 Diabetes Mellitus and Diabetic Emergencies\\nrMany advocate holding ACE inhibitors on the day ofsurgery because of concerns over hypotension that maybe refractory to vasopressors such as ephedrine.\\n➣ Beta blockers are underused in high-risk diabetic pts,those with prior MI or known ischemia or thoseundergoing major surgeries such as vascular & thoracicprocedures.\\nrMonitor for neuroglycopenic sequelae while on betablockers.\\nrContraindications are those that are common to non-diabetics.\\n➣ Diastolic dysfunction is usually treated with beta blocker,calcium channel blocker or ACE inhibitor.\\nhematologic\\n■Increased incidence of chronic anemia, especially renal insuf-ﬁciency\\n■Chronic renal-insufﬁcient diabetic at increased risk of coag-ulopathy & platelet dysfunction\\nmetabolic-nutritional\\n■Type 1 diabetics have an obligate need for insulin.\\n■Type 2 pts may or may not need insulin or insulin combinedw/ oral agents.\\n■Type 2 pts who are controlled w/ diet or oral agents mayrequire insulin intraoperatively or perioperatively because ofstress hormone response & insulin resistance & excessive glu-coneogenesis or withdrawal of oral agent control.\\n■Hemoglobin A-1-c allows a look back at how well controlledthe diabetic has been over the past 6 or so wks.\\n■Diabetics are at increased risk for additional endocrine dys-function.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 71}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\nDiabetes Mellitus and Diabetic Emergencies 57\\ngastrointestinal\\n■Progressive renal compromise develops commonly in type 1and type 2 DM.\\n■Evaluate w/ urinalysis to identify proteinuria, the ﬁrst signof diabetic nephropathy & bacteria, since bacteruria may beasymptomatic.\\n➣ Degree of albuminuria correlates w/ risk for cardiovascu-lar & renal disease.\\n■Pts w/ elevated creatinine have increased risk of furtherpostop renal compromise or failure.\\n➣ Particularly elderly undergoing cardiac or vascular surgery\\n➣ Use of renal protectants variably successful\\n➣ Must maintain adequate ﬂuid replacement & intravascu-lar volume\\n➣ No role for prophylactic dopamine\\n➣ N-acetyl-cysteine (NAC) for high-risk pts (creatinine>1.5–2.0 mg/dL) undergoing a contrast study such as a\\ncardiac cath, CT; 600 mg bid NAC day of contrast study\\n■Lower insulin requirements w/ increasing renal insufﬁciency.If creatinine clearance is 10–50 cc/min, cut insulin in half; if<10 cc/min, lower to 25–50% of normal.\\n➣ Gastroparesis is common in pts w/ autonomic neuropa-thy.\\nrMay have malabsorption process as well\\nrTherefore may be at risk for aspiration. Balance factw/ airway assessment and presence of stiff joint syn-drome.\\nneuropsychiatric\\n■Increased incidence of depression\\n■Mood & personality swings may be related to swings inglucose; must rule out & treat hypoglycemia. Identify signiﬁ-cant hyperglycemia ( >250 mg/dL), ketoacidosis.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 72}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\n58 Epilepsy\\nEPILEPSY\\nGEBHARD WAGENER, MD\\noverview\\n■10% of the population has a seizure at one point in their life.\\n■Simple partial seizures: 1 system involved, no loss of con-sciousness\\n■Complex partial seizures: >1 system, loss of consciousness\\npossible\\n■Generalized seizures: always w/ loss of consciousness; eitherconvulsive or nonconvulsive\\nﬂuids and electrolytes\\n■Usually unremarkable\\n■Hyponatremia & hypoglycemia may cause seizures.\\n■Carbamazepine can cause water retention & hyponatremia.\\ncardiopulmonary\\n■Usually unremarkable\\nhematologic\\n■Felbamate: aplastic anemia\\n■Valproic acid: thrombocytopenia, hypoﬁbrinogenemia &dose-related leukopenia\\nmetabolic-nutritional\\n■Folate deﬁciency: phenytoin\\ngastrointestinal\\n■Unremarkable\\nneuropsychiatric\\n■Sedation, dyskinesias, ataxia w/ all anti-epileptics'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 73}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\nGeriatric Patient 59\\nGERIATRIC PATIENT\\nHUGH R. PLAYFORD, MD\\noverview\\nN/A\\nﬂuids and electrolytes\\n■Progressive decline in renal function w/ age\\n➣ Vulnerable to ﬂuid overload\\n➣ Prone to accumulation of drugs/toxins dependent onrenal metabolism/excretion\\n■Decreased renal blood ﬂow, decreased glomerular ﬁltrationrate (both parallel decline in cardiac output)\\n■Serum creatinine often normal or low even in the presence ofsigniﬁcant renal dysfunction (less muscle mass & turnover w/aging)\\n■Decreased urinary concentrating ability\\n➣ Decreased ability to retain sodium or ﬂuids if hypovolemic\\n➣ Prone to hyponatremia\\n➣ Decreased ability to excrete acid urine\\ncardiopulmonary\\n■Decreased responsiveness of autonomic nervous system\\n■Decreased cardiac output (preserved w/ physical ﬁtness)\\n■Decreased oxygen requirements\\n■Resting stroke volume largely unchanged\\n■Less chronotropic & inotropic responsiveness to stress & cat-echolamines\\n■Decreased heart rate in general (increased parasympatheticactivity, degenerative changes to sinus node and/or cardiaccontractility)\\n■Congestive heart failure common (hypertension, ischemicheart disease)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 74}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\n60 Geriatric Patient\\n■Hypertension common (decreased compliance of blood ves-sels, renovascular causes)\\n➣ Increased systolic & diastolic BP\\n■General decline in ventilatory function & gas exchange\\n■Impaired ventilation\\n➣ Decreased lung elasticity (destruction of pulmonaryparenchyma), decreased thoracic compliance (calciﬁca-tion of costochondral cartilages)\\n➣ Dorsal kyphosis, increased anterior-to-posterior diame-ter, decreased chest expansion\\n➣ Increased residual volume, increased functional residualcapacity\\n➣ Decreased vital capacity, decreased FEV1\\n■Progressive hypoxemia w/ age (airway closure, decreased car-diac output w/ increased ventilation-perfusion matching)\\nhematologic\\nN/A\\nmetabolic-nutritional\\n■Increased incidence of diabetes mellitus (decreased insulinrelease, insensitivity of receptor to insulin)\\n■Hypothyroidism (esp. subclinical) common, up to 13% ofelderly (esp. females)\\n■Frequent association w/ arthritis (rheumatoid & osteoarthri-tis)\\ngastrointestinal\\n■Decreased hepatic blood ﬂow (parallels the decline in cardiacoutput)\\n➣ Alters clearance of drugs dependent on hepatic elimina-tion\\n■Decreased gastric emptying\\nneuropsychiatric\\n■Progressive decline in CNS activity\\n■Progressive loss of neurons, esp. in cerebral cortex'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 75}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\nGeriatric Patient GI Disease 61\\n■Decline in conduction velocity of peripheral nerves\\n■Possible decreased number of ﬁbers in spinal cord tracts\\n■Implication: decreased dosing requirements of injected &inhaled anesthetic agents\\n■Altered patterns of sleep (decreased slow-wave stage 4)\\n➣ More time in bed, less time asleep, relatively easily aroused\\n➣ Daytime fatigue\\n➣ Poor tolerance of changes in sleep-wake cycle\\n➣ Prone to sleep apnea (related to obstruction, depressantdrugs, CNS deterioration)\\n■Prone to delirium\\n➣ Pathology (eg, myocardial infarction, infection) or phar-macology\\n➣ Sudden onset, ﬂuctuating course over 24 hrs w/ noctur-nal exacerbation, decreased consciousness, globally dis-ordered attention, common hallucinations, impaired ori-entation, unpredictable psychomotor activity, frequentlyincoherent speech, often related to physical illness or drugtoxicity\\n➣ Needs to be distinguished from dementia (insidious onset,stable course over 24 hrs, no change in level of con-sciousness, usually normal attention, uncommon halluci-nations, impaired orientation, usually normal psychomo-tor activity, difﬁculty ﬁnding words, uncommonly relatedto physical illness or drug toxicity)\\nGI DISEASE\\nGEBHARD WAGENER, MD\\noverview\\nUpper GI diseases\\n■Hiatal hernia\\n■Achalasia'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 76}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\n62 GI Disease\\n■Esophagitis\\n■Esophageal infections: Candida\\n■Gastrinoma\\n■Gastric ulcer\\n■Gastric carcinoma\\n■Pyloric stenosis: pediatrics\\n■Duodenal ulcer\\nLower GI diseases\\n■Small bowel obstruction\\n■Irritable bowel disease\\n■Carcinoid\\n■Ulcerative colitis\\n■Crohn’s disease\\n■Pseudomembranous colitis\\n■Diverticulitis\\n■Appendicitis\\n■Colonic obstruction\\n■Colon carcinoma\\nOthers\\n■Malabsorption: small bowel\\n■Maldigestion: pancreas\\n■Pancreatitis\\nPatients receiving long-term steroid treatment for ulcerative\\ncolitis (less common for Crohn’s disease) may develop osteo-porosis.\\nOsteomalacia & osteoporosis are common after gastrojejunos-\\ntomy (Billroth II) or total gastrectomy: Vitamin D & calcium mal-absorption.\\nﬂuids and electrolytes\\n■Inadequate intake\\n➣ Dehydration\\n■Vomiting, gastric ﬁstula or aspiration'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 77}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\nGI Disease 63\\n➣ Hypochloremic metabolic alkalosis\\n➣ Hypokalemia: GI loss & increased renal secretion as aresponse to alkalosis\\n➣ Dehydration\\n■Bowel obstruction (severe disturbances more common w/small bowel obstruction):\\n➣ Dehydration (ﬂuid sequestered into bowel wall)\\n➣ Hypokalemia\\n➣ Possible lactic acidosis in bowel ischemia or perforation(hyperkalemic)\\n■Diarrhea\\n➣ Hypochloremic, non-anion gap acidosis\\n➣ Hypokalemia\\n➣ Dehydration\\n■Bowel preparation for colon surgery\\n➣ Dehydration & metabolic alkalosis\\n■Pancreatitis\\n➣ Lactic acidosis, hypocalcemia, dehydration, sepsis\\ncardiopulmonary\\n■Dehydration common in most diseases: tachycardia,hypotension, hyperdynamic state\\n■Hypokalemia common: causing cardiac hyperpolarization,conduction delays, re-entry & ectopic tachycardia\\n■Carcinoid\\n➣ Serotonin, kinins & histamine release: vasoconstriction orvasodilation\\n➣ Cardiac (mostly right ventricular & tricuspid valve) ﬁbri-nous plaques\\n➣ Bronchoconstriction\\n■Pancreatitis\\n➣ ARDS\\n➣ Right pleural effusion\\n■Increased intra-abdominal pressure'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 78}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\n64 GI Disease\\n➣ Decreased functional residual capacity\\n➣ Increased airway pressure w/ positive-pressure ventila-tion\\n➣ Hypoxia\\nhematologic\\n■Anemia\\n➣ Iron deﬁciency: w/ chronic bleeding ulcer, colonic polypsor tumors\\n➣ Vitamin B12 (cobalamin) deﬁciency anemia: megalo-blastic: w/ pernicious anemia, sprue or after resection ofterminal ileum or gastrectomy\\n■Leukocytosis w/ left shift\\n➣ Perforation, strangulation, diverticulitis\\nmetabolic-nutritional\\n■Malnutrition common w/ any chronic GI diseases\\n■Vitamin deﬁciency: A, B, E, K,B12\\n■Malabsorption (small bowel diseases): weight loss, vitamindeﬁciency, less steatorrhea\\n■Maldigestion (pancreatic diseases): marked steatorrhea\\n■Diabetes: diarrhea, steatorrhea, mobility disorder, gastro-paresis\\n■Pts often receive total parenteral nutrition (TPN): sudden ces-sation of TPN (eg, intraop) can cause marked hypoglycemia:always give glucose-containing infusion & measure blood glu-cose frequently when stopping TPN.\\ngastrointestinal\\n■Motility disorders\\n➣ Achalasia\\n➣ Diabetic gastroparesis\\n➣ Acute pseudo-obstruction (Ogilvie)\\n■Obstruction\\n➣ Small bowel obstruction: adhesion, tumor'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 79}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\nGI Disease Hemoglobinopathies 65\\n➣ Large bowel obstruction: volvulus, tumor, ischemic colitis,pseudomembranous colitis (Clostridium difﬁcile)\\n➣ Acute intestinal ischemia\\n■Infectious/Inﬂammatory\\n➣ Perforation\\n➣ Appendicitis\\n➣ Diverticulitis\\n➣ Pancreatitis\\n➣ Inﬂammatory bowel disease\\n■Hemorrhagic\\n➣ Gastric ulcer\\n➣ Gastric cancer\\n➣ Duodenal ulcer\\n➣ Colon carcinoma\\n➣ Trauma\\n■Malabsorption\\n➣ Inﬂammatory bowel disease\\n➣ Sprue\\nneuropsychiatric\\n■Stress can cause ﬂare up of inﬂammatory bowel disease.\\n■Chronic GI disease can lead to anger, shame, depression.\\nHEMOGLOBINOPATHIES\\nDOUGLAS B. COURSIN, MD, AND KARL WILLMANN, MD\\noverview\\n■Anemia secondary to abnormal hemoglobin ( >300 variants)\\n➣ Sickle cell disease\\nrInherited hemoglobinopathy\\nrWide range of symptoms & severity\\nrHomozygotes (SS): sickle cell disease; heterozygotes(SA), sickle cell trait\\nrSickle cell thalassemia (SC)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 80}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\nHemoglobinopathies 67\\nrAcidosis\\nrHypotension\\nrHypoxemia\\nrSupportive care advised even for those w/ SA or trait\\nrAdequate hydration\\nrJudicious consideration of transfusion therapy asneeded to decrease hemoglobin S level to <30%; not\\nroutinely advocated since it does not necessarilyimprove outcome\\nrAim to maintain Hct at least 30.\\nrSome receive hydroxyurea.\\nrSome younger pts w/ extreme symptoms may ben-eﬁt from bone marrow transplantation.\\nrPerioperative\\nrEarly evaluation & in some cases admission to tuneup\\nrHydrate\\nrTransfuse as needed if Hct <30 & if symptoms w/\\nvery high Hgb S level\\nrSupplemental O\\n2\\nrAvoid respiratory depression & respiratory acido-sis.\\nrAvoid circulatory deﬁciency & stasis.\\nrMaintain intravascular volume, normothermia,normal acid-base balance, oxygenation.\\nrTourniquets reported by some to be safe to usewhen indicated\\nrNo evidence that one anesthetic agent or techniqueis better than another\\nrPostop maneuvers to maintain oxygenation, avoidacidosis, treat pain\\n➣ Thalassemia\\nrRepresents a number of inherited abnormalities inhemoglobin synthesis & structure'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 81}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\n68 Hemoglobinopathies\\nrMajor & minor\\nrAffects those of Mediterranean/Middle Eastern/Indian subcontinent descent most commonly\\nrMost common hemoglobinopathy\\nrBeta-thalassemia major (Cooley’s anemia) (severe)\\nrRare\\nrUnable to form beta-globin chain of hemoglobin;therefore, adult hemoglobin A is not formed\\nrComplex process w/ excessive hemoglobin syn-thesis, multiple complications including jaundice,hepatosplenomegaly & risk of infection\\nrHemochromatosis\\nrBeta-thalassemia minor\\nrHeterozygote (trait) state of thalassemia comparedto homozygote thalassemia major\\nrMore common than previously appreciated & farmore common than thalassemia major\\nrAlpha-thalassemia\\nrLack production of alpha chain of hemoglobin\\nrHomozygote, uniformly lethal in utero or asneonate\\nrHeterozygote (trait)\\nrMild anemia, usually microcytic & hypochromic\\nrOccasional pts have signiﬁcant hemolysis & mayneed splenectomy.\\nrOccasionally require transfusion therapy\\nrSickle thalassemia disease\\nrUsually less severe than SS disease or thalassemiamajor but more symptomatic than SA (trait)\\nrAnemia mild: Hgb 10–12 g/dL\\nrStill at risk for veno-occlusive crises\\nrAnesthetic priorities in thalassemia\\nrDepend on severity of disease\\nrIf pt is transfusion-dependent, evaluate heart & liverfunction carefully because of potential iron toxicity.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 82}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\nHemoglobinopathies 69\\nrExtramedullary hematopoiesis may cause enlargedfacial bones, resulting in difﬁcult airway mgt &laryngoscopy.\\n■Anemia secondary to enzyme abnormalities\\n➣ G6PD\\nrAffects 10% of African Americans, mainly males\\nrWide variation in enzyme function\\nrChronic hemolysis\\nrDrugs that form peroxides by interacting w/ oxyhe-moglobin may trigger.\\nrMay lead to DIC\\nrAnesthetic agents do not trigger.\\nrMain concerns over antibiotics (sulfa, PCN, INH,nitrofurantoins, antimalarials), also acetaminophen,methylene blue, possibly nitroprusside & others\\nFor a more complete listing, see a standard hematology or phar-macology text.\\nﬂuid and electrolytes\\nN/A\\ncardiopulmonary\\nN/A\\nhematologic\\nN/A\\nmetabolic/nutritional\\nN/A\\ngastrointestinal\\nN/A\\nneuropsychiatric\\nN/A'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 83}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\n70 HemophiliaA&H emophilia B\\nHEMOPHILIA A & HEMOPHILIA B\\nKARL WILLMANN, MD, AND D. B. COURSIN, MD\\noverview\\n■Both Hemophilia A & B are X-linked recessive disorders ofcoagulation. Hemophilia A is a deﬁcit of factor VIII or defec-tive factor VIII. Hemophilia B is either a deﬁciency or non-functional factor IX. In both diseases, severity depends on thelevel of circulating functional factors.\\n■Hemophilia A & B\\n➣ Mild: 5–25% normal factor VIII/IX levels\\n➣ Moderate: 1–4% normal factor VIII/IX levels\\n➣ S e v e r e :0t o<1% normal factor VIII/IX levels\\n■Severe disease can result in hemarthroses, usually of the largerjoints (knee, hip, shoulder, elbow & ankles). There is usuallyno excessive bleeding w/ minor cuts. Severe disease can alsocause muscle hemorrhages & easy bruising. Pts can also havelife-threatening intracranial hemorrhage\\n■Hemophilia A occurs in 1/10,000 male infants.\\n■Hemophilia B occurs in 1/25,000–50,000 male infants.\\n■Goals for anesthesia are to increase deﬁcient factors to highenough levels to prevent excessive bleeding both intraop &postop.\\nﬂuid & electrolytes\\n■No special concerns\\ncardiopulmonary\\n■No special concerns\\nhematologic\\n■Deﬁcient or defective clotting factors, causing coagulopathy.Pts have normal platelet & PT but prolonged PTT. One cannot'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 84}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\nHemophiliaA&H e mophilia B Herbal Therapy 71\\ndistinguish between hemophilia A&Be x cept by factor analy-\\nsis. Pts w/ mild disease may not be recognized until surgery ortrauma. History of excessive bleeding w/ dental work, heavymenses, epistaxis & lacerations w/ elevated PTT warrant fur-ther evaluation for possible hemophilia.\\nmetabolic-nutritional\\nN/A\\ngastrointestinal\\n■Pts who have required blood transfusion & factor therapy inthe past are at risk for HIV & hepatitis B & C infections & thesequelae of those diseases.\\n■Pts can have GI bleeds.\\n■Pts may have hematuria & obstructive symptoms w/ renaldysfunction.\\n■Follow Bun/Cr/urinalysis.\\nneuropsychiatric\\n■Pts may have chronic pain & narcotic dependency afterrepeated joint hemarthroses.\\n■Pts are also at risk for spontaneous intracranial hemorrhage.\\nHERBAL THERAPY\\nJONATHAN T. KETZLER, MD\\noverview\\n■Herbal medications are biochemically active compounds thatmay interact w/ drugs used by anesthesiologists.\\n■Herbal remedies are not subject to testing by the FDA.\\n■Lack of herbal standardization makes deﬁnitive diagnosis ofherb-anesthesia interaction difﬁcult.\\n■American public spends $5 billion on alternative medicine.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 85}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\n72 Herbal Therapy HIV & AIDS\\n■Compounds are used to ﬁght depression, raise energy levels& improve memory.\\n■While 22% of pts take herbal meds, only 7 out of 10 tell theirdoctors.\\n■ASA advises pts to stop herbal meds 2 wks prior to surgery.\\n■ASA advises pts who continue to take herbal meds to bring thebottle to surgery.\\nﬂuid & electrolytes\\nN/A\\ncardiopulmonary\\nN/A\\nhematologic\\nN/A\\nmetabolic/nutritional\\nN/A\\ngastrointestinal\\nN/A\\nneuropsychiatric\\nN/A\\nHIV & AIDS\\nGEBHARD WAGENER, MD\\noverview\\nN/A\\nﬂuids and electrolytes\\n■No special care unless diarrhea, vomiting: hypochloremicalkalosis'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 86}, page_content='P1: SBT0521759385p2-B CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:27\\nHIV & AIDS 73\\n■Nephropathy w/ proteinuria possible\\ncardiopulmonary\\n■Pulmonary: PCP pneumonia, lung abscess, TB, bacterialpneumonias (Pseudomonas, streptococcal pneumonia)\\n■Cardiac\\n➣ Myocarditis (toxoplasmosis, Cryptosporidiae, CMV, Cox-sackie B virus)\\n➣ Pericardial effusion common (25%)\\n➣ Abnormal echocardiogram in 50% of pts w/ AIDS\\n➣ Endocarditis, left ventricular dysfunction\\nhematologic\\n■Neutropenia, immunosuppression\\n■Anemia\\n■Thrombocytopenia\\nmetabolic-nutritional\\nOften malnutrition: AIDS wasting syndrome\\ngastrointestinal\\n■Diarrhea, nausea, vomiting common\\n■GI infections: CMV, Herpes, Candida\\nneuropsychiatric\\n■AIDS dementia: increased sensitivity to benzodiazepines,opioids\\n■Neoplasm & infections common: Cryptosporidiae, toxoplas-mosis, progressive multifocal leukoencephalopathy: incr-eased ICP possible\\n■More likely to develop extrapyramidal symptoms from neu-roleptics\\n■Polyneuropathy: distal & symmetric'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 87}, page_content='P1: SBT0521759385p2-C CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:48\\n74 Hypertension\\nHYPERTENSION\\nMUHAMMED ITANI, MD, AND JONATHAN T. KETZLER, MD\\noverview\\n■Deﬁnition: systemic BP >140/90 on 3 separate measurements\\n■Essential hypertension accounts for >95% of pts.\\n■Secondary hypertension accounts for <5%; causes:\\n➣ Oral contraceptive pills: most common cause in females\\n➣ Excessive alcohol consumption: most common cause inmales\\n➣ Renovascular hypertension: most common secondaryhypertension overall\\n➣ Pheochromocytoma\\n➣ Cushing’s disease\\n➣ Conn’s syndrome\\n➣ Aortic coarctation\\n➣ Hyperthyroidism\\n■Hypertension is the most important risk factor for cerebralstroke.\\n■CAD is the most common cause of death in untreated hyper-tension.\\n■Hypertension is the major cause of congestive heart failure,arterial aneurysms & end-stage renal disease.\\n■Hypertensive crisis: acute diastolic BP increase above 130 mmHg; the urgency for treatment is deﬁned by the rate of BPincrease\\n■Hypertension is common in diabetics & highly associated w/diabetic nephropathy.\\nﬂuids and electrolytes\\n■Hypertensive pts tend to be hypovolemic due to:\\n➣ Vascular constriction & compensated decreased intravas-cular volume'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 88}, page_content='P1: SBT0521759385p2-C CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:48\\nHypertension 75\\n➣ Diuretic-induced intravascular ﬂuid depletion\\n■Conn’s disease: may have hypernatremia & hypokalemia\\n■May have hyperkalemia w/ ACE inhibitor therapy & hypo-kalemia w/ diuretic therapy (except w/ spironolactone), butno increased risk for cardiac arrhythmias is seen\\ncardiopulmonary\\n■Hypertension can be caused by obstructive sleep apnea; 30%of older or obese pts have sleep-disordered breathing.\\n■Renovascular disease: upper abdominal bruit may be present;can conﬁrm diagnosis by MRA\\n■Concentric cardiac hypertrophy & LV wall thickening\\n■Diastolic dysfunction of varying degrees depends on the sever-ity & chronicity of BP elevation; eventually both systolic &diastolic dysfunction may take place.\\n■LV hypertrophy predisposes to myocardial ischemia & infarc-tion.\\nhematologic\\nN/A\\nmetabolic-nutritional\\n■40% of pts w/ essential hypertension have high serum choles-terol levels ( >200 mg/dL).\\n■Pts may have insulin resistance, dyslipidemia diabetes & obe-sity.\\n■50% of pts have glucose intolerance.\\n■Progressive loss of renal function occurs w/ poorly controlledhypertension.\\n■Primary hyperaldosteronism (Conn’s syndrome): hyperten-sion, hypernatremia, hypokalemia\\n■CT scan or MRI shows hyperplastic glands or adrenal glandadenoma.\\n■Pheochromocytoma is a rare cause of secondary hypertensionw/ episodic swings in BP or sustained markedly increased BP.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 89}, page_content='P1: SBT0521759385p2-C CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:48\\n76 Hypertension ICU Patient Scheduled for Intercurrent Surgery\\ngastrointestinal\\nN/A\\nneuropsychiatric\\n■History of cerebrovascular disease (carotid artery stenosis) w/subsequent stroke or TIAs\\n■Increased sympathetic nervous system tone\\n■Encephalopathy may develop in chronic hypertensives if dias-tolic BP >150 mm Hg; parturient may develop encephalopa-\\nthy at a diastolic BP <100 mm Hg.\\n■Shift of the autoregulation curve to the right; this may bereversed w/ volatile anesthetics & ACE inhibitor treatment\\nICU PATIENT SCHEDULED FOR INTERCURRENT SURGERY\\nDOUGLAS B. COURSIN, MD\\noverview\\n■Focus on type of critical illness/unit.\\n➣ Tailor pt’s needs for speciﬁc problems.\\n➣ Organ-speciﬁc\\nrCCU, Neuro, CT surg, Pediatric\\nrEmergent ops for cardiac surgery from CCU & CT surg\\nrOrgan-speciﬁc issues\\nrPacer\\nrAssist devices\\nrRecent antithrombotics/lytics/anticoagulants\\nrAnti-dysrhythmic drugs\\n➣ General\\nrMed-surg\\n■Critically ill pts commonly require anesthesia care.\\n➣rSedation/analgesic/paralytic meds\\nrPain-sparing procedures & blocks\\nrTransport'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 90}, page_content='P1: SBT0521759385p2-C CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:48\\nICU Patient Scheduled for Intercurrent Surgery 77\\nrAngiographic procedures: radiology, cath lab\\nrGeneral anesthesia in or out of OR\\nrBedside procedure\\nrProvision of inhaled anesthesia for severe reactive air-way disease\\nrWide age range\\nrDoes the procedure need to be done out of the ICU?\\nrAre there alternatives if the pt is deemed too unstable?\\nrCould the same or lesser procedure be safely per-formed in the ICU w/ adequate result?\\nrPercutaneous trach\\nrPercutaneous feeding tube placement\\nrDrainage/irrigation\\nrPreemptive care is crucial.\\nrWhat was pt’s premorbid state of health?\\nrNursing home pts may be more prone to coloniza-tion w/ resistant organisms.\\nrComorbid pathology may direct preventive modal-ities & selection of monitoring & guide prognosis.\\nrKey areas\\nrCV risk stratiﬁcation\\nrUnderlying pulmonary reserve\\nrRenal compromise\\nrHepatic reserve\\nrSynthetic function\\nrAlbumin\\nrImmune status\\nrIs pt immunocompetent?\\nrAcquired vs. inherited immunocompromise\\nrEndocrinopathy: intrinsic or acquired\\nrDiabetes mellitus\\nrAdrenal insufﬁciency\\nrPanhypopituitarism\\nrThyroid dysfunction'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 91}, page_content='P1: SBT0521759385p2-C CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:48\\n78 ICU Patient Scheduled for Intercurrent Surgery\\nrWhy is the pt in the ICU?\\nrHow long has the pt been there?\\nrReview pt’s problem list, since crucial pieces of infomay be overlooked w/out a systematic review.\\nrWhat is the mechanism of injury?\\nrTrauma vs. other\\nrOrgan system review\\nrCNS\\nrMental status\\nrBaseline neuro function, esp. in elderly, CNSinfected & those w/ neurovascular compromise,stroke, hypoperfusion, trauma\\nrWhat meds is the pt receiving that may alter men-tal status?\\nrIs the pt on anticonvulsants? Might the pt needanticonvulsants perioperatively?\\nrHow might these affect anesthesia meds, effecton paralytics?\\nrWhat is the pt’s need for ICP meds?\\nrOsmotics\\nrLoop diuretics\\nrBarbiturate therapy\\nrCV\\nrPrevious MI\\nrCardiac reserve\\nrRecent echo, invasive monitoring\\nrCHF\\nrDiastolic dysfunction\\nrHas the pt recently received antithrombotic oranticoagulant meds?\\nrBaseline rhythm\\nrSinus vs. other\\nrIntermittent rhythm\\nrRisk for atrial ﬁb'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 92}, page_content='P1: SBT0521759385p2-C CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:48\\nICU Patient Scheduled for Intercurrent Surgery 79\\nrRisk for heart block or conduction delay\\nrNeed for external or internal pacemaker\\nrPresence of pacemaker/AICD\\nrExternal\\nrInternal\\nrType & mode\\nrPlan for what to do in OR\\nrAssessment of cardiac function\\nrInvasive/noninvasive modalities\\nrUO, hemodynamics, SvO 2, gastric tonometry,\\nlactate, acid-base, etc.\\nrTherapies altering cardiac function\\nrMechanical (IABP, VAD, ECMO)\\nrPharmacological (sympathetic agonists &antagonists, vasopressors, ACE inhibitors, PDEinhibitors, etc.)\\nrPulmonary\\nrSmoker\\nrChronic disease\\nrInfectious\\nrAirway assessment (presence of an artiﬁcial air-way, difﬁculty of establishing airway [eg, facialtrauma])\\nrVentilated: invasive vs. noninvasive vs. partial,such as nighttime CPAP or BiPAP\\nrGas exchange PaO\\n2/FiO 2\\nrWill pt need a unique form of ventilatory sup-port, pressure control, oscillation, high frequency,other?\\nrIs this available in OR?\\nrPharmacological therapies\\nrSympathomimetics, anticholinergics, antimus-carinics, steroids (systemic or inhaled), antimi-crobials'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 93}, page_content='P1: SBT0521759385p2-C CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:48\\n80 ICU Patient Scheduled for Intercurrent Surgery\\nrPulmonary side effects (opioids, beta antago-nists)\\nrHepatic\\nrSynthetic function\\nrImmune function\\nrHepatitis\\nrActive\\nrOld\\nrLiver function tests\\nrHepatocellular enzymes: ALT, AST\\nrHepatic synthesis: INR, albumin\\nrCanalicular: alk phos, bilirubin, GGT\\nrRenal\\nrAdequate reserve\\nrExternal support (eg, IHD, CVVHDF, peritonealdialysis), frequency, adequacy\\nrDiuretics\\nrNephrotoxic agents\\nrFunction\\nrUrinalysis\\nrCulture\\nrCreatinine, estimated clearance\\n■Therapies requiring continuation outside the ICU need to beassessed.\\n➣ Ventilation\\n➣ Cardiovascular support\\n➣ Renal replacement therapies can often be suspendedintraoperatively.\\n➣ Anticoagulation (systemic, regional [eg, w/ dialysis])\\n➣ Antimicrobials\\n➣ Withhold activated protein C if there is a prospect of inter-ventional therapy.\\n➣ Analgesics & sedatives'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 94}, page_content='P1: SBT0521759385p2-C CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:48\\nICU Patient Scheduled for Intercurrent Surgery 81\\n➣ Nutritional support may require modiﬁcation (eg, re-placement of enteral nutrition w/ IV dextrose).\\n■Must provide level of care at least equal to ICU during trans-port & while out of ICU in OR or radiology or during outsideintervention\\n■Does pt require isolation?\\n➣ Why?\\n➣ Resistant infection\\n➣ Biologic/chemical exposure\\n➣ Other\\n■Despite our best efforts, ICU pts have signiﬁcantly higher mor-bidity & mortality than non-ICU pts.\\n➣ Discuss w/ surgeon/radiologist/cardiologist prior to pro-cedure.\\n➣ Discuss w/ family.\\n■Clarify code status.\\n➣ DNR\\n➣ Suspended during procedure\\n■Ensure adequacy of:\\n➣ Consent\\n➣ Handover from ICU staff\\n➣ Blood product availability\\n➣ Monitoring\\n➣ Therapies at destination (ventilator, number of pumps,infusions, etc.)\\nﬂuid and electrolytes\\n■Current maintenance\\n■Current need for ongoing resuscitation\\n➣ Hypovolemia\\n➣ Bleed\\n➣ Distributive shock such as sepsis\\n➣ Spinal shock'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 95}, page_content='P1: SBT0521759385p2-C CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:48\\n82 ICU Patient Scheduled for Intercurrent Surgery\\n➣ Recent burn\\n➣ Ongoing third-space losses related to open wounds, ﬁstu-lae, etc.\\n■Identify electrolyte abnormalities & current therapy.\\n➣ Hyponatremia\\nrDilutional\\nrTotal body\\nrSIADH\\nrCerebral salt-wasting process\\nrCurrent level & anticipated rate of correction\\nrTake into account what intraoperative ﬂuids will do tocorrect this & possibility of overly rapid correction.\\n➣ Hypernatremia\\nrDiabetes insipidus\\nrHypovolemia: total body salt status\\nrNeed for salt & water\\nrCalculate free water deﬁcit.\\nrTake into account what intraoperative ﬂuids will do tocorrect this & possibility of overly rapid correction.\\n➣ Hyperkalemia\\nrSpurious vs. real: hemolysis\\nrRenal function\\nrPotassium-containing solutions\\nrPotassium-sparing meds\\nrDiuretics: spironolactone\\nrACE inhibitors\\nrECG changes\\n➣ Hypokalemia\\nrECG changes\\nrClinical context\\nrDiuretics\\nrDiuresis\\nrWhat is the degree?\\nrCalculate total body deﬁcit.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 96}, page_content='P1: SBT0521759385p2-C CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:48\\nICU Patient Scheduled for Intercurrent Surgery 83\\nrHow fast do you need to correct?\\nrMonitoring\\nrECG\\nrFrequent serum potassium levels\\n➣ Hypermagnesemia\\nrRenal function\\nrExogenous administration\\n➣ Hypomagnesemia\\nrDiuretics\\nrAminoglycosides\\nrDiarrhea\\nrDiabetes\\nrOther meds\\nrRhythm\\n➣ Hyperphosphatemia\\nrRenal function\\nrCalcium\\nrCalcium ×phosphorus >75, possible metastatic depo-\\nsits of calcium phosphate\\n➣ Hypophosphatemia\\nrDegree\\nrRisk for rhabdomyolysis\\nrWeakness\\nrEtiology\\nrCOPD\\nrNutritional\\n➣ Hyperchloremia\\nrHas pt received large saline volumes & does pt have anon-anion gap acidosis?\\n➣ Hypochloremia\\nrDiuretic-induced\\nrHigh NG losses\\n➣ Hypercalcemia\\nrMalignancy'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 97}, page_content='P1: SBT0521759385p2-C CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:48\\n84 ICU Patient Scheduled for Intercurrent Surgery\\nrPTH\\nrResorption\\nrWhat is the phosphorus level?\\nrWhat is the calcium-phosphorus index?\\nrExcessive ingestion/infusion\\n➣ Hypocalcemia\\nrRenal function\\nrPostop\\nrDiuretics\\nrWhat is the QTc on the ECG?\\nrWhat drugs is pt receiving that might prolong the QTc& increase the chance of torsades de pointes?\\n■Evaluate current acid-base balance.\\n➣ Is there a metabolic, respiratory or combined acidosis oralkalosis?\\nrDoes it need to be corrected preop?\\nrIs the procedure likely to exacerbate this?\\nrNeed for high minute ventilation\\nrLactic acid production/undermetabolism\\nrDoes pt require NaCO\\n3, THAM, ongoing dialysis, other?\\ncardiopulmonary\\n■Hemodynamic assessment\\n➣ Blood pressure\\n➣ Rhythm\\n➣ Rate\\n■Risk\\n➣ Ischemia: demand or myocardium at risk\\n➣ Acute coronary syndrome\\n➣ Recent MI\\n■Type of hemodynamic monitoring & access, ongoing or antic-ipated\\n➣ Is it sufﬁcient for the anticipated procedure?\\n➣ Do you need to intensify level of hemodynamic monitor-ing or access?'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 98}, page_content='P1: SBT0521759385p2-C CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:48\\nICU Patient Scheduled for Intercurrent Surgery 85\\n➣ Arterial catheter\\n➣ CVP/PAC\\n➣ PICC\\n➣ Echocardiographic\\n➣ Noninvasive cardiac output\\n■Need for vasopressors\\n➣ Dose & mode of delivery\\nrPump type & compatibility w/ anesthesia systems\\nrAdequacy of infusion; do you need another bag of theinfusion?\\n➣ Inotrope\\n➣ Vasoconstrictor\\n➣ Vasodilator\\n■Need for rate or rhythm control\\n➣ Dose, mode of delivery, adequacy of drug\\nrBeta blocker\\nrCalcium channel blocker\\nrAmiodarone\\nrAntidysrhythmic\\nrLidocaine\\nrProcainamide\\nrOther\\nrIs the pt paced?\\nrTemporary\\nrInternal\\nrExternal\\nrPermanent\\nrMode\\nrProgrammable\\nrDo you need to integrate the pacer & place into a de-fault mode prior to surgery or exposure tocautery?\\n■Is there an AICD in place? What is its status & does it need tobe modiﬁed for the perioperative period?\\n■Is an assist device in place?'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 99}, page_content='P1: SBT0521759385p2-C CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:48\\n86 ICU Patient Scheduled for Intercurrent Surgery\\n➣ Are you organized to transport w/ the device & have itfunction out of the ICU?\\n■Is an assist device possibly required?\\n➣ IABP\\n➣ LVAD/RVAD\\n■What is the pt’s respiratory status?\\n➣ How tenuous is the pt?\\n➣ What is the pt’s baseline pulmonary function/reserve?\\n➣ Recent ABG\\n➣ With the current respiratory status, will be it adequate forthe procedure planned? Can the status be improved ormodiﬁed to tolerate the procedure?\\n■What is the mode of ventilation?\\n➣ Invasive\\n➣ Noninvasive\\n➣ Can you reproduce the mode of ventilation in the OR, ordo you need an ICU ventilator placed in the OR?\\n➣ What are the ventilator settings?\\n➣ Can you adequately ventilate the pt on transfer?\\nrAttempt Ambu bag w/ PEEP prior to transfer.\\nrIf above is unsuccessful, use transfer ventilator orabort.\\nhematologic\\n■Is the pt anemic? Leukopenic? Thrombocytopenic?Pancytopenic?\\n➣ Does the pt require protective isolation?\\n■Does the pt have blood type & cross-matched or screened?\\n➣ Does the pt need specialized blood products?\\nrIrradiated\\nrFiltered\\nrHLA-typed\\n➣ Does the pt have an antibody?\\nrAnti-I & cold antibodies require warmed blood.\\n■Has the pt been transfused before?'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 100}, page_content='P1: SBT0521759385p2-C CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:48\\nICU Patient Scheduled for Intercurrent Surgery 87\\n■Has the pt consented to transfusion?\\n■Is the pt’s oxygen delivery adequate?\\n■Does the pt require transfusion preop or intraop?\\n➣ Red cells\\n➣ Platelets\\n➣ Plasma\\n➣ Specialized blood components\\n■Does the pt have DIC or an inherited coagulopathy?\\n➣ Coags: INR, aPTT\\n➣ Platelets\\n➣ Need for replacement factors\\n■Is the pt receiving drugs associated w/ bleeding or clotting? Ifstopped, when?\\n➣ Antiplatelets\\n➣ Antithrombotics\\n➣ Anticoagulants, including activated protein C\\n➣ Lytic agents\\n➣ Plasminogen inhibitors\\n■Does the pt have heparin-induced thrombocytopenia(antibody)?\\n■Does the pt have hemolysis?\\n➣ Smear\\n➣ Bilirubin, hemosiderin, haptoglobin\\nmetabolic-nutritional\\n■Is the pt hypermetabolic?\\n➣ Fever\\n➣ Sepsis/infection\\n■Is the pt overfed?\\n➣ High carbohydrate load\\n■Could the pt have a refeeding syndrome?\\n➣ Recent starvation/malnourishment\\n➣ Hypokalemia\\n■What is the status of the nutritional supplementation?\\n➣ IV dextrose'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 101}, page_content='P1: SBT0521759385p2-C CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:48\\n88 ICU Patient Scheduled for Intercurrent Surgery\\n➣ IV TPN\\n➣ Enteric nutrition\\n➣ Does the nutritional delivery need to be modiﬁed for theprocedure?\\nrEg, change the enteric nutrition to IV\\nrCare to maintain blood sugars, especially if usinginsulin\\ngastrointestinal\\n■Is the pt at risk for stress ulceration?\\n➣ Has the pt had a GI bleed?\\n➣ Does the pt have varices?\\n■Is the pt receiving acid suppression?\\n➣ H2 blocker\\n➣ Proton pump inhibitor\\n■Does the pt have altered GI motility?\\n➣ NG in place\\n➣ Ileus\\n➣ Aspiration risk\\n➣ Recent tube feedings\\n■Does the pt have diarrhea?\\n➣ Etiology\\n■Hepatic function\\n➣ Adequacy of hepatic synthetic function\\nrGlucose\\nrProtein\\nrCoag factors\\n➣ Does the pt have active hepatitis?\\n➣ Drug metabolism\\nrVolume of distribution\\nrDrug clearance\\n■Renal\\n■What is the pt’s baseline renal function?\\n➣ How much urine does the pt make?'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 102}, page_content='P1: SBT0521759385p2-C CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:48\\nICU Patient Scheduled for Intercurrent Surgery IHSS 89\\n➣ Does the pt respond to diuretics?\\n➣ Is the pt adequately hydrated?\\n➣ What is the pt’s risk for postop renal insufﬁciency/\\nfailure?\\nrDiabetes mellitus\\nrAge\\nrCHF, low cardiac output, hypotension, hypovolemia\\nrOngoing nephrotoxic agents\\nrBaseline renal compromise\\n➣ Is acute, acute-on-chronic, or chronic dysfunction or fail-\\nure present?\\n■Does the pt require dialytic support?\\n➣ Hemodialysis\\n➣ Renal replacement therapy\\n➣ Peritoneal\\n■How recently was the pt dialyzed? What are the most recentlytes & acid-base status?\\n■Will the pt need dialytic support during surgery?\\n■Do drug doses need to be altered because of low GFR?\\nneuropsychiatric\\n■Delirium is common.\\n■Is the pt on sedatives/antipsychotic meds?\\n■Depression: antidepressants, MAOIs, amphetamines\\n■Drug interactions\\nIDIOPATHIC HYPERTROPHIC SUBAORTICSTENOSIS (IHSS)\\nROBERT N. SLADEN, MD\\noverview\\n■Etiology\\n➣ Autosomal dominant inheritance'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 103}, page_content='P1: SBT0521759385p2-C CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:48\\n90 IHSS\\n➣ Variable penetrance\\n■Variable onset, slow progression, manifests in second tofourth decade\\n■Key symptoms similar to aortic stenosis\\n➣ Angina\\n➣ Syncope or presyncope\\n➣ Sudden death (during exertion)\\nﬂuid & electrolytes\\nN/A\\ncardiopulmonary\\n■Hemodynamic proﬁle: hypodynamic\\n■Left ventricle (LV) undergoes asymmetric hypertrophy (pres-sure overload)\\n➣ EF is increased >0.7 (end-systolic collapse).\\n➣ Restricted forward cardiac output: impaired circulatory\\nreserve, effort intolerance, dyspnea\\n➣ Syncope or sudden death may occur w/ LV outﬂow tract\\n(LVOT) obstruction.\\n■Mitral regurgitation\\n➣ Rapid systolic ejection creates Venturi effect in aortic out-\\nﬂow tract.\\n➣ Pulls mitral valve anterior during systole (systolic anterior\\nmotion [SAM])\\n➣ Degree of SAM & mitral regurgitation very variable\\n■Impaired myocardial oxygen balance (MVO 2)\\n➣ Increased demand (increased afterload, contractility)\\n➣ Decreased supply (decreased aortic diastolic pressure,\\nthickened myocardium)\\n➣ Angina may occur w/out coronary artery disease (CAD).\\n➣ Earlier-onset angina w/ concomitant CAD\\n■Diagnosis'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 104}, page_content='P1: SBT0521759385p2-C CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:48\\nIHSS 91\\n➣ Rapid, short-lived upstroke to pulse (reﬂects aortic ejec-\\ntion)\\n➣ Pansystolic murmur radiating to axilla (mitral regurgita-\\ntion)\\n➣ Cardiomegaly on chest radiograph\\n➣ Left ventricular hypertrophy (LVH) on ECG\\n➣ Increasing gradient across aortic valve (critical: peak >70\\nmm Hg, mean >50 mm Hg)\\n➣ Decreasing aortic valve area (normal 2–4 cm2, critical\\n<1.0 cm2)\\n■Acute decompensation (low cardiac output syndrome)\\n➣ Acute atrial ﬁbrillation, tachyarrhythmias (loss of atrial\\nkick)\\n■Late manifestations\\n➣ Congestive heart failure\\n➣ Sudden death\\n■Increased risk of perioperative myocardial ischemia\\n➣ Acute ischemia w/ relatively mild perturbations\\n➣ Low cardiac output syndrome (unable to respond to\\npostop demands)\\n➣ Cardiac arrest: CPR may be unsuccessful in overcoming\\nLVOT obstruction\\nhematologic\\nN/A\\nmetabolic/nutritional\\nN/A\\ngastrointestinal\\nN/A\\nneuropsychiatric\\nN/A'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 105}, page_content='P1: SBT0521759385p2-D CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:51\\n92 Ischemic Heart Disease\\nISCHEMIC HEART DISEASE\\nMUHAMMED ITANI, MD, AND JONATHAN T. KETZLER, MD\\noverview\\n■Leading cause of death & health care expenditure in USA\\n■Major cause of morbidity & loss of productivity\\n■May be present in up to 30% of older pts undergoing surgery\\n■Cardiac dysrhythmias are the major cause of sudden death.\\n■Risk factors: male gender, increasing age, hypercholes-terolemia, hypertension, cigarette smoking, diabetes melli-tus, obesity, sedentary lifestyle, family history of prematureischemic heart disease (male <55 yrs of age, female <65 yrs)\\n■Initial manifestations: angina pectoris, MI or sudden death\\nﬂuid & electrolytes\\nN/A\\ncardiopulmonary\\n■Pathophysiology: narrowing of coronary arteries by plaques;plaque rupture; acute thrombus; & myocardial oxygensupply/demand mismatch\\n■Manifestations: angina pectoris, acute MI or sudden death\\n■Sudden death due to dysrhythmias\\n■Angina pectoris\\n➣ Can be caused by coronary artery atherosclerosis,endothelial damage or coronary vasospasm (variant orPrinzmetal’s angina)\\n➣ Can be stable (reproducible w/ same extent of effort) orunstable (new onset, occurs w/ less effort, occurs at rest)\\n➣ Symptoms: retrosternal chest discomfort w/ radiation toneck, lower jaw, left shoulder & arm, back, right upperextremity & epigastrium\\n➣ Symptoms can be exacerbated by stress & relieved by restor nitroglycerine.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 106}, page_content='P1: SBT0521759385p2-D CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:51\\nIschemic Heart Disease 93\\n➣ Position or direct pressure does not affect symptoms.\\n➣ Symptoms last up to 30 min.\\n➣ Pts w/ stable angina may beneﬁt from pharmacologictreatment only (see below).\\n➣ Pts w/ unstable angina or severe anginal symptoms mayrequire nonpharmacologic treatment (revascularizationw/ angioplasty or surgery).\\n➣ Acute myocardial infarction (AMI)\\nrCaused by coronary artery plaque rupture & conse-quent lumen occlusion by platelet aggregation & throm-bin deposition\\nrMortality signiﬁcantly decreased by early reperfusiontherapy (thrombolytic therapy, angioplasty & stentingwithin 12 hrs of onset)\\nrPrognosis is determined by residual LV function, dys-rhythmias & residual ischemia.\\nrMortality is highest within the ﬁrst 3 months after onset.\\nrLV function can improve within the ﬁrst 3 months &must be measured after 3 months to determine long-term prognosis.\\nrPts may present w/ signs & symptoms of chest pain,apprehension, hypotension, tachycardia, LV or RVfailure, signs of congestive heart failure, dysrhythmias,new-onset murmur due to ischemic mitral valve regur-gitation.\\nrComplications may include ventricular dysrhythmias,atrial ﬁbrillation, heart block, pericarditis, ischemicmitral regurgitation, ventricular septal defect, cardiacrupture & tamponade, congestive heart failure, rightventricular infarction, CVA.\\nhematologic\\n■Relative lymphocytopenia w/ AMI\\n■Reactive leukocytosis w/ AMI'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 107}, page_content='P1: SBT0521759385p2-D CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:51\\n94 Ischemic Heart Disease Latex Allergy\\nmetabolic-nutritional\\n■Diabetes mellitus is the most common endocrine disorderassociated w/ IHD.\\n■Pts w/ diabetes may have blunted or no symptoms associatedw/ IHD (silent ischemia, silent MI).\\n■Pts on beta blockers may have masked sympathetic responseto hypoglycemia.\\n■Improved glucose control improves the outcome after AMI.\\ngastrointestinal\\n■Epigastric discomfort\\n■AMI may be associated w/ nausea & vomiting.\\n■Diffuse esophageal spasm may mimic symptoms of anginapectoris & may be relieved w/ nitroglycerine.\\n■Concomitant peripheral vascular disease may affect themesenteric arteries & cause abdominal angina.\\n■GI bleeding as a complication of anticoagulant and/or throm-bolytic therapy\\nneuropsychiatric\\n■CVA due to:\\n➣ Concomitant cerebrovascular disease\\n➣ Embolization of LV thrombus that forms w/ anterior &apical MI\\n■Intracerebral hemorrhage as a complication of thrombolytictherapy, esp. in elderly & hypertensive pts during the ﬁrst24 hrs after treatment\\n■Mental stress may accompany silent angina.\\n■Depression\\nLATEX ALLERGY\\nARTHUR ATCHABAHIAN, MD\\noverview\\n■Risk factors'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 108}, page_content='P1: SBT0521759385p2-D CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:51\\nLatex Allergy 95\\n➣ Healthcare worker\\n➣ Spina biﬁda\\n➣ Multiple surgeries\\n➣ Cerebral palsy\\n➣ History of allergy to fruits such as banana, avocado,papaya, kiwi, chestnuts\\n■Any reaction to latex (eg, balloons, dental care), including:\\n➣ Contact dermatitis\\n➣ Rhinitis\\n➣ Conjunctivitis\\n➣ Respiratory reaction\\n➣ Anaphylaxis should be considered as a sign of latex allergy.\\n■Any history of unexplained intraoperative anaphylaxis, espe-cially if not concomitant w/ induction, is strongly suggestive;pt should be treated as if having documented latex allergy.\\nﬂuids and electrolytes\\nNormal unless anaphylaxis occurs\\ncardiopulmonary\\n■Normal w/out crisis\\n■Anaphylaxis in a crisis, w/:\\n➣ Vasodilation\\n➣ Capillary leak\\n➣ Bronchospasm\\n➣ Up to cardiovascular collapse & cardiac arrest\\nhematologic\\nNormal, possible eosinophilia\\nmetabolic-nutritional\\nNormal except for possible fruit allergy (see overview)\\ngastrointestinal\\nNormal\\nneuropsychiatric\\nPts w/ spina biﬁda or cerebral palsy are at increased risk.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 109}, page_content='P1: SBT0521759385p2-D CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:51\\n96 Liver Disease\\nLIVER DISEASE\\nROBERT N. SLADEN, MD\\noverview\\nN/A\\nﬂuid & electrolytes\\n■Primary concerns: refractory edema & ascites\\n■Hypoalbuminemia +portal hypertension =ascites +intra-\\nvascular hypovolemia\\n■Secondary hyperaldosteronism\\n➣ Salt & water retention\\n➣ Potassium loss\\n➣ Hypokalemic metabolic alkalosis\\n➣ Generalized edema (anasarca)\\n➣ Progressive ascites, resistant to loop diuretics\\n■Consequences of ascites\\n➣ Decreased FRC\\n➣ Atelectasis\\n➣ Hypoxemia\\n➣ Decreased venous return & renal blood ﬂow (RBF)\\n➣ Spontaneous bacterial peritonitis (10% of pts)\\ncardiopulmonary\\n■Primary concerns: hyperdynamic circulation, hypoxemia\\n■Hyperdynamic circulation w/ ﬁxed low systemic vascularresistance (SVR)\\n■AV shunts in skin (nevi, erythema), GI tract, lung\\n■Impaired circulatory reserve (hypovolemia, sepsis, myocar-dial ischemia)\\n■Alcoholic cardiomyopathy (cirrhosis w/ or w/out thiaminedeﬁciency)\\n■Hepatopulmonary syndrome\\n➣ Hypoxemia (AV shunts), atelectasis'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 110}, page_content='P1: SBT0521759385p2-D CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:51\\nLiver Disease 97\\n➣ Rarely pulmonary hypertension\\n➣ Orthodeoxia: SpO 2decreases when upright\\n■Postop acute respiratory failure\\n➣ Pulmonary edema (hypoalbuminemia)\\n➣ Atelectasis (ascites)\\n➣ Pneumonia (aspiration, impaired resistance)\\nhematologic\\n■Primary concerns: factor VII deﬁciency, thrombocytopenia\\n➣ Factor VII deﬁciency\\n➣ Prolonged PT (impaired synthesis, vitamin K absorption)\\n■Thrombocytopenia\\n➣ Hypersplenism (portal hypertension), bleeding, DIC\\n■Factor V deﬁciency\\n➣ Acute marker after orthotopic liver transplantation\\n■Dysﬁbrinogenemia (abnormal ﬁbrinogen synthesis)\\n➣ Fibrinogen level may be normal.\\n■Macrocytic anemia\\n➣ Alcohol-induced bone marrow suppression\\nmetabolic-nutritional\\n■Primary concerns: hypoglycemia, malnutrition, infection\\n➣ Hypoglycemia (acute hepatic failure, end-stage liver dis-ease)\\n➣ Failure to synthesize glycogen\\n■Kwashiorkor (hypoalbuminemic protein malnutrition)\\n➣ Catabolic effects of hepatic failure\\n➣ Depleted lean body mass\\n➣ Hypoalbuminemia\\n➣ Low colloid oncotic pressure (COP)\\n➣ Exacerbates edema, ascites\\n■Immunocompromise\\n➣ Liver failure, malnutrition\\n➣ Nosocomial, opportunistic infections\\n➣ Wound dehiscence, ﬁstulas, bedsores'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 111}, page_content='P1: SBT0521759385p2-D CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:51\\n98 Liver Disease\\ngastrointestinal\\n■Primary concerns: portal hypertension, varices, jaundice\\n■Potential for active viral hepatitis (A, C, D)\\n■GI irritation\\n➣ Anorexia, hiccups, nausea, vomiting\\n➣ Delayed gastric emptying (increased risk of regurgitation,aspiration)\\n➣ Exacerbated by severe ascites (increased abdominal pres-sure)\\n■Major risk of GI hemorrhage\\n➣ Esophageal, gastric varices (portal hypertension)\\n➣ Hemorrhoids\\n■Increased risk of peptic ulcer disease (PUD)\\n➣ Differential diagnosis: varices\\n■Jaundice\\n➣ Late sign, index of obstruction rather than liver failure\\n➣ Exacerbated by renal failure (conjugated hyperbilirubine-mia)\\nRenal\\n■Primary renal concerns: multifactorial acute renal failure\\n➣ Hepatorenal syndrome\\nrObstructive jaundice (total bilirubin >8 mg/dL) or\\nsevere liver failure\\nrPortal endotoxemia\\nrIntense renal vasoconstriction (vasomotor nephropa-thy)\\nrPrerenal syndrome: oliguria w/ low urine sodium(10 mEq/L or less)\\n➣ Compartment syndrome\\nrTense ascites, increased renal venous pressure\\n➣ Acute tubular necrosis\\nrAcute hypovolemia (eg, GI bleeding)\\n➣ Delayed uremia\\nrBUN low (even w/ GI bleeding or ARF)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 112}, page_content='P1: SBT0521759385p2-D CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:51\\nLiver Disease Malignant Hyperthermia 99\\nrFailure of hepatic arginine cycle that converts urea toNH\\n3\\nneuropsychiatric\\n■Primary concerns: encephalopathy, neuropathy\\n■Hepatic encephalopathy\\n➣ Grade 1: confabulation, constructional apraxia\\n➣ Grade 2: drowsiness, asterixis, confusion\\n➣ Grade 3: stupor\\n➣ Grade 4: coma\\n■Fulminant hepatic failure\\n➣ Coma w/ acute cerebral edema (poor prognosis)\\n■Precipitating factors for acute encephalopathy\\n➣ Hypovolemia (excessive diuresis)\\n➣ Alkalosis (increased conversion of NH 4+to NH 3+)\\n➣ GI bleeding, surgery, infection\\n■Alcohol-induced encephalopathy\\n➣ Thiamine deﬁciency\\n➣ Wernicke’s encephalopathy (oculomotor palsy, cerebellarataxia)\\n➣ Korsakoff’s psychosis (amnesia, confabulation)\\nMALIGNANT HYPERTHERMIA\\nHUGH R. PLAYFORD, MD\\noverview\\nN/A\\nﬂuids and electrolytes\\nWithout crisis\\n■Usually unremarkable\\n■Creatinine kinase may be mildly elevated (poor sensitivity &speciﬁcity)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 113}, page_content='P1: SBT0521759385p2-D CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:51\\n100 Malignant Hyperthermia\\nIn a crisis\\n■Increased cellular metabolism\\n➣ Increased temperature, carbon dioxide, lactate, acid-emia, creatinine kinase, potassium, calcium, myoglobin;later increased BUN\\n➣ Decreased bicarbonate, oxygen\\ncardiopulmonary\\nWithout crisis\\n■Usually unremarkable\\nIn a crisis\\n■Acute pulmonary edema\\n■Elevation of end-tidal carbon dioxide\\n■Arrhythmias (usually related to hyperkalemia)\\nhematologic\\nWithout crisis\\n■Usually normal\\nIn a crisis\\n■DIC\\nmetabolic-nutritional\\nAssociated conditions\\n■Central core disease, Duchenne muscular dystrophy, King-Denborough syndrome, other myopathies (Schwartz-Jampelsyndrome, Fukuyama type of muscular dystrophy, Beckermuscular dystrophy, periodic paralysis, myotonia congenita,sarcoplasmic reticulum adenosine triphosphatase deﬁciency,mitochondrial myopathy)\\n■Masseter muscle spasm (controversial)\\nCoincidental conditions\\n■Sudden infant death syndrome, neuroleptic malignantsyndrome, other diseases (lymphomas, osteogenesis im-perfecta, glycogen storage disease)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 114}, page_content='P1: SBT0521759385p2-D CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:51\\nMalignant Hyperthermia Mitral Regurgitation 101\\nWithout crisis\\n■Usually normal\\nIn a crisis\\n■Hypermetabolism, hyperthermia, increased carbon dioxideproduction, muscular rigidity\\ngastrointestinal\\nN/A\\nneuropsychiatric\\nWithout crisis\\n■Usually normal\\n■May have evidence of associated conditions\\nIn a crisis\\n■Seizures, coma, muscular rigidity, paralysis\\nMITRAL REGURGITATION\\nROBERT N. SLADEN, MD\\noverview\\n■Etiology:\\n➣ Rheumatic fever (but less common than mitral stenosis)\\n➣ Mitral valve prolapse\\n➣ Acute or chronic ischemia (papillary muscle dysfunction)\\n➣ Severe dilated cardiomyopathy\\n■Variable onset, slow progression, manifests in third to sixthdecade\\nﬂuid & electrolytes\\nN/A\\ncardiopulmonary\\n■Hemodynamic proﬁle: hyperdynamic\\n■Left ventricle undergoes eccentric hypertrophy (volume over-load)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 115}, page_content='P1: SBT0521759385p2-D CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:51\\n102 Mitral Regurgitation\\n➣ Restricted forward cardiac output: impaired circulatoryreserve, effort intolerance, dyspnea\\n➣ Afterload is decreased by regurgitation into left atrium.\\n➣ This masks impaired function, preserves ejection fraction(EF).\\n➣ EF<0.5 implies ventricular decompensation.\\n■Left atrium is exposed to volume, pressure overload\\n➣ Pulmonary congestion, edema, hemoptysis\\n➣ Atrial ﬁbrillation inevitable w/ time\\n■Diagnosis\\n➣ Pansystolic murmur radiating to axilla, S3\\n➣ V wave on pulmonary artery wedge tracing (may becomeresorbed w/ time)\\n➣ Mitral regurgitation visualized on echo\\n■Acute decompensation (acute pulmonary congestion/edema)\\n➣ Acute atrial ﬁbrillation, tachyarrhythmias (loss of atrialkick)\\n■Late manifestations\\n➣ Cardiac cachexia\\n➣ Severe pulmonary hypertension, right ventricular dys-function, hepatic congestion\\n■Increased risk of postop cardiogenic shock, pulmonaryedema, atelectasis & pneumonia\\n➣ Left ventricle decompensates because afterload increased(left atrial “decanting” removed).\\n➣ Residual pulmonary edema\\n➣ High risk of postop atrial ﬁbrillation & other arrhythmias\\nhematologic\\n■Chronic atrial ﬁbrillation inevitable w/ time\\n➣ Constant risk of intracardiac thrombus & stroke\\n➣ Mandates anticoagulation, usually w/ coumadin (INR>2.0)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 116}, page_content='P1: SBT0521759385p2-D CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:51\\nMitral Regurgitation Mitral Stenosis 103\\n➣ Will require careful planning for perioperative discontin-uation\\nmetabolic-nutritional\\n■Cardiac cachexia\\n➣ Decreased muscle mass\\n➣ Decreased FRC & ventilatory reserve\\ngastrointestinal\\nN/A\\nneuropsychiatric\\nN/A\\nMITRAL STENOSIS\\nROBERT N. SLADEN, MD\\noverview\\n■Etiology: rheumatic fever (still prevalent in underdevelopedcountries)\\n➣ Slow progression, manifests in third to sixth decade\\nﬂuid & electrolytes\\nN/A\\ncardiopulmonary\\n■Hemodynamic proﬁle: hypodynamic\\n■Left ventricle spared, small; brunt borne by left atrium\\n➣ Restricted cardiac output: impaired circulatory reserve,effort intolerance, dyspnea\\n➣ Increased left atrial pressure: pulmonary congestion,edema, hemoptysis\\n➣ Atrial ﬁbrillation inevitable w/ time\\n■Diagnosis conﬁrmed by ﬁnding gradient >10 mm Hg across\\nmitral valve.\\n➣ Gradient may be relatively low at rest.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 117}, page_content='P1: SBT0521759385p2-D CUNY1088/Sladen 0 521 75938 5 May 28, 2007 9:51\\n104 Mitral Stenosis\\n➣ True severity of mitral stenosis unmasked by tachycardia(increased gradient)\\n■Acute decompensation (acute pulmonary congestion/edema)\\n➣ Tachycardia, increased cardiac output (increased pul-monary artery pressure)\\n➣ Acute atrial ﬁbrillation, tachyarrhythmias\\n➣ Sepsis, labor & delivery\\n■Late manifestations\\n➣ Cardiac cachexia\\n➣ Severe pulmonary hypertension, right ventricular dys-function, hepatic congestion\\n■Increased risk of postop pulmonary edema, atelectasis &pneumonia\\n➣ Residual pulmonary edema\\n➣ Risk of “ﬂash” pulmonary edema w/ increased cardiacoutput\\nhematologic\\n■Chronic atrial ﬁbrillation inevitable w/ time\\n➣ Constant risk of intracardiac thrombus & stroke\\n➣ Mandates anticoagulation, usually w/ coumadin (INR>2.0)\\n➣ Will require careful planning for perioperative discontin-uation\\nmetabolic-nutritional\\n■Cardiac cachexia\\n➣ Decreased muscle mass\\n➣ Decreased FRC & ventilatory reserve\\ngastrointestinal\\nN/A\\nneuropsychiatric\\nN/A'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 118}, page_content='P1: SBT0521759385p2-D˙a CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:12\\nMorbid Obesity 105\\nMORBID OBESITY\\nHUGH R. PLAYFORD, MD\\noverview\\nN/A\\nﬂuids and electrolytes\\n■Increased blood & plasma volume\\ncardiopulmonary\\n■Hypertension\\n■Increased cardiac output (via stroke volume, not heart rate)\\n■Pulmonary hypertension (chronic hypoxemia and/or increa-sed blood volume)\\n■Coronary artery disease (2x risk of non-obese)\\n■Ventricular hypertrophy and/or dysfunction (left & right)\\n■Restrictive pulmonary disease (thoracic & abdominal weightloading)\\n➣ Increased work of breathing\\n■Difﬁcult airway\\n■Obesity hypoventilation syndrome or Pickwickian syndrome\\n■Chronic hypoxemia\\nhematologic\\n■Hypercoagulability\\n■Polycythemia (secondary to hypoxemia)\\nmetabolic-nutritional\\n■Increased metabolism (increased O 2consumption, CO 2pro-\\nduction)\\n■Diabetes mellitus\\ngastrointestinal\\n■Hiatal hernia\\n■Gastroparesis'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 119}, page_content='P1: SBT0521759385p2-D˙a CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:12\\n106 Morbid Obesity Multiple Sclerosis\\n■Fatty liver inﬁltration\\n■Cholelithiasis\\nneuropsychiatric\\n■Psychological disorders\\nMULTIPLE SCLEROSIS\\nKARL WILLMANN, MD\\noverview\\n■Multiple sclerosis (MS) is an autoimmune demyelinating dis-ease that affects both the spinal cord & brain. It does not affectperipheral nerves.\\n➣ Occurs in females more frequently than males\\n➣ More common in Northern Hemisphere\\n➣ More common in Caucasians\\n■Disease characterized by remission & relapse of symptoms\\n➣ Symptoms may include:\\nrParesthesias\\nrSpasticity\\nrOptic neuritis\\nrMuscular weakness\\nrUrinary incontinence\\nrAtaxia\\n➣ May be benign w/ mild symptoms & long periods of remis-sion\\n➣ May progress relentlessly w/ permanent symptoms &severe disability, including quadriparesis.\\n■Pathophysiology is a cycle of CNS inﬂammation, demyelina-tion & axonal damage w/ plaque formation.\\n■Diagnosis\\n➣ Clinical ﬁndings combined w/ brain imaging\\n➣ MRI: plaques in spine or brain are characteristic of MS'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 120}, page_content='P1: SBT0521759385p2-D˙a CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:12\\nMultiple Sclerosis 107\\n➣ CSF: increased levels of IgG\\n➣ CNS nerve studies: slowed conduction (increased latencyon evoked potentials)\\n■Wide range of symptoms, depending on plaque location\\n➣ Isolated visual disturbances (optic nerve involvement)\\n➣ Spasticity & muscular weakness\\n➣ Gait disturbances\\n➣ Bladder dysfunction\\n➣ Seizure disorders\\nﬂuid and electrolytes\\n■No special concerns from MS itself\\ncardiopulmonary\\n■No special concerns from MS itself\\nhematologic\\n■No special concerns from MS itself\\nmetabolic-nutritional\\n■No special concerns unless disease is severe enough to limitadequate nutritional intake\\ngastrointestinal\\n■Pharyngeal or laryngeal dysfunction (increased risk of aspira-tion)\\nneuropsychiatric\\n■Symptoms depend on the degree of cortex involvement; mayinclude:\\n➣ Emotional disturbance\\n➣ Seizure\\n➣ Memory disturbance\\n➣ Cognitive decline'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 121}, page_content='P1: SBT0521759385p2-D˙a CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:12\\n108 Muscular Dystrophy\\nMUSCULAR DYSTROPHY\\nJONATHAN T. KETZLER, MD\\noverview\\n■Muscular dystrophies are a group of primary muscular disor-ders of unknown cause.\\n■Often benign in childhood but progress rapidly w/ age\\n■Duchenne’s muscular dystrophy is the most common & severetype.\\n■Characterized by degeneration of muscle ﬁbers w/ inﬁltrationby fat & ﬁbrous tissue\\n■Early symptoms of weakness in proximal muscles & musclesof the pelvic girdle\\n■Typically begins btwn ages 2 & 7\\n■Becker’s dystrophy is similar to Duchenne’s but onset is later& progression slower.\\n■Fascioscapulohumeral dystrophy & limb-girdle dystrophycome on in adulthood & are not nearly as severe.\\nﬂuid & electrolytes\\nN/A\\ncardiopulmonary\\n■Cardiac muscle is involved w/ dystrophic process.\\n■Almost all pts have some cardiac abnormality, but only 10%are clinically signiﬁcant.\\n■Diastolic dysfunction is present in >80% of pts.\\n■Ejection fraction is decreased in 21% of pts.\\n■Most pts do not have cardiovascular symptoms.\\n■Death is rarely the result of cardiovascular disease.\\n■Death usually results from pneumonia.\\n■Atrophy of paraspinous muscles leads to kyphoscoliosis.\\n■Poor respiratory function is due to involvement of diaphragm& accessory muscles & scoliosis.\\n■May have pulmonary hypertension from chronic sleep apnea'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 122}, page_content='P1: SBT0521759385p2-D˙a CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:12\\nMuscular Dystrophy Myasthenia Gravis 109\\nhematologic\\nN/A\\nmetabolic/nutritional\\nN/A\\ngastrointestinal\\nN/A\\nneuropsychiatric\\nN/A\\nMYASTHENIA GRAVIS\\nKARL WILLMANN, MD\\nD. B. COURSIN, MD\\noverview\\n■Myasthenia gravis (MG) is an autoimmune disease in whichantibodies act against acetylcholine receptors at the neuro-muscular junction, which results in weakness & easily fati-gable muscles. The disease is classiﬁed into several groupsdepending on severity & muscles involved.\\n➣ Group I: Ocular muscles only (20% of pts)\\n➣ Group II A: Mild generalized symptoms, usually sparingrespiratory muscles\\n➣ Group II B: More severe, rapid progression of symptoms,may involve respiratory muscles\\n➣ Group III: Rapid onset & progression, high mortality rate\\n➣ Group IV: Severe form that usually is a progression of typesIIA & IIB\\n■Incidence around 1 in 20,000; women affected twice as fre-quently as men\\n■70–90% of patients w/ MG have circulating anti-acetylcholinereceptor antibodies.\\n■T-helper cell activation in thymus leads to antibody forma-tion.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 123}, page_content='P1: SBT0521759385p2-D˙a CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:12\\n110 Myasthenia Gravis\\n■Antibodies damage postsynaptic membrane via comple-ment-mediated reaction w/ increased degradation & de-creased formation of acetylcholine receptors.\\n■90% of pts have thymic abnormalities (atrophy, hyperplasia,thymoma).\\n■Poor correlation btwn levels of antibodies & clinical severityof disease.\\n■Associated often w/ other autoimmune diseases (systemiclupus erythematosus, rheumatoid arthritis, pernicious ane-mia, thyroiditis)\\n■May be initiated/exacerbated by viral infections, pregnancy,stress, surgery, hyperthermia\\n■Diagnosed by EMG, edrophonium test & presence of anti-acetylcholine receptor antibodies\\n■Therapeutic modalities include cholinesterase inhibitors(increase concentration of Ach at nicotinic postsynapticmembrane), thymectomy, immunosuppressants, corticos-teroids, plasmapheresis.\\n■Pts often are taking anticholinesterases & immunosuppres-sive therapies, which will affect perioperative mgt.\\n■Underdosage of anticholinesterases can lead to skeletal mus-cle weakness.\\n■Overdosage of anticholinesterases can lead to abdominalcramping, vomiting, diarrhea, salivation, bradycardia, skele-tal muscle weakness.\\nﬂuid and electrolytes\\n■Not signiﬁcant except w/ renal failure related to meds\\ncardiopulmonary\\n■Usually not signiﬁcant\\n■Patients with both a thymoma & MG may have a focalmyocarditis presenting as atrial ﬁbrillation or atrioventricularblock.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 124}, page_content='P1: SBT0521759385p2-D˙a CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:12\\nMyasthenia Gravis Neuroleptic Malignant Syndrome 111\\n■Some association w/ LV diastolic dysfunction (but preserva-tion of systolic function)\\n■In late stages, MG can precipitate signiﬁcant respiratory fail-ure.\\nhematologic\\n■Not signiﬁcant except in relation to steroids & immunosup-pressive meds\\nmetabolic-nutritional\\n■Not signiﬁcant except if bulbar dysfunction makes adequatenutritional intake impossible\\ngastrointestinal\\n■No signiﬁcant concerns\\nneuropsychiatric\\n■Skeletal muscle weakness, esp. w/ repetition\\n■May follow relapsing-remitting course\\n■Any muscle may be affected, although more likely to be inner-vated by cranial nerves\\n■Dysphagia, dysarthria, pulmonary aspiration, diplopia, lowerlimb weakness\\n■Consider MG in the differential diagnosis when assessing res-piratory failure.\\nNEUROLEPTIC MALIGNANT SYNDROME\\nHUGH R. PLAYFORD, MD\\noverview\\nN/A\\nﬂuids and electrolytes\\n■Acute phase\\n➣ Hyperkalemia & renal insufﬁciency related to rhabdomy-olysis'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 125}, page_content='P1: SBT0521759385p2-D˙a CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:12\\n112 Neuroleptic Malignant Syndrome\\n➣ Hypovolemia related to diaphoresis\\n■Chronic\\n➣ Usually fully resolved\\ncardiopulmonary\\n■Acute phase\\n➣ May have signs of autonomic dysfunction (hypertension& hypotension, tachycardia, tachypnea, diaphoresis)\\n➣ Muscular weakness & rigidity may contribute to hypercap-nic respiratory failure, failure of airway protective reﬂexes.\\n■Chronic\\n➣ Usually fully resolved\\nhematologic\\n■Acute\\n➣ Leukocytosis common\\n■Chronic\\n➣ Usually fully resolved\\nmetabolic-nutritional\\n■Not affected\\ngastrointestinal\\n■Not affected\\nneuropsychiatric\\n■Probably related to inhibition of central dopaminergic neu-rons by neuroleptic drugs\\n■Typically associated w/ haloperidol, ﬂuphenazine, clozapine,thiothixene, triﬂuoroperazine, thioridazine, chlorpromazine\\n■Less commonly associated w/ droperidol, prochlorperazine,promethazine, metoclopramide\\n■Also in Parkinson’s pts w/ withdrawal of L-dopa\\n■Variable relation to neuroleptic drugs (ﬁrst day of therapy toafter many months of therapy)\\n■not associated w/ malignant hyperthermia'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 126}, page_content='P1: SBT0521759385p2-D˙a CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:12\\nNeuroleptic Malignant Syndrome Obstetric Patient 113\\n■No genetic association\\n■Clinical state\\n➣ Hyperthermia\\n➣ Muscle rigidity & weakness (may develop rhabdomyolysis& subsequent renal dysfunction)\\n➣ Autonomic dysfunction (hypertension & hypotension,tachycardia, tachypnea, diaphoresis, urinary inconti-nence)\\n➣ Mental status changes (delirium, mutism, stupor)\\n■Chronic sequelae may develop\\n➣ Renal insufﬁciency/failure\\n➣ Dementia, parkinsonism, cerebellar dysfunction\\n■Mgt largely supportive\\n➣ Cessation of neuroleptic\\n➣ Consider dantrolene, bromocriptine, L-dopa\\n➣ ECT has been used in selected cases.\\n■Always consider the underlying reason for the use of neurolep-tics in the ﬁrst place!\\nOBSTETRIC PATIENT HAVING INTERCURRENT SURGERY\\nJONATHAN T. KETZLER, MD\\noverview\\n■2% of parturients have intercurrent surgery.\\n■75,000 anesthetics per year\\n■Most commonly treated problems of this age group\\n➣ Trauma\\n➣ Appendicitis, cholelithiasis, torsion or ruptured ovariancyst\\n➣ Breast tumors\\n➣ Cervical incompetence\\n■Less common but serious: intracranial aneurysms, cardiacvalvular disease, pheochromocytoma'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 127}, page_content='P1: SBT0521759385p2-D˙a CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:12\\n114 Obstetric Patient\\n■Many are laparoscopic procedures.\\n■Preterm delivery is the greatest cause of fetal loss.\\n■Prevention & treatment of preterm labor is the most difﬁcultproblem to deal with.\\n➣ Usually not related to anesthetic but rather to underlyingdisease & surgery\\n■Physiologic changes of pregnancy persist for 6 wks postpar-tum.\\n■Balance beneﬁts of procedure against risks to both mother &child.\\n■Greatest risk of fetal death if procedure done in ﬁrst trimester\\nﬂuid & electrolytes\\n■Increased mineralocorticoid activity\\n➣ Sodium retention\\n➣ Increased body water content\\ncardiopulmonary\\n■Cardiovascular\\n➣ Increased cardiac output (up to 50%) secondary toincreases in heart rate (15–20%) & stroke volume\\n➣ Decrease in systemic (particularly in uterine & renal beds)& pulmonary vascular resistance\\n➣ Decrease in vascular responsiveness, increase in barore-ceptor responsiveness\\n➣ Slight decrease in arterial pressure as vasodilatationexceeds increased CO\\n➣ Aortocaval compression when supine unless positionedfor left lateral uterine displacement\\n➣ ECG may show left axis deviation, sinus tachycardia, pre-mature atrial contractions, paroxysmal supraventriculartachycardia.\\n■Pulmonary\\n➣ Higher oxygen consumption, lower pCO 2due to elevated\\nminute ventilation'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 128}, page_content='P1: SBT0521759385p2-D˙a CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:12\\nObstetric Patient 115\\n➣ Decreased ERV, FRC, RV\\n➣ Increased IRV\\n➣ Thus, TLC remains the same.\\n➣ Increased mucosal vascularity (possible upper airwayobstruction)\\n➣ Bronchorelaxation (secondary to progesterone)\\n➣ Lung compliance unchanged\\nhematologic\\n■Increases in total blood volume, plasma volume (both up to40–50%)\\n■Increase in total red cell volume (20%)\\n■Dilutional anemia as increase in blood volume >increase in\\nred cell mass\\n■Hb to 11–12 g/dL, Hct to 35%\\n■WBC to 8,000–10,000/mm3\\n■Platelets generally unchanged\\n■Plasma ﬁbrinogen increases by around 50%.\\n■Clotting factor activity variable\\n■Serum cholinesterase decreases by 20%.\\n■Decreased plasma proteins (albumin >globulins) may in-\\ncrease free concentration of protein-bound drugs.\\nmetabolic/nutritional\\n■Increased oxygen consumption (20% above normal)\\n■Hyperglycemia w/ glucose intolerance\\ngastrointestinal\\n■Gastric motility, pH & lower esophageal tone may bedecreased.\\n■A parturient is considered a full stomach if she has eaten sinceher last menstrual period!\\nneuropsychiatric\\n■Requirement for local anesthetic decreased\\n■MAC for inhaled agents decreased'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 129}, page_content='P1: SBT0521759385p2-D˙a CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:12\\n116 Parkinson’s Disease\\nPARKINSON’S DISEASE\\nROBERT N. SLADEN, MD\\noverview\\n■Onset in sixth & seventh decade; family history; affects males>females\\n■Progressive necrosis of substantia nigra & CNS dopaminedepletion\\n■Exacerbations & remissions\\n■Characteristic features\\n➣ Tremor (foreﬁnger & thumb, “pill rolling”)\\n➣ Rigidity (+ tremor =“cogwheel rigidity”)\\n➣ Bradykinesia (loss of facial expression, slurring of speech)\\n➣ Increased secretions\\n■Systemic disease w/ generalized debility\\n➣ Anemia\\n➣ Muscle wasting\\n➣ Poor nutrition\\n➣ Susceptible to aspiration, infection, hypothermia\\nﬂuid & electrolytes\\nN/A\\ncardiopulmonary\\n■Chronic dopaminergic therapy\\n➣ Vasodilation, systemic hypotension\\nhematologic\\nN/A\\nmetabolic/nutritional\\nN/A\\ngastrointestinal\\nN/A'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 130}, page_content='P1: SBT0521759385p2-D˙a CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:12\\nParkinson’s Disease Patient with a Transplant 117\\nneuropsychiatric\\n■Tremor, rigidity, bradykinesia (see above)\\n■Intellectual function preserved\\nPATIENT WITH A TRANSPLANT\\nARTHUR ATCHABAHIAN, MD\\noverview\\nImmunosuppression\\n■Corticosteroids\\n■Cyclosporine (Neoral or Sandimmune), FK-506 (tacrolimus,Prograf)\\n➣ Both meds target T-lymphocytes.\\n➣ Nephrotoxicity through renal vasoconstriction (cyclos-porine >FK-506)\\n➣ Hypertension, hyperkalemia, hyperglycemia\\n➣ Neurotoxicity (tremors, confusion, seizures)\\n■Rapamycin (sirolimus, Rapamune)\\n➣ Targets T cells through a mechanism different fromcyclosporine & FK-506\\n➣ Thrombocytopenia, dyslipidemia\\n■Mycophenolate (Cellcept), azathioprine (Imuran)\\n➣ Antimetabolites that inhibit lymphocyte proliferation\\n➣ Leukopenia, thrombocytopenia, anemia\\n■Monoclonal antibodies (only IV, administered to treat acuterejection)\\n➣ Possible severe pulmonary edema w/ OKT-3\\nOther meds\\n■Prophylactic antibiotics\\n➣ TMP-SMX to prevent PCP (usually long-term)\\n➣ Ganciclovir or acyclovir to prevent CMV & EBV (usuallyonly during periods of intense immunosuppression)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 131}, page_content='P1: SBT0521759385p2-D˙a CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:12\\n118 Patient with a Transplant\\nIndication for transplant\\n■Heart Tx: CAD, dilated CM, viral myocarditis\\n■Renal Tx: diabetes mellitus, vasculitis, glomerulonephritis,uncontrolled hypertension, obstruction\\n■Liver Tx: cirrhosis w/ or w/out potential for recurrence, biliarymalformation, acute hepatic failure\\n■Lung Tx: cystic ﬁbrosis, end-stage emphysema, alpha-1 antit-rypsin deﬁciency, primary pulmonary hypertension\\n■Time elapsed since transplantation (determines risk of rejec-tion & susceptibility to infection)\\nTransplant function\\n■History of rejection (2 episodes of rejection on average forheart Tx recipients)\\nﬂuids and electrolytes\\n■Steroid treatment w/ possible water & sodium retention\\n■Chronic renal insufﬁciency possible because of renal toxicityof some immunosuppressants, esp. cyclosporine\\n■Hepatorenal syndrome associated w/ chronic liver dysfunc-tion\\n■Osteoporosis is a side effect of long-standing steroid treat-ment.\\ncardiopulmonary\\nEvaluate for CAD\\n■Pts often at risk because of diabetes mellitus, hypercholes-terolemia, hypertension, smoking history\\nHeart Tx\\n■Denervated w/ no vagal inﬂow\\n➣ Resting heart rate increased\\n➣ No response to anticholinergics such as atropine\\n➣ Normal response to circulating catecholamines\\n■Susceptible to accelerated atherosclerosis'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 132}, page_content='P1: SBT0521759385p2-D˙a CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:12\\nPatient with a Transplant 119\\n➣ Typically diffuse lesions not accessible to angioplasty orrevascularization\\n■Frank-Starling mechanism is the main mechanism to adjustcardiac output\\n➣ Maintain adequate ﬂuid status to preserve preload\\n■A portion of the native atria remains\\n➣ Possibly two types of P waves on EKG\\nLiver Tx\\n■If cirrhotic, peripheral & pulmonary shunting may take timeto normalize.\\n■Pleural effusion possible, especially on the right side\\n■Ascites may decrease FRC.\\nRenal Tx\\n■Hyperdynamic circulation with ﬁxed low SVR & peripheralshunting may take time to normalize.\\nLung Tx\\n■Loss of ciliary function because of denervation\\n➣ Propensity to mucous plugging & pneumonia\\n■Single lung: contralateral diseased lung still present, w/ shunt\\nhematologic\\n■Anemia due to malnutrition, bone marrow suppression byimmunosuppressive treatment, frequent blood sampling\\n■Thrombocytopenia due to bone marrow suppression\\n■Leukopenia due to bone marrow suppression\\n■Coagulopathy due to uremia, hepatic insufﬁciency\\nmetabolic-nutritional\\n■Induced glucose intolerance or diabetes mellitus, preexistingor secondary to steroid treatment\\n■Malnutrition\\n■Hypercatabolism due to steroid treatment\\ngastrointestinal\\n■Gl bleed due to steriods, uremia, esophageal varices'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 133}, page_content='P1: SBT0521759385p2-E CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:23\\n120 Patient with a Transplant Pheochromocytoma\\nneuropsychiatric\\n■Possible neuropsychiatric side effects of immunosuppressivetreatment\\n➣ Confusion, seizures, coma\\n■Sensory and/or autonomic neuropathy due to diabetes mel-litus and/or uremia\\nPHEOCHROMOCYTOMA\\nGIUDITTA ANGELINI, MD\\noverview\\n■Adrenal medulla tumors produce, store & secrete catecho-lamines (both epinephrine & norepinephrine).\\n■Occur in 0.1% of hypertensive pts\\n■Undiagnosed & untreated, there is a high mortality.\\n■Surgical management curative in around 90%\\n■Present in third to ﬁfth decade of life in both genders w/hypertension (sometimes paroxysmal w/ heart failure, MI,dysrhythmias, cerebral hemorrhage), headache, palpitations,tremor, diaphoresis, pallor or ﬂushing\\n■5% inherited as autosomal dominant\\n■May be part of MEN IIA or IIB\\n■10% multiple tumors, 10% extra-adrenal, 10% malignant\\n■Differential diagnosis includes:\\n➣ Essential hypertension\\nrUnknown cause\\n➣ Primary renal disease\\nrNephritis, renal artery stenosis, renal infarction\\n➣ Endocrine\\nrAdrenocortical hyperfunction, thyroid disease, pheo-chromocytoma, acromegaly\\n➣ Hemodynamic alterations\\nrIncreased peripheral resistance, increased intravascu-lar volume'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 134}, page_content='P1: SBT0521759385p2-E CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:23\\nPheochromocytoma 121\\n➣ Sympathetic stimulation\\nrLight anesthesia, hypoxia, hypercarbia\\n➣ Neurogenic\\nrSeizure activity, elevated ICP, denervation of carotidsinus\\n➣ Miscellaneous\\nrMalignant hyperthermia, neuroleptic malignant syn-drome, carcinoid syndrome, toxemia of pregnancy\\nﬂuid and electrolytes\\n■Pts w/ pheochromocytoma may have elevated blood sugar.\\n■Reduced intravascular volume\\ncardiopulmonary\\n■Sympathetic paraganglia are a possible location for a pheo-chromocytoma.\\n■Epinephrine, norepinephrine, dopamine are usually secretedfrom the tumor.\\n■Beta-adrenergic stimulation\\n➣ Adenylcyclase stimulates production of cAMP & subsequ-ent inward Ca ++ ﬂux w/ enhanced myosin & actin inter-\\nactions.\\n■Alpha-adrenergic stimulation\\n➣ Enhances Ca ++ inﬂux as well but also inositol triphos-\\nphate\\n■Synthesis of catecholamines\\n➣ Active transport of tyrosine into postganglionic sympa-thetic nerve endings\\n■Breakdown by catechol-o-methyl transferase (COMT)\\n■Also breakdown by monoamine oxidase (MAO)\\n■Diaphoresis & palpitations are common associated symptomsof pheochromocytoma.\\n■Hypertension can be paroxysmal in 35%; otherwise sustained\\n■Left ventricular hypertrophy clinically & on ECG\\n■Catecholamine-induced cardiomyopathy may present asheart failure and/or dysrhythmias.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 135}, page_content='P1: SBT0521759385p2-E CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:23\\n122 Pheochromocytoma Platelet Disorders\\n■Chest x-ray may show cardiomegaly.\\nhematologic\\n■Hemoconcentration secondary to reduced intravascularvolume\\nmetabolic-nutritional\\n■Weight loss, pallor & fever can all be symptoms of pheochro-mocytoma.\\ngastrointestinal\\n■Most often found in the adrenal medulla\\n■Symptoms of pheochromocytoma can include nausea & vom-iting.\\nneuropsychiatric\\n■Found in the chromafﬁn cells of the sympathetic nervoussystem\\n■Headache is a common symptom of pheochromocytoma.\\n■Pts can become encephalopathic from hypertension.\\nPLATELET DISORDERS\\nKARL WILLMANN, MD\\noverview\\n■There are numerous platelet disorders, w/ many etiologies.\\n■Abnormalities of platelet number or platelet function\\n■Thrombocytopenia\\n➣ Platelet dilution\\n➣ Platelet destruction\\n➣ Platelet consumption\\n➣ Inadequate platelet production\\n➣ Sequestration\\n■Decreased function'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 136}, page_content='P1: SBT0521759385p2-E CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:23\\nPlatelet Disorders 123\\n➣ Uremia\\n➣ Antiplatelet agents (cyclooxygenase agents, PDEi, adeno-sine receptor antagonists, glycoprotein IIb/IIIa receptorantagonists, cephalosporins & some penicillins)\\n■Drugs, viral illness, massive transfusion, renal disease, auto-immune disease, excessive destruction or sequestration, dec-reased production, congenital, preeclampsia, HELLP syn-drome & idiopathic causes are often the source of plateletdysfunction & decreased number, which lead to a bleedingdiathesis.\\n■Heparin-induced thrombocytopenia (HIT) may develop in upto 5% of patients who receive heparin.\\n➣ Development of thrombocytopenia variable in onset\\n➣ May present as thrombocytopenia, bleeding, thrombosis\\n➣ IgG antibodies directed against platelet-heparin com-plexes\\nﬂuid and electrolytes\\n■No special concerns\\ncardiopulmonary\\n■No special concerns\\nhematologic\\n■Massive transfusions can lead to a dilutional thrombocyto-penia.\\n■Cardiac bypass can lead to platelet destruction & thrombocy-topenia.\\n■Disease processes such as myeloproliferative & dysplastic syn-dromes may produce low numbers & dysfunctional platelets.\\n■Bone marrow suppression related to radiation & chemother-apy may lead to thrombocytopenia.\\n■In DIC there may an accelerated use of platelets, leading to adecreased platelet count.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 137}, page_content='P1: SBT0521759385p2-E CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:23\\n124 Platelet Disorders Polycythemia\\n■Other autoimmune diseases may lead to platelet destruction,such as rheumatoid arthritis, thrombocytopenia purpura, sys-temic lupus erythematosus.\\n■There may be splenic sequestration of platelets, leading tothrombocytopenia.\\nmetabolic-nutritional\\n■No special concerns\\ngastrointestinal\\n■H2blocking drugs such as cimetidine & ranitidine may have\\na deleterious effect on platelet production/destruction.\\n■Hepatic failure may contribute to thrombocytopenia via bonemarrow suppression.\\n■Uremia may lead to poor platelet function related to toxiccompounds that decrease the ability of platelets to bind toexposed endothelium.\\n■These compounds can be dialyzed off; therefore, dialysis canimprove platelet function.\\n■There may also be some interaction w/ von Willebrand factor,causing poor platelet function. This may respond to desmo-pressin (DDAVP) therapy.\\n■Renal failure may also affect bone marrow production ofplatelets.\\nneuropsychiatric\\n■No special concerns\\nPOLYCYTHEMIA\\nKARL WILLMANN, MD, AND DOUGLAS B. COURSIN, MD\\noverview\\n■Polycythemia is deﬁned as abnormally high Hgb ( >16.5 in\\nwomen or >18.5 in men) or Hct (>48 in women or >52 in\\nmen) due to increased number of RBCs.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 138}, page_content='P1: SBT0521759385p2-E CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:23\\nPolycythemia 125\\n■Polycythemia classiﬁed as:\\n➣ Relative: an increase in Hct or Hgb due to a decrease inplasma volume\\nrOccurs w/ dehydration\\nrMay be a chronic process (obesity, hypertension, other)\\n➣ Absolute: absolute real increase in red cell mass, alsoknown as erythrocytosis\\n➣ Primary\\nrInherited or acquired mutation that results in abnormalerythroid production\\nrMost common cause is polycythemia vera\\nrA myeloproliferative process (includes CML, essen-tial thrombocytopenia, myeloid metaplasia) thatresults in an increase in all cell lines, RBCs, platelets& white cells\\nrSlightly more common in men, usually over 50\\nrStarts as a latent & relatively asymptomatic process,then converts to a proliferative phase where pts areincreasingly at risk for hyperviscosity\\nrPts frequently have headaches, diastolic hyper-tension, plethora, injected conjunctiva.\\nrMay complain of periodic burning in ﬁngers &toes from ischemia\\nrHepatosplenomegaly from proliferation\\nrPlatelets are dysfunctional.\\nrMore rarely, a familial variant\\n➣ Secondary\\nrCaused by circulating plasma factors that stimulate ery-thropoiesis\\nrMost commonly erythropoietin (EPO)\\nrSeen pathologically in tumors that secrete EPO(endocrine, liver, uterine, renal)\\nrOccurs in smokers, hypoxemic pts, those living ataltitude, morbidly obese, COPD, obstructive sleepapnea'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 139}, page_content='P1: SBT0521759385p2-E CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:23\\n126 Polycythemia\\nrHeavy smokers (>1 ppd) have increased carboxyhe-moglobin levels w/ a very high afﬁnity for oxygen;may result in poor oxygen delivery to tissues, caus-ing hypoxia.\\nrHct usually <55%\\n➣ Unapparent polycythemia: red cell mass is increased, butso is the plasma volume, so polycythemia is unrecog-nized\\n➣ Most commonly secondary to chronic hypoxia or an EPO-secreting renal tumor, less commonly polycythemia vera\\n➣ Differentiate etiology by history, physical, lab testing.\\nrHistory: smoker, chronic lung disease, carbon monox-ide exposure, blood doping w/ EPO, gout, family history,pruritus, vascular effects (TIAs, angina, peripheral vas-cular thrombosis), bleeding, peptic ulceration, abdom-inal discomfort from nephrolithiasis or splenomegaly\\nrPhysical exam: SpO\\n2, cyanosis, clubbing, hepatos-\\nplenomegaly, breathing pattern\\nrLabs\\nrPolycythemia vera\\nrHigh WBCs, platelets\\nrHigh Hgb, Hct\\nrLow plasma volume\\nrSat>92% on room air unless underlying pulmonary\\npathology, CO level <5%\\nrLow serum EPO level in polycythemia vera\\nrMay also see increased bilirubin, uric acid\\n➣ Main one we need to be concerned about is polycythemiavera, because of associated risk of thrombosis, bleeding &increased perioperative morbidity & mortality if unrecog-nized & untreated.\\nrInitial treatment: lower Hct via phlebotomy to <46%\\nrBleeding & thrombosis (arterial and/or venous) are themajor complications.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 140}, page_content='P1: SBT0521759385p2-E CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:23\\nPolycythemia 127\\nﬂuid and electrolytes\\n■Maintain normovolemia to limit sludging & potential forthrombosis. See “Hematologic” section.\\n■Pts may have hyperuricemia w/ increased risk for gout or kid-ney stones.\\ncardiopulmonary\\n■Increased risk for myocardial ischemia when Hct very high &w/ abnormal prothrombotic platelet dysfunction; see “Hema-tologic” section\\nhematologic\\n■The most signiﬁcant risk is for both arterial & venous throm-bosis.\\n➣ Increased viscosity w/ higher Hct\\n➣ Increased thrombosis from platelet dysfunction as well asincreased risk for bleeding\\n➣ Pts at risk for myocardial ischemia/infarction, cerebralischemia/stroke, peripheral arterial occlusion, deep veinthrombosis\\n■Therapy for polycythemia may induce AML (radioactive phos-phate, busulphan).\\nmetabolic-nutritional\\n■Due to the increased production of red blood cells, pts maybe iron-deﬁcient.\\ngastrointestinal\\n■Pts w/ hepatic vein thrombosis may be at increased risk forgastric and esophageal varices & bleeding as well as liver dys-function.\\n■Patients may have hyperuricemia with increased risk for goutor kidney stones.\\nneuropsychiatric\\n■No speciﬁc considerations'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 141}, page_content='P1: SBT0521759385p2-E CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:23\\n128 Psychiatric Disorders\\nPSYCHIATRIC DISORDERS\\nJONATHAN T. KETZLER, MD\\noverview\\n■Depression\\n➣ Mood disorder characterized by sadness & pessimism\\n➣ Usually multifactorial in origin\\n➣ Treatment is based on the presumption that mani-festations are due to brain deﬁciency of dopamine,norepinephrine & serotonin or due to altered receptoractivities.\\n➣ As many as 50% of pts w/ severe depression have highlevels of cortisol.\\n■Mania\\n➣ Mood disorder characterized by elation, hyperactivity &ﬂight of ideas\\n➣ May alternate w/ depression\\n➣ Thought to be due to high levels of norepinephrine in thebrain\\n➣ Treated primarily w/ lithium but may add haloperidol orlorazepam\\n■Schizophrenia\\n➣ Pt displays disordered thinking, withdrawal, paranoiddelusions & auditory hallucinations.\\n➣ Thought to be due to excess levels of dopamine in the brain\\n➣ Antipsychotic drugs are the only treatment.\\n■Neuroleptic malignant syndrome (NMS)\\n➣ A rare complication of antipsychotic therapy\\n➣ Haloperidol most common inducing agent but also asso-ciated w/ butyrophenones, phenothiazines & thioxan-thenes\\n➣ Occurs hrs to wks after administration\\n➣ Manifest by muscle rigidity, hyperthermia, rhabdomyoly-sis, autonomic instability & altered consciousness'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 142}, page_content='P1: SBT0521759385p2-E CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:23\\nPsychiatric Disorders Restrictive Lung Disease 129\\n➣ Fatal in 20–30% of cases; death caused by renal failure ordysrhythmias\\n➣ Treated w/ dantrolene or bromocriptine\\n➣ Pts w/ history of NMS should be treated the same as ptsw/ potential for malignant hyperthermia.\\nﬂuid & electrolytes\\nN/A\\ncardiopulmonary\\nN/A\\nhematologic\\nN/A\\nmetabolic/nutritional\\nN/A\\ngastrointestinal\\nN/A\\nneuropsychiatric\\nN/A\\nRESTRICTIVE LUNG DISEASE\\nHUGH R. PLAYFORD, MBBS\\noverview\\n■Extrapulmonary abnormalities\\n➣ Abdomen: obesity, pregnancy, ascites\\n➣ Skin: circumferential skin burns w/ contractures, obesity\\n➣ Musculoskeletal: kyphoscoliosis (combination of kypho-sis & scoliosis), scoliosis alone, kyphosis alone, thora-coplasty, syringomyelia, vertebral & spinal cord tumors,poliomyelitis\\n➣ Pleural: pleural effusion, empyema\\n■Pulmonary interstitial abnormalities'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 143}, page_content='P1: SBT0521759385p2-E CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:23\\n130 Restrictive Lung Disease\\n➣ Idiopathic pulmonary ﬁbrosis (IPF)/cryptogenic ﬁbrosisalveolitis (CFA) most common (3–8/100,000 persons)\\n➣ Other causes include the ﬁbroproliferative phase of acuterespiratory distress syndrome (ARDS), desquamativeinterstitial pneumonia (DIP), respiratory bronchiolitisinterstitial lung disease (RBILD), nonspeciﬁc interstitialpneumonia (NSIP), acute interstitial pneumonia (AIP),lymphoid interstitial pneumonia (LIP), cryptogenic orga-nizing pneumonia.\\nﬂuids and electrolytes\\n■Usually normal\\ncardiopulmonary\\n■Usually progresses toward respiratory failure\\n➣ IPF\\nrProgressive course w/out spontaneous remissions irre-spective of therapy\\nrRespiratory failure within 3–8 yrs of onset of symptoms\\nrSubset of pts stabilize after an initial period of decline.\\nrMean survival of IPF from the onset of symptoms isabout 3–5 yrs.\\n➣ Kyphoscoliosis\\nrMore indolent course\\nrClinical symptoms correlate to the degree of the spinalcurvature.\\nrSome pts remain asymptomatic; others progress to res-piratory failure & cor pulmonale.\\nrPts w/ scoliotic curve of >70 degrees are at high risk of\\ndeveloping respiratory failure.\\nrSpinal curvature tends to increase with age by about 15degrees every 20 yrs.\\nrAngles >100 degrees are associated w/ dyspnea; >120\\ndegrees may result in alveolar hypoventilation & corpulmonale.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 144}, page_content='P1: SBT0521759385p2-E CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:23\\nRestrictive Lung Disease 131\\n➣ Cor pulmonale from hypoxemic pulmonary vasoconstric-tion or anatomic abnormalities; may be treated by supple-mental oxygen, correction of reversible causes of hyper-capnia, mgt of sleep-disordered breathing\\n➣ Initial symptoms are cough (usually nonproductive) &dyspnea.\\nrCough may become paroxysmal & debilitating.\\nrFevers, sweats, chills suggest intercurrent infection.\\n➣ Late phases develop cyanosis & cor pulmonale.\\n➣ Examination\\nrRapid, shallow breathing pattern\\nrEnd-inspiratory rales (“Velcro”-like) in around 85%\\nrClubbing present in 25–93%, hypertrophic osteo-arthropathy\\nrMay have evidence of pulmonary hypertension (loudP\\n2, right ventricular heave, jugular venous disten-\\ntion), right ventricular failure (dependent edema, hep-atomegaly)\\n■PFTs\\n➣ PFT abnormalities correlate poorly w/ the angle of thedeformity.\\n➣ Relate to loss of normal thoracic kyphosis, location of thecurve, number of vertebral bodies involved\\n➣↓TLC,↓VC,↓IC (TLC-FRC), ↓FRC\\n➣↓or normal RV, ↓ERV (FRC-RV)\\n➣↓FEV 1\\n➣↓Diffusing capacity (V/Q inequality & ↓vascular bed)\\n➣ Alveolar hypoventilation from ↑VD/VTratio\\n➣↓VTw/ preservation of anatomic & alveolar dead space\\n➣↓VTallows a decreased work of breathing.\\n➣↓Pulmonary compliance\\n➣ Pressure-volume curves are shifted downward & to theright.\\n■ABGs\\n➣ Kyphoscoliosis'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 145}, page_content='P1: SBT0521759385p2-E CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:23\\n132 Restrictive Lung Disease Rheumatoid Arthritis\\nrUsually normal oxygenation until pt develops hyper-capnia\\nrNocturnal hypoxemia & hypercapnia may develop ear-lier.\\nrAAG usually <25 mm Hg, even in late stages (V/Q\\ninequality, underventilation of hemithorax)\\n➣ IPF\\nrResting hypoxemia\\nrMild respiratory alkalosis\\nhematologic\\n■Polycythemia may be present secondary to chronic poly-cythemia.\\nmetabolic-nutritional\\n■High work of breathing increases metabolic load, elevates rest-ing energy expenditure.\\n■Malnutrition may be present.\\ngastrointestinal\\n■Not signiﬁcantly involved\\nneuropsychiatric\\n■Not signiﬁcantly involved\\nRHEUMATOID ARTHRITIS\\nROBERT N. SLADEN, MD\\noverview\\n■Systemic disease w/ generalized debility\\n➣ Anemia\\n➣ Muscle wasting\\n➣ Poor nutrition\\n➣ Susceptible to infection, hypothermia\\n■Progressive bilateral, symmetrical arthropathy'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 146}, page_content='P1: SBT0521759385p2-E CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:23\\nRheumatoid Arthritis Scleroderma 133\\n➣ Knees, elbows, wrists, metacarpophalangeal, metatar-sophalangeal\\n➣ Impaired mobility\\n➣ Severe deformity: difﬁcult positioning & access\\n■Airway considerations\\n➣ Temporomandibular joint (limited mouth opening)\\n➣ Atlantoaxial joint, odontoid process (limited head exten-sion, ﬂexion)\\nﬂuid & electrolytes\\nN/A\\ncardiopulmonary\\n■Restrictive lung disease\\n➣ Rheumatoid nodules\\n➣ Interstitial pulmonary ﬁbrosis\\n■Pleural effusions\\nhematologic\\nN/A\\nmetabolic/nutritional\\nN/A\\ngastrointestinal\\nN/A\\nneuropsychiatric\\nN/A\\nSCLERODERMA\\nARTHUR ATCHABAHIAN, MD\\noverview\\n■New name is “systemic sclerosis.”\\n■Pathogenesis is related to small vessel destruction & ﬁbrosisof skin & multiple organs'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 147}, page_content='P1: SBT0521759385p2-E CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:23\\n134 Scleroderma\\n➣ Widespread symmetric, leathery induration of skin\\n➣ Involvement of muscles, bones, heart, lungs, intestinaltract\\n■CREST syndrome: calcinosis, Raynaud’s phenomenon, eso-phageal hypomotility, sclerodactyly, telangiectasis\\n➣ This variant is usually more benign & less progressive.\\n■A variety of autoantibodies are found in scleroderma, includ-ing antibodies to smooth muscle, rheumatoid factor, antin-uclear antibodies (ANA) & antibodies to nuclear compon-ents.\\n➣ ANA & antibodies to Scl-70 (a non-histone nuclear pro-tein) are highly speciﬁc for scleroderma.\\n➣ Antibodies to centromere are associated w/ CREST syn-drome.\\n■More common in women 30–50 yrs of age\\n■Pregnancy can accelerate progression of disease; high inci-dence of spontaneous abortion & premature labor\\n■Acute renal failure is the leading cause of death.\\n■Musculoskeletal\\n➣ Thickening & non-pitting edema of skin\\nrLater on, skin becomes tight, w/ ﬂexion contractures.\\n➣ Proximal myopathy w/ elevated CK\\n➣ Inﬂammatory arthritis, possible avascular necrosis offemoral head\\n➣ Nonerosive synovitis leading to carpal tunnel syndrome\\nﬂuids and electrolytes\\n■Possible involvement of renal arteries w/ progression to renalfailure\\n➣ Acute drop in renal blood ﬂow can trigger acute renal fail-ure w/ malignant hypertension, a medical emergency.\\n➣ Symptoms include headache, visual disturbances, en-cephalopathy, seizures, oligo-anuria, edema, CHF, arrhy-thmias.\\n➣ Physiopathology is hyperreninemia due to renal angiopa-thy, leading to severe renal vasospasm.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 148}, page_content='P1: SBT0521759385p2-E CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:23\\nScleroderma 135\\n➣ Treatment of acute renal crisis w/ ACE inhibitors has sig-niﬁcantly reduced mortality.\\n➣ Treatment of malignant hypertension w/ sodium nitro-prusside or nicardipine is necessary in addition to ACEinhibitor administration.\\n➣ Normotensive renal crisis is possible, especially in ptsreceiving high doses of steroids.\\n■Pt may be on steroid therapy, w/ associated side effects.\\ncardiopulmonary\\n■Rare myocardial ﬁbrosis leading to CHF; more common ifmyositis\\n■Dysrhythmias or conduction abnormalities\\n■Pericarditis, pericardial effusion, w/ or w/out tamponade\\n■Oral & nasal telangiectasias\\n■Hypertension from involvement of renal arteries\\n■CREST syndrome\\n■Near-constant pulmonary restrictive syndrome & impaireddiffusion capacity from ﬁbrosis, similar to idiopathic pul-monary ﬁbrosis\\n■Common thickening of pulmonary vessels w/ pulmonaryhypertension leading to cor pulmonale\\n■Increase in dead space from widening of airways\\nhematologic\\n■Possible impaired coagulation due to malabsorption of vita-min K from intestinal hypomotility & bacterial overgrowth\\nmetabolic-nutritional\\n■Pt may be on steroid therapy, with associated side effects.\\n■Possible malabsorption from intestinal hypomotility & bacte-rial overgrowth\\ngastrointestinal\\n■Oral dryness\\n■Esophageal hypomotility & reduced lower esophageal sphinc-ter tone'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 149}, page_content='P1: SBT0521759385p2-E CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:23\\n136 Scleroderma Sickle Cell Disease\\n■Bacterial overgrowth from intestinal hypomotility\\nneuropsychiatric\\n■Cranial nerve neuropathy because of compression by thick-ened connective tissue\\n■Dry keratoconjunctivitis\\nSICKLE CELL DISEASE\\nARTHUR ATCHABAHIAN, MD\\noverview\\n■Abnormal beta chain of hemoglobin due to substitution ofvaline for glutamic acid at the 6 position. The abnormalhemoglobin is designated HbS.\\n■Sickle cell trait (heterozygous): 10% black population in theUS; 20–40% HbS. Asymptomatic.\\n■Sickle cell disease (homozygous): 0.3–1% black population inthe US; 70–98% HbS. Anemia with Hb 5–10 g/dL. Survivalbeyond age 30 is rare.\\n■Diagnosis by electrophoresis of Hb\\n■HbS tends to form aggregates (tactoids) when deoxygenated,hence sickling of erythrocytes, with shortened life span (10–20days instead of 120).\\n➣ Oxyhemoglobin dissociation curve also shifted to the right\\nrIncreased intracellular 2,3 DPG; facilitates oxygen deliv-ery to tissues\\n➣ Homozygous: sickling at tissue PO 2of 40 mm Hg\\n➣ Heterozygous: sickling at tissue PO 2of 20 mm Hg\\n➣ Sickling also triggered by\\nrAcidosis\\nrHypothermia\\nrDehydration\\nrBlood stasis'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 150}, page_content='P1: SBT0521759385p2-E CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:23\\nSickle Cell Disease 137\\n➣ Radiographic contrast dye causes sickling in vitro.\\nrRisks of angiography are unclear.\\n➣ Vaso-occlusion is more likely w/ a higher Hct\\nrPredicted ﬁnal Hct is a criterion for choosing btwntransfusion & exchange transfusion.\\nrKeep Hct around 25–30.\\n■Acute complications\\n➣ Vaso-occlusive crisis\\n➣ Chest syndrome\\n➣ Hepatic crisis\\n➣ Bone marrow necrosis & fat embolism\\n➣ Cerebral vascular occlusion\\n➣ Priapism\\n➣ Splenic infarction & sequestration\\n➣ Aplastic crisis\\n➣ Asplenic sepsis syndrome\\n■Musculoskeletal\\n➣ Common avascular femoral head necrosis\\n➣ Rare bone marrow necrosis w/ fat embolism\\nrFever, severe bone pain, neurologic signs & respiratorydistress\\nrExchange transfusion can be lifesaving.\\n➣ Osteomyelitis, often caused by Salmonella sp.\\n➣ Gout common because of the increased nucleic acidcatabolism\\n➣ Leg ulcers common\\nﬂuids and electrolytes\\n■Renal medulla site of frequent occlusive events because of lowtissue PO\\n2\\n➣ Papillary necrosis w/ hematuria\\n➣ Impaired ability to concentrate urine\\n➣ Leads to renal failure'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 151}, page_content='P1: SBT0521759385p2-E CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:23\\n138 Sickle Cell Disease\\n■Even pts w/ sickle cell trait have been shown to developmedullary infarcts & to have a higher incidence of hematuria.\\ncardiopulmonary\\n■High cardiac output due to anemia, w/ common ﬂow murmur\\n■LV dysfunction can be a consequence of chronic transfusionw/ iron deposition.\\n■Cor pulmonale secondary to repeated pulmonary emboli\\n■Multiple pulmonary infarcts lead to increased A-a gradient,decreased TLC & FVC.\\n■Acute chest syndrome\\n➣ Painful crisis\\n➣ Fever\\n➣ Pleuritic chest pain\\n➣ Pulmonary inﬁltrate, often transient\\n➣ Differential includes pneumonia & pulmonary embo-lism.\\n➣ Supportive treatment w/ analgesics, hydration & oxygentherapy\\n➣ Consider exchange transfusion if PO 2cannot be main-\\ntained >75 mm Hg.\\nhematologic\\n■Splenomegaly frequent in small children\\n➣ Because of repeated infarcts, most pts are functionallyasplenic by age 6.\\n➣ Decreased production of antibodies & increased risk ofbacterial infection (esp. encapsulated organisms suchasStreptococcus pneumoniae &Haemophilus influenzae;\\nalso E. coli UTI & Salmonella osteomyelitis)\\n➣ Pts w/ less severe forms (eg, Hb SC disease) will still havea functional spleen into adulthood.\\n■Vaso-occlusive crisis\\n➣ Often triggered by infection or trauma\\n➣ Acute onset of intense pain, often abdominal or thoracic'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 152}, page_content='P1: SBT0521759385p2-E CUNY1088/Sladen 0 521 75938 5 May 28, 2007 10:23\\nSickle Cell Disease 139\\n➣ May last only minutes or as long as 3 wks\\n➣ Treat w/ analgesics, hydration, alkalinization & oxygensupplementation.\\n■Aplastic crisis\\n➣ Bone marrow depression triggered by viral infections (par-vovirus B19)\\n➣ Fever, anorexia, nausea & vomiting, headache, abdominalpain\\n➣ Severe anemia w/ mild leukopenia & thrombocytopenia,low reticulocyte count\\n➣ Self-limited, with recovery usually by 2 wks\\n➣ Treat w/ transfusion as needed.\\n■Sequestration crisis\\n➣ Pooling of erythrocytes in spleen & liver\\n➣ Left upper quadrant pain, shock\\n➣ Possible acute hypovolemia or even sudden death\\n➣ Immediate transfusion\\n■Priapism\\n➣ May resolve spontaneously w/ supportive treatment ornecessitate exchange transfusion and/or surgery\\nmetabolic-nutritional\\n■Usually normal\\ngastrointestinal\\n■The liver is also a site of vascular occlusion\\n➣ Painful enlargement\\n➣ Hyperbilirubinemia\\n➣ Function usually preserved\\n➣ Decreased activity of plasma cholinesterase possible\\n■Chronic hemolysis leads to elevated plasma bilirubin\\n➣ High incidence of cholelithiasis\\n■Chronic transfusion leads to a high prevalence of viral hepa-titis\\n➣ In some cases to iron overload w/ cirrhosis'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 153}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\n140 Sickle Cell Disease Spinal Cord Injury\\nneuropsychiatric\\n■Vascular occlusion manifests as cerebral infarcts in children& hemorrhage in adults\\n➣ Treatment w/ exchange transfusion\\n➣ Recurrence rate decreased by maintenance transfusions\\nSPINAL CORD INJURY\\nHUGH R. PLAYFORD, MBBS, AND GEBHARD WAGENER, MD\\noverview\\n■Acute: Spinal shock\\nDeﬁnition\\n■Up to 3 wks after injury\\n■Loss of sensation, temperature regulation & spinal cordreﬂexes below injury\\n■Mortality due to\\n➣ Aspiration\\n➣ Respiratory failure\\n➣ Pneumonia\\nChronic stage\\n■>3 wks after injury\\n➣ Sympathetic system hyperactive: autonomic hyper-reﬂexia\\n➣ Spinal reﬂexes return\\n➣ Chronic infections: urinary tract, pulmonary\\n➣ Renal failure often causes signiﬁcant mortality.\\n➣ Transection above C2 to C4 causes paralysis of thediaphragm.\\n➣ Pt cannot maintain adequate oxygenation & ventilation,requiring immediate intubation & mechanical ventilation.\\n➣ Musculoskeletal\\nrAcute:'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 154}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\nSpinal Cord Injury 141\\nrFlaccidity below injury\\nrChronic:\\nrOsteoporosis, muscular atrophy & pathologic frac-tures common\\nrMuscle spasm & spasticity requiring medication\\nrContractures requiring intense physiotherapy and/orsurgery\\nrDecubital ulcers common\\nﬂuids and electrolytes\\n■Acute\\n➣ Pt may have signiﬁcant intravascular volume depletion,depending on other injuries & degree of systemic vasodi-latation.\\n➣ Hyponatremia common in acute stages\\n■Chronic\\n➣ Hypercalcemia from prolonged immobilization\\n➣ Renal insufﬁciency common (chronic urinary tract infec-tions, nephrolithiasis)\\ncardiopulmonary\\n■Acute\\n➣ Altered autonomic outﬂow (initial hyperactivity, then hy-poactivity)\\n➣ Short-lived hypertension (increased systemic vascularresistance, increased cardiac contractility, increased dys-rhythmias), then hypotension (decreased systemic vascu-lar resistance w/ blood pooling in the capacitance vessels)& bradycardia (decreased activity of the T1-4 cardiac accel-erator ﬁbers) leading to spinal shock\\n➣ Spinal shock typically lasts for 3 days to about 6 wks.\\n➣ In the setting of unopposed vagal tone, the usual tachy-cardic response to hypovolemia & hypotension may notbe seen.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 155}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\n142 Spinal Cord Injury\\n➣ Cardiac arrest: occasionally seen on tracheal suctioning,esp. in the presence of hypoxia (unopposed vasovagalreﬂex)\\n➣ Cardiopulmonary changes may also be related to otherinjuries (thoracic, hemorrhage, etc.).\\n➣ Injuries above C5 lead to diaphragmatic paralysis (w/paradoxical abdominal excursion); pt will need ventila-tory support.\\n➣ Pts w/ injuries above T1 may have signiﬁcant hypoventi-lation.\\n➣ Pulmonary edema related to neurogenic etiology (tran-sient centrally mediated alpha-adrenergic sympatheticdischarge) or excessive ﬂuid replacement\\n➣ Beta2-agonist nebulizer therapy may further decrease SVR& contribute to hypotension.\\n➣ Pulmonary embolism: secondary to prolonged immobi-lization\\n■Chronic\\n➣ Pulmonary complications are very common, particularlyw/ high cervical spine injuries.\\n➣ Pts w/ injuries above T1 may have signiﬁcant hypoventi-lation.\\n➣ Injuries above C5 lead to diaphragmatic paralysis; pt willneed ventilatory support.\\n➣ Pulmonary function improves w/ intercostals & abdomi-nal muscle spasticity leading to increased abdominal mus-cle elastic recoil & decreased end-expiratory volume.\\n➣ Hypoventilation leads to V/Q inequality, increased deadspace, hypoxia, hypercarbia, pulmonary vasoconstriction,sputum retention, atelectasis, pneumonia & respiratoryfailure.\\n➣ PFTs: decreased VC, decreased TV , decreased TLC, de-creased ERV , decreased FEV1, decreased FVC, decreasedexpiratory ﬂow rates, decreased FRC, increased residualvolume'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 156}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\nSpinal Cord Injury 143\\n➣ Postural hypotension & bradycardia (esp. if level aboveT4)\\n➣ ABGs may show hypoxemia w/ or w/out hypercarbia.\\n➣ Cardiac arrest: occasionally seen on tracheal suctioning,esp. in the presence of hypoxia (unopposed vasovagalreﬂex)\\n➣ Pulmonary embolism: secondary to prolonged immobi-lization\\nhematologic\\n■Acute\\n➣ Anemia is usually a consequence of other injuries &hemodilution (to manage hypotension related to systemicvasodilatation).\\n■Chronic\\n➣ Very high risk of DVTs, PTEs\\n➣ Iatrogenic coagulopathy from prophylactic or therapeuticanticoagulants\\n➣ Anemia from chronic renal insufﬁciency or chronic use ofNSAIDs\\nmetabolic-nutritional\\n■High injury level (above T1) may interfere w/ thermoregula-tion, leading to poikilothermia.\\ngastrointestinal\\n■Acute\\n➣ Gastric retention leading to gastric atony, paralytic ileus,abdominal distention\\n■Chronic\\n➣ High risk of constipation, needing long-term use oflaxatives & purgatives\\n➣ GI bleeding related to NSAIDs\\nneuropsychiatric\\n■Incidence 11.5 to 53.4 per million population\\n■Typically'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 157}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\n144 Spinal Cord Injury\\n➣ Males 15–25 yrs\\n➣ Related to motor vehicle accidents\\n➣ Involve cervical spine (often C5/6)\\n➣ Most common site of thoracolumbar injury is T12/L1.\\n■Associated w/ other trauma in 25–65% of cases\\n➣ Consider spinal cord injury in all polytrauma or uncon-scious patients until proven otherwise!\\n➣ Head (including intracranial injury, facial injuries)\\n➣ Consider the possibility of vertebral artery injury (esp. ifbrain stem or cerebellar dysfunction).\\n➣ Thorax (rib fractures, hemothorax, pneumothorax)\\n■Acute manifestations depend on the injury (primary & sec-ondary; eg, hypotension & hypoxemia), level of injury, area ofinjury (complete or incomplete) & may give a pattern of spinalshock.\\n➣ Sensory: loss of visceral & somatic sensation\\n➣ Motor: ﬂaccid paralysis, absent deep tendon reﬂexes,abdominal reﬂexes & plantar responses\\n➣ Autonomic: initial hypertension, then hypotension &bradycardia, retention of feces & urine, poikilothermia\\n➣ Psychological issues: frequent development of depres-sion\\n■Spinal cord blood ﬂow inﬂuenced by:\\n➣ MAP (normal autoregulation 50–150 mm Hg, may be dis-rupted in injury)\\n➣ Arterial PaCO 2(blood ﬂow increases linearly from 50 to\\n90 mm Hg, decreases w/ hyperventilation)\\n➣ Endogenous endorphins (decrease blood ﬂow by inducinghyperventilation & hypotension)\\n■Therapy is largely supportive.\\n■Supportive therapy for acute spinal injury\\n➣ Cardiovascular, respiratory: see above\\n➣ Immobilize spinal column to prevent further mechanicaldamage to spinal cord.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 158}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\nSpinal Cord Injury 145\\n➣ Prevent the development of secondary spinal cord injuries(hypoxemia, hypotension).\\n■Speciﬁc therapy for acute spinal injury\\n➣ Methylprednisolone load (30 mg/kg) IV , then infusion(5.4 mg/kg/hr for 23 hrs)\\n➣ Associated w/ some sensory & motor improvement\\n➣ Other speciﬁc therapies not proven (naloxone, TRH,hypothermia, hyperbaric oxygen, catecholamine antag-onists, diuretics, calcium channel blockers)\\n➣ Surgery is occasionally needed to achieve alignment,decompress injured spinal cord & stabilize the spine.\\n■Chronic spinal injury\\n➣ Autonomic: urinary & fecal retention, risk of autonomichyperreﬂexia, gastroparesis, poikilothermia\\n➣ Sensory: pts frequently have patchy return of sensation;common to have chronic pain syndrome\\n➣ Motor: depends on level of injury, presence of contrac-tures\\n➣ Psychological: chronic pain syndrome & depression com-mon\\n■Autonomic hyperreﬂexia\\n➣ Can develop when spinal shock has resolved & w/ returnof spinal cord reﬂexes\\n➣ Acute generalized autonomic hyperactivity in responseto cutaneous or visceral stimuli BELOW spinal cordlesion\\n➣ Stimuli may include distention of bladder, bowel, or intes-tine; skin stimulation; pyelonephritis; muscle spasm; uter-ine contractions; surgery.\\n➣ Unlikely if injury is below T10\\n➣ 65–85% of pts w/ level above T7 have autonomic hyper-reﬂexia.\\n➣ Related to lack of supraspinal inhibition on thoracolum-bar sympathetic outﬂow'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 159}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\n146 Spinal Cord Injury Stroke\\n➣ Stimulus elicits reﬂex sympathetic activity (if neuro-logically intact, the higher centers would modulate w/inhibitory impulses).\\n➣ Sympathetic overactivity BELOW the lesion (hyperten-sion)\\n➣ Parasympathetic activity ABOVE the lesion (bradycar-dia, nasal stufﬁness, headache, blurred vision, cutaneousvasodilatation)\\n➣ Mgt: ganglion blocking drugs, alpha blockers (phen-tolamine), direct-acting vasodilators (nitroprusside), orgeneral or regional anesthesia\\nSTROKE\\nGEBHARD WAGENER, MD\\noverview\\nPerioperative stroke\\n■Deﬁnition\\n➣ Stroke: cerebral infarction, w/ symptoms lasting >24 hrs\\n➣ Transient ischemic attack (TIA): symptoms <24 hrs\\n➣ Reversible ischemic neurologic deﬁcit (RIND): symptoms24–72 hrs\\n■Incidence: 0.02–0.7%\\n■Pathophysiology\\n➣ Mostly thrombotic or embolic\\n➣ Hypercoagulable state after surgery:\\n➣ Increase in ﬁbrinogen/factor VII, decrease in AT III\\n➣ Extended postop bedrest\\n➣ Dehydration\\n■Embolic or thrombotic event leads to decrease in regionalcerebral blood ﬂow (CBF) below ischemic threshold (approx.10 mL/10 g brain tissue/min):'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 160}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\nStroke 147\\n➣ Depolarization of membranes & calcium inﬂux\\n➣ Proteolysis\\n➣ Release of excitatory amino acids (glutamate, others)\\n■Early (intracellular/cytotoxic) & late (extracellular/break-down of blood-brain barrier) edema leads to ischemicarea around focus of stroke (ischemic penumbra/brain atrisk).\\n■Average occurrence: 7 days postop (rarely intraop)\\n■Increased risk w/:\\n➣ Age\\n➣ Previous stroke (1.5–3%)\\n➣ Kind of surgery\\nrCardiac surgery (3–5%) >vascular surgery (0.8-3%) >\\ngeneral\\n➣ Comorbidities\\nr(Asymptomatic) carotid stenosis\\nrValvular heart disease\\nrAtrial ﬁbrillation\\nrPatent foramen ovale\\nrHypercoagulability: polycythemia, thrombocytosis,pregnancy, oral contraceptives\\nrHypertension\\nrDiabetes mellitus\\nrSmoking\\nrObesity\\nrProlonged bedrest\\n■Outcome:\\n➣ 30% mortality when perioperative\\n➣ 30% long-term disability\\n■Musculoskeletal:\\n➣ Pts w/ stroke:\\nrEvaluate & document deﬁcit prior to surgery.\\n➣ To prevent perioperative stroke:\\nrAvoid unnecessary bedrest.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 161}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\n148 Stroke\\nﬂuids and electrolytes\\n■Pts w/ stroke:\\n➣ Malnutrition & dehydration possible: hypernatremia, hy-perkalemia\\n■To prevent perioperative stroke:\\n➣ In pts w/ high risk for perioperative stroke:\\nrEnsure adequate hydration: avoid polycythemia\\ncardiopulmonary\\n■Pts w/ stroke:\\n➣ Previous stroke risk factor for coronary artery disease\\n➣ Depending on other risk factors, extent of surgery &exercise tolerance: will likely require preop evaluation ofmyocardial ischemia.\\n➣ Assess baseline BP .\\n■To prevent perioperative stroke:\\n➣ In pts w/ carotid stenosis:\\nrAssess extent of stenosis & baseline BP .\\nrAvoid hypotension.\\nhematologic\\n■Dehydration can lead to polycythemia & increased bloodviscosity.\\n■Consider aspirin for thrombocytosis.\\nmetabolic/nutritional\\nN/A\\ngastrointestinal\\nN/A\\nneuropsychiatric\\n■Pts w/ stroke:\\n➣ Pts require early rehab & social & emotional support.\\n➣ Attempt to listen to & understand pts w/ aphasia.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 162}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\nSubacute Bacterial Endocarditis Prophylaxis 149\\nSUBACUTE BACTERIAL ENDOCARDITIS PROPHYLAXIS\\nJONATHAN T. KETZLER, MD\\noverview\\n■Etiology\\n➣ Most pts w/ endocarditis have no known predisposing car-diac lesion.\\nrThere has been a shift from endocarditis predominantlyin those w/ rheumatic heart disease, to those w/ con-genital heart disease, to those w/ degenerative disease(including mitral valve prolapse) & to those w/ previ-ously normal valves.\\n➣ P t sa tr i s k\\nrStructural congenital heart defects\\nrAcquired valvular heart disease\\nrEndocardial pacemakers\\nrProsthetic valves, conduits, shunts\\nrPrevious endocarditis\\n➣ Pts not at risk\\nr“Innocent” murmurs\\nrNonstructural heart disease (eg, arrhythmias)\\n➣ More likely in pts who use IV drugs & those w/ indwellingcatheters or who have undergone cardiac surgery\\n➣ In subacute endocarditis caused by organisms of low viru-lence, at most 20% follow identiﬁable medical proceduresthat cause bacteremias.\\nﬂuid/electrolytes\\nN/A\\ncardiopulmonary\\nN/A\\nhematologic\\nN/A'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 163}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\n150 SBE Prophylaxis Systemic Lupus Erythematosus\\nmetabolic/nutritional\\nN/A\\ngastrointestinal\\nN/A\\nneuropsychiatric\\nN/A\\nSYSTEMIC LUPUS ERYTHEMATOSUS\\nARTHUR ATCHABAHIAN, MD\\noverview\\n■Autoimmune disease of unclear etiology\\n➣ Genetic factors: association w/ HLA-DR2, -DR3, -A1 & -B8,as well as w/ C2 & C4 complement components deﬁcit\\n➣ More common in black women of childbearing age\\n➣ Most likely related to lymphocyte dysfunction & immunecomplex formation\\n■Antibodies against nuclear & cytoplasmic structures are a hall-mark of SLE but can be found in other disease.\\n➣ Antibodies to native double-stranded DNA are highlydiagnostic for SLE.\\n■Stresses such as surgery, pregnancy or sepsis can cause exac-erbation.\\n■Drug-induced lupus (essentially caused by procainamide,hydralazine & quinidine), w/ slower progression\\n■Musculoskeletal\\n➣ Avascular necrosis of femoral head\\n➣ Symmetric arthritis involving hands, wrists, elbows, knees& ankles\\n➣ Proximal myopathy w/ elevated CK'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 164}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\nSystemic Lupus Erythematosus 151\\n➣ Characteristic malar erythematous rash w/ classically abutterﬂy shape\\nrPresent in <50% of pts\\nﬂuids and electrolytes\\n■Glomerulonephritis w/ hematuria & proteinuria, evolvinginto renal failure\\n➣ Renal involvement in 75% of pts\\n➣ Most commonly diffuse proliferative glomerulonephritis\\n■Steroid treatment common\\ncardiopulmonary\\n■Pericarditis common but rarely symptomatic\\n■Myocarditis resulting in conduction abnormalities, tachycar-dia or even CHF\\n■Libman-Sacks endocarditis (noninfectious)\\n➣ Involves aortic & mitral valves, usually w/out signiﬁcantvalvular dysfunction\\n➣ Predisposition to bacterial endocarditis & thromboem-bolic disease\\n■Common fetal congenital heart block in children of womenw/ lupus\\n■Lupus pneumonia\\n➣ Dry cough\\n➣ Dyspnea\\n➣ Fine basilar rales\\n➣ Pleural effusion\\n➣ Diffuse inﬁltrates on chest x-ray\\n➣ Hypoxemia\\n➣ Restrictive picture on PFTs\\n➣ Possible evolution into acute respiratory failure\\n➣ Difﬁcult to differentiate from infectious pneumonia\\n➣ Diagnosis of elimination\\n■Possible progressive pulmonary ﬁbrosis'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 165}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\n152 Systemic Lupus Erythematosus\\n■High incidence of pulmonary emboli due to hypercoagulabletendency\\nhematologic\\n■Autoimmune hemolytic anemia common\\n➣ Warm IgG, occasionally cold IgM\\n➣ Usually responsive to high-dose steroids\\n➣ Other treatment options include immunosuppressivetreatment, Danatrol, IVIG or plasmapheresis\\n■Splenomegaly common; splenectomy sometimes helpful\\n■Acute immune thrombocytopenia\\n➣ Similar to ITP\\n➣ Initiate IVIG or steroids if platelets <50,000/mm3\\n■Rare thrombotic thrombocytopenic purpura\\n➣ Possible hemolytic-uremic syndrome\\n➣ Fever, purpura, microangiopathic hemolytic anemia &renal dysfunction\\n➣ High mortality despite plasmapheresis & high-dosesteroids\\n■Leukopenia common\\n■Antiphospholipid antibodies\\n➣ Lupus anticoagulant (prolonged PTT but tendency tothrombosis)\\n➣ Anticardiolipin antibody\\n➣ Increased risk of spontaneous abortion\\n■Increased sensitivity to infection, even w/out steroid orimmunosuppressive treatment\\nmetabolic-nutritional\\n■Usually normal\\n■Possible steroid side effects, esp. induced diabetes mellitus\\ngastrointestinal\\n■Abnormal LFTs common'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 166}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\nSystemic Lupus Erythematosus Thalassemia 153\\n■Lupoid hepatitis w/ recurrent jaundice, hepatomegaly &hyperglobulinemia, possibly fatal\\n■Possible intestinal ischemia manifesting as acute abdomen\\n■Possible acute pancreatitis\\n➣ Due to SLE or meds (eg, steroids, azathioprine, thiazidediuretics)\\n■Possible inﬂammatory bowel disease w/ ulcerative colitis\\nneuropsychiatric\\n■Cerebral “vasculitis” leading to mood disturbances, psychosis,dementia and/or seizures\\n■Peripheral neuropathy involving cranial & peripheral nervesin 10% of cases\\n■Rare transverse myelitis w/ paresis or ﬂaccid paralysis of 1 ormore limbs\\n➣ Unusual recovery despite early treatment w/ steroids\\nTHALASSEMIA\\nARTHUR ATCHABAHIAN, MD\\noverview\\n■Thalassemia is the result of deletion of one or more genes cod-ing for the alpha (on chromosome 6) or beta (on chromosome11) subunits of hemoglobin.\\n■Alpha-thalassemia major (4 deleted alpha genes) is incom-patible w/ life & leads to death in utero.\\n■Hemoglobin H disease (HbH; 3 deleted alpha genes)\\n➣ Limited production of HbF in utero & HbA after birth\\n➣ Hb Bart (4 gamma chains) & Hb H (4 beta chains) precip-itate in RBCs, leading to premature destruction in bonemarrow & spleen.\\n■Alpha-thalassemia minor (ATM; 2 deleted alpha genes)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 167}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\n154 Thalassemia\\n➣ Alpha-thalassemia 0: Both genes are absent from the samechromosome\\n➣ Alpha-thalassemia +: One gene is missing from each chro-\\nmosome. The +form tends to be slightly more severe, w/\\nslightly lower hemoglobin levels.\\n■Alpha-thalassemia silent (1 deleted alpha gene)\\n➣ Minor changes, possible mild anemia\\n■Beta-thalassemia major (BTM) =Cooley’s anemia (both beta\\ngenes are deleted)\\n➣ Presence of HbA2 (2 alpha & 2 delta chains) & HbF (2 alpha& 2 gamma chains)\\n➣ Severe anemia develops by 1–2 months, w/ need forchronic transfusion.\\n➣ Need for chelation to prevent hemosiderosis\\n➣ Predominantly in pts of Mediterranean descent\\n■Beta-thalassemia minor (1 deleted beta gene)\\n➣ Increased production of HbA2 (2 alpha & 2 delta chains)\\n➣ Mild microcytic hypochromic anemia\\n■Beta-thalassemia major will be discussed in this chapter.\\nﬂuids and electrolytes\\n■Usually normal\\ncardiopulmonary\\n■CHF possible because of iron overload (less frequent w/ chela-tion)\\n■Common SVT & pericarditis\\n■High sensitivity to digoxin\\nhematologic\\n■Microcytic, hypochromic anemia\\n■Bone marrow hyperactivity\\n➣ Thinning of cortical bone\\n➣ Deformities (“chipmunk face”)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 168}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\nThalassemia Thyroid and Parathyroid Disease 155\\n■Splenomegaly constant, w/ possible hypersplenism & throm-bocytopenia requiring splenectomy\\nmetabolic-nutritional\\n■Usually normal\\ngastrointestinal\\n■Liver enlarged because of extramedullary hematopoiesis\\n➣ Possible decreased function & decreased production ofcoagulation factors\\nneuropsychiatric\\n■Spinal cord compression secondary to destruction of vertebralbodies by hyperactive bone marrow is possible.\\nTHYROID AND PARATHYROID DISEASE\\nGIUDITTA ANGELINI, MD\\noverview\\n■Thyroid gland\\n➣ Develops from 3rd & 4th branchial arch, descends towardneck\\n➣ Lingual thyroid is in arrested development & potentiallyonly functioning thyroid tissue.\\n➣ Lingual thyroid usually bleeds more profusely w/ biopsy.\\n■Hypothyroidism\\n➣ Incidence related to amount of iodide in the diet.\\n➣ Incidence: overt 5/1,000, subclinical 15/1,000 in endemicareas\\n➣ Primary hypothyroidism\\nrAutoimmune\\nrHashimoto’s thyroiditis\\nrIrradiation, previous131I therapy, surgical removal\\nrSevere iodine depletion'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 169}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\n156 Thyroid and Parathyroid Disease\\nrMeds: iodines, PTU, methimazole\\n➣ Secondary hypothyroidism\\nrPituitary\\nrHypothalamic\\n➣ Symptoms & signs\\nrReduced metabolic activity, cold intolerance, weightgain\\nrLethargy, slow mental function\\nrBradycardia, depressed myocardial contractility, peri-cardial effusion\\nrDelayed tendon reﬂexes\\nrDecreased ventilatory response to hypoxemia/hyper-carbia\\n■Hyperthyroidism\\n➣ Thyrotoxicosis affects 2% of women, 0.2% of men.\\n➣ Etiology\\nrIntrinsic thyroid disease (hyperfunctioning thyroidadenoma, toxic multinodular goiter)\\nrAbnormal TSH stimulation (Graves’ disease, tro-phoblastic tumor)\\nrDisorders of hormone storage or release (thyroiditis)\\nrExcess TSH (pituitary thyrotropin)\\nrExtrathyroid (struma ovarii, functioning follicular car-cinoma)\\nrExogenous thyroid (iatrogenic, iodine-induced)\\n➣ Most common: multinodular goiter of Graves’ disease\\n➣ Symptoms & signs\\nrIncreased metabolic activity, heat intolerance, nightsweats\\nrRestlessness, agitation, tremor\\nrPalpitations, tachycardia (at rest, sleep), atrial ﬁbrilla-tion\\nrLoss of weight'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 170}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\nThyroid and Parathyroid Disease 157\\nrGoiter\\n■Parathyroid hormone (PTH)\\n➣ Increases reabsorption of calcium in the kidney; mobiliza-tion of calcium from bone\\n➣ Increases renal excretion of phosphate\\n➣ Increases renal clearance & alkalinization of urine\\n➣ Inhibition of renal sodium reabsorption, increased freewater clearance\\n➣ Increased vitamin D activity\\n➣ Increased PTH secretion\\nrHypocalcemia & hypomagnesemia\\nrBeta-adrenergic agonists\\nrGlucocorticoids\\n■Calcitonin\\n➣ Secreted by parafollicular cells in the thyroid\\n➣ Increases renal excretion of calcium & reabsorption bybone\\n➣ Deﬁciency in total thyroidectomy & abundance inmedullary thyroid cancer\\n■Primary hyperparathyroidism\\n➣ Incidence\\nrAbout 25/100,000\\nrSingle adenoma (80%)\\nrMultiple adenomata (10–20%)\\nrHyperplasia (9%)\\nrCarcinoma (rare)\\n➣ Symptoms & signs\\nrMost pts are asymptomatic.\\nrSymptoms related to hypercalcemia\\nrPolyuria, polydipsia, nephrolithiasis\\nrIncreased bone resorption\\nrSkeletal muscle weakness & fatigability\\nrPeptic ulceration & constipation'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 171}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\n158 Thyroid and Parathyroid Disease\\nrDepression, psychosis, confusion, memory loss\\nrHypertension, short QTc, heart block, bundle branchblock\\nrRenal manifestations (10%)\\nrOsteitis ﬁbrosa cystica (rare unless neglected)\\nrEarly surgery decreases morbidity & mortality.\\n■Secondary & tertiary hyperparathyroidism\\n➣ Renal disease: impaired hydroxylation of vitamin D leadsto:\\n➣ Hypocalcemia, leads to hyperphosphatemia &\\n➣ Parathyroid hyperplasia & autonomous hypersecretion\\n➣ Requires surgical treatment in about 5% of cases in whichmedical treatment is ineffective\\nﬂuid and electrolytes\\n■Hypothyroidism\\n➣ Hyponatremia, hypoglycemia\\n■Hyperparathyroidism\\n➣ Hypercalcemia: dehydration\\n➣ Nephrolithiasis, nephrocalcinosis\\n➣ Tubular injury\\nrProximal tubular acidosis, aminoaciduria, glycosuria\\nrNephrogenic diabetes insipidus\\ncardiopulmonary\\n■Hypothyroidism\\n➣ Bradycardia, impaired myocardial function\\n➣ Abnormal baroreceptor function\\n➣ Decreased spontaneous ventilation & dyspnea\\n➣ Serous cavity effusions & peripheral edema\\n➣ Angina may be precipitated by rapid thyroid replacement.\\n■Hyperthyroidism\\n➣ Palpitations, atrial ﬁbrillation\\n➣ Congestive heart failure, ischemic heart disease\\n■Hyperparathyroidism'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 172}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\nThyroid and Parathyroid Disease 159\\n➣ Hypertension\\n➣ Hypercalcemia: QT prolongation, heart block & bundlebranch block\\nhematologic\\n■Hypothyroidism\\n➣ Decreased plasma volume\\n➣ Anemia\\n■Hyperthyroidism\\n➣ Thrombocytopenia\\nmetabolic-nutritional\\n■Hypothyroidism\\n➣ Cool, myxedematous extremities\\n➣ Hoarse voice, amenorrhea, hair loss\\n■Hyperthyroidism\\n➣ Heat intolerance, sweating\\n➣ Gynecomastia\\n■Hyperparathyroidism\\n➣ Bone loss, but risk of fracture not greatly increased\\n➣ Chondrocalcinosis, pseudogout\\n➣ Juxta-articular erosions, synovitis, periarthritis & pericap-sular calciﬁcation\\ngastrointestinal\\n■Hypothyroidism\\n➣ Weight gain, poor appetite & constipation\\n■Hyperthyroidism\\n➣ Weight loss, increased appetite & diarrhea\\n■Hyperparathyroidism\\n➣ Constipation, peptic ulcer, pancreatitis\\nneuropsychiatric\\n■Hypothyroidism\\n➣ Lethargy, weakness, loss of concentration & memory'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 173}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\n160 Thyroid and Parathyroid Disease Transfusion Therapy\\n➣ Hearing loss, paresthesias & delayed tendon reﬂex relax-ation\\n➣ Carpal tunnel syndrome\\n■Hyperthyroidism\\n➣ Hyperactivity, tremor\\n➣ Fatigue, weakness, proximal myopathy\\n■Hyperparathyroidism\\n➣ Depression, personality changes & memory impairment\\n➣ Overt psychosis\\n➣ Obtundation (severe hypercalcemia)\\nTRANSFUSION THERAPY\\nDOUGLAS B. COURSIN, MD, AND KARL WILLMANN, MD\\noverview\\nRoughly 10–12 million units of blood are transfused annually inUSA; about 2/3 are administered perioperatively.\\n■Mainly transfuse blood as component therapy\\n➣ Packed RBCs\\n➣ Fresh-frozen plasma (FFP)\\n➣ Platelets\\n➣ Cryoprecipitate\\n➣ Specialized factors\\n■Use of autologous predonation, acute normovolemic hemod-ilution w/ reinfusion of the pt’s saved blood & cell salvage tech-niques are alternatives to allogeneic transfusion in selectedclinical situations.\\n➣ Blood substitutes using modiﬁed human blood, xenobi-otic blood solutions or ﬂuorocarbons are currently inves-tigational.\\n■Transfusion guidelines as outlined below focus on adults &older children; seek expert advice for premature infants & chil-dren<4 months of age. Guidelines continue to evolve.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 174}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\nTransfusion Therapy 161\\n➣ Major concerns w/ transfusions\\nrBloodborne infectious disease\\nrRisks continue to decrease but are not zero.\\nrHIV, hepatitides, other viral, bacterial, parasitic\\nrImmune modulation\\nrTransfusion reaction\\nrTransfusion-related acute lung injury (TRALI)\\nrStorage defects\\n➣ Various organizations have recommendations\\nrAmerican Society of Anesthesiologists: http://www.asahq.org/publicationsAndServices/blood\\ncomponent.\\nhtml\\nrAmerican Red Cross: http://www.newenglandblood.org/professional/guidelines.htm\\nrAmerican College of Physicians, American Society ofClinical Pathologists, American Association of BloodBankers fairly similar\\n➣ Guidelines must be tailored to the individual pt & his orher clinical circumstances.\\n➣ Trend is to lower transfusion triggers.\\n➣ Consider:\\nrSpeed of blood loss/anemia\\nrCoagulation parameters\\nrCardiopulmonary reserve\\nrIf you elect to tolerate a lower Hgb, be certain toensure adequate volume replacement & intravascularvolume.\\nrFull type & cross-match required to determine compat-ibility\\nrMainly use packed RBCs\\nrA unit of packed RBCs will increase the Hgb by 1 g/dLor Hct by about 3% unless the pt is severely anemic,Hct<20, or actively bleeding.\\nrLeukoreduction of RBCs is increasingly performed.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 175}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\n162 Transfusion Therapy\\nrUsually leukoreduced at the time of donation\\nrCan do this at the time of administration using spe-cial ﬁlters, but will slow rate of administration\\nrControversial, but many feel leukoreduction limitsfebrile reactions & may result in improved outcomecompared to non-leukoreduced RBCs\\nrDetermine transfusion trigger on an individualizedbasis.\\nrNever administer RBCs for volume expansion alone orto enhance wound healing.\\nrCurrent guidelines\\nrTo reverse or treat tissue hypoxia by increasing RBCmass & oxygen delivery\\nrMost advocate transfusing normovolemic pts whohave Hgb <7 g/dL.\\nrExceptions\\nrPts w/ active ongoing active blood loss that is unre-sponsive to crystalloid or colloid infusion\\nrPts w/ acute myocardial ischemia/infarction\\nrPts w/ anemia & CVA\\nrPts w/ symptomatic sickle cell anemia\\n➣ FFP\\nrFFP contains all clotting factors.\\nr1 unit of FFP increases clotting factors by about 2.5%.\\nrFFP indications\\nrPts w/ documented coagulation factor deﬁciencieswho are actively bleeding or undergoing an invasiveprocedure w/ signiﬁcant risk for bleeding\\nrEtiologies of coagulopathy\\nrCongenital\\nrAcquired\\nrLiver disease\\nrDIC\\nrDilutional'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 176}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\nTransfusion Therapy 163\\nrAnticoagulant use\\nrHeparin\\nrWarfarin\\nrThrombin inhibitors\\nrLabs to guide FFP indications\\nrINR>1.5x normal\\nrAPTT >1.5x normal\\nrManagement of HUS or TTP\\nrAs part of treatment w/ plasma exchange or plasma-pheresis\\nrSpeciﬁc plasma protein deﬁciencies\\nrAntithrombin III\\nrC-1 esterase\\n➣ Platelets\\nrNeed for platelets may be secondary to quantitative orqualitative defects\\nrThrombocytopenia: low number, quantitative\\nrBone marrow suppression & low production\\nrSequestration (spleen, RES, liver)\\nrDestruction\\nrAntibody\\nrSepsis\\nrDrug-related\\nrThrombocytopathy: abnormal function, qualitative\\nrDrug-related\\nrPost cardiopulmonary bypass or extracorporealsupport\\nrStore platelets at room temperature, as opposed to RBCs& FFP.\\nrEach unit of platelets contains 60 mL plasma.\\nrPlatelets may be random donor, single donor or HLA-typed donor.\\nrUse depends on indication, availability, underlyingpathology & prior exposure to platelets.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 177}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\n164 Transfusion Therapy\\nrIndications\\nrPrevent & treat surgical bleeding\\nrUsually aim to transfuse if platelet count <50,000\\nrSome use a threshold of >70–100,000 in pts under-\\ngoing ophthalmologic or neurosurgical procedures.\\nrHigh suspicion or lab documentation of qualitativedefect\\nrSelected bypass pts\\nrSelected renal failure pts\\nrReverse effects of drug-induced thrombocytopenia\\nrNSAIDs\\nrASA\\nrAntiplatelet drugs\\nrPersantine\\nrGlycoprotein IIb/IIIA inhibitors\\nrOther\\nrPlatelets should not be transfused in pts w/ heparin-induced thrombocytopenia (HIT), idiopathic throm-bocytopenia (ITP), TTP, HUS, or post-transfusionpurpura unless there is life-threatening bleeding (sug-gest hematology guidance).\\n■Cryoprecipitate\\n➣ Indications\\nrConsult hematology for mgt of coagulation disorderssuch as hemophilia, vWf deﬁciency & other rare coag-ulopathies or hypercoagulable state.\\nrFibrinogen <100 mg/dL\\nrFactor VIII, IX or vWf deﬁciency\\nrAs part of ﬁbrin glue local application\\n■Special products\\n➣ CMV-negative products (use only if the recipient is CMV-negative)\\nrStem cell or solid organ transplant pt\\nrPregnant woman'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 178}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\nTransfusion Therapy 165\\nrAIDS, severe immunosuppression, Hodgkin’s\\nrStatus post splenectomy\\n➣ Irradiated cells\\nrStem cell recipient\\nrIntrauterine transfusions\\nrDirected donation blood from a relative\\nrSevere immunosuppression, AIDS, Hodgkin’s, pt un-dergoing high-dose chemotherapy or radiation ther-apy\\nrRecipients of HLA-matched platelets\\n➣ Factor VIIa\\nrCurrently available for patients w/ factor VII deﬁciency\\nrSome case reports of broader use in the bleeding pt\\n■Special considerations\\n➣ Suspected transfusion reaction\\nrMay be acute or delayed\\nrIf you suspect an immediate reaction:\\nrStop the transfusion.\\nrSymptoms may range from minor, such as fever, toshock, hematuria, DIC, etc.\\nrSupportive care directed at speciﬁc type of reactionsuspected\\nrClerical check\\nrSend both anticoagulated & clotted blood samplesfrom pt to lab for evaluation, along w/ suspectedblood product.\\nrSend urinalysis to lab.\\nrCommunicate w/ blood bank about results & need foradditional information or testing.\\nrNo further transfusion of blood products unless life-threatening hemorrhage & until cleared by bloodbank\\n➣ Transfusion-related acute lung injury (TRALI)\\nrhttp://www.fda.gov/cber/ltr/trali101901.htm'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 179}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\n166 Transfusion Therapy\\nrhttp://www.google.com/search?hl=en&ie=ISO-8859–1&q=TRALI\\nrSee [PDF] Transfusion Related Acute Lung Injury(TRALI)\\nrRelatively rare (0.02% of all transfusions), but a majorcause of post-transfusion morbidity & mortality\\nrResults in part from an antibody response of the donorto recipient WBCs\\nrDonor most often multiparous woman\\nrOften, not always, HLA sensitized\\nrMay require “second hit” from hypoxia or other not fullyunderstood recipient factors\\nrDevelops within 1–6 hrs of transfusion, may be as lateas 24 hrs\\nrAll blood products may cause\\nrRapid onset of acute respiratory insufﬁciency\\nrDyspnea, shortness of breath, cyanosis, hypotension,fever & pulmonary edema may develop.\\nrNo deﬁnitive test to establish diagnosis; one of exclu-sion\\nrChest x-ray often shows diffuse inﬁltrates.\\nrRule out cardiogenic or volume overload.\\nrTreatment is supportive.\\nrStop current blood transfusion if suspected.\\nrOxygen, noninvasive or invasive ventilatory sup-port\\nrReport it to your blood bank.\\nﬂuid and electrolytes\\n■Transfuse through normal saline-containing infusions toavoid hemolysis, crenation or chelation of anticoagulant.\\ncardiopulmonary\\n■Transfusion trigger for pts w/ acute coronary syndrome oracute MI is Hgb 10–11.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 180}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\nTransfusion Therapy von Willebrand’s Disease 167\\nhematologic\\nN/A\\nmetabolic-nutritional\\nN/A\\ngastrointestinal\\n■Renal compromise is a complication of transfusion reactionfrom pigment; diuresis & supportive care are needed.\\nneuropsychiatric\\nN/A\\nVON WILLEBRAND’S DISEASE\\nKARL WILLMANN, MD, AND D. B. COURSIN, MD\\noverview\\n■von Willebrand’s disease is a bleeding diathesis character-ized by mucocutaneous bleeding, epistaxis, menorrhagia,easy bruising & prolonged bleeding time. It is an autosomaldominant genetic disease representing a deﬁciency or defectof von Willebrand factor (vWf).\\n■Clear family history not always present, as disease severityvaries substantially\\n■vWf has several roles in the coagulation cascade, includingprotecting factor VIII from degradation & binding of plateletsto damaged endothelium.\\n■Platelet numbers are normal & PTT is normal unless severedisease. PT is normal.\\n■Of the inherited bleeding disorders, it is the most common.\\n■There are 5 subtypes of von Willebrand’s disease.\\n■The diagnosis is made by antigen immunoassay of vWf:Ag &ristocetin cofactor activity (vWf:Co). Along w/ immunoassays,immunoelectrophoresis distinguishes between the different'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 181}, page_content='P1: SBT0521759385p2-F CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:7\\n168 von Willebrand’s Disease\\ntypes. There are several multimers of different sizes that makeup vWf.\\n➣ Type I: Most common. Decreased vWf:Ag & vWf:Co; nor-mal multimers, just decreased number.\\n➣ Type IIa: Decreased vWf:Ag & greatly decreased vWf:Co w/decrease in medium & large multimers\\n➣ Type IIb: Decreased vWf:Ag & near-normal vWf:Co; abnor-mal large multimers that bind to platelets w/out normalactivity\\n➣ Type III: No vWf:Ag or vWf:Co, no vWf present\\n➣ Type IV: Decreased vWf:Ag & vWf:Co, w/ normal vWf, butplatelet GPIb receptor binds only large multimers\\nﬂuid and electrolytes\\n■No special concerns\\ncardiopulmonary\\n■No special concerns\\nhematologic\\n■There are several types; see “Overview.” Pt may have hadprevious transfusions of coagulation factors for excessivebleeding. These pts are at risk for virally transmitted diseasessuch as hepatitis & HIV.\\nmetabolic-nutritional\\n■No special concerns\\ngastrointestinal\\n■Pts who have received factor therapy from random donors areat risk for hepatitis & its sequelae.\\nneuropsychiatric\\n■No special concerns'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 182}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\nPART TWO\\nPharmacology\\n169'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 183}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\nADRENAL & PITUITARY DISEASE\\nGIUDITTA ANGELINI, MD\\npharmacology\\n■Bromocriptine\\n➣ Dopamine agonist\\n➣ First-line treatment for prolactinoma\\n➣ Potential treatment for acromegaly (primary treatmentsurgical): start at 1 mg qd & titrate against prolactin con-centration to 5–15 mg qd.\\n➣ Alternative therapy: cabergoline\\n➣ Monitor visual ﬁeld defects during therapy.\\n➣ Medical therapy curative in 95% of cases, w/ regression ofvisual ﬁeld defects in 75% of cases\\n➣ No evidence of teratogenicity, but usually stopped duringpregnancy\\n➣ Surgery indicated after failure or intolerance to medicaltherapy\\n■Somatostatin\\n➣ Potential treatment for acromegaly (see bromocriptine)\\n■Metyrapone, betaconazole\\n➣ Reverse side effects of increased concentrations of circu-lating cortisol\\n■Surgery is primary therapy in:\\n➣ Acromegaly\\n➣ ACTH tumors\\n➣ TSH adenomas\\n➣ Gonadotroph adenomas\\ndrug dosing\\nN/A\\n170'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 184}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\nAdult Congenital Heart Disease Alcohol Abuse 171\\nADULT CONGENITAL HEART DISEASE\\nMARY E. McSWEENEY, MD\\npharmacology\\n■Negative inotropic & chronotropic agents\\n➣ Use to decrease outﬂow obstruction in pts w/ subvalvularstenosis.\\n➣ Avoid in pts w/ high PVR: result in increased R-to-L shunt\\n■Vasodilators\\n➣ Avoid in pts w/ high PVR: result in increased R-to-L shunt\\n■Alpha-adrenergic agonists\\n➣ Use in pts w/ shunts & high PVR to maintain diastolicperfusion pressure, increase SVR & prevent increased R-to-L shunt.\\ndrug dosing\\nN/A\\nALCOHOL ABUSE\\nJONATHAN T. KETZLER, MD\\npharmacology\\n■Mechanisms of alcohol-induced CNS depression\\n➣ Potentiates gamma-aminobutyric acid (GABA) (inhibitoryamino acid)\\n➣ Inhibits n-methyl-D-aspartate (NMDA) (excitatory aminoacid)\\n■Also acts on noradrenergic, dopaminergic, serotoninergic &opioid pathways\\n■Chronic exposure: decreased GABA synthesis, increasedNMDA synthesis'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 185}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\n172 Alcohol Abuse Ankylosing Spondylitis\\n■Abrupt withdrawal: relative lack of GABA, relative excess ofNMDA\\n■Alcohol withdrawal may cause kindling:\\n➣ Repeated exposures to electric/chemical stimuli causeprogressively exaggerated neuronal response (kindling).\\n➣ Repeated withdrawal over time leads to increased CNSexcitability (exacerbated withdrawal syndrome).\\nrAnti-kindling agents such as carbamazepine (Tegretol)are effective in treating alcohol withdrawal syndrome,esp. anxiety & agitation.\\ndrug dosing\\n■N/A\\nANEMIA\\nDOUGLAS B. COURSIN, MD AND KARL WILLMANN, MD\\npharmacology\\n■Little effect on pharmacology other than changes w/ asso-ciated abnormal binding proteins & end-organ pathology inliver or kidney\\n■Hemolysis may damage kidneys.\\ndrug dosing\\n■Little effect on drug dosing unless associated abnormal bind-ing proteins or end-organ pathology in liver or kidney\\nANKYLOSING SPONDYLITIS\\nHUGH R. PLAYFORD, MD\\npharmacology\\nN/A'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 186}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\nAnkylosing Spondylitis Aortic Regurgitation 173\\ndrug dosing\\nN/A\\nANTICOAGULATION THERAPY\\nJONATHAN T. KETZLER, MD\\npharmacology\\nN/A\\ndrug dosing\\nN/A\\nAORTIC REGURGITATION\\nROBERT N. SLADEN, MD\\npharmacology\\n■Chronotropic, inotropic agents are useful.\\n➣ Tachycardia helps maintain forward CO (shorter diastolicregurgitant time).\\n➣ Increased contractility compensates for regurgitant frac-tion.\\n■Avoid negative inotropic & chronotropic agents:\\n➣ Decrease cardiac output\\n➣ Slower heart rate increases diastolic regurgitant time.\\n■Avoid alpha-adrenergic agents:\\n➣ Increase SVR & regurgitation\\n■Vasodilator agents may decrease SVR & increase forwardejection:\\n➣ Limited by decreased diastolic in perfusion pressure,impaired MVO\\n2\\n■Common maintenance meds & side effects\\n➣ Digoxin (digitoxic conduction disorders, arrhythmias)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 187}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\n174 Aortic Regurgitation Aortic Stenosis\\n➣ Loop diuretics (hypokalemia, hyponatremia)\\n➣ Coumadin (bleeding)\\ndrug dosing\\nN/A\\nAORTIC STENOSIS\\nROBERT N. SLADEN, MD\\npharmacology\\n■Negative inotropic & chronotropic agents can decrease gradi-ent, improve MVO\\n2\\n➣ Beta blockers (metoprolol, esmolol)\\n➣ Calcium channel blockers (verapamil, diltiazem)\\n■Alpha-adrenergic agents can support diastolic perfusion pres-sure during hypotension\\n➣ Phenylephrine (pure alpha-agonist) increases SVR, reﬂexbradycardia (preferred).\\n➣ Norepinephrine (mixed agent) increases contractility(avoid).\\n■Avoid chronotropic, inotropic agents\\n➣ Increased contractility increases pressure gradient acrossaortic valve\\n➣ Tachycardia decreases diastolic ﬁll time, impairs MVO 2\\n➣ May precipitate angina, syncope, sudden death\\n■Avoid vasodilator agents\\n➣ Decrease diastolic perfusion pressure, impair MVO 2\\n➣ Increase gradient across aortic valve\\n➣ Adverse effects exacerbated by reﬂex tachycardia\\n■Use diuretics w/ care (excess decreases preload)\\n■Common maintenance meds & side effects\\n➣ Beta blockers (bronchoconstriction)\\n➣ Calcium channel blockers (low cardiac output)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 188}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\nAortic Stenosis Carcinoid Syndrome 175\\ndrug dosing\\nN/A\\nBRONCHOSPASTIC DISEASE\\nHUGH PLAYFORD, MD\\npharmacology\\n■Usually unchanged\\n■No evidence of tolerance to beta-2 agonists w/ chronic treat-ment\\ndrug dosing\\nN/A\\nCARCINOID SYNDROME\\nGIUDITTA ANGELINI, MD\\npharmacology\\n■Octreotide\\n■Steroids\\n➣ Treat bronchospasm\\n■Theophyllines\\n➣ Treat bronchospasm\\n■Aprotinin\\n➣ Treat ﬂushing & hypotension\\n■Ondansetron\\n■Ranitidine/Benadryl\\ndrug dosing\\n■Octreotide\\n➣ Half-life 160 min\\n➣ 50–500 mcg SQ q8h can be administered as maintenance'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 189}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\n176 Carcinoid Syndrome Chronic Obstructive Pulmonary Disease\\n➣ 10–300 mcg/hr IV continuous infusion\\n➣ When discontinued, weaning must occur over 1 wk.\\nCHEMOTHERAPEUTIC AGENTS\\nJONATHAN T. KETZLER, MD\\nscreening and evaluation\\n■Anthracyclines\\n➣ There are no tests to determine which pts will developheart failure.\\n➣ Do gated radionucleotide blood pooled study or echocar-diogram as baseline before patient receives a cumulativedose of 400 mg/m\\n2& before each following treatment.\\n➣ Because injury can continue for years after treatment,ideally a full cardiac evaluation should be done within 1month of elective surgery.\\n■Bleomycin\\n➣ Chest x-ray & pulmonary function tests to evaluate forpneumonitis & pulmonary ﬁbrosis\\ndrug dosing\\nN/A\\nCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)\\nHUGH R. PLAYFORD, MBBS\\npharmacology\\nMinimal change\\ndrug dosing\\nN/A'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 190}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\nChronic Renal Failure 177\\nCHRONIC RENAL FAILURE\\nROBERT N. SLADEN, MD\\npharmacology\\n■Most IV anesthetic agents are lipid-soluble & non-ionized\\n➣ Hepatic biotransformation to active or inactive water-soluble metabolites\\n➣ Excreted in bile or urine\\n■Lipid-insoluble, highly ionized drugs (mostly muscle relax-ants)\\n➣ Directly excreted by kidney\\n■Renal disease alters anesthetic & parenteral drug clearance:\\n➣ Decreased blood ﬂow (drug delivery)\\n➣ Increased unbound free fraction of highly protein-bounddrugs (hypoalbuminemia, acidosis)\\n➣ Decreased enzymes & transport processes that removedrug from blood\\n■Duration of action (bolus or short-lived infusion)\\n➣ Dependent on redistribution, not elimination\\n➣ Loading dose is not decreased (unless unbound free frac-tion increased).\\n➣ Maintenance doses decreased (drug accumulates w/repeated dosing)\\n■Pharmacodynamics altered even if pharmacokinetics notchanged\\n➣ Pts are debilitated, w/ depleted lean body mass.\\n➣ Risk of respiratory depression (opioid or volatile anes-thetics)\\n■Reduce all drug dosages by 25–50%.\\ndrug dosing\\n■Drugs independent of renal function for elimination\\n➣ Enzymatic or spontaneous breakdown in the blood\\n➣ Accumulation is unlikely'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 191}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\n178 Chronic Renal Failure\\n■Examples\\n➣ Succinylcholine\\n➣ Atracurium, cisatracurium\\n➣ Remifentanil\\n➣ Esmolol\\n■Drugs w/ increased unbound fraction in hypoalbuminemia\\n➣ Increased free or active fraction\\n➣ Decrease doses 20–50% (depends on severity of hypoal-buminemia)\\n■Examples\\n➣ Thiopental\\n➣ Methohexital\\n➣ Diazepam\\n■Drugs predominantly dependent on renal elimination\\n➣ Loading doses remain unaltered\\n➣ Eliminate or decrease maintenance dose.\\n■Examples\\n➣ Gallamine, metubine\\n➣ Digoxin\\n➣ Penicillins,cephalosporins,aminoglycosides,vancomycin\\n➣ Cyclosporine A\\n■Drugs partially dependent on renal elimination\\n➣ Decrease maintenance doses by 30–50%.\\n➣ Titrate carefully to effect.\\n■Examples\\n➣ Anticholinergic, cholinergic agents\\n➣ Pancuronium, pipecuronium\\n➣ Vecuronium, rocuronium, doxacurium\\n➣ Milrinone, amrinone\\n➣ Phenobarbital\\n➣ Aprotinin, aminocaproic acid, tranexamic acid\\n■Drugs w/ active metabolites that are renally eliminated\\n➣ Prolonged effect despite rapid hepatic biotransformationof parent compound'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 192}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\nChronic Renal Failure Cocaine Toxicity 179\\n➣ Decrease maintenance doses by 30–50%, or avoid alto-gether.\\n■Examples\\n➣ Morphine (morphine-3-glucuronide, morphine-6-glucu-ronide, normorphine)\\n➣ Meperidine (normeperidine)\\n➣ Diazepam (desmethyldiazepam, oxazepam)\\n➣ Midazolam (l-hydroxymidazolam)\\n➣ Pancuronium (3-hydroxypancuronium)\\n➣ Vecuronium (desacetylvecuronium)\\n➣ Sevoﬂurane, enﬂurane (ﬂuoride)\\n➣ Sodium nitroprusside (thiocyanate)\\nCOCAINE TOXICITY\\nMARY E. McSWEENEY, MD\\npharmacology\\n■Benzoylmethylecgonine (cocaine)\\n➣ Crystalline form: made by dissolving alkaloid in hydroch-loric acid; forms water-soluble salt (usual street cocaine)\\n➣ Crack: unpuriﬁed freebase cocaine: formed by combiningcocaine hydrochloride w/ sodium bicarbonate & cookingin water; makes an oil-like substance that separates fromwater & forms small pieces (rocks), which can be smoked\\n➣ Freebase: ether extracted (rarely used)\\n■Absorption: absorbed from mucus membranes & respiratory,GI & GU tracts\\n■Onset: peak effect inhaled (smoked) 1–3 minutes, IV route3–5 minutes, intranasal route 20 minutes, GI route up to 90minutes\\n■Half-life: IV or inhalational administration associated w/ a60-minute half-life, vasoconstriction associated w/ theintranasal route prolongs the half-life to 2–3 hrs'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 193}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\n180 Cocaine Toxicity Congestive Heart Failure\\n■Metabolism: by plasma & hepatic cholinesterase & nonenzy-matic hydrolysis to inactive water-soluble metabolites (ben-zoylecgonine, ecgonine methyl ester), which are excreted inthe urine along with a small amount (10–20%) of unchangedcocaine. Those w/ decreased cholinesterase activity (fetuses,infants, pregnant women, elderly, patients w/ liver disease orpseudocholinesterase deﬁciency) are at higher risk.\\ndrug dosing\\nN/A\\nCONGESTIVE HEART FAILURE\\nMUHAMMED ITANI, MD, AND JONATHAN T. KETZLER, MD\\npharmacology\\n■Angiotensin-converting enzyme inhibitors (ACEI)\\n➣ Drugs\\nrCaptopril (short acting)\\nrEnalapril(at) (intermediate acting, only IV ACEI)\\nrLisinopril, ramipril (long acting)\\n➣ Alleviate symptoms & prolong survival\\n➣ Affect remodeling of the myocardium\\n➣ Relieve symptoms & conserve potassium\\n■Diuretics\\n➣ Drugs\\nrMedullary thick ascending loop (mTAL): furosemide,bumetanide, torsemide, ethacrynic acid\\nrDistal tubule: hydrochlorothiazide, metolazone\\nrDistal tubule, collecting duct (potassium-sparing):aldosterone antagonists: spironolactone\\n➣ Relieve circulatory & pulmonary congestion\\n➣ Decrease atrial & ventricular diastolic pressures & wallstress; improve subendocardial perfusion'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 194}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\nCongestive Heart Failure 181\\n➣ K+supplementation may be needed (loop, thiazide diuret-\\nics).\\n➣ Hyperkalemia may occur w/ K-sparing diuretics (spirono-lactone).\\n➣ Hypovolemia, prerenal azotemia & low cardiac outputmay occur.\\n■Oral vasodilators\\n➣ Prazosin (alpha-antagonist)\\n■IV vasodilators\\n➣ Arterial dilators (afterload reduction): dihydropyridinecalcium blockers (nicardipine)\\n➣ Venodilators (preload reduction): NTG\\n➣ Balanced vasodilators (arterial +venous dilation): SNP,\\nnesiritide\\n➣ Relax both arterial & venous vessels & improve stroke vol-ume & decrease LV pressure; useful in diastolic dysfunc-tion\\n■Digoxin\\n➣ Actions\\nrEnhances inotropy & decreases activation of sympa-thetic nervous system\\nrDose by level in CHF w/ SR (0.5–1.5 ng/mL): dose-dependent inotropy\\nrDose by ventricular rate in AF; seek subtoxic AV block\\nrDecrease maintenance dose in renal insufﬁciency\\n➣ Toxicity\\nrExacerbated by hypokalemia, hypercalcemia, hypo-magnesemia\\nrSymptoms: anorexia, nausea\\nrDysrhythmias (sinus bradycardia, PAT w/ block, Vbigeminy, refractory VT)\\nrTreat w/ correction of predisposing factor: atropine(bradycardia); lidocaine, phenytoin (VT).'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 195}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\n182 Congestive Heart Failure Cor Pulmonale and RHF\\n➣ Anesthetic planning w/ digoxin toxicity\\nrDelay elective surgery.\\nrConsider digoxin antibodies.\\nrAvoid sympathomimetic drugs (ketamine) & calcium.\\nrAvoid high levels of volatile agents.\\nrAvoid hyperventilation (ie, respiratory alkalosis &hypokalemia).\\nrAdminister K for tachyarrhythmias (w/ normal renalfunction & absence of heart block)\\nrSB: atropine; VT: lidocaine, phenytoin (may be refrac-tory to cardioversion)\\ndrug dosing\\nN/A\\nCOR PULMONALE AND RHF\\nMUHAMMED ITANI, MD, AND JONATHAN T. KETZLER, MD\\npharmacology\\n■Volatile anesthetic agents\\n➣ Well-tolerated, potent bronchodilators\\n■N2O\\n➣ AVOID: induces pulmonary vasoconstriction, may worsenpulmonary hypertension\\n■Inhaled nitric oxide\\n➣ Speciﬁc pulmonary vasodilator\\n➣ May help decrease pulmonary arterial pressure\\n■Neuromuscular blocking agents (NMBA)\\n➣ May be used safely in pts w/ RV failure\\n■Intravenous induction agents (propofol, thiopental)\\n➣ AVOID or use slowly & cautiously.\\n➣ May induce severe systemic hypotension (uncompen-sated w/ ﬁxed pulmonary vasoconstriction)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 196}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\nCor Pulmonale and RHF Diabetes Mellitus and Diabetic Emergencies 183\\n■Opioids & sedatives\\n➣ Use extreme caution, esp. preoperatively & in awake pts.\\n➣ Risk of hypoventilation & worsening of arterial hypoxemia\\ndrug dosing\\n■Altered, depending on severity of hepatic or renal failure\\nDIABETES MELLITUS AND DIABETIC EMERGENCIES\\nDOUGLAS B. COURSIN, MD\\npharmacology\\n■Most routine meds can be given prior to surgery; in particu-lar, beta blockers, meds to decrease gastric acid (H2 blockers,proton pump inhibitors). ACE inhibitors are usually held theday of surgery to avoid hypotension.\\n■Hold oral hypoglycemic agents the day of surgery, althoughacarbose can be administered.\\n■Insulin\\n➣ Type 1 diabetics always require some basal insulin.\\n➣ Obtain a fasting blood sugar prior to administering preopinsulins.\\n➣ Regular is routinely held, unless blood glucose >250 mg/\\ndL.\\n■Any pharmacokinetic changes usually secondary to advancedrenal disease\\ndrug dosing\\n■Insulin\\n➣ Ultra-short, short, intermediate, long acting\\n➣ Vary as to onset of action & duration\\n➣ Often given as split doses\\nrA M&P M\\nrGiven as boluses of ultra-short or short-acting agentsw/ meals'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 197}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\n184 Diabetes Mellitus and Diabetic Emergencies Epilepsy\\n➣ For perioperative use\\nrRegular is usually held\\nr1/2 to 2/3 of the normal intermediate-acting agents aregiven on the day of surgery w/ appropriate IV access &glucose monitoring & supplementation\\nrGlargine is peakless, given in the PM, can be given thenight before surgery & then additional supplementa-tion\\n➣ Ultrashort acting\\nrLispro or aspart, not used intraoperatively\\n➣ Short acting\\nrRegular: preparation used for continuous insulin infu-sion\\nrOtherwise usually hold day of surgery to avoid hypo-glycemia\\n➣ Intermediate to long acting\\nrNPH\\nrLente\\n➣ Long acting\\nrUltralente\\nrGlargine\\n■Administered at nighttime\\n■Peakless\\n■Oral hypoglycemic agents: hold day of surgery\\n➣ Do not restart metformin postop until sure that renal &hepatic functions are adequate.\\nEPILEPSY\\nGEBHARD WAGENER, MD\\npharmacology\\n■Liver enzyme induction (cytochrome P450) by carbamaze-pine, phenytoin, barbiturates'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 198}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\nEpilepsy The Geriatric Patient 185\\n■Increased resistance to neuromuscular blocking agents (esp.phenytoin)\\n■Carbamazepine & phenytoin levels may be elevated up to 1wk postop.\\n■Except for gabapentin: hepatic elimination\\ndrug dosing\\nN/A\\nTHE GERIATRIC PATIENT\\nHUGH R. PLAYFORD, MD\\npharmacology\\nPharmacokinetics\\n■Usually manifest as increased elimination half-life\\n➣ Decreased renal clearance (digoxin, antibiotics, pancuro-nium)\\n➣ Increased hepatic clearance (propranolol, lidocaine,vecuronium)\\n➣ Increased volume of distribution (diazepam) related toincreased total fat content & decreased serum albumin\\n➣ Leads to accumulation of drugs (and /or metabolites) &increased incidence of adverse events\\nPharmacodynamics\\n■In general, decreased responsiveness of receptors (esp. cate-cholamines)\\n■Neuromuscular junction receptors unchanged w/ aging\\nElimination\\n■Renal dysfunction will prolong the elimination half-lives ofrenally metabolized & eliminated drugs.\\n■Hepatic dysfunction will prolong the elimination half-lives ofhepatically metabolized & eliminated drugs.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 199}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\n186 The Geriatric Patient Hemophilia A & Hemophilia B\\ndrug dosing\\nN/A\\nGI DISEASE\\nGEBHARD WAGENER, MD\\npharmacology\\n■Oral bioavailability erratic w/ GI disease\\n■Protein loss common w/ enteropathies\\n■Dehydration causes decreased blood volume.\\ndrug dosing\\nN/A\\nHEMOGLOBINOPATHIES\\nDOUGLAS B. COURSIN, MD, AND KARL WILLMANN, MD\\npharmacology\\n■Little effect on pharmacology other than changes w/ asso-ciated abnormal binding proteins & end-organ pathology inliver or kidney\\n■Hemolysis may damage kidneys.\\ndrug dosing\\n■Little effect on drug dosing unless associated abnormal bind-ing proteins or end-organ pathology in liver or kidney\\nHEMOPHILIA A & HEMOPHILIA B\\nKARL WILLMANN, MD, AND D. B. COURSIN, MD\\npharmacology\\n■No special concerns'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 200}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\nHemophili aA&H e mophilia B Herbal Therapy 187\\ndrug dosing\\n■Pts w/ hepatitis & liver dysfunction require drug dosing appro-priate to the degree of liver failure.\\nHERBAL THERAPY\\nJONATHAN T. KETZLER, MD\\npharmacology\\n■Cayenne ( Capsicum annuum )\\n➣ Other names: cayenne, chili pepper, paprika\\n➣ Uses\\nrExternal: muscle soreness\\nrInternal: GI distress\\n➣ Issues\\nrMay cause blisters when applied topically\\nrMay cause hypothermia when used internally\\n■Danshen ( Salvia miltiorrhiza )\\n➣ Other names: tanshen, red sage, red ginseng, Chinese sage\\n➣ Uses\\nrIschemic heart disease\\nrAtherosclerotic disease\\nrAntioxidant\\nrAntihypertensive\\n➣ Issues\\nrMay cause bleeding\\n■Dong quai ( Angelica sinensis )\\n➣ Other names: dang gui, tang kuei\\n➣ Uses\\nrThe “ultimate herb” for women\\nrRestores menstrual regularity & hormonal balance\\nrBlood thinner\\nrAntiarrhythmic'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 201}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\n188 Herbal Therapy\\nrHematopoietic\\nrAntioxidant\\n➣ Issues\\nrMay cause bleeding\\n■Echinacea (Echinacea purpurea)\\n➣ Other names: purple cone ﬂower\\n➣ Uses\\nrColds, urinary tract infections, bronchitis, topically forwounds & burns\\n➣ Issues\\nrMay cause inﬂammation of liver if used w/ certain othermeds, such as anabolic steroids or methotrexate\\nrMay decrease the effectiveness of corticosteroids\\n■Ephedra (Ephedra sinica)\\n➣ Other names: ephedrine, ma-huang, Chinese joint ﬁr\\n➣ Uses\\nrOver-the-counter diet pills\\nrAdded energy\\nrBacteriostatic\\nrAntitussive\\n➣ Issues\\nrIn late December 2003, FDA banned ephedra from themarketplace because of health concerns.\\nrArrhythmias\\nrMay interact w/ certain antidepressants or certain BPmeds to cause dangerous elevations in BP or heart rate\\nrEnhanced sympathomimetic effects when used w/MAO inhibitors\\nrHypertension when used w/ oxytocin\\nrMay cause stroke or death in certain individuals\\n■Feverfew (Tanacetum parthenium)\\n➣ Other names: featherfew, midsummer daisy\\n➣ Uses\\nrMigraines\\nrAntipyretic'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 202}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\nHerbal Therapy 189\\nrAnxiety\\nrJoint stiffness\\n➣ Issues\\nrPlatelet inhibition\\nrRebound headache\\nr5–15% of users develop aphthous ulcers & GI upset.\\n■Garlic ( Allium sativum )\\n➣ Other names: clove garlic, ajo\\n➣ Uses\\nrLower lipids\\nrLower BP\\nrAntiplatelet\\nrAntioxidant\\nrBlood thinner\\n➣ Issues\\nrEnhances effect of warfarin\\nrMay decrease effectiveness of AIDS therapy, especiallysaquinavir\\n■Ginger ( Zingiber ofﬁcinale )\\n➣ Other names: black ginger, African ginger\\n➣ Uses\\nrAntiemetic\\nrAntispasmodic\\n➣ Issues\\nrMay increase bleeding by inhibiting thromboxane syn-thetase\\nrIncreased sedation\\n■Ginkgo ( Gingko biloba )\\n➣ Other names: maidenhair tree, fossil tree\\n➣ Uses: circulatory stimulant\\n➣ Issues: may increase bleeding, especially in pts alreadytaking certain anti-clotting meds\\n■Ginseng ( Panax ginseng )\\n➣ Other names: American ginseng, Chinese ginseng, Koreanginseng'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 203}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\n190 Herbal Therapy\\n➣ Uses\\nrEnergy enhancer\\nrAphrodisiac\\nrAntioxidant\\n➣ Issues\\nrDecreased effectiveness of warfarin\\nrSomnolence\\nrHypertonia\\nrEdema\\nrTachycardia\\nrEnhanced response to sympathomimetics\\nrPostmenopausal bleeding\\nrMania in pts on phenelzine\\n■Goldenseal (Hydrastis canadensis)\\n➣ Other names: orange root, yellow root, ground raspberry,tumeric root, eye root\\n➣ Uses\\nrDiuretic\\nrAnti-inﬂammatory\\nrLaxative\\nrHemostatic\\n➣ Issues\\nrOverdose may cause paralysis.\\nrCauses excretion of free water, not sodium\\nrMay worsen edema\\nrMay worsen hypertension\\n■Kava-Kava (Methysticum)\\n➣ Other names: kawa awa pepper\\n➣ Uses: anxiolytic\\n➣ Issues\\nrMay enhance the sedative effects of anesthesia\\nrMay increase the effects of certain anti-seizure meds\\nrMay cause serious liver injury\\nrMay worsen the symptoms of Parkinson’s disease'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 204}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\nHerbal Therapy 191\\nrCan enhance the effects of alcohol\\nrMay increase the risk of suicide in pts w/ certain typesof depression\\n■Licorice ( Glycyrrhiza glabra )\\n➣ Other names: licorice root, sweet root\\n➣ Uses\\nrGI ulcers\\nrAntitussive\\nrBronchitis\\nrMost licorice candy contains little or no herbal licorice,but check product ingredients (“licorice ﬂavoring” issafer than “licorice extract,” or “natural licorice”).\\n➣ Issues\\nrMay increase BP\\nrMay cause hypokalemia\\nrMay increase swelling\\nrContraindicated in hepatic & renal insufﬁciency\\n■Milk Thistle ( Silmarin )\\n➣ Uses: liver disease\\n➣ Issues\\nrShould be no issues if taken as directed\\nrHas caused diarrhea in animals\\nrOne case of urticaria reported in Russia\\n■Saw Palmetto ( Serenoa repens )\\n➣ Other names: sabal, cabbage palm\\n➣ Uses\\nrBenign prostatic hypertrophy\\nrAnti-androgenic\\n➣ Issues: interferes w/ hormone therapy\\n■St. John’s Wort ( Hypericum perforatum )\\n➣ Other names: hardhay, amber goatweed\\n➣ Uses\\nrAntidepressant\\nrAnxiolytic'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 205}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\n192 Herbal Therapy HIV & AIDS\\n➣ Issues\\nrMay enhance the sedative effects of anesthesia\\nrEnhanced sympathomimetic effects when used w/MAO inhibitors\\nrMay cause photosensitivity\\n■Valerian (Valeriana ofﬁcinalis)\\n➣ Other names: all heal, setwall, vandal root\\n➣ Uses\\nrSedative\\nrAnxiolytic\\n➣ Issues: may enhance the sedative effects of anesthesia\\ndrug dosing\\nN/A\\nHIV & AIDS\\nGEBHARD WAGENER, MD\\npharmacology\\nHAART (highly active antiretroviral therapy)\\n■Nucleoside reverse transcriptase inhibitors (NRTIs): anemia,neutropenia, induction of liver enzymes\\n➣ AZT, didanosine, lamivudine\\n■Non-nucleoside reverse transcriptase inhibitors (NNRTIs):induce cytochrome P450,\\n➣ Nevirapine, efavirenz\\n■Protease inhibitors (PIs): inhibit cytochrome P-450, CAD,hyperglycemia, may prolong fentanyl half-life\\n➣ Saquinavir, ritonavir, nelﬁnavir\\n■Benzodiazepines & opioids: increased sensitivity w/ AIDSdementia\\n■Neuroleptics: extrapyramidal symptoms more likely'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 206}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\nHIV & AIDS ICU Patient Scheduled for Intercurrent Surgery 193\\ndrug dosing\\nN/A\\nHYPERTENSION\\nMUHAMMED ITANI, MD AND JONATHAN T. KETZLER, MD\\npharmacology\\nN/A\\ndrug dosing\\nN/A\\nICU PATIENT SCHEDULED FOR INTERCURRENT SURGERY\\nDOUGLAS B. COURSIN, MD\\npharmacology\\n■Altered pharmacokinetics/dynamics\\n➣ Bioavailability via enteric & subcutaneous route unpre-dictable\\n➣ Both PK & PD can be unpredictable\\n➣ Limited data for some medication use in ICU pts\\n➣ End-organ dysfunction\\nrRenal\\nrHepatic\\nrCombined renal/hepatic\\n➣ Altered receptor function\\n➣ Drug compatibility\\nrDo you have adequate access to infuse all of the drugs& anesthetic agents needed?\\n➣ ICU pts receive an average of 10–15 meds; chance of druginteraction is high.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 207}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\n194 ICU Patient Scheduled for Intercurrent Surgery IHSS\\ndrug dosing\\n■Titrate to effect\\n■Volume of distribution may be signiﬁcantly altered, especiallyin renal/hepatic dysfunction, hypoalbuminemic state.\\n➣ May require larger doses for effect (eg, nondepolarizingagents)\\n➣ Clearance may be prolonged.\\n➣ Take into account changes in kinetics of highly protein-bound meds.\\n■Concurrent pathology may create agonist or antagonisticresponse to meds.\\nIDIOPATHIC HYPERTROPHIC SUBAORTICSTENOSIS (IHSS)\\nROBERT N. SLADEN, MD\\npharmacology\\n■Negative inotropic & chronotropic agents can decrease gradi-ent, improve MVO\\n2\\n➣ Beta blockers (metoprolol, esmolol)\\n➣ Calcium channel blockers (verapamil, diltiazem)\\n■Alpha-adrenergic agents can support diastolic perfusion pres-sure during hypotension\\n➣ Phenylephrine (pure alpha-agonist) increases SVR, reﬂexbradycardia (preferred).\\n➣ Norepinephrine (mixed agent) increases contractility(avoid).\\n■Avoid chronotropic, inotropic agents\\n➣ Increased contractility increases pressure gradient acrossaortic valve.\\n➣ Tachycardia decreases diastolic ﬁll time, impairs MVO 2\\n➣ May precipitate angina, syncope, sudden death'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 208}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\nIHSS Ischemic Heart Disease 195\\n■Avoid vasodilator agents\\n➣ Decrease diastolic perfusion pressure, impair MVO 2\\n➣ Increase gradient across aortic valve\\n➣ Adverse effects exacerbated by reﬂex tachycardia\\n■Use diuretics w/ care (excess decreases preload).\\n■Common maintenance meds & side effects\\n➣ Beta blockers (bronchoconstriction)\\n➣ Calcium channel blockers (low cardiac output)\\ndrug dosing\\nN/A\\nISCHEMIC HEART DISEASE\\nMUHAMMED ITANI, MD, AND JONATHAN T. KETZLER, MD\\npharmacology\\n■Antiplatelet drugs\\n➣ Drugs\\nrAspirin\\nrClopidogrel (Plavix)\\nrPlatelet glycoprotein IIb/IIIa receptor inhibitors (abcix-imab)\\n➣ Indications\\nrDecrease risk of cardiac events in pts w/ IHD\\nrDuring AMI w/ pain onset\\nrPlacement of coronary artery stents\\n■Nitrates\\n➣ Drugs\\nrNitroglycerine (sublingual, IV, spray, ointment, patch)\\nrIsosorbide\\n➣ Advantages\\nrMay decrease frequency, duration & severity of angina\\nrMay increase exercise tolerance'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 209}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\n196 Ischemic Heart Disease\\nrDecrease myocardial preload & afterload\\nrDecrease myocardial oxygen consumption\\nrVasodilate coronaries & collaterals\\n➣ Limitations\\nrRapid tolerance w/ sustained therapy\\nrHypotension & headaches\\n■Beta blockers\\n➣ Drugs\\nrLong acting: nadolol (non-selective), atenolol (beta-1selective), sotalol\\nrIntermediate acting: propranolol (non-selective), me-toprolol (beta-1 selective)\\nrShort acting: esmolol (beta-1 selective)\\n➣ Advantages\\nrDecrease myocardial oxygen consumption by decreas-ing contractility\\nrIncrease myocardial perfusion by decreasing heart rate& increasing diastolic time\\nrVery beneﬁcial for pts w/ stable angina\\nrDecrease risk of death & reinfarction in pts w/ historyof previous MI\\nrShould be given as early as possible in patients w/ AMI\\n➣ Side effects\\nrBeta-2 antagonism (bronchospasm, exacerbate periph-eral vascular disease)\\nrExcessive myocardial depression (worsened CHF)\\n➣ Contraindications\\nrAbsolute: unstable CHF, severe conduction disease\\nrRelative: severe reactive airways disease, COPD\\n■Calcium channel blockers (CCBs)\\n➣ Drugs\\nrPotent negative inotropic/chronotropic effects: vera-pamil\\nrMild negative inotropic/chronotropic effects: diltiazem'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 210}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\nIschemic Heart Disease 197\\nrPure vasodilators (dihydropyridines): nifedipine, nicar-dipine, isradipine, nimodipine\\n➣ Advantages & limitations\\nrVerapamil & diltiazem are effective in relieving anginapectoris & decreasing symptom severity & frequencycaused by vasospasm (Prinzmetal’s angina).\\nrNot as effective as beta blockers in decreasing incidenceof reinfarction\\nrDihydropyridines are not recommended as they mayincrease adverse cardiac events.\\n■Thrombolytic therapy\\n➣ Drugs\\nrStreptokinase\\nrtPA (tissue plasminogen activator)\\nrReteplase\\n➣ Indications\\nrTreatment of acute coronary syndromes\\n■Heparin\\n➣ Indications\\nrIn combination w/ aspirin to treat unstable angina\\nrAfter thrombolytic therapy for 3–5 days in AMI\\nrFor anticoagulation if AF persists >24–36 hrs\\nrFor anticoagulation when LV thrombus is present\\n■Warfarin\\n➣ Indications\\nrLong-term treatment of unstable angina\\nrCombination w/ aspirin more effective than aspirinalone\\nrLong-term treatment w/ AF or LV thrombus\\n■ACE inhibitors\\n➣ Drugs\\nrShort acting: captopril\\nrIntermediate acting: enalapril ( +IV enalaprilat)\\nrLong acting: lisinopril, ramipril'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 211}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\n198 Ischemic Heart Disease\\n➣ Indications & advantages\\nrAdministered in all pts w/ AMI as BP allows\\nrBeneﬁcial in pts w/ signiﬁcant LV dysfunction after AMI(EF<40%)\\nrLong-term administration decreases risk of reinfarction& CHF.\\n➣ Limitations\\nrWorsened renal function in pts w/ renal insufﬁciency\\nrSide effects (eg, cough) may be less w/ angiotensinreceptor blockers (ARBs) such as losartan.\\n■Lidocaine\\n➣ Indications\\nrOnly for ventricular dysrhythmias in the setting of AMI\\n■Magnesium sulfate\\n➣ Indications\\nrOnly in pts w/ AMI & torsades de pointes\\ndrug dosing\\n■Volatile anesthetics (isoﬂurane, desﬂurane & sevoﬂurane) aresafe in the absence of severe CHF.\\n■High-dose opioids (50–100 mcg/kg fentanyl) may be used.\\n■CAUTION: combination of opioids & nitrous oxide mayincrease PVR & impair myocardial contractility.\\n■Benzodiazepines have minimal cardiovascular effects & aresafe to use for anesthetic induction. CAUTION: Higher dosesin hypovolemic pts may cause unwanted hypotension.\\n■Etomidate may be the drug of choice for induction if severecardiovascular disease is present, or if any decrease in BP isdetrimental.\\n■Propofol & thiopental should be used w/ caution because ofthe risk of hypotension, especially in pts w/ severe IHD & CHF.\\n■AVOID sympathomimetic agents (pancuronium, ketamine).\\n■CAUTION: CCBs may increase sensitivity to depolarizing &nondepolarizing neuromuscular blocking agents.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 212}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\nLatex Allergy Liver Disease 199\\nLATEX ALLERGY\\nARTHUR ATCHABAHIAN, MD\\npharmacology\\nNormal\\ndrug dosing\\nNormal\\nLIVER DISEASE\\nROBERT N. SLADEN, MD\\npharmacology\\n■Most IV anesthetic agents are lipid-soluble & non-ionized.\\n➣ Hepatic biotransformation to active or inactive water-soluble metabolites\\n➣ Excreted in bile or urine\\n■Only lipid-insoluble, highly ionized drugs directly excreted bythe kidney\\n➣ Mostly neuromuscular blockers\\n■Liver disease alters anesthetic & parenteral drug clearance:\\n➣ Decreased blood ﬂow (drug delivery)\\n➣ Increased unbound free fraction of highly protein-bounddrugs (hypoalbuminemia, acidosis)\\n➣ Decreased enzymes & transport processes that removedrug from blood\\n■Modeofbiotransformationaffectssusceptibilitytoliverinjury:\\n➣ Cytochrome CP 450: very sensitive (eg, midazolam)\\n➣ Glucuronide conjugation: more robust (eg, lorazepam)\\n■Pharmacodynamics altered even if pharmacokinetics notchanged\\n➣ Pts are debilitated, w/ depleted lean body mass.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 213}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\n200 Liver Disease Malignant Hyperthermia\\n➣ Risk of respiratory depression (opioid or volatile anesthet-ics)\\n■Decrease all drug dosages by 25–50%.\\ndrug dosing\\n■Drugs independent of renal function for elimination\\n➣ Enzymatic or spontaneous breakdown in the blood\\n➣ Accumulation unlikely\\n➣ Succinylcholine (pseudocholinesterase)\\n➣ Atracurium/cisatracurium (Hofmann elimination)\\n➣ Remifentanil (plasma esterase)\\n➣ Esmolol (RBC esterase)\\n■Drugs w/ increased unbound fraction in hypoalbuminemia\\n➣ Increased free or active fraction\\n➣ Decrease doses 20–50% (depending on degree of hypoal-buminemia).\\n➣ Thiopental, methohexital, diazepam\\n■Drugs predominantly dependent on hepatic biotransforma-tion\\n➣ Certain volatile agents (>20%: methoxyﬂurane, halo-thane)\\n➣ Most perioperative drugs\\n➣ Avoid or decrease dosage in liver failure.\\n➣ All benzodiazepines\\n➣ All opioids\\n➣ Nondepolarizing muscle relaxants (except atracurium,cisatracurium)\\nMALIGNANT HYPERTHERMIA\\nHUGH R. PLAYFORD, MD\\npharmacology\\nN/A'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 214}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\nMalignant Hyperthermia Mitral Stenosis 201\\ndrug dosing\\nN/A\\nMITRAL REGURGITATION\\nROBERT N. SLADEN, MD\\npharmacology\\n■Chronotropic, inotropic agents are useful.\\n➣ Tachycardia helps maintain CO (ﬁxed stroke volume).\\n➣ Increased contractility compensates for regurgitant frac-tion.\\n➣ Acute pulmonary hypertension, congestion, edema\\n■Common maintenance meds & side effects\\n➣ Digoxin (digitoxic conduction disorders, arrhythmias)\\n➣ Loop diuretics (hypokalemia, hyponatremia)\\n➣ Coumadin (bleeding)\\ndrug dosing\\nN/A\\nMITRAL STENOSIS\\nROBERT N. SLADEN, MD\\npharmacology\\n■Avoid chronotropic, inotropic agents.\\n➣ Tachycardia, increased CO increases pressure gradientacross mitral valve.\\n➣ Acute pulmonary hypertension, congestion, edema\\n■Common maintenance meds & side effects\\n➣ Digoxin (digitoxic conduction disorders, arrhythmias)\\n➣ Loop diuretics (hypokalemia, hyponatremia)\\n➣ Coumadin (bleeding)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 215}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\n202 Mitral Stenosis Morbid Obesity\\ndrug dosing\\nN/A\\nMORBID OBESITY\\nHUGH R. PLAYFORD, MD\\npharmacology\\nChanges in pharmacokinetics relate to:\\n■Increased cardiac output\\n■Blood volume\\n■Lean body mass\\n■Organ size\\n■Fat mass\\nHydrophilic drugs will have relatively normal volume of distri-bution, elimination half-lives & clearance.\\nLipophilic drugs have greater volume of distribution, prefer-\\nential fat distribution, increased elimination half-life.Plasma proteins\\n■Albumin levels unchanged (binding unchanged)\\n■Alpha-1-glycoprotein increased (increased free fraction basicdrugs)\\n■Triglycerides increased\\n■Cholesterol increased\\n■Free fatty acids increased\\nPharmacodynamics\\n■Pseudocholinesterase activity increased\\n■Increase succinylcholine dose to 1.2–1.5 mg/kg.\\nElimination\\n■Hepatic metabolism\\n■Phase I metabolism (oxidation, reduction, hydrolysis) un-changed (ie, little change to drugs w/ low intrinsic clearance)\\n■Phase II metabolism (glucuronidation, sulfation) increased\\n■High-extraction clearance compound clearance increased'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 216}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\nMorbid Obesity Multiple Sclerosis 203\\n■Renal metabolism\\n■Glomerular ﬁltration rate increased\\n■Tubular secretion increased\\ndrug dosing\\nN/A\\nMULTIPLE SCLEROSIS\\nKARL WILLMANN, MD\\npharmacology\\nPharmacotherapy of MS\\n■Immunomodulation\\n➣ ABC therapy\\nrA=Interferon beta 1-a (Avonex)\\nrB=Interferon beta 1-b (Betaseron)\\nrC=Glatiramer acetate (Copaxone)\\n➣ IVIG (intravenous gamma globulin)\\n➣ Interferon B\\nrAntiviral, used when symptoms ﬂuctuate\\n➣ Glatiramer acetate (Copaxone)\\nrUsed when resistance to interferon B develops\\n■Immunosuppression\\n➣ Corticosteroids\\nrTreats acute symptoms\\nrReduces inﬂammatory process & length of relapse\\n➣ Azathioprine (Imuran)\\n➣ Methotrexate (Folex)\\nrAt low doses, inhibits immune responses causing MS\\n■Anesthetic interactions\\n➣ Benzodiazepines\\nrChronic use may potentiate general anesthetics.\\n➣ Opioids\\nrChronic use leads to tolerance.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 217}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\n204 Multiple Sclerosis Muscular Dystrophy\\n➣ Steroids\\nrRecent or prolonged use indicates perioperative stress-dose steroid supplementation.\\n➣ Dantrolene (Dantrium)\\nrIncreased sensitivity to non-depolarizing muscle relax-ants\\n■Toxicity\\n➣ Mitoxantrone (Novantrone)\\nrDose-related long-term cardiac toxicity at cumulativedoses of 100–140 mg\\nrHeart failure & cardiomyopathy have been described atlower doses.\\nrLeukopenia, thrombocytopenia\\n➣ Interferon beta 1-a (Avonex)\\nrLiver dysfunction & enzyme elevation\\nrAnemia, leukopenia, thrombocytopenia\\n➣ Interferon beta 1-b (Betaseron)\\nrLiver dysfunction & enzyme elevation\\nrHypertension, leukopenia\\n➣ Glatiramer acetate (Copaxone)\\nrHypertension, eosinophilia\\n➣ IVIG\\nrRenal dysfunction & acute renal failure\\nrHigh-dose: hepatitis (nonviral)\\ndrug dosing\\nN/A\\nMUSCULAR DYSTROPHY\\nJONATHAN T. KETZLER, MD\\npharmacology\\n■Succinylcholine may cause rhabdomyolysis, hyperkalemia,malignant hyperthermia & cardiac arrest.\\n➣ Response may occur w/ subclinical disease.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 218}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\nMuscular Dystrophy Myasthenia Gravis 205\\n■Nondepolarizing muscle relaxants may result in prolongedparalysis.\\n■Calcium channel blockers may prolong or even cause neuro-muscular blockade.\\ndrug dosing\\nN/A\\nMYASTHENIA GRAVIS\\nKARL WILLMANN, MD, AND D. B. COURSIN, MD\\npharmacology\\n■Pts on anticholinesterases will have prolonged effects w/ bothdeplorizing & non-depolarizing agents.\\n■In general, if neuromuscular blockade is needed, then use ofnondepolarizing neuromuscular agent would be preferred.\\n■Depolarizing agents may be unpredictable (resistant, pro-longed, normal responses).\\n➣ MG pt not treated w/ anticholinesterases will be resis-tant to neuromuscular blockade induced by depolarizingagents.\\n➣ MG pt treated w/ anticholinesterases (inhibit anti-cholinesterases) may have prolonged neuromuscularblockade induced by depolarizing agents.\\n➣ Successive doses of depolarizing agents may induce phaseII blockade.\\n■Pts very sensitive to nondepolarizing agents w/ a high risk ofprolonged blockade\\n■Much interpatient variability of response to neuromuscularblockade\\n■Atracurium & cis-atracurium are good agents as they haverelative short half-lives & do not accumulate w/ repeateddoses.\\n■Must monitor neuromuscular blockade'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 219}, page_content='P1: IBE0521759385P1secC1 CUNY1088/Sladen 0 521 75938 5 May 29, 2007 8:48\\n206 Myasthenia Gravis Obstetric Patient\\n■Remember that inhalational agents can depress neuromus-cular transmission.\\ndrug dosing\\n■Not all pts require neuromuscular blocking drugs.\\n■Pts are more susceptible to respiratory decompensationwhen given narcotics & anxiolytics, which depress respiratorydrive.\\n■Pts are very sensitive to nondepolarizing agents, usuallyrequiring only 10% of the normal dose.\\n■Pts are usually resistant to depolarizing agents & require 2–3times the normal dose.\\n■Consider the supplemental role of inhalational agent depres-sion of neuromuscular transmission.\\n■Monitor neuromuscular blockade w/ a peripheral nerve stim-ulator.\\nNEUROLEPTIC MALIGNANT SYNDROME\\nHUGH R. PLAYFORD, MD\\npharmacology\\n■Unchanged\\ndrug dosing\\nN/A\\nOBSTETRIC PATIENT HAVING INTERCURRENT SURGERY\\nJONATHAN T. KETZLER, MD\\npharmacology\\n■Teratogenic effects of anesthetics have not been demon-strated & probably do not exist.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 220}, page_content='P1: IBE0521759385P1secC2 CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:9\\nObstetric Patient Parkinson’s Disease 207\\n■Nitrous oxide\\n➣ No adverse effect on human pregnancy has been demon-strated.\\n➣ Decreases uterine blood ﬂow in animals\\n■Benzodiazepines\\n➣ Anecdotal association w/ abnormalities of oral cleft; notsubstantiated in prospective studies w/ diazepam\\n■Inhaled agents, IV agents, narcotics & local anesthetics havelong history of safety.\\ndrug dosing\\n■MAC of inhalational anesthetics decreased in the ﬁrst tri-mester\\n■Lower doses of local anesthetics required for equivalent der-matomal spread (epidural venous engorgement & possibleincreased neural sensitivity)\\nPARKINSON’S DISEASE\\nROBERT N. SLADEN, MD\\npharmacology\\n■Disease represents imbalance between CNS dopaminergic &cholinergic transmission.\\n■Therapy attempts to enhance dopaminergic & block cholin-ergic transmission.\\n■Dopaminergic therapy (decreases rigidity, tremor, bradykine-sia)\\n➣ L-dopa\\n➣ Carbidopa\\n➣ Bromocriptine\\n■Anticholinergic therapy (decreases secretions)\\n➣ Atropine'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 221}, page_content='P1: IBE0521759385P1secC2 CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:9\\n208 Parkinson’s Disease Pheochromocytoma\\n■Pharmacologic considerations relate to side effects & interac-tions of drug therapy for the disease.\\ndrug dosing\\nN/A\\nPATIENT WITH A TRANSPLANT\\nARTHUR ATCHABAHIAN, MD\\npharmacology\\n■Chronic renal insufﬁciency\\n➣ Increased extracellular volume\\n➣ Decreased protein binding\\n➣ Decreased elimination of meds dependent on renal func-tion (eg, digoxin, curare, pancuronium)\\n■Chronic hepatic insufﬁciency\\n➣ Hypoalbuminemia w/ decreased protein binding\\n➣ Decreased elimination of meds dependent on hepaticfunction (eg, morphine, vecuronium)\\ndrug dosing\\nAdjust for renal or hepatic function.\\nPHEOCHROMOCYTOMA\\nGIUDITTA ANGELINI, MD\\npharmacology\\n■Hypertensive response to histamine, glucagon, droperidol,tyramine, metoclopramide, cytotoxic drugs, saralasin, tri-cyclic antidepressants, phenothiazines\\ndrug dosing\\nN/A'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 222}, page_content='P1: IBE0521759385P1secC2 CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:9\\nPlatelet Disorders Polycythemia 209\\nPLATELET DISORDERS\\nKARL WILLMANN, MD\\npharmacology\\n■Drugs such as tricyclic antidepressants, chlorpromazine,cocaine, diltiazem, lidocaine, penicillins, cephalosporins &beta blockers may have negative impact on platelet func-tion.\\n■Drugs such as aspirin, NSAIDs, dipyridamole, ticlopidine,clopidogrel, abciximab & other glycoprotein IIb/IIIa receptorantagonists inhibit normal platelet function.\\n■Other drugs may affect bone marrow production of platelets,such as thiazides, diuretics, sulfonamides, alcohol.\\n■Other drugs may potentially mediate immunologically causedplatelet destruction, such as heparin, cephalosporins & quini-dine.\\ndrug dosing\\n■No special concerns\\nPOLYCYTHEMIA\\nKARL WILLMANN, MD, AND DOUGLAS B. COURSIN, MD\\npharmacology\\nNo speciﬁc considerations\\ndrug dosing\\n■Pts may be receiving hydroxyurea or busulfan to suppressmyeloproliferative diseases; interactions w/ these drugs arepossible.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 223}, page_content='P1: IBE0521759385P1secC2 CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:9\\n210 Psychiatric Disorders\\nPSYCHIATRIC DISORDERS\\nJONATHAN T. KETZLER, MD\\npharmacology\\n■Tricyclic antidepressants\\n➣ Used for treatment of depression & chronic pain\\n➣ All work at nerve synapses to block neuronal reuptake ofcatecholamines, serotonin or both.\\n➣ Desipramine & nortriptyline most common because fewerside effects & less sedating\\n➣ Amitriptyline, imipramine, protriptyline & doxepin aremore sedating.\\n➣ Clomipramine is used to treat obsessive-compulsive dis-order.\\n➣ Most have anticholinergic actions\\nrDry mouth, blurred vision, prolonged gastric emptying& urinary retention\\nrAmitriptyline has most effect, doxepin has least.\\n➣ Quinidine-like cardiac effects\\nrTachycardia, ﬂattened T waves, PR, QRS & QT prolon-gation\\n➣ St. John’s wort is being used as an OTC antidepressant (see“Herbal Therapy” in the Pharmacology section)\\n■Monoamine oxidase inhibitors (MAOIs)\\n➣ Block the oxidative deamination of amines\\nrMAO A selective for serotonin, dopamine & norepine-phrine\\nrMAO B selective for tyramine & phenylethylamine\\n➣ Agents available are nonselective MAOIs\\n➣ Side effects include orthostatic hypotension, agitation,tremor, seizures, muscle spasm, urinary retention, pares-thesia & jaundice.\\n➣ Hypertensive crisis occurs after ingestion of tyramine-containing foods such as red wine & cheeses.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 224}, page_content='P1: IBE0521759385P1secC2 CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:9\\nPsychiatric Disorders Rheumatoid Arthritis 211\\n■Atypical antidepressants\\n➣ Available agents are primarily selective serotonin reuptakeinhibitors\\n➣ Include ﬂuoxetine, sertraline & paroxetine\\n➣ Few or no anticholinergic effects\\n➣ Side effects include headache, agitation & insomnia.\\ndrug dosing\\nN/A\\nRESTRICTIVE LUNG DISEASE\\nHUGH R. PLAYFORD, MBBS\\npharmacology\\nNot signiﬁcantly altered\\ndrug dosing\\nN/A\\nRHEUMATOID ARTHRITIS\\nROBERT N. SLADEN, MD\\npharmacology\\n■Pharmacologic considerations relate to side effects & interac-tions of drug therapy for the disease.\\n■Aspirin\\n➣ Platelet dysfunction (variable, lasts 7–10 days after lastdose)\\n➣ NSAIDs\\nrPlatelet dysfunction (variable, lasts 24 hrs after lastdose)\\nrGastric irritability, erosion (decreased risk with COX-2inhibitors)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 225}, page_content='P1: IBE0521759385P1secC2 CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:9\\n212 Rheumatoid Arthritis\\nrNephrotoxicity (not prevented by use of COX-2 inhibi-tors)\\n➣ Steroids\\nrAdrenal suppression\\nrImpaired immune response\\nrPeptic ulcer (& increased GI risk w/ NSAIDs)\\nrPsychosis\\nrCushing’s syndrome (abnormal fat deposition: “moonfacies,” “buffalo hump”)\\nrHypertension\\nrGlucose intolerance & frank diabetes\\nrSkin fragility (easy bruising, injury)\\n■Azothiaprine (Imuran)\\n➣ Bone marrow suppression, immune suppression, liverdysfunction, pancreatitis\\n■Cyclophosphamide (Cytoxan)\\n➣ Hemorrhagic cystitis\\n■Methotrexate\\n➣ Bone marrow suppression, dermatitis\\ndrug dosing\\n■Drugs independent of renal function for elimination\\n➣ Enzymatic or spontaneous breakdown in the blood\\nrAccumulation is unlikely\\nrSuccinylcholine (pseudocholinesterase)\\n➣ Atracurium/cisatracurium (Hofmann elimination)\\nrRemifentanil (plasma esterase)\\nrEsmolol (RBC esterase)\\n➣ Drugs w/ increased unbound fraction in hypoalbu-minemia\\nrIncreased free or active fraction\\nrDecrease doses 20–50% (depending on degree ofhypoalbuminemia)\\nrThiopental, methohexital, diazepam'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 226}, page_content='P1: IBE0521759385P1secC2 CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:9\\nRheumatoid Arthritis Sickle Cell Disease 213\\n➣ Drugs predominantly dependent on hepatic biotransfor-mation\\nrCertain volatile agents ( >20%: methoxyﬂurane, halo-\\nthane)\\nrMost perioperative drugs\\nrAvoid or decrease dosage in liver failure.\\nrAll benzodiazepines\\nrAll opioids\\nrNondepolarizing muscle relaxants (except atracurium,cisatracurium)\\nSCLERODERMA\\nARTHUR ATCHABAHIAN, MD\\npharmacology\\n■Possible renal insufﬁciency w/ increased extracellular volume& decreased protein binding\\n■Possible malabsorption w/ hypoproteinemia, leading toincreased unbound fraction of protein-bound drugs\\ndrug dosing\\n■Adjust for renal function.\\n■Consider following levels for highly protein-bound drugs.\\n■Use lower doses of opioids because of higher sensitivity.\\nSICKLE CELL DISEASE\\nARTHUR ATCHABAHIAN, MD\\npharmacology\\n■Depends on extent of hepatic & renal involvement\\ndrug dosing\\n■Depends on extent of hepatic & renal involvement'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 227}, page_content='P1: IBE0521759385P1secC2 CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:9\\n214 Spinal Cord Injury SBE Prophylaxis\\nSPINAL CORD INJURY\\nHUGH R. PLAYFORD, MBBS, AND GEBHARD WAGENER, MD\\npharmacology\\n■No signiﬁcant implications\\ndrug dosing\\n■No signiﬁcant implications\\nSTROKE\\nGEBHARD WAGENER, MD\\npharmacology\\nTo prevent perioperative stroke:\\n■Barbiturates reduce cerebral metabolic rate (CMR), but noadequate clinical data for use in acute stroke\\n■Propofol reduces CMR, cerebral blood ﬂow (CBF) & glutamaterelease: may reduce infarct size & restore local CBF in ischemicareas\\n■Inhalational agents: reduce infarct size by redistributing CBF\\ndrug dosing\\nPts w/ stroke:\\n■Avoid succinylcholine w/ signiﬁcant hemiplegia or hyper-kalemia.\\nIf pt is on anti-seizure medication (phenytoin):\\n■Shortened half-life of non-depolarizing neuromuscularblockers\\nSUBACUTE BACTERIAL ENDOCARDITIS PROPHYLAXIS\\nJONATHAN T. KETZLER, MD\\npharmacology\\nN/A'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 228}, page_content='P1: IBE0521759385P1secC2 CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:9\\nSBE Prophylaxis Systemic Lupus Erythematosus 215\\ndrug dosing\\n■American Heart Association has published recommendationsfor antibiotic treatment of gram-positive & HACEK endocardi-tis. However, therapy should always be guided by sensitivityof offending organism.\\nDental/Upper Respiratory Tract Surgery\\n■Low- to medium-risk malformation, no allergy to penicillins\\n➣ Amoxicillin 3 g orally 1 hr befor e & 6 hrs after procedure\\n■High-risk malformation, no allergy to penicillins\\n➣ Amoxicillin as above or, at physician discretion, ampicillin1gI V +gentamicin 1.5 mg/kg IV 0.5 hr before procedure,\\nrepeat in 8 hrs if required (or amoxicillin 1.5 g PO)\\n■Penicillin allergy\\n➣ Erythromyci n1go r ally 1 hr before & 0. 5 g 6 hrs later,\\nor clindamycin 300 mg 1 hr before & 150 mg 6 hrs afterprocedure, or vancomycin 1 g slowly IV over 1 hr, starting1 hr before\\nGenitourinary/Gastrointestinal Procedures\\n■Oral for low-risk GU/GI procedures, no penicillin allergy\\n➣ Amoxicillin 3 g orally 1 hr befor e & 6 hrs after procedure\\n■Parenteral, no penicillin allergy\\n➣ Ampicillin 1 g PLUS IV gentamicin 1.5 mg/kg IV 0.5 hrbefore procedure, repeat both drugs in 8 hrs if required(or amoxicillin 1.5 g PO)\\n■Penicillin allergy\\n➣ Vancomycin 1 g slowly IV over 1 hr, starting 1 hr before,PLUS gentamicin 1.5 mg/kg IV, repeat in 8 hrs if required\\nSYSTEMIC LUPUS ERYTHEMATOSUS\\nARTHUR ATCHABAHIAN, MD\\npharmacology\\n■Possible renal insufﬁciency w/ increased extracellular volume& decreased protein binding'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 229}, page_content='P1: IBE0521759385P1secC2 CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:9\\n216 Systemic Lupus Erythematosus Thyroid and Parathyroid Disease\\ndrug dosing\\n■Adjust for renal function.\\nTHALASSEMIA\\nARTHUR ATCHABAHIAN, MD\\npharmacology\\n■Depends on extent of hepatic & renal involvement\\ndrug dosing\\n■Depends on extent of hepatic & renal involvement\\nTHYROID AND PARATHYROID DISEASE\\nGIUDITTA ANGELINI, MD\\npharmacology\\n■Hyperthyroidism\\n➣ Thyroxine (T 4) has half-life of 7 days.\\n➣ Tri-iodothyronine (T 3) has half-life of 1.5 days.\\n➣ Carbimazole & propylthiouracil block the synthesis of thy-roxine but take 6–8 wks to work.\\nrSevere reactions: agranulocytosis, hepatitis, aplasticanemia, lupus-like syndromes\\nrIntolerance to these drugs indicates thyroidectomy.\\n➣ Propranolol & other longer-acting beta blockers have beenused successfully to treat the symptoms of thyrotoxicosis.\\n■Hyperparathyroidism\\n➣ Hypercalcemia enhances digitalis toxicity.\\ndrug dosing\\n■Hypothyroidism\\n➣ Impaired drug metabolism'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 230}, page_content='P1: IBE0521759385P1secC2 CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:9\\nThyroid and Parathyroid Disease von Willebrand Disease 217\\n■Hyperthyroidism\\n➣ Increased clearance & distribution of propofol, mayrequire higher dosage.\\nTRANSFUSION THERAPY\\nDOUGLAS B. COURSIN, MD, AND KARL WILLMANN, MD\\npharmacology\\nN/A\\ndrug dosing\\nN/A\\nVON WILLEBRAND DISEASE\\nKARL WILLMANN, MD, AND D. B. COURSIN, MD\\npharmacology\\n■Avoid drugs that inhibit platelet function.\\ndrug dosing\\n■No special concerns unless severe liver dysfunction from hep-atitis'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 231}, page_content='P1: IBE0521759385P1secC2 CUNY1088/Sladen 0 521 75938 5 June 7, 2007 14:9\\n218'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 232}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nPART THREE\\nClinicalManagement\\n219'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 233}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nADRENAL & PITUITARY DISEASE\\nGIUDITTA ANGELINI, MD\\nscreening & evaluation\\n■Basal prolactin concentration\\n➣ Most common adenoma is prolactinoma.\\n➣>20 ng/mL is abnormal.\\n➣ Differential diagnosis: gonadotroph adenoma (compres-\\nsion), stress\\n■TSH\\n➣ Primary hypothyroidism can cause pituitary enlargement\\n&secondary compression w/ associated hyperprolactine-\\nmia.\\n➣ Hypothyroidism should be treated preop.\\n➣ Primary TSH-secreting adenoma w/ elevated TSH in the\\nsetting of elevated thyroid hormones is extremely rare.\\n■Morning cortisol\\n➣ Compression of sella structures from any adenoma can\\ncause hypopituitarism, which requires investigation ofcortisol level.\\n➣ Elevated levels suggest Cushing’s syndrome.\\n➣ Cortisol level maintained w/ dexamethasone suppression\\ntest except pituitary Cushing’s, which may suppress w/high dose\\n■Measure ACTH concentration under dexamethasone sup-\\npression.\\n➣ Undetectable level: adrenal tumor\\n➣ 10–100 ng/L: pituitary-dependent tumor\\n➣>200 ng/L: ectopic ACTH secretion\\n➣ Selective petrosal sinus sampling of ACTH after CRH stim-\\nulation can conﬁrm pituitary Cushing’s syndrome.\\n■Growth hormone concentration\\n➣ Random >5ng/mL: abnormal\\n220'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 234}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nAdrenal & Pituitary Disease 221\\n➣ Failure to suppress to <1ng/mL following 75-g glucose\\nload: diagnostic\\n■MRI is superior to CT for imaging the pituitary.\\npreoperative preparation\\n■Assess visual function (visual ﬁeld defects, third cranial nerve).\\n■Assess for signs & symptoms of increased ICP.\\n■Acromegaly\\n➣ Assess macroglossia & thickening of pharyngeal tissues,thickened vocal cords, reduction in laryngeal aperture:difﬁcult airway\\n➣ 25% have enlarged thyroid, which may compress trachea.\\n➣ Thickened periepiglottic folds may result in recurrentlaryngeal nerve palsy.\\n➣ Sleep apnea may be severe; respiratory failure is threefold\\nhigher in this population.\\n➣ Assess treatment of hypertension & glucose intolerance.\\n■Cushing’s syndrome\\n➣ Assess mgt of hypertension & glucose intolerance.\\n➣ 18% have severe sleep apnea.\\n➣ Anticipate gastroesophageal reﬂux disease.\\n➣ Anticipate suppressed immune system.\\n➣ Fragile skin makes IV access problematic.\\noperative preparation\\n■Transsphenoidal approach is used most commonly\\n(fewer postop complications than sublabial or endonasalapproach).\\n➣ Lower risk of postop seizures\\n➣ Minimal risk of trauma or hemorrhage\\n➣ Less likely for total ablation of pituitary & postop need forhormone replacement\\n■Transcranial approach: large tumor, small/non-pneumatized\\nsphenoid sinus'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 235}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n222 Adrenal & Pituitary Disease\\nanesthesia\\n■Continue preop hormone replacement during operative\\nperiod, w/ hydrocortisone on the day of surgery.\\n■Airway mgt in acromegalics will require large masks & longerblades.\\n➣ Ventilation w/ bag & mask is generally straightforward w/an oral airway.\\n➣ Ptsw /glottic stenosis & vocal cord paresis, especially\\nw/ pharyngeal mucosal hypertrophy, are likely to requireﬁberoptic intubation.\\n➣ Intubating laryngeal mask airway has been used success-fully.\\n➣ Equipment for tracheostomy should be available.\\n■Cocaine used for nasal vasoconstriction has been associatedw/ arrhythmias & MI.\\n➣ Xylometazoline is an alpha agonist that when combinedw/ lidocaine can be equivalent to cocaine.\\n■Lumbar drains may be placed.\\n➣ 10-mL aliquots of 0.9% saline can be introduced to pro-duce prolapse of suprasellar portion of tumor into opera-tive ﬁeld.\\n➣ Should the dura be breached during surgery, the cathetercan be left in place to control CSF leak.\\n■Ptwill be positioned supine w/ head-up tilt; surgeon will be at\\nhead of table or just to the right or left, so appropriate securedairway approach is necessary.\\n■Inhalation or IV anesthetic is equivalent, but avoid nitrous\\noxide in pts w/ increased ICP.\\n■Short-acting agents are important to allow for quick emer-gence & neurologic assessment.\\n■Excessive hyperventilation may make suprasellar extension\\nless accessible.\\n■Most stimulating period is during transsphenoidal access.\\n■Bilateral maxillary block has been successful for transsphe-noidal approach.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 236}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nAdrenal & Pituitary Disease 223\\n■Standard ASA monitors\\n➣ Comorbidities may require more invasive monitoring,\\nespecially in Cushing’s pts.\\n➣ Ifasteep head-up tilt is used, monitoring for venous air\\nembolism may be required.\\n➣ Visual evoked potentials have a high incidence of false\\nnegatives & false positives in the OR & are easily interferedw/ by anesthetic agents.\\n■Cefuroxime is recommended for prophylaxis preop.\\n■Transsphenoidal approach has rare complications of carotid\\nor pons disruption.\\n■Transcranial approach has rare complications of frontal lobe\\nischemia, trauma to carotid or optic chiasm & anosmia sec-ondary to damage to olfactory tract.\\nwake up & emergence\\n■Smooth & rapid emergence is essential.\\n■Mayhave throat pack to remove & nasal packs, which need to\\nstay in place\\nicu or pacu\\n■Usually only transcranial approach requires ICU.\\n■Given nasal packs, all pts w/ transsphenoidal surgery must be\\nfully awake postop before being moved to general ﬂoor, sinceCPAP is relatively difﬁcult to administer.\\n■Transcranial approach will require more opioid analgesia.\\n■Endocrinologist: continued hormone replacement\\n■Hydrocortisone is usually imperative in most cases in which\\nit has been used preop.\\n➣ Prolactinomas w/ >20% of pituitary remaining likely can\\nbe quickly reduced.\\n➣ Ptsw/Cushing’s syndrome likely will require slower wean-\\ning over wks.\\n■Diabetes insipidus\\n➣ Occurs when >80% of neurons synthesizing vasopressin\\nare destroyed'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 237}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n224 Adrenal & Pituitary Disease Adult Congenital Heart Disease\\n➣>1Lo fdilute urine in 12 hrs (<300 mOsmol/kg)\\n➣ Plasma sodium concentration >143 mmol/L\\n➣ Plasma osmolality >295 mOsmol/kg\\n➣ Awake pts should be allowed free access to ﬂuid.\\n➣ DDAVP may be administered 0.04–0.1 mcg 1–3 times daily;can also be administered intranasally.\\n■Hyponatremia can be related to excessive DDAVP or SIADH\\n➣ Fluid restriction is indicated for transitory SIADH sec-ondary to pituitary disruption.\\n➣ Cerebral salt wasting w/ natriuresis & diuresis requires\\nadministration of hypertonic saline over 24–48 hrs.\\n➣ Rapid replacement will result in central pontine myelinol-ysis.\\n■Bilateral adrenalectomy surgery for ACTH tumors requiresmineralocorticoid & glucocorticoid supplementation.\\n➣ Carries risk of Nelson’s syndrome w/ hyperpigmentation& compression of parapituitary structures secondary tomelanocyte-stimulating hormone\\n■Vocal cord changes in acromegaly mostly resolve after 10 days.\\n■While left ventricular size may normalize after surgery inpts w/ acromegaly, interstitial myocardial ﬁbrosis does notresolve & left ventricular dysfunction persists.\\nADULT CONGENITAL HEART DISEASE\\nMARY E. McSWEENEY, MD\\nscreening & evaluation\\nStudies\\n■Review echo & cath studies to determine anatomy, blood ﬂowcharacteristics & ventricular function.\\nNote whether elevated PVR is reversible.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 238}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nAdult Congenital Heart Disease 225\\n■EKG (heart block, ischemic changes, arrhythmia, ventricular&atrial enlargement)\\n■Chest x-ray: anatomy, CHF, diaphragmatic paresis, atelectasis\\n■Labs (elevated Hct & platelets commonly associated w/hypoxic lesions; platelet function often abnormal & clottingfactors often reduced)\\nPhysical exam\\n■Hypoxemia: clubbing of nails, cyanosis\\n■Ventricular hypertrophy (apical heave)\\n■Congestive heart failure (elevated neck veins, edema, hep-\\natomegaly)\\npreoperative preparation\\n■No contraindication to preop sedation in adults w/ CHD;\\npts w/ high PVR generally beneﬁt from anxiolysis as long ashypoventilation is avoided\\n■Diuretics are usually held the morning of surgery to ensure\\nadequate intravascular volume.\\n■Antibiotics for prevention of bacterial endocarditis arerequired for all but the most benign of CHD lesions (such\\nas pts status post primary repair of ASD or VSD) in cases w/any potential for bacterial seeding.\\n■Useair ﬁlters in venous lines for any pt w/ possibility of R-to-L\\nshunting.\\noperative preparation\\nN/A\\nanesthesia\\n■Ptsw/severe pulmonary hypertension can be high risk w/\\nboth general & regional anesthesia. Nerve blocks are prefer-able to general, spinal or epidural anesthesia when possible.\\n➣ Fixed PVR is unresponsive to pharmacologic treatment.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 239}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n226 Adult Congenital Heart Disease\\n➣ Avoid factors known to increase PVR: hypothermia, aci-\\ndosis, hypercarbia, hypoxia & endogenous or exogenouscatecholamines w/ alpha-adrenergic effects.\\n➣ Hypovolemia & systemic vasodilation both increase R-to-\\nL shunt.\\n■Volatile anesthetics are tolerated well in most pts w/ CHD.\\n➣ Negative chronotropic & inotropic actions are dose-\\ndependent.\\n■Nitrous oxide\\n➣ Mayb eused to supplement volatile anesthetics for induc-\\ntion.\\n➣ Avoid for maintenance (increased PVR, intravascular bub-\\nble enlargement).\\n■Vascular access can be complicated by anatomy or previoussurgical procedures\\n➣ Femoral vein thrombosis or ligation\\n➣ Discontinuity of IVC & RA\\n➣ Reduced lower extremity BP w/ coarctation\\n➣ Discontinuity of subclavian artery w/ BT anastomosis\\n➣ Artifactually elevated right arm BP w/ supravalvular aorticstenosis\\nwake up & emergence\\n■Avoid coughing & straining on extubation; can worsen R-to-L\\nshunt.\\n■General anesthesia & intubation\\nConsider gradual wake up & extubation in ICU.\\nicu or pacu\\n■Optimize pain control to minimize straining, which canworsen R-to-L shunt.\\n■ICU care strongly recommended postop for any pt w/ complexor cyanotic CHD recovering from anesthesia & surgery'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 240}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nAlcohol Abuse 227\\nALCOHOL ABUSE\\nJONATHAN T. KETZLER, MD\\nscreening & evaluation\\n■Screening strategies to identify pts w/ alcohol abuse\\n➣ Physical ﬁndings\\nrRhinophyma, telangiectasias\\nrTremulousness, unexplained tachycardia, elevated BP\\nrUnexplained hepatosplenomegaly, peripheral neu-\\nropathy\\nrUnexplained physical trauma.\\n➣ Physical exam may be completely normal.\\n■Evaluate end-organ damage.\\n➣ Macrocytosis (MCV 100–110 fL): 90% of cases, precedes\\novert anemia\\n➣ Elevated liver enzymes (AST, ALT, GGT)\\n➣ Alcoholic hepatitis: AST ≫ALT (>2.0) is highly speciﬁc.\\nrSerumcarbohydrate-deﬁcient transferrin (CDT): ap-\\nproved by FDA as indicator of chronic heavy alcoholconsumption (sensitivity 60–70%, speciﬁcity 80–90%)\\n■Prompt intervention prior to surgery\\npreoperative preparation\\n■Abstinence (at least 1 month)\\n➣ Decreases risk of postop complications\\n■Detoxiﬁcation (depends on patient motivation, urgency of\\nsurgery)\\noperative preparation\\n■Prophylaxis of alcohol withdrawal\\n➣ Decreased risk of postop complications & prolonged ICU\\nstay.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 241}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n228 Alcohol Abuse\\n➣ Benzodiazepines (diazepam, lorazepam or chlordiaze-poxide)\\nanesthesia\\n■Anticipate larger dose requirement for induction of action(increased volume of distribution).\\n➣ Eg,p ropofol, fentanyl, pancuronium\\n■Alcoholics require signiﬁcantly larger doses of fentanyl thannondrinkers to achieve adequate analgesia at the time ofsurgery.\\n■Acute alcohol consumption: Anticipate prolonged duration ofsome drug action (eg, propranolol, phenobarbital).\\n■Chronic alcohol consumption: Anticipate shortened dura-tion of some drug action (induction of cytochrome P450system).\\n■Anticipate increased sympathetic & cortisol response tosurgical stress; immunosuppression & increased postopmorbidity.\\n■Surgical stress response can mimic, precipitate & exacerbate\\nalcohol withdrawal syndromes.\\nIntraoperative hypoxemia or hypotension increases risk of\\npostop delirium.\\nwake up & emergence\\nN/A\\nicu or pacu\\n■Increased risk of postop:\\n➣ Arrhythmias (without overt cardiac disease).\\nr“Holiday heart syndrome” (binge drinking)\\n➣ Bleeding\\n➣ Surgical site infections\\n➣ Impaired wound healing\\n➣ Prolonged intubation & ICU stay'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 242}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nAnemia and Hemoglobinopathies 229\\nANEMIA AND HEMOGLOBINOPATHIES\\nDOUGLAS B. COURSIN, MD AND KARL WILLMANN, MD\\nscreening and evaluation\\n■CBC, Hgb not routinely acquired for most outpatients & manyinpatients\\n■Identify high-risk pts ( +active or known history of anemia)\\n➣ Obtain CBC\\nrDetermines WBC, Hct, Hgb, platelet count & indices\\nrReticulocyte count: bone marrow activity\\npreoperative preparation\\n■Identify anemia in high-risk pts or those undergoing high-risk\\nsurgery.\\n■Determine if anemia is of physiologic importance.\\n■Determine etiology:\\n➣ Acute or chronic: Compensated or not?\\n➣ Ifblood loss: Is it controlled? Does procedure need to be\\nperformed to control bleeding?\\n➣ Ifsecondary to nutrient deﬁciency: Does pt require sup-\\nplementation (iron, vitamin B12, folate)? Is pt at riskfor associated pathology? Neurologic disease w/ vitaminB12 deﬁciency? Abnormal homocysteine metabolism &folate?\\n➣ Would the pt beneﬁt from perioperative EPO?\\nrFacilitate autologous predonation\\nrAugment perioperative treatment of anemia\\nrAvailable drugs: human recombinant EPO, darbopo-\\nietin\\n■Transfusion therapy\\n➣ Based on acuity and severity of anemia, associated pathol-\\nogy, risk of surgery/procedure'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 243}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n230 Anemia and Hemoglobinopathies\\noperative preparation\\n■Address need for transfusion.\\n■Type & screen or cross-match if needed & not already per-formed.\\n■Determine availability of blood preop.\\nanesthesia\\n■Maintain O 2delivery.\\n➣ Correct hypovolemia.\\n➣ Avoid meds that depress cardiac function.\\n➣ Avoid left shift in O 2dissociation curve:\\nrAvoid hypothermia (but may provide CNS protection).\\nrAvoid acute alkalosis.\\n➣ Avoid N 2Oi npts w/ vitamin B12 or folate deﬁciencies.\\n➣ “Transfusion trigger” based on level of anemia, antici-\\npated blood loss, individual reserve\\nwake up and emergence\\n■Maintain O 2delivery by maintaining good circulatory\\nstatus\\n■Treat shivering, excessive tachycardia or hypertension.\\nicu or pacu\\n■>50% of ICU pts are anemic within 72 hrs of ICU admi-ssion.\\n■1/7 ICU pts per day receive a transfusion in the ICU.\\n■Over a third of all ICU pts receive transfusion during their ICUcourse.\\n■Risk of transfusion increases with length of ICU stay.\\n■Transfusions are independently associated w/ increased\\nlength of ICU stay, morbidity & mortality.\\n■Increase transfusion trigger: CNS injury, myocardial ischemiaor infarction'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 244}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nAnkylosing Spondylitis 231\\nANKYLOSING SPONDYLITIS\\nHUGH R. PLAYFORD, MD\\nscreening and evaluation\\n■Note the following:\\n➣ Previous anesthesia (difﬁculty w/ intubation, nerve\\nblocks, positioning)\\n➣ Spinal fracture\\n➣ Spinal surgery\\n➣ Medications (NSAIDs, corticosteroids, phenylbutazone,\\nsulfasalazine, azathioprine, methotrexate, cyclophos-phamide)\\n■Look for physical signs of:\\n➣ CHF, arrhythmia, uveitis, upper & lower motor nerve signs\\n➣ Limited mouth opening, vocal abnormality, limited neckmovement, neck pain\\n■Relevant lab studies\\n➣ Hct, CBC\\n➣ ABGs on room air\\n➣ ECG, chest x-ray\\n➣ W/ or w/out echo\\n➣ PFTs (usually restrictive pattern w/ slight to moderatedecreased in VC & TLC, normal to increased FRC & VC, nor-mal airﬂow rates, decreased maximal expiratory & inspi-ratory pressures)\\n➣ Cervical spine x-ray (w/ ﬂexion-extension)\\npreoperative preparation\\n■Airway evaluation (w/ or w/out ENT laryngeal assessment)\\n■W/ or w/out preparation for awake ﬁberoptic nasopharyngealintubation\\n■Pulmonary function assessment'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 245}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n232 Ankylosing Spondylitis\\n■Positioning considerations\\n■Minimize sedative or opioid premeds.\\n■Neurologic exam for upper & lower motor nerve deﬁcits.\\n■Analgesic considerations intraop & postop (avoid respiratorydepressants)\\noperative preparation\\n■Minimize sedative or opioid premeds.\\n■Use universal & aseptic precautions throughout.\\n■Difﬁcult airway preparation\\n➣ Antisialagogue\\n➣ Nasal preparation\\n➣ Difﬁcult airway cart (including ﬁberoptic bronchoscope)\\n■Invasive hemodynamic monitoring if:\\n➣ Cardiopulmonary insufﬁciency\\n➣ Large ﬂuid shifts anticipated\\n■Carew/ positioning, pad pressure points\\nanesthesia\\n■Regional anesthesia\\n➣ Not contraindicated\\n➣ Document any neurologic deﬁcits preop.\\n➣ Skeletal abnormality may make regional block technicallydifﬁcult & response to local anesthetic unpredictable.\\n■General anesthesia\\n➣ Consider positioning difﬁculties (including perioperative\\nspinal fracture).\\n➣ Potential for difﬁcult airway\\n➣ Preoxygenation (limited respiratory reserve)\\n➣ Avoid myocardial depressants if limited cardiac reserve.\\n➣ Low pulmonary compliance but usually normal lung com-pliance\\nwake up and emergence\\n■Avoid excessive sedation.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 246}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nAnkylosing Spondylitis Anticoagulation Therapy 233\\n■Optimize analgesia w/out respiratory depression.\\n■Extubate when fully awake.\\nicu or pacu\\n■Careful respiratory monitoring\\nANTICOAGULATION THERAPY\\nJONATHAN T. KETZLER, MD\\nscreening and evaluation\\nN/A\\npreoperative preparation\\nN/A\\noperative preparation\\nN/A\\nanesthesia\\n■Anesthetic mgt of the pt receiving thrombolytic therapy\\n➣ Thrombolytic drugs should be avoided for 10 days follow-ing the puncture of noncompressible vessels.\\nrIdeally this would include lumbar puncture, neuraxial\\nanesthesia & epidural steroid injection.\\n➣ Itshould be determined preoperatively whether ﬁbri-\\nnolytic or thrombolytic drugs have been used preopera-tively or might be used intraoperatively or postoperatively.There are no clear data to suggest how long neuraxial anes-thesia should be avoided after the use of these drugs.\\n➣ Ptswho do receive neuraxial anesthesia at or near the time\\nof treatment w/ ﬁbrinolytic or thrombolytic drugs shouldhave their neurologic status monitored at intervals of nomore than 2 hrs.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 247}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n234 Anticoagulation Therapy\\nrIfpt has a neuraxial catheter in place, avoid drugs that\\nmight interfere w/ neurologic exam.\\n➣ Although there are no recommendations for timing ofthe removal of a neuraxial catheter after the use of ﬁb-rinolytic or thrombolytic drugs, the measurement of ﬁb-rinogen (one of the last clotting factors to recover) may be\\nhelpful.\\n■Anesthetic mgt of the pt receiving unfractionated heparin\\n➣ There are no contraindications to the use of neuraxialanesthesia in the pt receiving subcutaneous (mini-dose)heparin.\\nrDelaying the injection until after the block may reducethe risk of neuraxial bleeding.\\nrProlonged therapy in debilitated pts may increase the\\nrisk of neuraxial bleeding.\\nrPtsreceiving heparin for >4days should have a platelet\\ncount because of the risk of heparin-induced thrombo-cytopenia.\\n➣ Intraoperative anticoagulation can be combined w/ neu-\\nraxial anesthesia, w/ the following cautions:\\nrAvoid neuraxial anesthesia in pts w/ other coagu-\\nlopathies.\\nrDelay anticoagulation w/ heparin for 1 hr after place-ment of the needle.\\nrRemove indwelling neuraxial catheters 2–4 hrs after the\\nlast heparin dose, after the pt’s coagulation status hasbeen evaluated.\\nrDelay re-heparinization until 1 hr after the catheterhas been removed.\\nrThe pt should be monitored postoperatively for earlydetection of motor blockade. Minimal concentration oflocal anesthetics should be used for better detection ofspinal hematoma.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 248}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nAnticoagulation Therapy 235\\nrThere are no data to suggest that a bloody or difﬁcultneuraxial needle placement should require cancella-tion of the case. Discuss the speciﬁc risks & beneﬁtsof continuing w/ the surgeon.\\n➣ There are insufﬁcient data to determine whether there isan increased risk of neuraxial hematoma if neuraxial anes-thesia is combined w/ the full anticoagulation of cardiacsurgery.\\nrThe pt should be monitored postoperatively for earlydetection of motor blockade. Minimal concentration oflocal anesthetics should be used for better detection ofspinal hematoma.\\nrThe concurrent use of meds that also affect the clottingcascade, such as antiplatelet therapy, low-molecular-weight heparin (LMWH) & oral anticoagulants, may\\nincrease the risk of neuraxial hematoma.\\n■Anesthetic mgt of the pt receiving low-molecular-weight hep-arin (LMWH)\\n➣ These recommendations were developed using the exten-sive experience of European anesthesiologists w/ LMWH.\\nrThe level of anti-Xa is not predictive of the risk of bleed-ing, so it is not helpful in the mgt of pts undergoingneuraxial anesthesia.\\nrThe concurrent use of meds that also affect the clottingcascade, such as antiplatelet therapy, unfractionatedheparin & oral anticoagulants, may increase the risk ofneuraxial hematoma.\\nrDelay the initiation of LMWH for 24 hrs postoperatively\\nif there is the presence of blood during needle place-ment.\\nrTraumatic needle or catheter placement may cause an\\nincreased risk of neuraxial hematoma; discuss the spe-ciﬁc risks & beneﬁts of continuing w/ the surgeon.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 249}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n236 Anticoagulation Therapy\\nrPreop LMWH\\nrPtso nLMWH preoperatively should be assumed to\\nhave altered coagulation, so delay placement of a nee-dle until 10–12 hrs after the last dose of LMWH.\\nrInpts on higher-than-prophylactic doses, such as\\nenoxaparin 1 mg/kg q12h, enoxaparin 1.5 mg/kgdaily, dalteparin 120 U/kg q12h, dalteparin 200 U/kgdaily or tinzaparin 175 U/kg daily, delay placement ofthe needle at least 24 hrs.\\nrAvoid neuraxial techniques in pts who have received\\nLMWH 2 hours before, because this is the peak ofanticoagulant activity.\\nrPostop LMWH\\nrMgt of pts receiving postop LMWH is based on totaldose, timing of ﬁrst postop dose & dosing schedule.\\nrTwice-daily dosing may be associated w/ an increasedrisk of neuraxial hematoma.\\nrRegardless of anesthetic technique, give the ﬁrst\\ndose no sooner than 24 hours postop, & only in thesetting of adequate surgical hemostasis.\\nrContinuous catheters may be left in overnight & re-moved the next morning 2 hrs prior to the ﬁrstdose.\\nrSingle daily dose approximates the European appli-cation.\\nrGive the ﬁrst post dose 6–8 hrs postop.\\nrThe second dose should not be given sooner than 24hrs after the ﬁrst dose.\\nrNeuraxial catheters may be left indwelling & shouldbe removed no sooner than 10–12 hrs after the lastdose of LMWH.\\nrSubsequent dosing should occur no sooner than 2 hrsafter catheter removal.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 250}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nAnticoagulation Therapy 237\\n■Regional anesthetic mgt of the patient on oral anticoagulants\\n➣ These recommendations are based on warfarin pharma-cology, the clinical relevance of vitamin K coagulationfactor levels/deﬁciencies & case reports of spinal hema-tomas.\\n➣ Stop oral anticoagulation 4–5 days prior to planned pro-\\ncedure.\\nrEarly after discontinuation of warfarin therapy, thePT/INR reﬂects predominantly factor VII levels; how-ever, levels of factors II, VII, IX & X may not be adequateuntil 5–7 days.\\nrThe concurrent use of meds that also affect the clottingcascade, such as antiplatelet therapy, unfractionatedheparin & LMWH, may increase the risk of neuraxialhematoma without affecting the PT/INR.\\nrForpts receiving a preop dose of oral anticoagulants,\\ncheck PT/INR before placement of neuraxial anesthesiaif the dose was given >24 hours prior or if a second dose\\nhas been given.\\nrForpts who receive low-dose warfarin therapy dur-\\ning epidural analgesia, monitor PT/INR daily & beforecatheter removal.\\nrStudies evaluating the use of warfarin w/ epidural\\nanalgesia used daily doses of 5 mg warfarin. Higherdoses require more intensive monitoring of coagula-tion studies.\\nrWhen thromboprophylaxis is initiated w/ warfarin,remove the catheter while the INR is <1.5.\\nrInpts w/ indwelling neuraxial catheters, withhold war-\\nfarin if the INR is >3.0.\\nrThere are no recommendations for removal of a neu-raxial catheter in pts w/ therapeutic levels of antico-\\nagulation.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 251}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n238 Anticoagulation Therapy\\nrUselower doses of warfarin in pts who are likely to have\\nan enhanced response to the drug.\\n■Anesthetic mgt of the pt receiving antiplatelet meds\\n➣ Antiplatelet meds include NSAIDs, thienopyridine deriva-tives (ticlopidine, clopidogrel) & platelet GP IIb/IIIa antag-onists (abciximab, eptiﬁbatide, tiroﬁban). They exertdiverse effects on platelet function.\\n➣ There is no way to extrapolate btwn groups of drugsregarding neuraxial anesthesia.\\n➣ No test, including bleeding time, adequately assesses\\nantiplatelet therapy.\\nrCareful preop assessment of a history of easy bruis-\\ning or bleeding, female gender & increased age shouldbe used to make decisions regarding neuraxial anes-thesia.\\n➣ The use of NSAIDs alone should not interfere w/ the per-formance of neuraxial anesthesia.\\nrThis includes timing of single shot or catheter techni-ques, postop monitoring & timing of catheter removal.\\n➣ The risk of spinal hematoma w/ ticlopidine & clopidogrel& the GP IIb/IIIa antagonists is not known.\\n➣ Recommendations are based on labeling precautions &the surgical, interventional cardiology/radiology experi-ence.\\nrBased on labeling & surgical reviews, the suggested timeinterval btwn discontinuation of thienopyridine ther-apy & neuraxial blockade is 14 days for ticlopidine, 7days for clopidogrel.\\nrPlatelet GP IIb/IIIa inhibitors exert a profound effect onplatelet function.\\nrFollowing administration, the time to normal plateletaggregation is 24–48 hrs for abciximab, 4–8 hrs for epti-ﬁbatide & tiroﬁban.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 252}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nAnticoagulation Therapy 239\\nrAvoid neuraxial techniques until platelet function has\\nrecovered.\\nrGP IIb/IIIa antagonists are contraindicated within 4 wksof surgery.\\nrIfaG PIIb/IIIa antagonist is administered in the postop\\nperiod (following a neuraxial technique), the pt shouldbe carefully monitored neurologically.\\n➣ The concurrent use of other meds affecting clottingmechanisms, such as oral anticoagulants, unfractionatedheparin & LMWH, may increase the risk of bleedingcomplications.\\n➣ Cyclooxygenase-2 inhibitors have a minimal effect on\\nplatelet function & should be considered in pts whorequire anti-inﬂammatory therapy in the presence of anti-\\ncoagulation.\\n■Anesthetic mgt of the patient receiving herbal therapy\\n➣ Asigniﬁcant number of surgical pts use alternative\\nmeds.\\n➣ There is no evidence that herbal therapy representsan added risk for development of neuraxial hema-toma.\\n➣ There is no evidence that neuraxial anesthesia should beavoided or surgery cancelled if the pt has used herbal ther-apies.\\n➣ There are no data on the concurrent use of other forms ofanticoagulation w/ herbal therapies.\\nrConcurrent use of other forms of anticoagulation w/\\nherbal therapy may increase the risk of neuraxial hema-toma.\\n➣ There is no test to assess the adequacy of hemostasis inpts using herbal meds.\\n➣ The use of herbal medicine alone should not interfere w/the performance of neuraxial anesthesia.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 253}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n240 Anticoagulation Therapy\\nrThis includes timing of single shot or catheter tech-niques, postop monitoring or the timing of catheterremoval.\\n■New anticoagulants (direct thrombin inhibitors and fonda-\\nparinux)\\n➣ New antithrombotic drugs target various steps in the\\nhemostatic system, such as inhibiting platelet aggrega-tion, blocking coagulation factors or enhancing ﬁbri-nolysis.\\n➣ The most extensively studied are antagonists of speciﬁcplatelet receptors & direct thrombin inhibitors.\\n➣ Many of these antithrombotic agents have prolonged half-\\nlives & are difﬁcult to reverse w/out the administration ofblood components.\\n➣ Thrombin inhibitors\\nrRecombinant hirudin derivatives include desirudin,\\nlepirudin, bivalirudin.\\nrRecombinant hirudin derivatives inhibit both free &\\nclot-bound thrombin.\\nrArgatroban, an L-arginine derivative, has a similarmechanism of action.\\nrThere are no case reports of spinal hematoma relatedto neuraxial anesthesia among pts who have received athrombin inhibitor.\\nrSpontaneous intracranial bleeding has been re-ported.\\nrThere are no recommendations regarding risk assess-ment & pt mgt.\\nrIdentiﬁcation of interventional cardiac & surgical risk\\nfactors associated w/ bleeding after invasive proceduresmay be helpful.\\n➣ Fondaparinux\\nrFondaparinux produces its antithrombotic effectthrough factor Xa inhibition.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 254}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nAnticoagulation Therapy 241\\nrThe FDA released fondaparinux with a black box warn-ing similar to that of the LMWHs & heparinoids.\\nrThe actual risk of spinal hematoma with fondaparinuxis unknown.\\nrUntil further clinical experience is available, perfor-\\nmance of neuraxial techniques should occur underconditions used in clinical trials (single needle pass,atraumatic needle placement, avoidance of indwellingneuraxial catheters).\\n■Summary\\n➣ The consensus paper concludes by stating:\\n➣ “Practice guidelines or recommendations summarize\\nevidence-based reviews. However, the rarity of spinalhematoma deﬁes a prospective-randomized study, andthere is no current laboratory model. As a result, theseconsensus statements represent the collective experienceof recognized experts in the ﬁeld of neuraxial anesthe-sia and anticoagulation. They are based on case reports,clinical series, pharmacology, hematology, and risk fac-tors for surgical bleeding. An understanding of the com-plexity of this issue is essential to patient management; acookbook approach is not appropriate. Rather, the deci-sion to perform spinal or epidural anesthesia/analgesiaand the timing of catheter removal in a patient receiv-ing antithrombotic therapy should be made on an indi-vidual basis, weighing the small, though deﬁnite risk ofspinal hematoma with the beneﬁts of regional anesthe-sia for a speciﬁc patient. Alternative anesthetic and anal-gesic techniques exist for patients considered an unac-ceptable risk. The patient’s coagulation status shouldbe optimized at the time of spinal or epidural needle/catheter placement, and the level of anticoagulationmust be carefully monitored during the period of epidu-ralcatheterization. Indwelling catheters should not be'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 255}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n242 Anticoagulation Therapy Aortic Regurgitation\\nremoved in the presence of therapeutic anticoagulation,\\nas this appears to signiﬁcantly increase the risk of spinalhematoma. It must also be remembered that identiﬁ-cation of risk factors and establishment of guidelineswill not completely eliminate the complication of spinalhematoma. Vigilance in monitoring is critical to allowearly evaluation of neurologic dysfunction and promptintervention. We must focus not only on the preventionof spinal hematoma, but also optimization of neurologicoutcome.”\\nwake up and emergence\\nN/A\\nicu or pacu\\nN/A\\nAORTIC REGURGITATION\\nROBERT N. SLADEN, MD\\nscreening and evaluation\\n■Note the following:\\n➣ Symptoms (dyspnea, syncope, congestive heart\\nfailure)\\n➣ Signs of progressive disease (pulse pressure, ECG changes,\\ncardiomegaly, degree of AR)\\n➣ Presence of associated CAD (increased risk)\\n■Look for physical signs of:\\n➣ LVH (apical heave)\\n➣ Congestive heart failure (elevated neck veins, edema, hep-\\natomegaly)\\n■Relevant lab studies\\n➣ Hct (anemia is poorly tolerated by low CO)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 256}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nAortic Regurgitation 243\\n➣ PT, INR (if on coumadin for atrial ﬁb)\\n➣ BUN, creatinine (prerenal syndrome)\\n➣ ECG (LVH w/ or w/out strain)\\n➣ Chest x-ray (LVH)\\n➣ TTE, TEE (AR, LVH, LAH)\\npreoperative preparation\\n■Continue preop meds:\\n➣ Digoxin (inotropy, rate control for atrial ﬁb)\\n➣ Diuretics for pulmonary edema\\n■Plan perioperative anticoagulation:\\n➣ Hold coumadin at least 3 days preop.\\n➣ Check INR prior to surgery.\\n■Consider preop admission for control of:\\n➣ Rapid atrial ﬁb\\n➣ Symptomatic pulmonary edema or congestive heart\\nfailure\\n■Plan perioperative antibiotics:\\n➣ Increased risk of bacterial endocarditis\\noperative preparation\\n■Review hemodynamic principles:\\n➣ Maintain sinus rhythm (atrial kick, to maximize ventricu-\\nlar ﬁlling)\\n➣ Maintain faster heart rate (decrease diastolic regurgitant\\ntime)\\n➣ Maintain adequate preload (maximize ventricular\\nﬁlling)\\n➣ Useinotropic, chronotropic agents (maintain contractil-\\nity, heart rate)\\n➣ Dopamine (beta-adrenergic dose range)\\n➣ Dobutamine (inodilator, provides afterload reduction)\\n➣ Avoid systemic vasoconstrictors.\\n■Acute (new-onset) atrial ﬁb'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 257}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n244 Aortic Regurgitation\\n➣ Poorly tolerated, can induce acute decompensation, lowcardiac output syndrome\\n➣ Treat aggressively whenever it occurs (esmolol, amio-\\ndarone, early cardioversion).\\n■Avoid excessive sedative or opioid premed:\\n➣ Suppresses catecholamines, induces bradycardia\\n➣ Increased risk of respiratory depression (hypercarbiaincreases PVR)\\n■Use ﬂuids & inotropic +chronotropic agents to treat hypo-\\ntension:\\n➣ Maintain preload, diastolic perfusion pressure.\\n➣ Use ephedrine (mixed agonist, increases contractility, may\\ninduce tachycardia).\\n➣ Avoid vasoconstrictors (phenylephrine, norepinephrine):\\nincrease SVR\\n■Invasive hemodynamic monitoring, TEE\\n➣ Moderate to large ﬂuid shifts anticipated\\n➣ Presence of symptoms\\nanesthesia\\n■Regional anesthesia is relatively contraindicated:\\n➣ Sympathetic block may induce dangerous hypotension,worsen MVO\\n2\\n➣ Avoid spinal anesthesia (abrupt onset of block)\\n➣ Careful continuous spinal or epidural anesthesia may be\\ntolerated\\n➣ Adequate ﬂuid load prior to placement (maintain preload)\\n■General anesthesia\\n➣ Take measures to maintain faster heart rate & adequatecontractility\\n➣ Preoxygenate\\n➣ Adequate ﬂuid load prior to induction (maintain preload)\\n➣ Treat hypotension w/ ephedrine\\n➣ Treat bradycardia w/ ephedrine, dopamine, dobutamine'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 258}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nAortic Regurgitation 245\\n■Choose maintenance regimen that maintains faster heart rate,avoids myocardial depression:\\n➣ Consider low-dose isoﬂurane (increased heart rate), des-\\nﬂurane (increased sympathetic tone).\\n➣ Consider total IV anesthetic (fentanyl, sufentanil, remifen-\\ntanil), but watch for bradycardia.\\nwake up and emergence\\n■Attempt to suppress catecholamines on emergence (tach-\\nyarrhythmias)\\n➣ Judicious use of sympatholytic opioid (fentanyl, sufen-\\ntanil, remifentanil)\\n➣ Avoid morphine (histamine, catecholamine release)\\n■Potential complications on emergence\\n➣ Delayed emergence (low cardiac output, increased phar-\\nmacodynamic effects)\\n➣ Acute pulmonary hypertension\\n➣ Acute pulmonary congestion, edema\\n➣ Hypoxemia, acute respiratory failure\\nicu or pacu\\n■Maintain cardiac output\\n➣ Maintain preload (ﬂuids)\\n➣ Aggressive treatment of atrial arrhythmias (esmolol, amio-darone, cardioversion)\\n➣ Maintain or increase contractility (dopamine)\\nrDecrease afterload with vasodilators (nitroprusside,\\nnicardipine)\\nrIncrease contractility, decrease afterload with inodila-\\ntors (dobutamine, milrinone)\\n■Consider short period of postop mechanical ventilation if AR\\nsevere:\\n➣ Allows controlled emergence\\n➣ Avoids reversal (ie, need for muscarinic agents [brady-\\ncardia])'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 259}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n246 Aortic Regurgitation Aortic Stenosis\\n➣ Facilitates evaluation of cardiac, ventilatory function\\n➣ Allows control of pulmonary hypertension, appropriatediuresis prior to extubation\\n■Restart preop meds (digoxin, diuretics) as soon as possible.\\n■For chronic atrial ﬁb:\\n➣ Anticoagulation required >24 hrs to prevent intracardiac\\nthrombus formation\\n➣ Restart oral coumadin when pt is able to take orally.\\n➣ Ifnot, start IV heparin & continue until pt is able to take\\noral meds.\\nAORTIC STENOSIS\\nROBERT N. SLADEN, MD\\nscreening and evaluation\\n■Note the following:\\n➣ Symptoms (angina, syncope, congestive heart failure)\\n➣ Signs of progressive disease (ECG changes, valve gradient\\n&a r ea)\\n➣ Presence of associated CAD (increased risk)\\n■Look for physical signs of:\\n➣ Left ventricular hypertrophy (apical heave)\\n➣ Congestive heart failure (elevated neck veins, edema, hep-\\natomegaly)\\n■Relevant lab studies\\n➣ Hct (anemia is poorly tolerated by low CO)\\n➣ PT, INR (if on coumadin for AF)\\n➣ BUN, creatinine (prerenal syndrome)\\n➣ ECG (LVH w/ or w/out strain)\\n➣ Chest x-ray (LVH)\\npreoperative preparation\\n■Continue preop meds:\\n➣ Beta blockade or calcium blockade (negative inotropy,\\nchronotropy)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 260}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nAortic Stenosis 247\\n➣ Digoxin (rate control for atrial ﬁbrillation)\\n➣ Diuretics for pulmonary edema\\n■Plan perioperative anticoagulation\\n➣ Hold coumadin at least 3 days preoperatively.\\n➣ Check INR before surgery.\\n■Consider preop admission for control of:\\n➣ Rapid atrial ﬁbrillation\\n➣ Symptomatic pulmonary edema or congestive heart fail-\\nure\\n■Plan perioperative antibiotics:\\n➣ Decrease risk of bacterial endocarditis\\noperative preparation\\n■Review hemodynamic principles\\n➣ Maintain sinus rhythm (atrial kick, to maximize ventricu-\\nlar ﬁlling).\\n➣ Maintain slow heart rate (increase diastolic ﬁll time).\\n➣ Maintain adequate preload (maximize ventricular ﬁll-\\ning).\\n➣ Avoid inotropic, chronotropic agents.\\n➣ Avoid systemic vasodilators.\\n➣ Maintain SVR (& coronary diastolic perfusion pressure).\\n■Acute (new-onset) atrial ﬁbrillation\\n➣ Poorly tolerated; can induce acute decompensation, low\\ncardiac output syndrome\\n➣ Treat aggressively whenever it occurs (esmolol, amio-\\ndarone, early cardioversion).\\n■Ensure adequate sedative or opioid premedication\\n➣ Suppress catecholamines, avoid tachyarrhythmias.\\n➣ Butincreased risk of respiratory depression (low cardiac\\noutput)\\n■Useﬂuids & vasoconstrictor agents to treat hypotension\\n➣ Maintain preload, diastolic perfusion pressure.\\n➣ Avoid ephedrine, norepinephrine (mixed agonists, in-\\ncrease contractility, may induce tachycardia).'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 261}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n248 Aortic Stenosis\\n➣ Useapure vasoconstrictor (phenylephrine); reﬂex brady-\\ncardia is also helpful.\\n■Invasive hemodynamic monitoring, TEE\\n➣ Moderate to large ﬂuid shifts anticipated\\n➣ Presence of symptoms\\nanesthesia\\n■Regional anesthesia is relatively contraindicated\\n➣ Sympathetic block may induce dangerous hypotension,worsen MVO\\n2\\n➣ Avoid spinal anesthesia (abrupt onset of block)\\n➣ Careful continuous spinal or epidural anesthesia may be\\ntolerated\\n➣ Adequate ﬂuid load before placement (maintain preload)\\n■General anesthesia\\n➣ Take measures to maintain slow heart rate & adequateperfusion pressure.\\n➣ Preoxygenate\\n➣ Adequate ﬂuid load before induction (maintain preload)\\n➣ Treat hypotension w/ phenylephrine.\\n➣ Treat tachycardia w/ esmolol.\\n■Avoid pancuronium (tachycardia), ketamine (sympath-\\nomimetic).\\n■Choose maintenance regimen that maintains slow heart rate,suppresses sympathetic response\\n➣ Avoid isoﬂurane (increased heart rate); desﬂurane\\n(increased sympathetic tone).\\n➣ Consider sympatholytic opioid (fentanyl, sufentanil,remifentanil).\\nwake up and emergence\\n■Attempt to suppress catecholamines on emergence\\n➣ Judicious use of sympatholytic opioid (fentanyl, sufen-tanil, remifentanil)\\n➣ Avoid morphine (histamine, catecholamine release).'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 262}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nAortic Stenosis Bronchospastic Disease 249\\n■Consider dexmedetomidine infusion\\n➣ Sympatholytic, provides analgesia w/out respiratory\\ndepression\\n➣ Canbecontinued through tracheal extubation & beyond\\n➣ Dose carefully: can potentiate beta blockade, delay anes-thetic emergence\\n■Potential complications on emergence\\n➣ Delayed emergence (low cardiac output, increased phar-\\nmacodynamic effects)\\n➣ Acute myocardial ischemia, pulmonary congestion,\\nedema\\nicu and pacu\\n■Control pain & anxiety (avoid tachycardia); see above\\n■Consider short period of postop mechanical ventilation if AS\\nsevere\\n➣ Allows controlled emergence\\n➣ Avoids reversal (ie, need for anticholinergic agents\\n[tachycardia])\\n➣ Facilitates evaluation of cardiac, ventilatory function\\n➣ Careful sedation is essential: dexmedetomidine very\\nuseful\\n■Restart preop meds (beta, calcium blockade) as soon as pos-\\nsible.\\nBRONCHOSPASTIC DISEASE\\nHUGH PLAYFORD, MD\\nscreening and evaluation\\n■Consider impact of the asthma & the mgt therapies.\\n■History of asthma\\n➣ Duration of asthma & triggers\\n➣ Therapy & compliance'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 263}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n250 Bronchospastic Disease\\n➣ Need for ER visit, hospitalizations, intubation & ventila-tion\\n➣ Need for systemic steroids & doses\\n➣ Exercise tolerance\\n➣ Patient monitoring of asthma severity (peak ﬂow meters)\\n■Symptoms\\n➣ Cough\\n➣ Upper or lower respiratory tract infection\\n➣ Exercise tolerance\\n■Signs\\n➣ Hyperexpansion of thorax\\n➣ Degree of respiratory distress\\n➣ Airway obstruction (prolonged expiratory time, wheeze)\\n➣ Cough\\n■Investigations\\n➣ PFTs & spirometry: before & after bronchodilators\\n➣ Chest x-ray: rarely useful but may help differentiate othercauses of respiratory failure\\n➣ ABGs: if there are concerns regarding the adequacy of ven-tilation or oxygenation\\n➣ Sputum MCS: if there are concerns regarding a lower res-piratory tract infection\\npreoperative preparation\\n■Use care w/ preanesthetic agents that may cause respiratory\\ndepression.\\n■Anticholinergic agents may increase viscosity of secretions(preventing adequate clearance).\\n■H2 receptor antagonists controversial\\n➣ H2 receptor mediates bronchodilatation; H-1 receptormediates bronchoconstriction.\\n➣ H2 receptor antagonist may prevent bronchodilation ANDunmask H1-mediated bronchoconstriction.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 264}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nBronchospastic Disease 251\\n■Optimally manage any pre-existing airway obstruction\\n➣ Continue pt’s usual therapy for asthma to the time of anes-\\nthetic induction.\\n➣ Consider chest physiotherapy, systemic hydration, appro-\\npriate antibiotics & optimizing bronchodilator therapy.\\n■Forpts on recent & current systemic steroids, supplemen-\\ntal doses of steroids will be needed to prevent unmasking ofadrenal suppression.\\noperative preparation\\n■Goals\\n➣ Speciﬁc to the asthma: Optimize any airway obstruction.\\n➣ Speciﬁc to anesthesia: Depress airway reﬂexes to avoid\\nbronchospasm in response to mechanical stimulation.\\n■Regional anesthesia may be a consideration.\\nanesthesia\\n■Goals\\n➣ Have adequate depth of anesthesia during the periods of\\nairway provocation (intubation, incision, extubation).\\n■Induction agents (benzodiazepines, barbiturates, propofol,\\netomidate) have little airway reﬂex depressant actions.\\n■Ketamine\\n➣ Prevents increased airway resistance better than thiopen-\\ntone (via the sympathomimetic effect)\\n➣ Increased secretions may counteract this.\\n■Inhalational agents\\n➣ Used to ensure adequate depth of anesthesia to suppress\\nairway reﬂexes\\n➣ BUThalothane sensitizes the myocardium to car-\\ndiac dysrhythmic effects of beta-agonists & aminophy-lline.\\n➣ Enﬂurane, isoﬂurane & sevoﬂurane appear as effective ashalothane in reversing induced bronchospasm.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 265}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n252 Bronchospastic Disease\\n■Lidocaine\\n➣ IV bolus (1.5 mg/kg given about 1 min before intubation)may be used to suppress airway reﬂexes.\\n➣ IV infusion (1–3 mg/kg/hr) may be used to suppress airwayreﬂexes in the place of volatile anesthesia.\\n➣ Intratracheal lidocaine may provide local anesthesia of theupper airway but may also provoke bronchospasm by thepresence of the solution.\\n■Select neuromuscular blockers to minimize the release of his-tamine.\\n➣ Atracurium has been associated w/ intraop bron-\\nchospasm.\\n➣ Succinylcholine associated w/ histamine release but noevidence of increased airway resistance\\n■Ventilation\\n➣ Avoid the development of pulmonary hyperinﬂation (gas\\ntrapping) or barotraumas.\\n➣ Slow inspiratory rate w/ long I:E ratio to allow sufﬁ-\\ncient expiratory time for expiratory airﬂow to return tozero\\n➣ Minimize (or avoid) PEEP.\\n➣ Humidify & warm the inspired gases.\\n■Maintain adequate hydration (possibly prevent the develop-\\nment of viscous secretions).\\nwake up and emergence\\n■Aim to extubate while anesthesia is sufﬁcient to suppress air-way hyperresponsiveness.\\n■Lidocaine (IV bolus or infusion may be useful)\\nicu or pacu\\nN/A'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 266}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nCarcinoid Syndrome 253\\nCARCINOID SYNDROME\\nGIUDITTA ANGELINI, MD\\nscreening & evaluation\\nN/A\\npreoperative preparation\\n■Ingeneral, preoperative course reﬂects intraoperative course.\\noperative preparation\\nN/A\\nanesthesia\\n■Variable depending on degree of hormone secretion\\n■50% of pts w/ intraoperative bronchospasm may have no pre-vious history.\\n■Benzodiazepine premedication\\n➣ Anxiety can trigger carcinoid episode.\\n■100 mcg octreotide given on induction\\n■Smooth induction w/ propofol or etomidate & nondepolarizer\\n➣ Hypotension, hypertension, hypercapnia can trigger car-\\ncinoid episode.\\n➣ Thiopental & succinylcholine can release histamine.\\n■Usefentanyl & derivatives.\\n➣ Morphine can release histamine.\\n■Arterial line for BP monitoring\\n■Central line may be indicated for ﬂuid resuscitation w/\\nor w/out pulmonary artery catheter for pts w/ cardiacdisease.\\n■General or regional anesthesia acceptable\\n■Direct & indirect sympathomimetic drugs can stimulate\\nrelease of hormones, so treat hypotension w/ octreotide &\\nﬂuid.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 267}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n254 Carcinoid Syndrome Chemotherapeutic Agents\\n■Treat hypertension w/ octreotide & increased anesthesia.\\n■Treat bronchospasm w/ octreotide & inhaled ipratropium.\\nwake up & emergence\\nN/A\\nicu or pacu\\n■Monitor blood glucose closely.\\nCHEMOTHERAPEUTIC AGENTS\\nJONATHAN T. KETZLER, MD\\nscreening and evaluation\\n■Anthracyclines\\n➣ There are no tests to determine which pts will developheart failure.\\n➣ Do gated radionucleotide blood pooled study or echocar-diogram as baseline before patient receives a cumulativedose of 400 mg/m\\n2& before each following treatment.\\n➣ Because injury can continue for years after treatment,ideally a full cardiac evaluation should be done within 1month of elective surgery.\\n■Bleomycin\\n➣ Chest x-ray & pulmonary function tests to evaluate forpneumonitis & pulmonary ﬁbrosis\\npreop preparationoperative preparation\\nN/A\\nanesthesia\\n■Anthracyclines\\n➣ Avoid cardiodepressant drugs.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 268}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nChemotherapeutic Agents Chronic Obstructive Pulmonary Disease 255\\n➣ Mayneed pulmonary artery catheter or intraoperative\\ntransesophageal echocardiography if cardiac function isin question\\n■Bleomycin\\n➣ Avoid supplemental oxygen; keep as close to FIO 2of 0.21\\nas oxygenation permits.\\n➣ Ifpulmonary compliance is low, alternative modes of ven-\\ntilation may be needed. Consider ICU ventilator & total IVanesthesia\\nwake up & emergence\\nN/A\\nicu or pacu\\n■Seerecommendations under “ Anesthesia.”\\nCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)\\nHUGH R. PLAYFORD, MBBS\\nscreening & evaluation\\n■Assess for severity of disease & any reversible components(reactive airway disease, infection).\\n■Aside from history & examination, consider PFTs, ABGs, spu-tum culture & sensitivity.\\n■GOLD Guidelines: classiﬁcation of severity of COPD\\nStage Classiﬁcation\\n0: At risk Normal spirometry\\nChronic symptoms (cough, sputumproduction)\\n1: Mild COPD FEV1/FVC <70%\\nFEV1 >80% predicted\\nW/ or w/out chronic symptoms (cough,sputum production)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 269}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n256 Chronic Obstructive Pulmonary Disease\\n2: Moderate COPD FEV1/FVC <70%\\n30%>FEV1<80% predicted\\nW/ or w/out chronic symptoms (cough,sputum production, dyspnea)\\n3: Severe COPD FEV1/FVC <70%\\nFEV1 <30% predicted or FEV1 <50%\\npredicted plus respiratory failure orclinical signs of right heart failure\\n■Identify & eradicate acute bacterial infection w/ antibiotics &physical therapy.\\n■Optimize the strength of skeletal muscles (nutrition, physicaltherapy, avoidance of hypokalemia).\\n■Smoking\\n➣ Smoking associated w/ increased postop pulmonary com-plications\\n➣ Carbon monoxide leads to increased carboxyhemoglobin,tissue hypoxia, shift of oxygen dissociation curve; elimi-nation half-time for carbon monoxide about 4–6 hrs.\\n➣ Smoking also induces mucus hypersecretion, impair-ment of mucociliary transport & small airway narrowing;these recover slowly after smoking cessation (up to8 wks).\\n➣ Immune system interference (need about 6 wks of cessa-tion to recover)\\n➣ Hepatic enzyme recovery after 6–8 wks of abstinence\\n➣ But smokers have lower incidence of DVT after surgery.\\n➣ Recommend that pt cease smoking before elective surgery.\\npreoperative preparation\\n■Eradicate any pulmonary infection.\\n■Optimize pulmonary therapy.\\n■Consider physical therapy & nutrition.\\n■Ptsareat increased risk of developing acute respiratory failure\\nduring postop period.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 270}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nChronic Obstructive Pulmonary Disease 257\\n■Plan intraoperative technique (regional, general, combined)\\n&postop analgesic regimen to have minimal pulmonary detri-\\nment.\\n■Postop impairment of pulmonary function likely w/:\\n➣ Any chronic disease that involves the lung\\n➣ Smoking history, persistent cough, and/or wheezing\\n➣ Chest wall & spinal deformities\\n➣ Morbid obesity\\n➣ Requirement for single lung anesthesia or lung resection\\n➣ Neuromuscular disease\\noperative preparation\\n■Bronchodilators rarely improve the FEV1 by >10%.\\n■Anticholinergic therapy\\n■Antibiotics\\n■Inﬂuenza vaccination\\n■Diuresis for cor pulmonale & right heart failure\\n■Supplemental oxygen titrated to the individual pt’s needs\\n■Physical training programs\\nanesthesia\\n■Regional anesthesia\\n➣ Potentially avoids respiratory depressant effects of seda-\\ntive drugs\\n➣ Avoid regional techniques that provide sensory anesthe-\\nsia above T6 (may decrease expiratory reserve volume &impair effectiveness to cough & clear secretions)\\n■General anesthesia\\n➣ Usecare w/ COPD pts w/ some airway reactivity: these\\npts may develop signiﬁcant laryngospasm and/or bron-chospasm w/ airway instrumentation.\\n➣ Volatile anesthesia allows humidiﬁcation, anesthesia\\ndelivery w/ a relatively rapid onset & offset, blunting ofairway reﬂexes & reﬂex bronchospasm & volatile-inducedbronchodilatation.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 271}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n258 Chronic Obstructive Pulmonary Disease\\n➣ Volatile anesthesia also attenuates regional hypoxic pul-monary vasoconstriction, leading to increased R-to-Lintrapulmonary shunting.\\n➣ Avoid nitrous oxide in the presence of pulmonary bullae\\n(nitrous oxide leads to enlargement & rupture & possibletension pneumothorax).\\n➣ Nitrous oxide technique also limits the FiO 2that can be\\ndelivered.\\n➣ Opioids may lead to prolonged respiratory depression; usejudiciously.\\n➣ Humidiﬁcation is used to prevent drying of secretions in\\nthe airways.\\n➣ Ventilation\\nrPrinciples are to allow adequate minute ventilation\\n&adequate minute ventilation & minimize the risk\\nof barotrauma & dynamic pulmonary hyperinﬂation(which can impair ventilation & circulation).\\nrTidal volume around 10 mL/kg, slow respiratory rate\\naround 6–10 breaths/min\\nrSlow r espiratory rate allows a long expiratory time to\\nreduce the risk of dynamic pulmonary hyperinﬂation.\\nrMay need to follow ABGs in addition to continuous\\npulse oximetry & capnography.\\nwake up & emergence\\n■Principles are to have the pt well analgesed w/ good effec-\\ntive cough & deep inspiration w/out any residual respiratorydepression.\\n■Extubation\\n➣ Ideally, extubate at the end of the surgical procedure(depends on procedure & duration of anesthesia).\\n➣ Tracheal tube increases airway resistance & risk of reﬂex\\nbronchoconstriction, limits the pt’s ability to clear secre-tions effectively & increases the risk of iatrogenic infection.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 272}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nChronic Obstructive Pulmonary Disease 259\\n■Analgesia\\n➣ Regional techniques using local anesthesia and/or neu-\\nraxial opioids may be able to avoid signiﬁcant respiratory\\ndepression.\\n➣ Neuraxial local anesthesia may lead to postural hypoten-\\nsion & interfere w/ postop ambulation & sputum clearance&incentive spirometry.\\n➣ Pt-controlled analgesia w/ systemic opioids may also min-\\nimize the risk of signiﬁcant respiratory depression.\\n➣ With any route of opioid, however, potent respiratory\\ndepression may develop; epidural opioids may depressventilation up to 12 hrs after administration.\\n➣ Consider other nonrespiratory-depressing analgesics as\\nadjunctive agents (acetaminophen, alpha-2 agonists suchas clonidine & dexmedetomidine, NSAIDs).\\n■Chest physical therapy & incentive spirometry\\nicu or pacu\\n■Continued intubation & ventilation in the postop period may\\nbe necessary in pts w/ severe COPD and/or major upperabdominal or thoracic surgery.\\n■Discontinuation of ventilation is based on the pt’s clinical\\ncondition (preexisting pulmonary impairment, surgical pro-cedure, duration of anesthesia) as well as indices of respiratoryfunction.\\n➣ The changes in pulmonary function that occur postop areprimarily restrictive; these changes added to preexistingCOPD may be catastrophic in the individual pt.\\n➣ Proportional decreases in all lung volumes, no change in\\nairway resistance\\n➣ FRC decreases from decreased abdominal excursion (eg,from abdominal operations), abnormal postop respira-tory pattern (shallow, rapid breaths).'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 273}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n260 Chronic Obstructive Pulmonary Disease Chronic Renal Failure\\n➣ Operative site is the most important factor: non-\\nlaparoscopic upper abdominal operations decrease FRCby40–50% >lower abdominal & thoracic decrease FRC by\\n30%>other operative sites decrease FRC by 15–20%.\\nCHRONIC RENAL FAILURE\\nROBERT N. SLADEN, MD\\nscreening and evaluation\\n■Note the following:\\n➣ Etiology of chronic renal failure (ie, presence of systemicdisease)\\n➣ Urine output (oliguric or polyuric)\\n➣ Type of dialysis (HD or CAPD) & most recent treatment\\n➣ Treatment w/ human recombinant erythropoietin\\n(EPO)\\n■Look for physical signs of anemia, LVH, CHF, neuropathy, sep-sis, malnutrition. Examine shunt sites and/or CAPD cathetersite for infection.\\n■Relevant lab studies\\n➣ Hct (anemia), CBC (leukocytosis)\\n➣ Electrolytes (assess acidosis by total CO2 if ABG impracti-cable)\\n➣ BUN, creatinine (look for recent change)\\n➣ Ivybleeding time (BT) (>15 min: platelet dysfunction)\\n➣ ECG (LVH, hyperkalemia)\\n➣ Chest x-ray (LVH, pulmonary congestion or edema)\\npreoperative preparation\\n■Hemodialysis\\n➣ Schedule day before elective surgery to avoid acute ﬂuid& electrolyte shifts.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 274}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nChronic Renal Failure 261\\n■CAPD\\n➣ Continue until time of surgery.\\n➣ Assess excessive abdominal girth (may compromise func-tional residual capacity).\\n■Preop blood transfusion only for:\\n➣ Acute blood loss\\n➣ Cardiopulmonary disease\\n➣ Major surgery with Hct <28%\\n■Transfuse during dialysis only:\\n➣ Avoid ﬂuid overload & hyperkalemia.\\n■Correct platelet dysfunction before major surgery:\\n➣ DDAVP 0.3 micrograms/kg over 20 min, or\\n➣ Cryoprecipitate 10 units (preferred if exposure to cate-\\ncholamines)\\n■Control labile/symptomatic hypertension\\n■Preop alpha-2 agonists (clonidine or guanabenz)\\n➣ Clonidine transdermal patch to prevent rebound hyper-tension\\noperative preparation\\n■Minimize sedative or opioid premeds.\\n■Aspiration prophylaxis\\n➣ Anticholinergic agent (glycopyrrolate preferred)\\n➣ H2blocker (famotidine preferred: least likelihood of\\nthrombocytopenia)\\n➣ Metoclopramide\\n➣ Sodium bicitrate\\n■Useuniversal & aseptic precautions throughout\\n➣ Avoid BP cuffs or arterial catheters on arm w/ AV ﬁstula/\\nshunt.\\n➣ Avoid urinary catheter in anuric or oliguric pts.\\n■Invasive hemodynamic monitoring\\n➣ Iflarge ﬂuid shifts anticipated\\n➣ Sepsis'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 275}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n262 Chronic Renal Failure\\n➣ Cardiopulmonary insufﬁciency\\n■Avoid pressure or stretch on ﬁstula sites, bony prominences,\\njoints\\n➣ Sensory neuropathy (pts do not feel positional discomfort)\\n➣ Renal osteodystrophy (fragile bones & joints)\\n■Use active warming devices to prevent hypothermia\\n➣ Forced-air convection blanket\\n■Consider intraoperative hemodialysis during CPB.\\nanesthesia\\n■Regional anesthesia\\n➣ Not contraindicated if coagulopathy corrected\\n➣ Avoid if increased risk of hypotension (autonomic neu-\\nropathy), infection.\\n➣ Watch for postop pulmonary edema (sympathetic blockwears off, increase in SVR).\\n■General anesthesia\\n➣ Aspiration precautions (head up, rapid sequence, cricoidpressure)\\n➣ Preoxygenate\\n➣ Adequate ﬂuid load (250–1,000 mL) prior to induction\\n■Succinylcholine is not contraindicated if:\\n➣ Serum K <5.0 mEq/L\\n➣ Ptdialyzed within last 24 hrs\\n■Avoid pancuronium & pipecuronium (prolonged action).\\n■After tracheal intubation, increase minute ventilation\\n➣ Compensate for chronic metabolic acidosis\\n■Keep maintenance ﬂuids to a minimum but fully replace ﬂuidlosses.\\n■Enﬂurane (ﬂuoride), sevoﬂurane (compound A)\\n➣ Theoretical possibility of nephrotoxicity\\n■Anticipate labile BP\\n➣ Hypotension (deep anesthesia, ﬂuid losses, positionalchanges)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 276}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nChronic Renal Failure 263\\n➣ Hypertension (inadequate anesthesia)\\n➣ Beta blockers or calcium blockers are helpful for control.\\n■Anticipate hyperkalemia\\n➣ Evoked by high-dose beta blockade\\n➣ Protects against digoxin-induced arrhythmias but may\\nexacerbate conduction block\\nwake up and emergence\\n■Anesthetic emergence may be delayed\\n➣ Pharmacokinetic (delayed elimination, active metabo-\\nlites)\\n➣ Pharmacodynamic (enhanced sensitivity to effects)\\n■Potential complications on emergence\\n➣ Vomiting, aspiration\\n➣ Hypertension\\n➣ Persistent neuromuscular blockade\\n➣ Respiratory depression\\n➣ Pulmonary edema\\nicu or pacu\\n■Chronic metabolic acidosis +CO2retention: acute acidosis,\\nhyperkalemia\\n■Consider short period of postop mechanical ventilation\\n➣ Allows controlled emergence\\n➣ Avoids reversal agents\\n➣ Facilitates evaluation of neurologic, ventilatory function\\n■Restrict maintenance ﬂuid; replace sequestration or overt\\nlosses.\\n■Anticipate & treat hyperkalemia.\\n■Hemodialysis\\n➣ Severe uremia, hyperkalemia, acidosis, acute ﬂuid over-\\nload\\n➣ Risk of hemodynamic instability, myocardial ischemia\\n■Peritoneal dialysis\\n➣ Hemodynamically stable'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 277}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n264 Chronic Renal Failure Cocaine Toxicity\\n➣ Slow; not suited for severe uremia, hyperkalemia, acidosis,\\nacute ﬂuid overload\\n➣ Abdominal distention may compromise functional resid-ual capacity.\\n■Continuous venovenous hemoﬁltration/dialysis (CVVH/D)\\n➣ Large-volume removal w/ stable hemodynamics\\n➣ Requires heparin, may promote bleeding\\nCOCAINE TOXICITY\\nMARY E. McSWEENEY, MD\\nscreening and evaluation\\n■History: most pts deny drug abuse; often associated w/ alco-hol, tobacco & other illicit drug use\\n■Physical exam: tachycardia, angina, tachypnea, agitation\\n■Metabolites: urine positive for cocaine metabolites (ben-\\nzoylecgonine, ecgonine methyl ester) for 72 hrs. Cocaine &\\nethanol used in combination is extremely common; look formetabolite (cocaethylene).\\npreoperative preparation\\n■Hypertension: use nitroglycerin, labetalol, phentolamine &hydralazine for control; conventional wisdom is to avoid pro-pranolol (beta blockade) because of potential for unopposedalpha-adrenergic stimulation, which exacerbates cocaine-induced vasoconstriction\\n■Hypotension: likely ephedrine-resistant; use phenylephrine(alpha agonist)\\n■Tachycardia: use combined alpha/beta antagonist (labetalol)\\n■Agitation & acute coronary syndrome associated w/ cocainetoxicity: ﬁrst-line treatment nitrates, benzodiazepines & oxy-gen (aspirin if not contraindicated before surgery), then asindicated above'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 278}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nCocaine Toxicity 265\\noperative preparation\\n■Monitoring\\n➣ V5 lead ECG, temperature, pulse oximetry, ETCO 2\\n➣ Consider arterial line, central line, urine catheter & PA\\ncatheter if myocardial ischemia or dysfunction suspected.\\nanesthesia\\n■Anesthetic\\n➣ Halothane may be avoided due to sensitization of\\nmyocardium to catecholamines.\\n➣ Regional anesthesia can be used.\\n■Controlling hypertension & tachycardia\\n➣ Nitroglycerine 0.5–2.0 mcg/kg/min IV\\n➣ Phentolamine 1–5 mg IV q5min or 1 mg/min continuous\\ninfusion\\n➣ Labetalol 10–20 mg IV q10min to maximum 200 mg\\n➣ Esmolol 10–20 mg IV q10min or 50–300 mcg/kg/min con-tinuous\\n➣ Hydralazine 10 mg IV q30min to maximum 40 mg\\n■Treating arrhythmias\\n➣ Lidocaine okay for treatment of VF & VT\\n➣ Consider NaHCO 3in presence of acidosis; decreases QRS\\nprolongation & incidence of VT\\n➣ Avoid epinephrine.\\n➣ Avoid IA antiarrhythmics (quinidine, procainamide,\\ndisopyramide); they exacerbate prolongation of QRS &QT.\\nwake up & emergence\\nN/A\\nicu or pacu\\n■ICU care for pts w/ cocaine toxicity'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 279}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n266 Cocaine Toxicity Congestive Heart Failure\\n■Altered pain perception (due to abnormalities in endorphinlevels & changes in mu & kappa opioid receptor densities)makes postop pain mgt a challenge in this population.\\nCONGESTIVE HEART FAILURE\\nMUHAMMED ITANI, MD, AND JONATHAN T. KETZLER, MD\\nscreening and evaluation\\n■Symptoms of left & right ventricular failure (LVF, RVF)\\n➣ Fatigue, dyspnea at rest, orthopnea, ankle swelling, loss ofappetite\\n■History & physical exam\\n➣ Tachypnea, crackles: pulmonary congestion/edema (LVF)\\n➣ S4, S3 heart sound (LVF)\\n■Peripheral edema & JVD (LVF, RVF)\\n■Chest x-ray\\n➣ Cardiomegaly, pulmonary congestion, edema & pleural\\neffusion\\n➣ Early signs of LV: pulmonary venous distention, perivas-cular edema\\n➣ Kerley lines (septal edema): A (upper), B (lower), C (basew/ honeycomb pattern)\\n➣ Late signs: interstitial & alveolar edema, pleural & sub-pleural effusions\\n➣ Chest x-ray may lag behind worsening (up to 12 hrs) &improving (up to 4 days) CHF\\n■EKG\\n➣ Cardiomyopathy: poor R-wave progression\\n➣ Prolonged conduction, LBBB, RBBB.\\n➣ Varying degrees of conduction disease (ﬁrst-, second- or\\nthird-degree HB)\\n➣ Evidence of old MI'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 280}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nCongestive Heart Failure 267\\npreoperative preparation\\n■Chronic therapy goal is to slow LV remodeling & dilated car-diomyopathy.\\n➣ Dietary control: low-sodium diet\\n➣ Regular exercise\\n➣ Diuretics: decrease pulmonary congestion w/out exces-\\nsive hypovolemia\\n➣ Long-term nitrates\\n■Acute treatment to relieve congestion & improve tissue perfu-\\nsion\\n➣ Restoration & maintenance of sinus rhythm (pharmaco-\\nlogic, cardioversion)\\n➣ Diuretics: decrease pulmonary congestion w/out exces-\\nsive decrease in preload\\n➣ Correction of precipitating factor (ischemia, hyperten-\\nsion)\\n➣ Inodilators (inotropic support +afterload reduction)\\nrCatecholamines: dobutamine\\nrPhosphodiesterase inhibitors: milrinone\\n■Invasive options\\n➣ Angioplasty or CABG to relieve CHF due to CAD\\n➣ Surgical valve repair to relieve valve problems\\n➣ Intra-aortic balloon counterpulsation (bridge to emer-\\ngency surgery)\\n➣ Heart transplant\\n➣ Ventricular assist devices (VAD): useful to unload the heart\\n&help recover its function; used mainly as bridge to heart\\ntransplant\\n➣ Acute treatment to relieve congestion & improve tissue\\nperfusion\\noperative preparation\\n■Delay surgery if cardiac status is not optimized.\\n■Administer oxygen preop to avoid hypoxia.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 281}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n268 Congestive Heart Failure\\n■Avoid dehydration and/or ﬂuid overload.\\n■For major surgery, consider invasive hemodynamic moni-\\ntoring:\\n➣ Arterial line, CVP (access for vasoactive drugs)\\n➣ PAcatheter\\n➣ Intraop TEE\\nanesthesia\\n■Induction: ketamine is useful\\n➣ Sympathomimetics may preserve BP: ketamine, desﬂu-\\nrane\\n➣ Avoid potent cardiac depressant agents: thiopental,\\npropofol, nitrous oxide.\\n➣ Judicious dosing of etomidate, opioids & benzodiazepines\\n➣ Usevolatile anesthetic agents w/ caution due to cardiode-\\npressant effect.\\n■Maintenance\\n➣ May use opioids as the sole maintenance agents\\n➣ Choice of neuromuscular blocking agent (NMBA): avoidhistamine releasers\\n➣ Positive-pressure ventilation may decrease pulmonary\\ncongestion & improve oxygenation.\\n➣ Inotropic drugs (dobutamine, milrinone) may be neededintraoperatively to optimize cardiac function.\\n➣ Regional anesthesia can be used safely & may improvecardiac output & decrease PVR.\\n➣ Spinal & rapid epidural anesthesia may precipitate severe\\nhypotension.\\nwake up & emergence\\n■Do not extubate until hemodynamically stable & pulmonaryedema under control.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 282}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nCongestive Heart Failure Cor Pulmonale and RHF 269\\n➣ Residual anesthesia may compromise ability to provide\\nwork of breathing required for pulmonary congestion/edema.\\n➣ Removal of positive pressure can precipitate acute pul-\\nmonary edema.\\n➣ Upper airway obstruction will exacerbate pulmonary con-\\ngestion/edema (negative pressure edema).\\nicu or pacu\\n■Consider a period of postop mechanical ventilation (see Wake\\nUp&E mergence).\\n■Rule out MI.\\n➣ New Q waves on ECG\\n➣ Troponin >2ng/mL >8hrs after non-cardiac surgery\\n■Aggressive pain control to avoid sympathetic activation &worsening of pulmonary edema\\n■Avoid/anticipate abrupt cessation of spinal or epidural\\nanesthesia:\\n➣ Abrupt cessation of sympathetic block\\n➣ Abrupt increase in afterload\\n➣ Mayprovoke acute CHF/pulmonary edema\\n■Continue & adjust inotropic support & preload/afterload\\nreduction.\\nCOR PULMONALE AND RHF\\nMUHAMMED ITANI, MD, AND JONATHAN T. KETZLER, MD\\nscreening and evaluation\\n■Evaluate etiology of cor pulmonale & severity of pulmonary\\npathology (see “Diseases” section).\\n■PFTs, ABGs (evaluate severity of COPD)\\n■Chest x-ray'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 283}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n270 Cor Pulmonale and RHF\\n➣ Decreased retrosternal space on lateral view (RVH)\\n➣ Prominent main PA\\n➣ Decreased pulmonary vascular markings (pulmonaryhypertension)\\n➣ Heart size may change between acute episodes.\\n■EKG\\n➣ Peaked P wave in leads II, III & AVF\\n➣ Right axis deviation & complete or incomplete RBBB\\n➣ CBC, electrolytes: secondary polycythemia, leukocytosis(active infection), K (digoxin therapy)\\n■TTE\\n➣ Assess RV function, RV systolic pressure.\\n➣ RA size, tricuspid valve\\n■Right heart cath\\n➣ PApressure, RVEDP, RV function\\n➣ Trial of IV or inhaled pulmonary vasodilators (nitric oxide,\\nprostacyclin)\\n➣ If response (80% of PPH): use in OR.\\npreoperative preparation\\n■Anticipate physiologic & pharmacologic factors that increasePVR:\\n➣ Arterial hypoxemia\\n➣ Hypercarbia\\n➣ Acidosis\\n➣ High doses of vasoconstrictor catecholamines (epine-phrine, norepinephrine)\\n■Judicious diuresis to relieve RV overload (RV is preload depen-\\ndent)\\n■Digoxin: increased risk of digitoxicity\\n➣ Exacerbated by hypoxemia, acidosis & hypokalemia\\n■Calcium channel blockers: effective in 33% of pts\\n■Treat active infection (commonly Haemophilus, Pneumococ-\\ncus)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 284}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nCor Pulmonale and RHF 271\\n■Anticoagulation: transition pts on coumadin for AF to IV hep-arin.\\n■PtsonIVprostacyclin\\n■Anticipate platelet inhibition & bleeding.\\n■Anticipate hypotension & arterial hypoxemia.\\noperative preparation\\n■Avoid heavy premedication.\\n➣ Sedatives, opioids suppress ventilatory drive.\\n➣ Psychological support may be more effective!\\n■Avoid anticholinergic agents (decrease the ability to clear\\nsecretions).\\n■Maintain hydration (RV preload).\\n■Obtain baseline ABGs.\\nanesthesia\\n■Induction\\n➣ Preoxygenation\\n➣ Ensure adequate ﬂuid loading prior to induction:\\nrAcute vasodilation is poorly tolerated.\\nrRVunable to generate increased ﬂow because of high\\nPVR\\nrLVpreload inadequate\\nrProfound refractory systemic hypotension may\\nresult.\\nrLow systemic pressure +high PA pressure: risk of RV\\nischemia\\n➣ Judicious IV induction (decrease doses 50–60%)\\n➣ Ensure adequate anesthetic depth for endotrachealintubation:\\nrAvoid bronchospasm, pulmonary vasoconstriction.\\n■Maintenance & monitoring\\n■Consider arterial line & CVP\\n■Frequent ABGs\\n■Assess RV preload & response to PVR'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 285}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n272 Cor Pulmonale and RHF\\n■Access for vasoactive drugs\\n➣ Consider PA catheter for major surgery, large ﬂuid shifts\\n➣ Maintenance\\nrTIVA (titrate dosage to avoid postop ventilatory depres-sion)\\nrLow-dose volatile agents (avoid myocardial depression)\\nrAvoid rapid increase in desﬂurane concentration: in-\\ncreased PVR.\\nrAvoid N\\n2Ow /TIVA: increases PVR.\\n➣ Judicious hyperventilation\\nrMild respiratory alkalosis protects against increase inPVR.\\n➣ Regional anesthesia\\nrSympathetic blockade poorly tolerated in pts w/ highPVR (hypotension)\\nrAvoid spinal anesthesia; careful titration of epidural\\nblock.\\nwake up & emergence\\n■Anticipate & treat physiologic & pharmacologic factors thatincrease PVR:\\n➣ Arterial hypoxemia\\n➣ Hypercarbia\\n➣ Acidosis\\n➣ Pain (increased endogenous catecholamines)\\n■Wake up\\n➣ Inselected cases, consider extubation under deep anes-\\nthesia.\\nrAvoid bronchoconstriction, increased PVR.\\n➣ Judicious titration of fentanyl and/or dexmedetomi-dine\\nrGoal is smooth emergence w/out pain.\\nicu or pacu\\n■Anticipate & treat physiologic & pharmacologic factors thatincrease PVR:'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 286}, page_content='P1: IBE0521759385P1secA CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nCor Pulmonale and RHF Diabetes Mellitus and Diabetic Emergencies 273\\n➣ Arterial hypoxemia\\n➣ Hypercarbia\\n➣ Acidosis\\n➣ Pain (increased endogenous catecholamines)\\n➣ Exogenous vasoconstrictor catecholamines (epinephrine,\\nnorepinephrine)\\n➣ Arginine vasopressin (AVP 1–4 u/hr) useful in vasodilatedshock\\nrIncreases SVR ≫than PVR\\n■Avoid excess opioids & sedatives that provoke hypercarbia.\\n■Hemodynamic mgt as above (ensure adequate RV preload,\\ndecrease PVR)\\n■Severe, labile pulmonary hypertension\\n➣ Inhaled nitric oxide (selective, expensive)\\n➣ Inhaled prostacyclin (less selective, inexpensive)\\nDIABETES MELLITUS AND DIABETIC EMERGENCIES\\nDOUGLAS B. COURSIN, MD\\nscreening and evaluation\\n■Diabetics have surgery & procedures more commonly than\\nnon-diabetics.\\n■1/3 to 1/2 of pts w/ diabetes do not know it at the time ofsurgery.\\n■Risk for perioperative complications greater for diabetics\\n■Tighter control limits long-term microvascular disease.\\n■History\\n➣ Does pt measure sugars? What do they run?\\n➣ How does pt respond to insulin?\\n➣ Does pt know what it feels like to have a hypoglycemicreaction? How does pt treat it?\\n➣ Signs or symptoms of autonomic or peripheral neu-\\nropathy, ischemic hart disease, CHF, renal insufﬁci-\\nency'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 287}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\n274 Diabetes Mellitus and Diabetic Emergencies\\n■Physical exam\\n➣ Loss of beat-to-beat variability in pulse, orthostasis, stock-ing/glove sensory loss\\n➣ Rales, peripheral edema, S4 (hypertension), S3 (CHF)\\n■Type 1 absolute insulin deﬁciency\\n➣ Always need a basal amount of insulin or will convert toketogenesis\\n➣ At risk for DKA\\n➣ Frequently have micro- & macrovascular disease involvingthe eye, peripheral vasculature, heart, kidneys, peripheral& autonomic nervous system\\nrShould screen for this in history, physical & individual-ized lab evaluation\\n■Type 2 DM develops secondary to relative deﬁciency of insulinor insulin hyporesponsiveness or resistance\\n➣ May or may not require oral hypoglycemics and/or insulin\\n➣ Many pts are obese & inactive, but increasing recognitionof younger (<25–30 yrs) active pts w/ a genetic predispo-sition to type 2\\n➣ Tighter control chronically may be beneﬁcial.\\n➣ Improved control perioperatively should be the goal tolimit infections & exacerbation of ischemia.\\n■Routine screening tests as needed\\n➣ Fasting blood sugar\\n➣ Urinalysis: check for albuminuria, WBCs, bacteria\\n➣ BUN/creatinine\\n➣ ECG: if history, signs or symptoms of ischemia, age >40,\\nundergoing major vascular or cardiac surgery\\npreoperative preparation\\n■Identify end-organ compromise.\\n■Optimize end-organ function & take steps to limit end-organinsult\\n➣ Heart'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 288}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\nDiabetes Mellitus and Diabetic Emergencies 275\\nrIf diastolic dysfunction, aim to keep heart rate slow & touse agents that optimize diastolic relaxation\\nrBeta block when needed & as able\\nrCHF increasingly common w/ age; diuretics may beassociated with various electrolyte abnormalities, hy-pokalemia, hyponatremia, hypomagnesemia\\nrIschemia may be silent.\\nrRecommend ECG if >40 yrs or earlier if suspected or\\nknown ischemia/infarct. Compare as able to older ECG.\\n➣ Kidney\\nrAdequate hydration & intravascular ﬂuid maintenance\\nrN-acetyl cysteine (NAC) if creatinine >1.5–1.8 mg/dL &\\ncontrast used\\noperative preparation\\n■Premedication\\n➣ Individualize\\n➣ Use of antacids, metoclopramide, H2 blocker, and/or pro-ton pump inhibitor as needed\\nanesthesia\\n■Technique\\n➣ General, regional or local as indicated\\n➣ Document neurologic status, coagulation function & sitesuitability prior to initiation of a neuraxial or majorregional block.\\n➣ Some advocate general over regional in pts w/ signiﬁcantbaseline neuropathy, uncontrollable airway or regionalsite compromise.\\n➣ Amputations for advanced peripheral vascular diseasemay be augmented by concurrent advanced peripheralneuropathy.\\n■Induction\\n➣ Increased risk for aspiration\\n➣ Increased risk of difﬁcult intubation'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 289}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\n276 Diabetes Mellitus and Diabetic Emergencies\\nrParticularly type 1 diabetics: 40% reported as difﬁcult\\nrLook for stiff joint syndrome\\nrPositive prayer sign when approximate palms of thehands\\nrImmobility of head & neck & other joints\\nrConsider awake, ﬁberoptic intubation; plan for difﬁcultairway management: see algorithm\\n➣ Presence of hyperglycemia & volume depletion and/orautonomic neuropathy may make pts more susceptibleto hypotension secondary to induction agents such asthiopental & propofol.\\nrConsider etomidate if cardiovascular or volume com-promise.\\nrConsider adjusted dose to avoid bolus effect.\\n➣ Positioning is crucial; higher incidence of skin & nerveinjury\\nrCareful padding; avoid extension, compression injury,burns\\n■Maintenance\\n➣ Total IV anesthesia\\n➣ Inhaled\\nrChoice based on speed onset/offset, metabolism, renalfunction, cost\\n➣ Type 1 diabetics or those w/ coronary artery disease, bowelobstruction or other contraindication, avoid N\\n2O to limit\\naltered homocysteine & methionine metabolism abnor-malities, gas expansion\\nwake up and emergence\\n■Risk for aspiration\\n■Risk of sympathetic response in pts w/ suspected or knownischemia\\n■If slow to awaken, obtain stat glucose to rule hypoglycemia.\\nicu or pacu\\n■Measure blood glucose at arrival to PACU/ICU.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 290}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\nDiabetes Mellitus and Diabetic Emergencies 277\\n■Increased risk for aspiration because of gastroparesis\\n■Diabetics require postop critical care more than non-diabetics.\\n■Increasing evidence that euglycemia (80–110 mg/dL) is thegoal for critically ill pts.\\n➣ Use of insulin and/or insulin/glucose/potassium infu-sions advocated\\nrUse regular insulin as infusion\\nrReliable insulin absorption if IV\\nrCareful follow-up of blood glucose, potassium levels.Prone to hypoglycemia, esp. if reversing DKA & whendrive glucose & potassium into the cell.\\n■Greater incidence of ischemia & worse outcome neurologi-cally & cardiovascularly if ischemia develops\\n➣ Can improve this by maintaining euglycemia\\n➣ Postop MI\\n➣ Postop stroke\\n➣ Postop infection\\n➣ Postop neuropathy\\n■Diabetic emergencies: hypoglycemia, DKA, nonketotic hyper-osmolar state (NKHS)\\n■Hypoglycemia\\n➣ More common in type 1 than type 2\\n➣ Increased incidence in pts on ACE inhibitors\\n➣ Crucial to avoid prolonged hypoglycemia\\n➣ Symptoms are neuroglycopenic\\nrConfusion, altered mental status, agitation progressingto somnolence, coma & eventually death\\n➣ Treat w/ IV glucose\\nrBolus 1/2 to 1 amp of D50, then follow w/ an infusionof D5 to D10W & serial blood glucose measurements\\n■DKA & NKHS are related states\\n➣ DKA mainly in type 1, NKHS usually in older type 2\\n➣ Both have signiﬁcant hyperglycemia & hyperosmolar-ity. Signiﬁcant osmotic diuresis; as they progress, pt'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 291}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\n278 Diabetes Mellitus and Diabetic Emergencies\\nbecomes acidotic, develops multiple electrolyte abnor-malities & may become increasingly depressed neurologi-cally. These are medical emergencies requiring aggressive,timely intervention. Signiﬁcant morbidity & mortality,usually from precipitating event.\\n■DKA: mainly type 1 but may occur in type 2 pts who chronicallyreceive insulin\\n➣ Usually precipitated by infection (most commonly respi-ratory or urinary tract) or stress\\nrMay be precipitated by:\\nrTrauma, surgery/critical illness (MI, stroke, pancre-atitis)\\nrFailure to take insulin\\nrAlcohol, drug use\\nrCorticosteroid use or large doses of thiazide diuretics\\nrOverexertion, heat stroke, inadequate oral intake, esp.in elderly\\n➣ Blood glucose usually <800–900 mg/dL\\nrHyperglycemia results in severe polyuria & polydipsia.\\n➣ Volume-depleted, acidotic, multiple electrolyte abnor-malities\\nrNeed ﬂuid resuscitation\\nrUsually 3–6 L depleted\\nrInitial replacement is w/ normal saline, then changeto 1/2 normal saline to aid replacement of free waterdeﬁcit & avoid hypernatremia\\nrMay add 20–40 mEq KCl to each liter of 1/2 normalsaline to replete K+ deﬁcits (if pt has reasonable renal\\nfunction & is making urine). This is equivalent of 3/4normal saline.\\nrIV insulin, bolus 5–20 units, then infusion at 5–10 unitsan hour. Aim to lower blood glucose by 100 mg/dLper hour; start dextrose infusion when blood glucoseis around 250 mg/dL.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 292}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\nDiabetes Mellitus and Diabetic Emergencies Epilepsy 279\\nrMaintain insulin infusion until serum ketones arecompletely cleared.\\nrCorrect electrolyte abnormalities\\nrMay be hyponatremic, but often spurious; as replaceﬂuids, change to 1/2 normal saline to replace freewater deﬁcit & avoid hypernatremia\\nrMay develop severe hypokalemia as volume replete &acidosis clears\\nrMay need large amounts of potassium\\nrOsmotic diuresis losses of K+\\nrK+/H+ cellular shifts as acidosis corrected\\nrMay need magnesium & phosphorus replacement\\nrMay use K\\n2PO 4as part of replacement for hypo-\\nkalemia\\nrRarely need HCO 3; if used, watch for overcorrection\\n& metabolic alkalosis\\nrCerebral edema a major complication, esp. for children\\nrCare w/ overcorrecting of glucose\\n■NKHS\\n➣ Older pts, more commonly type 2\\n➣ Little accumulation of ketoacids\\n➣ Blood glucose frequently >1,000 mg/dL\\n➣ Severe volume resuscitation: 8–10 L deﬁcits\\nrInitial resuscitation w/ normal saline. since pt is salt &water depleted\\n➣ May be very sensitive to insulin, so watch glucose carefully\\nEPILEPSY\\nGEBHARD WAGENER, MD\\nscreening and evaluation\\n■Causes for seizures:\\n➣ Hyponatremia'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 293}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\n280 Epilepsy\\n➣ Hypoglycemia\\n➣ Other electrolyte abnormalities\\n➣ Drug intoxication\\n➣ Intracranial hemorrhage\\n➣ Increased ICP\\n➣ Cyclosporin-induced seizures\\n➣ ETOH withdrawal\\n■Surgical treatment of seizure disorder\\n➣ For severe treatment-resistant seizure disorder\\n➣ 1/3 have no seizures after surgery, 1/3 less frequentseizures, 1/3 no change.\\nrMorbidity (hemiparesis & other neurologic deﬁcits):1–3%\\n■History/exam\\n➣ Nature, cause & frequency of seizures\\n➣ Date of last seizure\\n➣ Meds: last change of medication or dose\\n➣ Focused neurologic exam: rule out:\\nrPeripheral neuropathies\\nrIncreased ICP\\n➣ Surgical treatment of seizure disorder\\nrLocation of seizure focus\\n■Investigations\\n➣ Antiepileptic drug levels\\n➣ CBC\\n➣ LFT: drug-induced hepatic dysfunction\\n➣ Coagulation proﬁle: valproic acid\\n➣ Consider MRI, CT if increased ICP suspected.\\n➣ Surgical treatment of seizure disorder\\nrMRI, CT, cortical mapping, functional MRI, PET scan,water test to detect right/left hemispheric dominance\\npreoperative preparation\\n■Antiepileptic agents to be taken on day of surgery\\n■Surgical treatment of seizure disorder'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 294}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\nEpilepsy 281\\n➣ Pt will likely be off seizure meds to elicit seizure focus.\\noperative preparation\\n■Surgical treatment of seizure disorder\\n➣ Mostly awake craniotomy: inform pt about need for coop-eration, possibility of intraop awareness\\n➣ With head frame in place, no access to airway; ﬁberopticscope for intubation should be available in case of neuro-logic complications (stroke, hemorrhage)\\nanesthesia\\n■Barbiturates, benzodiazepine, inhalational agents & propo-fol increase seizure threshold (historical: enﬂurane decreasesseizure threshold).\\n■Propofol-induced opisthotonos is not seizure-related.\\n■Etomidate induces myoclonus but does not decrease seizurethreshold.\\n■Avoid ketamine.\\n■Avoid methohexital; can activate epileptogenic foci.\\n■Surgical treatment of seizure disorder\\n➣ Low-dose benzodiazepines, propofol for awake cran-iotomy. Benzodiazepines can be antagonized withﬂumazenil.\\n➣ Methohexital may be used to provoke seizures.\\nwake up and emergence\\n■Avoid hypercarbia & hyper-/hypotension in case of increasedICP.\\n■Emergence may be delayed: enzyme induction\\n■Surgical treatment of seizure disorder\\n➣ New neurologic deﬁcits require immediate intervention:CT scan & possible re-exploration for hemorrhage.\\nicu or pacu\\n■Depends on extent of surgery & condition of pt\\n■Surgical treatment of seizure disorder\\n➣ Observe pt in neurological intensive care unit.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 295}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\n282 The Geriatric Patient GI Disease\\nTHE GERIATRIC PATIENT\\nHUGH R. PLAYFORD, MD\\nscreening and evaluation\\n■Need to consider:\\n➣ Effects of aging per se\\n➣ Comorbidities\\n➣ Pharmacotherapy\\npreoperative preparation\\nN/A\\noperative preparation\\nN/A\\nanesthesia\\nN/A\\nwake up and emergence\\nN/A\\nicu or pacu\\nN/A\\nGI DISEASE\\nGEBHARD WAGENER, MD\\nscreening and evaluation\\nElectrolytes\\n■Sodium: measure of volume status & dehydration\\n■Chloride: low w/ vomiting or diarrhea\\n■BUN, BUN/creatinine ratio: measure of dehydration\\n■Creatinine: impaired renal function? prerenal dehydration?\\n■Glucose extremely important: check bicarbonate to evaluatemetabolic alkalosis, acidosis\\n■CBC: anemia? leukocytosis?'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 296}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\nGI Disease 283\\n■Lactate: elevated: perforation, strangulation or sepsis?\\n■LFTs\\n■Coagulation proﬁle\\n■Chest x-ray: position of diaphragm, basal atelectasis? air underdiaphragm: perforation: left often gastric, right often duode-nal or colonic?\\n■ECG\\n■Abdominal plain ﬁlm: obstructive: air-ﬂuid levels? free air?air/stool in rectum?\\n■Abdominal CT\\n■Echocardiogram: in intestinal ischemia: thrombus?\\npreoperative preparation\\n■Ensure adequate ﬂuid resuscitation; pts are frequentlyseverely dehydrated.\\n■Correct electrolyte abnormalities, esp. hypo- & hyperkalemia.\\noperative preparation\\n■Decompress stomach w/ orogastric or nasogastric tube.\\n■Abdominal CT\\n■Central venous catheter for evaluation of intravascular ﬂuidstatus\\nanesthesia\\n■Regional anesthesia almost always contraindicated\\n■Antibiotics prior to incision w/ anaerobic coverage\\n■Empty stomach & then remove gastric tube prior to inductionof anesthesia.\\n■Generous ﬂuid administration prior to induction to avoidpostinduction hypotension; pts are frequently severelydehydrated (compensate for bowel prep) & do not toleratevasodilation\\nRapid sequence induction for:\\n■Obstructive intestinal diseases\\n■Gastroesophageal reﬂux disease\\n■Hiatal hernia'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 297}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\n284 GI Disease\\n■Intestinal perforation\\n■Increased intra-abdominal pressure\\n■Motility disorders (eg, diabetic gastroparesis)\\nProlonged pre-oxygenation required with increased intra-abdominal pressure: FRC lowIn case of aspiration:\\n■Ventilate with FiO 2=1.0.\\n■Suction endotracheal tube.\\n■Consider ﬁberoptic bronchoscopy, especially w/ particulateaspiration.\\n■Prophylactic antibiotics or steroids not indicated\\nAvoid nitrous oxide:\\n■Intestinal gas volume is often increased in GI diseases (normal=100 cc).\\n■Increase in intestinal gas volume can lead to bowel ischemia& perforation.\\n■Nitrous oxide accumulation already seen within 20 min afterinitiation\\nAdequate muscle relaxation allows best operating conditions forsurgeon.\\nAbdominal surgery requires signiﬁcantly more ﬂuid adminis-\\ntration to compensate for third-space loss (8–10 mL/kg/h).\\nwake up and emergence\\n■Empty stomach w/ nasogastric or orogastric tube prior toemergence.\\n■Ensure that pt is awake & has adequate airway reﬂexes: highrisk for aspiration.\\nNeostigmine\\n■Increases intestinal motility (frequency & magnitude):parasympathomimetic: nausea, vomiting & rarely anastomo-sis breakdown\\n■Rule out pneumothorax prior to extubation if operation wasnear diaphragm: are breath sounds equal?'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 298}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\nGI Disease Hemoglobinopathies 285\\n■Postop ventilation often required in pts receiving largeamounts of IV ﬂuids; increased intra-abdominal pressuredecreases FRC.\\nicu or pacu\\nICU admission for:\\n■Continued resuscitation\\n■Hemodynamic instability\\n■Sepsis, peritonitis\\n■Postop ventilation\\nObserve for increase in abdominal pressure (measure abdominalgirth or bladder pressure).\\nFrequent hematocrit & hemoglobin measurements: rule out\\ncontinued bleedingFor decreased urine output postop:\\n■Most frequently hypovolemia\\n■Rule out increased intra-abdominal pressure.\\n■Acute tubular necrosis possible: preoperative or intraopera-tive hypotension & renal hypoperfusion: check urine sodium\\n■Fluid resuscitation often required for at least 12–24 hrs postop:continued sequestration of ﬂuid into bowel\\nHEMOGLOBINOPATHIES\\nDOUGLAS B. COURSIN, MD, AND KARL WILLMANN, MD\\nscreening and evaluation\\n■CBC, Hgb not routinely acquired for most outpatients & manyinpatients\\n■Identify high-risk pts ( +active or known history of anemia)\\n➣ Obtain CBC\\nrDetermines WBC, Hct, Hgb, platelet count & indices\\nrReticulocyte count: bone marrow activity'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 299}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\n286 Hemoglobinopathies\\npreoperative preparation\\n■Identify anemia in high-risk pts or those undergoing high-risksurgery.\\n■Determine if anemia is of physiologic importance.\\n■Determine etiology:\\n➣ Acute or chronic: Compensated or not?\\n➣ If blood loss: Is it controlled? Does procedure need to beperformed to control bleeding?\\n➣ If secondary to nutrient deﬁciency: Does pt require sup-plementation (iron, vitamin B12, folate)? Is pt at risk forassociated pathology? Neurologic disease w/ vitamin B12deﬁciency? Abnormal homocysteine metabolism & folate?\\n➣ Would the pt beneﬁt from perioperative EPO?\\nrFacilitate autologous predonation\\nrAugment perioperative treatment of anemia\\nrAvailable drugs: human recombinant EPO, darbopoi-etin\\n■Transfusion therapy\\n➣ Based on acuity and severity of anemia, associated pathol-ogy, risk of surgery/procedure\\noperative preparation\\n■Address need for transfusion.\\n■Type & screen or cross-match if needed & not already per-formed.\\n■Determine availability of blood preop.\\nanesthesia\\n■Maintain O 2delivery.\\n➣ Correct hypovolemia.\\n➣ Avoid meds that depress cardiac function.\\n➣ Avoid left shift in O 2dissociation curve:\\nrAvoid hypothermia (but may provide CNS protection).\\nrAvoid acute alkalosis.\\n➣ Avoid N 2O in pts w/ vitamin B12 or folate deﬁciencies.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 300}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\nHemoglobinopathies Hemophilia A & Hemophilia B 287\\n➣ “Transfusion trigger” based on level of anemia, antici-pated blood loss, individual reserve\\nwake up and emergence\\n■Maintain O 2delivery by maintaining good circulatory status\\n■Treat shivering, excessive tachycardia or hypertension.\\nicu or pacu\\n■>50% of ICU pts are anemic within 72 hrs of ICU admission.\\n■1/7 ICU pts per day receive a transfusion in the ICU.\\n■Over a third of all ICU pts receive transfusion during their ICUcourse.\\n■Risk of transfusion increases with length of ICU stay.\\n■Transfusions are independently associated w/ increasedlength of ICU stay, morbidity & mortality.\\n■Increase transfusion trigger: CNS injury, myocardial ischemiaor infarction\\nHEMOPHILIA A & HEMOPHILIA B\\nKARL WILLMANN, MD, & D. B. COURSIN, MD\\nscreening & evaluation\\n■Schedule surgery early in the week so that special needs forlaboratory & factor assays will be arranged for the preop, oper-ative & postop time.\\n■Hematologist consult prior to surgery\\npreoperative preparation\\n■Factor levels drawn prior to surgery\\n■IV access may difﬁcult. Avoid IM injections.\\n■Use invasive monitor only if necessary.\\noperative preparation\\n■Hemophilia A: pts require a factor level 40–100%, dependingon extent of surgery. These levels should be maintained 2–7'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 301}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\n288 HemophiliaA&H emophilia B\\ndays postop, depending again on the extent of surgery. In largeorthopedic surgeries, may need to maintain elevated factorVIII for several wks after surgery. Pts w/ mild to moderatedisease may require only desmopressin (DDAVP); this drugcan increase the level of activity of factor VIII 2–4x normal.\\n■Appropriate replacement of factors would be recombinantfactor VIII.\\n■Elimination half-life of recombinant factor VIII is about 8 hrs.\\n■Dosing: 1 U/kg of recombinant factor VIII should increaseplasma level of factor VIII by 0.02 U/mL, which is about a 2%increase in plasma activity.\\n■Pts who have had previous recombinant therapy may requirerecombinant factor VIIa if they have inhibitors to factor VIII(which occurs in 10–20%). This also is true for factor IX recom-binant therapy.\\n■In emergencies, both cryoprecipitate & FFP could be used.\\n■Hemophilia B: pts should have levels of factor IX 30–75%,depending on extent of surgery. Replacement can be solvent/detergent-treated pooled factor IX & recombinant factorIX. Elimination half-life of recombinant therapy is about24 hrs.\\n■Usual dose =body weight (kg) times desired factor IX increase\\n(%) times 1.2 IU/kg. Maintain postop levels at 15–40%.\\n■Regional anesthesia: use w/ caution in light of pt’s coagulopa-thy\\nanesthesia\\n■Induction\\n➣ Careful manipulation of airway to avoid bleeding\\n■Maintenance\\n➣ No special concerns\\nwake up & emergence\\n■Coughing & bucking on the endotracheal tube may lead totrauma of the airway & bleeding, causing airway compromise.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 302}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\nHemophili aA&H e mophilia B HIV & AIDS 289\\nicu or pacu\\n■Avoid drugs that may impair clotting, such as NSAIDs, ASA &ketorolac.\\n■Monitor factor levels as necessary.\\nHERBAL THERAPY\\nJONATHAN T. KETZLER, MD\\nscreening & evaluation\\nN/A\\npreop preparation\\nN/A\\noperative preparation\\nN/A\\nanesthesia\\nN/A\\nwake up & emergence\\nN/A\\nicu or pacu\\nN/A\\nHIV & AIDS\\nGEBHARD WAGENER, MD\\nscreening and evaluation\\nHistory/exam\\n■Rx therapy: On HAART? How long?\\n■Pulmonary: Recent cough, fever\\n■Cardiac: Exercise tolerance?\\n■GI: Diarrhea, nausea, vomiting? Weight loss?'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 303}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\n290 H I V&A I D S\\nInvestigations\\n■Chest x-ray: Pneumonia? Pleural effusions?\\n■ECG: Minimal voltage: Pleural effusion?\\n■CD-4 count: CDC classiﬁcation: grade 1, >499 normal, grade\\n2, 200–499; grade 3, <200/mcL (<50/mcL: high mortality)\\n■WBC\\n■Hct: anemia\\n■Platelet count: HIV-induced thrombocytopenia\\n■Echocardiogram: Pericardial effusion? LV function\\n■PFT: restrictive disease secondary\\n■Room air ABG\\npreoperative preparation\\n■HIV does not increase perioperative mortality.\\n■Treat pain adequately.\\n■Do not avoid opioids w/ IV drug users.\\noperative preparation\\n■Sterile technique for sterile procedures:\\n➣ Gown for central cannulations\\n■Prophylactic antibiotics\\n■Universal precautions!\\n■In case of needlestick injury\\n➣ Wash out wound w/ iodine +alcohol-containing antisep-\\ntic.\\n➣ Report to employee health or emergency room immedi-ately.\\n➣ Check HIV , hepatitis C, hepatitis B: health care worker, ptonly with consent\\n■Postexposure prophylaxis\\n➣ Zidovudine 250 mg BID\\nrLamivudine 150 mg BID\\nrIndinavir 800 mg TID or nelﬁnavir 750 mg TID\\n■Risk of infection: simple needlestick, 0.3–0.5%, w/ gloves 10–100x lower'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 304}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\nHIV & AIDS Hypertension 291\\nanesthesia\\n■Regional: preferable w/ pulmonary disease, but steriletechnique!\\n■Epidural: probably higher incidence of catheter infections\\n■Document polyneuropathy (relative contraindication)\\n■Avoid succinylcholine w/ severe polyneuropathy.\\nwake up and emergence\\n■May be slowed w/ AIDS dementia\\n■Monitor neuromuscular blockade w/ polyneuropathy.\\nicu or pacu\\n■Depends on extent of surgery\\n■Mechanical ventilation for respiratory complications w/ PCP:high mortality\\nHYPERTENSION\\nMUHAMMED ITANI, MD, & JONATHAN T. KETZLER, MD\\nscreening and evaluation\\n■History & physical exam: evaluate severity of symptoms, exer-cise tolerance\\n■EKG: acute ischemia, chronic LVH w/ strain, conduction dis-ease\\n■CXR: cardiomegaly, pulmonary congestion/edema, pleuraleffusion\\n■TTE: LVH, dilated cardiomyopathy\\n■MRA: upper abdominal bruits (renovascular hypertension)\\n■Lab evaluation: end-organ damage, electrolyte disturbances\\n■Special studies\\n➣ Pheochromocytoma: increased urinary vanillylmandelic& homovanillic acid\\n➣ Conn’s syndrome: high aldosterone, low renin'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 305}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\n292 Hypertension\\npreoperative preparation\\n■Uncontrolled HTN\\n➣ Delay elective surgery.\\n➣ Admit for end-organ failure & treat.\\n■Continue antihypertensive meds until surgery.\\n➣ Avoids rebound\\n➣ Maintain intravascular volume.\\n■Normotension decreases the risk of the pt becoming hypoten-sive & developing ischemia intraoperatively.\\n■Hypertensive pts have a higher incidence of MI during surgeryif they have a prior history of similar events & a higher inci-dence of stroke after carotid surgery.\\n■Do not stop clonidine & beta blockers; there is a high incidenceof rebound hypertension; ACE inhibitors don’t cause reboundhypertension if stopped preoperatively.\\n■ACE inhibitors can be kept the day before surgery if the surgerydoes not involve large ﬂuid shifts & blood loss.\\n■Stop angiotensin II receptor blockers, as pts have a higherincidence of severe BP drops intraoperatively.\\noperative preparation\\n■Sedation may decrease anxiety in pts & thus control high BPpreoperatively.\\n■Sedative requirements are reduced in pts on clonidine.\\n■Pts are hypovolemic, so adequate preop hydration can beimportant.\\n■Depending on the extent of cardiac disease, invasive monitors(CVP , arterial line) may be placed preoperatively.\\nanesthesia\\n■Induction\\n➣ Rapid-acting IV agents may be used for induction; dose &rapidity of introduction may be reduced due to the higherincidence of severe hypotension in these pts due to hypo-volemia & peripheral vasodilation.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 306}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\nHypertension 293\\n➣ Avoid ketamine because of potential to elevate BPmarkedly.\\n➣ Narcotics & inhalational anesthetics must be given toincrease anesthetic depth before laryngoscopy is done toavoid sudden marked BP increase.\\n➣ Short-acting beta blockers (esmolol) may be used toacutely control increase in heart rate & BP w/ laryn-goscopy.\\n➣ Fentanyl must be given in high doses (5–7 mcg/kg); inhala-tion agents should be given in 1.5 MAC doses to avoidcardiovascular response to intubation.\\n➣ Laryngoscopy should be done quickly ( <15 sec).\\n➣ Lidocaine IV or intratracheal (1 mg/kg) may be usedto attenuate the upper airway responses to intuba-tion.\\n➣ If difﬁcult or prolonged laryngoscopy is anticipated, IVnitroprusside or esmolol may be used for BP control.\\n➣ Take care to avoid hypotension because of all the abovemedication introduction.\\n■Regional anesthesia is a safe option & helps avoid the BPswings seen w/ general anesthesia if limited sympatheticblockade is anticipated.\\n■With central neuraxial blocks, severe drops in BP may beseen w/ chemical sympathectomies; aggressive ﬂuid hydra-tion may be done preop before the block is started to avoidthis.\\n■Maintenance\\n➣ Control the depth of anesthesia to avoid BP ﬂuctuations.\\n➣ Adjust the depth so that surgical stimulation does not pro-duce marked pressor response.\\n➣ Intraoperative hypotension is more common in pts whoseBP was poorly controlled preoperatively.\\n➣ Response to surgical stimulation is exaggerated in pts w/essential hypertension.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 307}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\n294 Hypertension\\n➣ Intraoperative hypotension can be controlled w/ ﬂuidadministration, sympathomimetics (phenylephrine,ephedrine) & decreasing the dose of inhalational agent.\\n➣ In surgeries involving sudden BP elevations (carotidsurgery), vasodilator infusions (nitroprusside) may be pre-pared & used accordingly.\\n➣ In pts w/ regional anesthesia, use adequate sedation toavoid anxiety & subsequent hypotension.\\n➣ General anesthesia can be maintained using:\\nrVolatile agents, low-solubility agents (sevoﬂurane, des-ﬂurane) may be preferred to highly soluble agentsbecause of rapidity & ease of controlling depth of anes-thesia.\\nrN\\n2O/narcotic technique\\nrNo preference of one muscle relaxant over the other\\n■Monitors\\n➣ Depends on extent of surgery & severity of disease\\n➣ 5-electrode EKG for myocardial ischemia detection\\n➣ Other standard ASA monitors\\n➣ Arterial line, PA catheter, CVP\\n➣ TEE w/ severe LV dysfunction\\nwake up & emergence\\n■Anxiety & pain control are very important to avoid hyperten-sive episodes.\\n■Titrate narcotics to avoid oversedation.\\n■May extubate at a deep level of anesthesia to avoid hyperten-sive response to upper airway instrumentation\\n■Watch out for ischemic cardiac events (MI).\\n■High risk of stroke w/ elevated BP\\nicu or pacu\\n■Hypertension is common due to pain & relative hypovolemia.\\n■Pain control is essential.\\n■May continue monitors used intraoperatively in PACU'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 308}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\nHypertension ICU Patient Scheduled for Intercurrent Surgery 295\\n■If hypertension persists, can use hydralazine (2.5–10 mg q10–20min), nitroprusside (0.5–10 mcg/kg/min), labetalol (0.1–0.5mg/kg q10min)\\n■Watch for hypertension-related complications:\\n➣ Myocardial ischemia\\n➣ Stroke\\n➣ CHF\\n➣ Dysrhythmias\\n➣ Bleeding\\n■Pts w/ acute or ongoing target organ damage (subarach-noid hemorrhage postop, encephalopathy, CHF , renal insuf-ﬁciency) may need immediate IV medication treatment inICU setting; goal is gradual decrease in diastolic BP to avoidischemia or infarction.\\n■Drop diastolic BP by 20% ﬁrst hour; subsequent decreaseshould be achieved over 24–48 hrs.\\n■Nitroprusside IV: 0.5–10 mcg/kg/min; watch for cyanide poi-soning.\\n■Hydralazine: watch for increase in ICP; may not be a choicein pts w/ neurologic disease\\n■Nitroglycerine: in hypertensive crisis secondary to myocardialischemia or cocaine overdose\\n■Beta blockers: avoid w/ cocaine overdose\\nICU PATIENT SCHEDULED FOR INTERCURRENT SURGERY\\nDOUGLAS B. COURSIN, MD\\nscreening and evaluation\\nSee “Overview” in the “Diseases” section.\\npreoperative preparation\\n■Full review of admission & ICU course\\n➣ Attention to current meds, access, ventilatory needs\\n➣ What is essential & what is not'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 309}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\n296 ICU Patient Scheduled for Intercurrent Surgery\\n➣ Continue or hold tube feedings.\\n➣ Continue or hold TPN.\\nrIf discontinued, follow glucose & evaluate for hypo-glycemia.\\n➣ Create ICU support & environment out of ICU in OR/cathlab, radiology suite.\\n■Transport\\n■Adequate equipment\\n➣ Adequate meds\\n➣ Adequate personnel\\n➣ Maintain normothermia.\\n➣ Maintain adequate ventilation.\\nrAvoid under- or over-ventilation.\\n■Consider starting anesthesia, at least analgesic & sedation(possibly neuromuscular paralysis), in ICU prior to transport,w/ careful observation of hemodynamic response.\\noperative preparation\\n■Create ICU support & environment out of ICU in OR/cath lab,radiology suite.\\n■Transport in & out of ICU location\\n➣ Adequate equipment\\nrAdequate meds\\nrAdequate personnel\\nrMaintain normothermia.\\nrMaintain adequate ventilation.\\nrAvoid under- or over-ventilation.\\n■Consider starting anesthesia, at least analgesic & sedation,in ICU prior to transport, w/ careful observation of hemody-namic response.\\n■Maintain glucose control.\\n➣ Is pt on an insulin infusion? Is it w/ or w/out dextrose? Isit w/ or w/out potassium supplementation?\\n➣ If pt is not on an insulin infusion, is he or she likely to needone, depending on procedure & degree of stress hormone'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 310}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\nICU Patient Scheduled for Intercurrent Surgery 297\\nresponse w/ insulin resistance & pro-inﬂammatory pro-cess, which may exacerbate hyperglycemia?\\nrTry to maintain glucose <150 mg/dL.\\n➣ Could the pt be relatively or absolutely adrenally in-sufﬁcient?\\nrDoes the pt need additional or stress dose of steroids?\\nanesthesia\\n■Titrate to effect.\\n■Pt’s hemodynamic reserve & response will dictate agents used& doses.\\n■Requirements may be hard to predict, depending on pharma-codynamic & kinetic variables & presence of tolerance.\\n■Aim for sedation, pain relief, amnesia & still pt.\\n■Be prepared for hypotension secondary to induction, diminu-tion of sympathetic nervous system, maintenance agents,patient positioning, ventilator requirements & operative tech-nique.\\n■Estimate & replace third-space losses.\\n■Maintain normal temperature.\\n➣ Active/passive warming\\n➣ Blood warmers\\n➣ Low-ﬂow or humidiﬁed gases\\n➣ Convection warmers\\n➣ If burn, warm room.\\n➣ If cold, actively warm.\\n➣ Fluid irrigation temperature\\nwake up and emergence\\n■Do you want the pt to emerge? Transport while asleep?\\n■Are you planning to extubate?\\n■Is the pt going to PACU or ICU postop?\\n■Can you adequately ventilate & support hemodynamically ontransfer to PACU or ICU?\\n➣ What do you need to travel?'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 311}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\n298 ICU Patient Scheduled for Intercurrent Surgery IHSS\\nrAirway equipment, O 2, ventilatory, Ambu, resuscitation\\nmeds, current infusions\\nicu or pacu\\n■Most pts will return to ICU unless their primary process hasbeen stabilized or reversed to a degree that would allow themto be transferred to an intermediate-care unit or ﬂoor bed.\\n■Key is to provide the same level of support as needed previ-ously or escalated during the course of surgery or a procedure.\\n■Notify ICU of transfer so that ventilatory & hemodynamic sup-port devices & meds are available on arrival.\\n■Consider transporting pt sedated & analgesed. If you planextubation after the procedure, may be ideally suited to per-form in ICU.\\n■Have adequate equipment, personnel, meds & O 2to transfer\\nback to ICU.\\n■On arrival, provide full report, particularly on intraoperativeﬂuids, transfusions, antibiotics & any untoward events suchas protracted hemodynamic changes or rhythm disturbancesor exacerbations of gas exchange & surgical procedure.\\n■Outline postop plan:\\n➣ Pain\\n➣ Sedation\\n➣ Ventilation\\n➣ Hemodynamic control\\n➣ Need for thermal regulation or support\\nIDIOPATHIC HYPERTROPHIC SUBAORTICSTENOSIS (IHSS)\\nROBERT N. SLADEN, MD\\nscreening and evaluation\\n■Note the following:\\n➣ Symptoms (angina, syncope, congestive heart failure)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 312}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\nIHSS 299\\n➣ Signs of progressive disease (ECG changes, valve gradient& area)\\n➣ Presence of associated CAD (increased risk)\\n■Look for physical signs of:\\n➣ Left ventricular hypertrophy (apical heave)\\n➣ Congestive heart failure (elevated neck veins, edema, hep-atomegaly)\\n■Relevant lab studies\\n➣ Hct (anemia is poorly tolerated by low CO)\\n➣ PT, INR (if on coumadin for atrial ﬁbrillation)\\n➣ BUN, creatinine (prerenal syndrome)\\n➣ ECG (LVH w/ or w/out strain)\\n➣ Chest x-ray (LVH)\\npreoperative preparation\\n■Continue preop meds:\\n➣ Beta blockade or calcium blockade (negative inotropy,chronotropy)\\n➣ Digoxin (rate control for atrial ﬁbrillation)\\n➣ Diuretics for pulmonary edema\\n■Plan perioperative anticoagulation:\\n➣ Hold coumadin at least 3 days preop.\\n➣ Check INR prior to surgery.\\n■Consider preop admission for control of:\\n➣ Rapid atrial ﬁbrillation\\n➣ Symptomatic pulmonary edema or congestive heartfailure\\n■Plan perioperative antibiotics:\\n➣ Decrease risk of bacterial endocarditis\\noperative preparation\\n■Review hemodynamic principles:\\n➣ Maintain sinus rhythm (atrial kick, to maximize ventricu-lar ﬁlling).\\n➣ Maintain slow heart rate (increase diastolic ﬁll time).\\n➣ Maintain adequate preload (maximize ventricular ﬁlling).'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 313}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\n300 IHSS\\n➣ Avoid inotropic, chronotropic agents.\\n➣ Avoid systemic vasodilators.\\n➣ Maintain SVR (& coronary diastolic perfusion pressure).\\n■Acute (new-onset) atrial ﬁbrillation\\n➣ Poorly tolerated, can induce acute decompensation, lowcardiac output syndrome\\n➣ Treat aggressively whenever it occurs (esmolol, amio-darone, early cardioversion).\\n■Ensure adequate sedative or opioid premedication\\n➣ Suppress catecholamines, avoid tachyarrhythmias\\n➣ BUT increased risk of respiratory depression (low cardiacoutput)\\n■Use ﬂuids & vasoconstrictor agents to treat hypotension\\n➣ Maintain preload, diastolic perfusion pressure.\\n➣ Avoid ephedrine, norepinephrine (mixed agonists, in-crease contractility, may induce tachycardia).\\n➣ Use a pure vasoconstrictor (phenylephrine); reﬂex brady-cardia is also helpful.\\n■Invasive hemodynamic monitoring, TEE\\n➣ Moderate to large ﬂuid shifts anticipated\\n➣ Presence of symptoms\\nanesthesia\\n■Regional anesthesia is relatively contraindicated\\n➣ Sympathetic block may induce dangerous hypotension,worsen MVO\\n2\\n➣ Avoid spinal anesthesia (abrupt onset of block).\\n➣ Careful continuous spinal or epidural anesthesia may betolerated.\\n➣ Adequate ﬂuid load prior to placement (maintain preload)\\n■General anesthesia\\n➣ Take measures to maintain slow heart rate & adequateperfusion pressure.\\n➣ Preoxygenate'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 314}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\nIHSS 301\\n➣ Adequate ﬂuid load prior to induction (maintain preload)\\n➣ Treat hypotension w/ phenylephrine.\\n➣ Treat tachycardia w/ esmolol.\\n■Avoid pancuronium (tachycardia), ketamine (sympathomi-metic).\\n■Choose maintenance regimen that maintains slow heart rate,suppresses sympathetic response\\n➣ Avoid isoﬂurane (increased heart rate), desﬂurane (in-creased sympathetic tone).\\n➣ Consider sympatholytic opioid (fentanyl, sufentanil, re-mifentanil).\\nwake up and emergence\\n■Attempt to suppress catecholamines on emergence\\n➣ Judicious use of sympatholytic opioid (fentanyl, sufen-tanil, remifentanil)\\n➣ Avoid morphine (histamine, catecholamine release).\\n■Consider dexmedetomidine infusion\\n➣ Sympatholytic, provides analgesia w/out respiratorydepression\\n➣ Can be continued through tracheal extubation & beyond\\n➣ Dose carefully: can potentiate beta blockade, delay anes-thetic emergence\\n■Potential complications on emergence\\n➣ Delayed emergence (low cardiac output, increased phar-macodynamic effects)\\n➣ Acute myocardial ischemia, pulmonary congestion,edema\\nicu and pacu\\n■Control pain & anxiety (avoid tachycardia); see above.\\n■Consider short period of postop mechanical ventilation if ASsevere:\\n➣ Allows controlled emergence'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 315}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\n302 IHSS Ischemic Heart Disease\\n➣ Avoids reversal (ie, need for anticholinergic agents[tachycardia])\\n➣ Facilitates evaluation of cardiac, ventilatory function\\n➣ Careful sedation is essential: dexmedetomidine veryuseful\\n■Restart preop meds (beta blockade, calcium blockade) as soonas possible.\\nISCHEMIC HEART DISEASE\\nMUHAMMED ITANI, MD, AND JONATHAN T. KETZLER, MD\\nscreening & evaluation\\n■History & physical exam\\n■Risk factor assessment\\n■Family history\\n■12-lead ECG\\n➣ May not show any abnormalities at rest or w/ no symp-toms, or may show evidence of old MI (Q waves in 2 ormore leads & >1/3 of the QRS complex length)\\n➣ May reveal ST segment depression >1 mm from baseline\\nw/ angina pectoris or ST-segment elevation w/ AMI orvariant angina\\n➣ Other changes w/ symptoms of angina pectoris: reversibleT-wave inversion\\n➣ Other ﬁndings w/ AMI: increased T-wave amplitude, fol-lowed by ST elevation, followed by Q-wave development& resolution of ST elevation\\n■Echocardiography can be used to assess global cardiac func-tion. It can also be used to assess regional wall motion abnor-malities & detect the presence of previous myocardial injury.LV function assessment is a major determinant of long-termprognosis. It is also used to diagnose LV thrombus in case ofapical & anterior wall MI.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 316}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\nIschemic Heart Disease 303\\n■Exercise electrocardiography is less accurate than imagingstudies to establish diagnosis of IHD but can give an idea aboutLV function & prognosis. It may not be feasible in patients w/severe PVD, limited exercise tolerance, paced rhythm, abnor-mal ST segment or aortic stenosis.\\n■Stress echocardiography is used w/ pharmacologic inductionof cardiac stress (dobutamine) or exercise to look at LV seg-mental wall function at rest & w/ stress. This can be also usedto differentiate between viable (hibernating, stunned) & non-viable (infarcted) myocardial segments. Echocardiography atrest can be used to assess LV function, which is an importantprognostic variable.\\n■Nuclear stress imaging is used to assess coronary perfusion atrest & after stress. Nuclear tracers (technetium, thallium) areused to measure coronary blood ﬂow.\\n■Positron emission tomography may be used to demonstrateregional myocardial blood ﬂow & metabolism, & hence via-bility.\\n■Coronary angiography provides information about the coro-nary anatomy & the extent & location of the lesions. It is indi-cated in pts w/ unstable angina despite maximal therapy. Itcan provide a road map to coronary revascularization & thefeasibility of percutaneous angioplasty or surgical treatmentdepending on the characteristics & location of the lesions.\\n■Cardiac enzyme elevation: CK, CK-MB & troponin (T & I). Tro-ponin is more speciﬁc than CK-MB; increases within 4 hoursafter AMI & remains elevated up to 1 wk.\\npreoperative preparation\\n■ACC/AHA Guideline Update on Perioperative CardiovascularEvaluation for Noncardiac Surgery can be used for risk strati-ﬁcation of patients w/ IHD. These guidelines can be found atthe following link:\\nhttp://www.americanheart.org/presenter.jhtml?identiﬁer =\\n3000370'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 317}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\n304 Ischemic Heart Disease\\n■Risk stratiﬁcation: assessment of the risk of developmentof cardiovascular complications perioperatively can be donebased on:\\n➣ Variables related to 4 major categories: nature of surgery(high, moderate or low risk), presence of IHD, presence ofCHF & presence of cerebrovascular disease\\n➣ Presence of comorbid conditions (diabetes mellitus, aorticstenosis, PVD)\\n➣ Exercise tolerance\\n➣ Studies may be ordered if disease severity has not beenassessed previously.\\n■History & physical exam to assess extent of disease, exercisetolerance & symptom pattern, in addition to history of comor-bid diseases\\n■Elective surgery in pts w/ a history of AMI should be delayed upto 6 months after the episode of AMI if possible. Intraoperativetachycardia can increase the risk of intraoperative ischemia &perioperative MI.\\n■Silent myocardial ischemia may be seen as only ECG changesw/ no history of symptoms. Almost 70–75% of ischemicepisodes in IHD pts are silent, as well as 10–15% of AMIs.\\n■Continue beta blockers; they were found to increase long-termsurvival in patients w/ IHD.\\n■Calcium channel blockers do not increase the negativeinotropic & vasodilatory effects of inhalational agents but maypotentiate the effects of depolarizing & nondepolarizing mus-cle relaxants.\\n■Stop ACE inhibitors the night before surgery to avoid severehypotension intraoperatively.\\n■Stop aspirin 1 wk before surgery if possible; anticoagulationmust be held to decrease risk of bleeding.\\n■Patients w/ coronary stents should have their surgery delayedat least 4 wks after stenting when possible.\\n■Lifestyle modiﬁcation may affect exercise tolerance (smokingcessation, diet).'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 318}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\nIschemic Heart Disease 305\\n■Cholesterol & triglyceride levels should be kept within accept-able range.\\n■Preop studies (ECG, chest x-ray, echocardiogram, etc.) maybe indicated depending on risk stratiﬁcation, IHD severity &disease progression.\\noperative preparation\\n■Minimizing the sympathetic system effects on the myo-cardium helps decrease the possibility of ischemic eventsperioperatively. This can be achieved by:\\n➣ Anxiolysis w/ sedatives/narcotics (benzodiazepines, opi-oids, scopolamine 0.4–0.6 mg IM or 0.2–0.4 mg IV)\\n➣ Continuation or administration of beta blockers\\n■Administration of nitroglycerine\\n■Maintain heart rate & blood pressure within 20% of normalvalues.\\nanesthesia\\n■Induction\\n➣ The main goal during induction is to avoid hyperten-sion & tachycardia, thereby decreasing drastic cardiacevents.\\n➣ Minimize extreme variation in heart rate & blood pressure.\\n➣ Avoid induction agents capable of stimulating sympa-thetic nervous system (ketamine, pancuronium).\\n➣ Control cardiovascular response to tracheal intubation bykeeping low duration of laryngoscopy ( <15 sec) or by phar-\\nmacologic means. Pharmacologic interventions includelidocaine IV 1.5 to 2 min before intubation (1.5–2 mg/kg),intratracheal lidocaine (2 mg/kg) at the time of laryn-goscopy, IV fentanyl 13 micrograms/kg, IV esmolol or IVnitroprusside.\\n➣ Continuous nitroglycerine infusion was not found todecrease the incidence of intraoperative myocardialischemia.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 319}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\n306 Ischemic Heart Disease\\n➣ Regional anesthesia may be preferred to general anesthe-sia if possible, as it tends to better block the stress responseto surgery. Hypotension associated w/ some regional tech-niques should be corrected by ﬂuids & sympathomimeticagents.\\n■Maintenance\\n➣ Volatile anesthetics (isoﬂurane, desﬂurane & sevoﬂurane)are safe to use w/ IHD, provided severe CHF is notpresent.\\n➣ Alternative technique may be high-dose narcotic agent w/oxygen & nitrous oxide.\\n➣ Avoid pancuronium to reduce sympathomimetic activity.\\n➣ Increased sensitivity to muscle relaxants may be seen inpts on calcium channel blockers.\\n➣ Keep BP & heart rate within 20% of awake values.\\n➣ Intraoperative ischemia may be treated with beta block-ers (esmolol) in case of tachycardia, IV nitrates in thecase of hypertension, or IV sympathomimetics & ﬂuidsw/ hypotension.\\n➣ Minimizing body heat loss is vital to avoid postop shiv-ering & precipitation of ischemic myocardial events. Thiscan be achieved w/ warm IV ﬂuids, warm operating roomatmosphere, forced warm air covers & irrigation of the sur-gical site w/ warm ﬂuids.\\n➣ To maintain adequate myocardial oxygen delivery, do notallow hemoglobin to drop below 10 g/dL.\\n■Monitors used depend on disease severity & operative proce-dure complexity.\\n➣ ECG: simplest & most commonly used. ST-segmentchanges are principally used to diagnose myocardialischemia. ST-segment analysis should be used for accu-rate determination of ST-segment changes. Most com-monly used leads are II & V5, since these reﬂect ischemicchanges in RCA & LAD distributions, respectively.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 320}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\nIschemic Heart Disease 307\\n➣ Pulmonary artery catheter: ischemia manifests as a sud-den increase in PCWP, in addition to new V waves in caseof new onset of ischemic mitral valve regurgitation. Thismay not be seen w/ small areas of ischemia. PA dias-tolic pressure is less sensitive to ischemic changes. SincePCWP is measured intermittently, it may be more valu-able in guiding treatment than detection of ischemia (ﬂu-ids & medication administration, & measuring changesin myocardial function & systemic vascular resis-tance).\\n➣ Central venous pressure may correlate w/ PCWP if EF =\\n0.5 & there is no evidence of LV dysfunction.\\n➣ Transesophageal echocardiography: most sensitive todetect intraoperative myocardial ischemia by detectingnew onset of regional wall motion abnormality\\nwake up and emergence\\n■Proper pain control is key to avoid myocardial ischemicevents.\\n■Muscle relaxants can be reversed w/ neostigmine in combina-tion w/ glycopyrrolate, as the latter produces less tachycardia.Nevertheless, atropine can be used w/ no adverse effects aslong as the pt is adequately beta blocked.\\n■Continuous ECG monitoring w/ ST-segment analysis isimportant to detect any myocardial ischemic events.\\n■Supplemental oxygen to maintain adequate oxygen satura-tion is important.\\n■Adequate heart rate & BP control as intraoperatively\\n■Treat tachycardia or hemodynamic instability.\\n■Avoid & treat shivering.\\nicu or pacu\\n■Supplemental oxygen is crucial.\\n■Pain control to avoid excessive sympathetic nervous systemstimulation'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 321}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\n308 Ischemic Heart Disease Latex Allergy\\n■Maintain adequate beta blockade.\\n■12-lead ECG as a baseline\\n■Prevention of shivering & maintenance of normothermia iscrucial to avoid oxygen desaturation & sympathetic nervoussystem activation.\\n■Troponin levels q8h 3x postop, speciﬁcally after major vascu-lar surgery. In pts w/ values 1.5 or above, mortality 6 monthspostop may be higher than those w/ lower values.\\n■Maintaining adequate oxygenation & tight pain control for 48to 72 hr postop is very important, since this is the period whenthe likelihood of developing AMI is highest.\\n■Reasonable control of blood glucose: keep blood glucose lev-els 100–180 mg/dL.\\nLATEX ALLERGY\\nARTHUR ATCHABAHIAN, MD\\nscreening and evaluation\\n■Biological testing includes RAST (radioallergosorbent test-ing), but speciﬁcity & sensitivity are questionable.\\n■Use tests (wearing a latex glove) or skin prick more reliable,but risk of serious reaction including anaphylaxis\\n■It is preferable to treat any at-risk pt as having demonstratedlatex allergy.\\npreoperative preparation\\n■First patient in operating room\\n■Surgical, operating room & PACU/ICU staff alerted\\n■A latex-free kit containing safe supplies should be available.\\n■Question any equipment to be used around the pt.\\n■Steroids/antihistamine pretreatment has not been shown tobe helpful.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 322}, page_content='P1: IBE0521759385P1secA2 CUNY1088/Sladen 0 521 75938 5 June 12, 2007 13:40\\nLatex Allergy 309\\noperative preparation\\n■Remove any latex-containing equipment while wearing vinylgloves, then discard gloves.\\n■Place signs on door to prevent entrance of outside personnelpotentially carrying latex particles.\\n■Remove rubber stopper on vials with a clamp prior to drawingmeds (although most do not contain latex).\\n■Use green latex-free bag on anesthesia machine (in latex-freekit).\\n■Use vinyl gloves & non-latex tourniquet (in latex-free kit).\\n■Surgical team should use latex-free sterile gloves (neoprene,PVC or other).\\n■Use PVC NIBP cuff or protect skin with Soffban (in latex-freekit).\\n■Do not use Elastoplast or fabric tape.\\n■Do not use injection ports on IV tubing, IV bags & burettes;place tape over them; inject meds or draw ﬂuid through 3-waystopcock.\\n■Ensure that kits (spinal, epidural, etc.) are latex-free; speciﬁ-cally, some syringes contain latex.\\n■Be fully prepared to treat bronchospasm and/or anaphylaxis.\\nanesthesia\\n■Use clear face masks, not black rubber masks.\\n■Do not use red rubber ETTs.\\n■All LMAs are safe.\\n■Inject meds or draw ﬂuid through 3-way stopcock; do not useinjection ports.\\n■Use silicone Foley catheter.\\n■Do not use Swan-Ganz catheter (balloon contains latex).\\nwake up and emergence\\n■Unremarkable'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 323}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n310 Latex Allergy Liver Disease\\nicu or pacu\\n■Single (isolation) room to prevent exposure to latex parti-\\ncles\\n■Ifpossible, one nurse for pt\\n■Similar precautions for monitoring equipment & medica-\\ntion/ﬂuid administration\\n■Ifnot previously done, counsel pt & family.\\n■Bracelet indicating latex allergy\\n■Allergist consultation\\n■Ptshould carry self-injecting epinephrine syringe.\\nLIVER DISEASE\\nROBERT N. SLADEN, MD\\nscreening & evaluation\\n■Signs of hepatocellular failure\\n➣ Spider nevi, palmar erythema, Dupuytren’s contracture\\n➣ Gynecomastia, testicular atrophy, loss of body hair\\n➣ Anasarca, ecchymoses, anemia, malnutrition\\n■Signs of portal hypertension\\n➣ Ascites, splenomegaly\\n➣ Caput medusae (engorged veins around umbilicus)\\n■Relevant lab studies\\n➣ Hct, CBC, prothrombin time\\n➣ Electrolytes (total CO 2if ABG impracticable)\\n➣ BUN, creatinine\\n➣ LFTs, arterial ammonia\\n➣ ECG & chest x-ray\\n■Child-Pugh classiﬁcation of preoperative risk in cirrhosis\\n➣ A: low risk ( <10% mortality)\\n➣ B: moderate risk (5–20% mortality)\\n➣ C: high risk (up to 75% mortality)\\n■Components of score'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 324}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nLiver Disease 311\\n➣ Jaundice (serum bilirubin)\\n➣ Hypoalbuminemia (serum albumin)\\n➣ PT, seconds >control\\n➣ Encephalopathy\\n➣ Ascites\\n➣ Nutrition\\n■Child’s A\\n➣ Serumbilirubin <2mg/dL\\n➣ Serumalbumin >3.5 mg/dL\\n➣ PT 1–4 seconds >control\\n➣ Encephalopathy grade 0\\n➣ Ascites absent\\n➣ Nutrition excellent\\n■Child’s B\\n➣ Serumbilirubin 2–3 mg/dL\\n➣ Serumalbumin 3–3.5 mg/dL\\n➣ PT 4–6 seconds >control\\n➣ Encephalopathy grade 1–2\\n➣ Ascites, easily controlled\\n➣ Nutrition good\\n■Child’s C\\n➣ Serumbilirubin >3mg/dL\\n➣ Serumalbumin <3mg/dL\\n➣ PT>6seconds >control\\n➣ Encephalopathy grade 3–4\\n➣ Ascites, difﬁcult to control\\n➣ Nutrition poor\\npreoperative preparation\\n■Postpone elective surgery (high morbidity & mortality):\\n➣ Acute viral hepatitis, Child’s C\\n➣ PT remains >3sec>control despite parenteral vitamin K\\nand/or FFP\\n■Hepatorenal syndrome'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 325}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n312 Liver Disease\\n➣ Discontinue spironolactone 3–4 days preop (promotes Kretention).\\n➣ Cautiously drain tense ascites.\\n➣ Consider TIPS (see below).\\n■Treat & remove precipitating factors of encephalopathy:\\n➣ Protein restriction, lactulose, neomycin\\n■Acute GI bleeding\\n➣ Fluid resuscitation, transfusion, correction of coagulopa-thy\\n➣ Establish diagnosis (varices vs. peptic ulcer)\\n➣ Refractory bleeding options: transjugular intrahepaticportasystemic shunt (TIPS), endoscopic sclerotherapy,Sengstaken-Blakemore tube (w/ or w/out tracheal intu-bation), vasopressin infusion, emergency decompression\\n■TIPS\\n➣ Decompresses portal hypertension, relieves ascites,\\nimproves renal function, decreases risk of endotoxemia,pulmonary edema, encephalopathy\\noperative preparation\\n■Minimize sedative or opioid premed.\\n➣ Ifnecessary, give small doses of IV sedation in induction\\nroom or OR under direct observation.\\n■Aspiration prophylaxis\\n➣ Anticholinergic agent (glycopyrrolate preferred)\\n➣ H2 blocker (famotidine preferred)\\n➣ Metoclopramide\\n➣ Sodium bicitrate\\n■Use universal & aseptic precautions throughout.\\n➣ All staff should have hepatitis B vaccine.\\n■Invasive hemodynamic monitoring\\n➣ Iflarge ﬂuid shifts anticipated\\n➣ High risk of perioperative acute renal failure (hepatorenal\\nsyndrome)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 326}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nLiver Disease 313\\n➣ Intravascular volume status difﬁcult to assess (ascites &\\nanasarca)\\n■Careful positioning\\n➣ Fragile skin, easy bruising\\n➣ Tense ascites (discomfort, respiratory compromise)\\n■Useactive warming devices to prevent hypothermia:\\n➣ Forced-air convection blanket\\nanesthesia\\n■Regional anesthesia\\n➣ Preserves hepatic blood ﬂow (HBF) if BP, cardiac output\\nmaintained\\n➣ Usually not practicable (coagulopathy, ascites)\\n■General anesthesia\\n➣ Drug handling is extremely variable.\\n➣ Alcoholics require large loading doses; elimination &emergence delayed\\n➣ Decrease doses of all sedative/anesthetic agents in severe\\nliver disease.\\n■Anesthetic induction\\n➣ Aspiration precautions (head up, rapid sequence, cricoidpressure)\\n➣ Preoxygenate\\n➣ Adequate ﬂuid load (250–1,000 mL) prior to induction\\n■Neuromuscular blockade\\n➣ Succinylcholine duration can be prolonged (low pseudo-\\ncholinesterase).\\n➣ Atracurium, cisatracurium preferred (elimination inde-\\npendent of liver function)\\n■Choice of anesthetic agents\\n➣ All volatile anesthetic agents decrease HBF.\\n➣ All opioids may accumulate.\\n➣ Propofol remains relatively short-acting in cirrhosis.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 327}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n314 Liver Disease\\n■Avoid hypercarbia, hypocarbia (cause portal constriction,\\ndecrease HBF).\\n➣ Anticipate intraoperative complications:\\nrHypoxemia (ascites, shunting)\\nrBleeding (coagulopathy)\\nrOliguria (vasomotor nephropathy)\\n➣ Renal protection used in hepatorenal syndrome (prophy-laxis not evidence-based):\\nrDopamine (use as diuretic and/or inotropic agent)\\nrFurosemide infusion\\nrFenoldopam (selective DA-1 dopaminergic agonist)\\n■Excessive volume loading can induce acute hepatic conges-\\ntion:\\n➣ Fluid restriction decreases venous oozing, bleeding.\\n➣ Keep CVP <10 mm Hg if possible.\\n➣ Defer ﬂuid resuscitation until after hepatic resection.\\nwake up & emergence\\n■Anesthetic emergence may be delayed.\\n■Potential complications on emergence\\n➣ Vomiting, aspiration\\n➣ Hypotension\\n➣ Persistent neuromuscular blockade\\n➣ Respiratory depression\\n➣ Acute respiratory failure\\n■Extubate trachea when pt fully awake.\\nicu&p a c u\\n■Consider short period of postop mechanical ventilation:\\n➣ Allows controlled emergence\\n➣ Facilitates evaluation of neurologic, ventilatory function\\n■Anticipate postop complications:\\n➣ Bleeding & refractory coagulopathy\\n➣ Oliguria & acute renal failure\\n➣ Encephalopathy'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 328}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nLiver Disease Malignant Hyperthermia 315\\n➣ Acute respiratory failure\\n➣ Sepsis & wound dehiscence\\n➣ Acute hepatic failure\\n➣ Chronic hepatic insufﬁciency (ascites, jaundice, malnu-trition, “failure to thrive”)\\nMALIGNANT HYPERTHERMIA\\nHUGH R. PLAYFORD, MD\\nscreening and evaluation\\nHistory\\n■Previous anesthetics & speciﬁc agents\\n■Family history (inheritance may be autosomal dominant,\\nautosomal recessive or multifactorial, or unclassiﬁed). Pen-etrance may be incomplete.\\n■Associated conditions (see “Malignant Hyperthermia” in the“Diseases” section)\\nExam\\n■Usually normal\\n■Mayhave evidence of associated conditions\\nInvestigations\\n■Open muscle biopsy & contractile testing\\n➣ Susceptible (abnormal response to both halothane & caf-\\nfeine)\\n➣ Equivocal (abnormal response to either halothane or caf-\\nfeine)\\n➣ Normal (no response)\\n■Chromosomal testing: 19q (limited sensitivity & speciﬁcity)\\n■Other (lymphocyte & platelet tests): less useful\\npreoperative preparation\\n■Goal is to reduce triggering episode.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 329}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n316 Malignant Hyperthermia\\n■Plan to be in an environment able to treat MH crisis (ifneeded).\\noperative preparation\\n■Remove or bypass vaporizers.\\n■Replace fresh gas outlet hose, breathing system tubing, carbondioxide absorbent.\\n■Flush machine (>10 min at 10 L/min, if unable to remove freshgas outlet hose >20 min at 10 L/min).\\n■Bain circuit acceptable for non-crisis anesthesia (circle forcrisis)\\n■Dantrolene availability for all\\n■Dantrolene prophylaxis is controversial. Consider for pts:\\n➣ W/ limited cardiac & cerebrovascular reserve\\n➣ Unable to tolerate hypermetabolism\\n➣ W/ history of awake stress-induced MH\\n➣ Dose 2.5 mg/kg IV at induction, 1.25 mg/kg IV/PO q6h for2–3 days\\nanesthesia\\nAvoid triggering agents:\\n■Succinylcholine, volatile anesthetics (halothane, enﬂurane,isoﬂurane, sevoﬂurane, desﬂurane)\\nUse non-triggering agents:\\n■IV induction agents (barbiturates, propofol, benzodiazepines,ketamine, droperidol)\\n■Narcotics & nitrous oxide\\n■Nondepolarizing neuromuscular blockers\\n■Local anesthetics (amides now seen as safe)\\n■Anticholinesterases & anticholinergics\\n■Catecholamines, digoxin, calcium\\nMonitoring (dictated by comorbidity)\\n■NIBP, ECG, pulse oximetry, capnometry, temperature'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 330}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nMalignant Hyperthermia Mitral Regurgitation 317\\nwake up and emergence\\nAnticholinesterases & anticholinergics regarded as safe\\nicu or pacu\\nPACU\\n■Monitor temperature for 4 hrs (if normal, discharge to ﬂoor or\\nhome).\\nICU if:\\n■MH crisis\\n■Surgical or comorbidity require\\nMITRAL REGURGITATION\\nROBERT N. SLADEN, MD\\nscreening and evaluation\\n■Note the following:\\n➣ History of atrial ﬁbrillation\\n➣ Symptoms of pulmonary edema (ie, dyspnea, hemoptysis,\\northopnea)\\n➣ Symptoms of congestive heart failure (ie, weight gain,\\nedema, anasarca)\\n■Look for physical signs of:\\n➣ Atrial ﬁbrillation\\n➣ Pulmonary edema (orthopnea, crackles)\\n➣ Congestive heart failure (elevated neck veins, edema, hep-\\natomegaly)\\n➣ Cardiac cachexia, “malar ﬂush”\\n■Relevant lab studies\\n➣ Hct (anemia of chronic disease)\\n➣ PT, INR (reversal of coumadin effect)\\n➣ BUN, creatinine (prerenal syndrome)\\n➣ ECG (atrial ﬁbrillation)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 331}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n318 Mitral Regurgitation\\n➣ Chest x-ray (left atrial & ventricular enlargement, pul-monary edema)\\npreoperative preparation\\n■Continue preop meds:\\n➣ Digoxin (rate control for atrial ﬁbrillation)\\n➣ Diuretics for pulmonary edema\\n■Plan perioperative anticoagulation:\\n➣ Hold coumadin at least 3 days preoperatively.\\n➣ Check INR before surgery.\\n■Consider preop admission for control of:\\n➣ Rapid atrial ﬁbrillation\\n➣ Symptomatic pulmonary edema or congestive heart fail-\\nure\\n■Plan perioperative antibiotics:\\n➣ Decrease risk of bacterial endocarditis\\noperative preparation\\n■Review hemodynamic principles:\\n➣ Maintain sinus rhythm (atrial kick, to maximize ventricu-lar ﬁlling)\\n➣ Maintain faster heart rate (increase forward cardiac out-put)\\n➣ Maintain adequate preload (maximize ventricular ﬁlling)\\n➣ Use inotropic, chronotropic agents (maintain forward\\nejection, faster heart rate)\\n➣ Provide afterload reduction w/ systemic vasodilators\\n(increase forward fraction of ejection)\\n■Control pulmonary hypertension:\\n➣ Avoid hypoxemia, hypercarbia, acidosis (induce pul-\\nmonary vasoconstriction)\\n➣ Use balanced vasodilators (nitroprusside)\\n➣ Severe: consider inhaled prostacyclin, inhaled nitric oxide\\n■Acute (new-onset) atrial ﬁbrillation'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 332}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nMitral Regurgitation 319\\n➣ Poorly tolerated, can induce acute decompensation, pul-\\nmonary edema\\n➣ Treat aggressively whenever it occurs (esmolol, amio-\\ndarone, early cardioversion)\\n■Ensure adequate sedative or opioid premedication:\\n➣ Suppress catecholamines, avoid tachyarrhythmias\\n➣ Butincreased risk of respiratory depression (low cardiac\\noutput)\\n■Consider perioperative vasodilation w/ nitroprusside (bal-\\nanced vasodilator)\\n➣ Provides preload & afterload reduction\\n■Useﬂuids & inotropic agents to treat hypotension\\n➣ Maintain preload, contractility\\n➣ Ephedrine may be useful (mixed agonist, increases con-\\ntractility, induces tachycardia)\\n➣ Excessive vasoconstriction (phenylephrine, norepine-\\nphrine) may increase regurgitation.\\n■Invasive hemodynamic monitoring\\n➣ Large ﬂuid shifts anticipated\\n➣ Rapid changes in afterload anticipated (may lead to rapid\\nchanges in regurgitant fraction)\\n➣ Presence of pulmonary congestion/edema or congestive\\nheart failure\\nanesthesia\\n■Regional anesthesia\\n➣ Precautions w/ prior coumadin therapy (avoid if INR still\\n>1.4)\\n➣ Sympathetic blockade (vasodilation, afterload reduction)\\ncan markedly improve regurgitation.\\n➣ Adequate ﬂuid load before placement (maintain preload)\\n➣ Systemic hypotension may induce low cardiac output.\\n➣ Beware of postop pulmonary edema (sympathetic block\\nwears off, increase in SVR).'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 333}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n320 Mitral Regurgitation\\n■General anesthesia\\n➣ Ptmay not tolerate lying ﬂat (orthopnea).\\n➣ Take measures to maintain heart rate, contractility (eg,dopamine, dobutamine).\\n➣ Preoxygenate\\n➣ Adequate ﬂuid load before induction (maintain preload)\\n■Avoid nitrous oxide\\n➣ Exacerbates underlying pulmonary hypertension\\n■Choose maintenance regimen that does not depress myo-cardium, induce bradycardia\\n➣ Avoid halothane, enﬂurane.\\n➣ Consider total IV anesthesia w/ opioid (fentanyl, sufen-tanil, remifentanil).\\nwake up and emergence\\n■Attempt to suppress catecholamines on emergence (tach-yarrhythmias)\\n➣ Judicious use of sympatholytic opioid (fentanyl, sufen-tanil, remifentanil)\\n➣ Avoid morphine (histamine, catecholamine release).\\n■Potential complications on emergence\\n➣ Delayed emergence (low cardiac output, increased phar-macodynamic effects)\\n➣ Acute pulmonary hypertension\\n➣ Acute pulmonary congestion, edema\\n➣ Hypoxemia, acute respiratory failure\\nicu and pacu\\n■Maintain cardiac output\\n➣ Maintain preload (ﬂuids).\\n➣ Aggressive treatment of atrial arrhythmias (esmolol, amio-darone, cardioversion)\\n➣ Maintain or increase contractility (dopamine).\\n➣ Decrease afterload w/ vasodilators (nitroprusside,nicardipine).'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 334}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nMitral Regurgitation Mitral Stenosis 321\\n➣ Increase contractility, decrease afterload with inodilators\\n(dobutamine, milrinone).\\n■Consider short period of postop mechanical ventilation if MR\\nsevere\\n➣ Allows controlled emergence\\n➣ Avoids reversal (ie, need for muscarinic agents [brady-\\ncardia])\\n➣ Facilitates evaluation of cardiac, ventilatory function\\n➣ Allows control of pulmonary hypertension, appropriatediuresis before extubation\\n■Restart preop meds (digoxin, diuretics) as soon as possi-\\nble.\\n■Forchronic atrial ﬁbrillation\\n➣ Anticoagulation required >24 hr to prevent intracardiac\\nthrombus formation\\n➣ Restart oral coumadin when able to take orally.\\n➣ Ifnot, start IV heparin & continue until able to take oral\\nmeds.\\nMITRAL STENOSIS\\nROBERT N. SLADEN, MD\\nscreening and evaluation\\n■Note the following:\\n➣ History of atrial ﬁbrillation\\n➣ Symptoms of pulmonary edema (ie, dyspnea, hemoptysis,\\northopnea)\\n■Look for physical signs of:\\n➣ Atrial ﬁbrillation\\n➣ Pulmonary edema (orthopnea, crackles)\\n➣ Cardiac cachexia, “malar ﬂush”\\n■Relevant lab studies\\n➣ Hct (anemia of chronic disease)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 335}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n322 Mitral Stenosis\\n➣ PT, INR (reversal of coumadin effect)\\n➣ BUN, creatinine (prerenal syndrome)\\n➣ ECG (atrial ﬁbrillation)\\n➣ Chest x-ray (left atrial enlargement, pulmonary edema)\\npreoperative preparation\\n■Continue preop meds:\\n➣ Digoxin (rate control for atrial ﬁbrillation)\\n➣ Diuretics for pulmonary edema\\n■Plan perioperative anticoagulation:\\n➣ Hold coumadin at least 3 days preop.\\n➣ Check INR before surgery.\\n■Consider preop admission for control of:\\n➣ Rapid atrial ﬁbrillation\\n➣ Symptomatic pulmonary edema\\n■Plan perioperative antibiotics:\\n➣ Decrease risk of bacterial endocarditis\\noperative preparation\\n■Review hemodynamic principles:\\n➣ Maintain sinus rhythm (atrial kick, to overcome mitral gra-dient).\\n➣ Maintain slow heart rate (increases diastolic ﬁll time forventricle).\\n➣ Avoid tachycardia (promotes pulmonary hypertension,\\nedema).\\n➣ Maintain adequate preload (overcome mitral gradient).\\n➣ Avoid inotropic, chronotropic agents (no beneﬁt to left\\nventricle).\\n➣ Avoid systemic vasodilators (afterload reduction is of no\\nbeneﬁt).\\n■Control pulmonary hypertension:\\n➣ Avoid hypoxemia, hypercarbia, acidosis (induce pul-\\nmonary vasoconstriction)\\n➣ Usevenodilators (nitroglycerin)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 336}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nMitral Stenosis 323\\n➣ Severe: consider inhaled prostacyclin, inhaled nitric\\noxide\\n■Acute (new-onset) atrial ﬁbrillation\\n➣ Poorly tolerated; can induce acute decompensation, pul-\\nmonary edema\\n➣ Treat aggressively whenever it occurs (esmolol, early car-\\ndioversion).\\n■Ensure adequate sedative or opioid premedication:\\n➣ Suppress catecholamines, avoid tachycardia\\n➣ Butincreased risk of respiratory depression (low cardiac\\noutput)\\n■Consider titratable beta blockade (esmolol) for rate control.\\n■Consider perioperative venodilation w/ nitroglycerin (selec-\\ntive venodilator):\\n➣ Avoid sodium nitroprusside (arterial hypotension).\\n■Choose an appropriate vasoconstrictor to treat hypotension:\\n➣ Usephenylephrine (pure alpha agonist, induces reﬂex\\nbradycardia).\\n➣ Avoid ephedrine (mixed agonist, induces tachycardia).\\n■Invasive hemodynamic monitoring\\n➣ Large ﬂuid shifts anticipated\\n➣ Presence of pulmonary congestion or edema\\nanesthesia\\n■Regional anesthesia\\n➣ Precautions w/ prior coumadin therapy (avoid if INR still\\n>1.4)\\n➣ Sympathetic blockade is helpful in controlling pulmonary\\ncongestion, edema\\n➣ Adequate ﬂuid load before placement (maintain preload)\\n➣ Systemic hypotension, reﬂex tachycardia may induce low\\ncardiac output, pulmonary hypertension.\\n➣ Beware of postop pulmonary edema (sympathetic block\\nwears off, increase in SVR).'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 337}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n324 Mitral Stenosis\\n■General anesthesia\\n➣ Ptmay not tolerate lying ﬂat (orthopnea).\\n➣ Take measures to control tachycardia (eg, esmolol,remifentanil).\\n➣ Preoxygenate.\\n■Adequate ﬂuid load before induction (maintain preload)\\n■Avoid pancuronium (tachycardia), ketamine (sympath-\\nomimetic).\\n■Avoid nitrous oxide:\\n➣ Exacerbates underlying pulmonary hypertension\\n■Choose maintenance regimen that maintains slow heart rate,suppresses sympathetic response:\\n➣ Avoid isoﬂurane (increased heart rate), desﬂurane (increa-\\nsed sympathetic tone).\\n➣ Consider sympatholytic opioid (fentanyl, sufentanil,remifentanil).\\nwake up and emergence\\n■Attempt to suppress catecholamines on emergence:\\n➣ Judicious use of sympatholytic opioid (fentanyl, sufen-tanil, remifentanil)\\n➣ Avoid morphine (histamine, catecholamine release).\\n■Consider dexmedetomidine infusion:\\n➣ Sympatholytic, provides analgesia w/out respiratorydepression\\n➣ Canb econtinued through tracheal extubation & be-\\nyond\\n➣ Dose carefully: can potentiate beta blockade, delay anes-thetic emergence\\n■Potential complications on emergence\\n➣ Delayed emergence (low cardiac output, increased phar-macodynamic effects)\\n➣ Acute pulmonary hypertension\\n➣ Acute pulmonary congestion, edema'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 338}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nMitral Stenosis Morbid Obesity 325\\n➣ Hypoxemia, acute respiratory failure\\nicu and pacu\\n■Control pain & anxiety (avoid tachycardia); see above.\\n■Consider short period of postop mechanical ventilation if\\nsevere disease:\\n➣ Allows controlled emergence\\n➣ Avoids reversal (ie, need for anticholinergic agents\\n[tachycardia])\\n➣ Facilitates evaluation of cardiac, ventilatory function\\n➣ Allows control of pulmonary hypertension, appropriatediuresis before extubation\\n■Restart preop meds (digoxin, diuretics) as soon as possible.\\n■Forchronic atrial ﬁbrillation\\n➣ Anticoagulation required >24 hr to prevent intracardiac\\nthrombus formation\\n➣ Restart oral coumadin when pt is able to take orally.\\n➣ Ifnot, start IV heparin & continue until pt is able to take\\noral meds.\\nMORBID OBESITY\\nHUGH R. PLAYFORD, MD\\nscreening and evaluation\\n■Note the following:\\n➣ Previous anesthesia (difﬁculty w/ intubation or airway\\nmaintenance, nerve blocks, positioning)\\n➣ Obesity hypoventilation syndrome, Pickwickian syn-drome\\n➣ Esophageal reﬂux\\n➣ Obesity meds\\nrSibutramide (hypertension, serotonin syndrome)\\nrFenﬂuramine-phenteramine (withdrawn from market,\\ncardiac valve defects)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 339}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n326 Morbid Obesity\\n■Look for physical signs of:\\n➣ Hypertension, L or R ventricular failure, pulmonary hyper-\\ntension\\n➣ Limited mouth opening, limited neck movement, intra-oral soft tissues\\n■Relevant lab studies\\n➣ Hct, CBC\\n➣ Serum biochemistry (incl. glucose, LFTs)\\n➣ ABGs on room air (hypoxemia [increased metabolic rate,V/Q mismatch], normocarbia)\\n➣ ECG, chest x-ray\\n➣ W/ or w/out echo\\n➣ Pulmonary function tests (usually restrictive pattern\\nw/ decreased ERV, VC, FRC & tidal volume, increasedRR)\\npreoperative preparation\\n■CPAP/BiPAP\\n➣ Continue to time of surgery.\\n➣ Ensure available immediately postop for wake up/emer-gence/PACU/postop course.\\n■Reﬂux meds\\n➣ Continue to time of surgery.\\n■Glucose intolerance\\n➣ Manage as per diabetic routine (fasting, hypoglycemics,Dextrostix, timing of surgery).\\noperative preparation\\n■Avoid respiratory depressants until in OR.\\n■Avoid subcutaneous or intramuscular routes (unpredictable\\nabsorption).\\n■Anti-sialogogue if awake intubation considered\\n■Gastric regurgitation precautions (decreased volume, increa-\\nsed pH)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 340}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nMorbid Obesity 327\\n➣ H2 receptor antagonist, gastric prokinetic, gastric tube\\n■Appropriate equipment for obese pts\\n➣ Operating tables, gurneys\\n➣ Padding of pressure points\\nanesthesia\\n■Monitoring & equipment\\n➣ Blood pressure\\nrNIBP (w/ appropriate cuff size)\\nrInvasive arterial monitoring\\n➣ ECG (II, aVF , V5 for cardiac ischemia)\\n➣ Other invasive monitoring as indicated (pulmonary artery\\ncatheters, echo)\\n➣ Respiratory parameters\\nrSaO 2,w/orw/out ABGs\\nrEtCO 2\\n➣ Peripheral nerve stimulator (w/ or w/out needle elec-\\ntrodes)\\n➣ Temperature (prevent hypothermia, shivering, subse-\\nquent hypoxia)\\nrMonitoring\\nrForced-air warmers\\n■Airway mgt\\n➣ Forgeneral anesthesia, consider endotracheal tube\\nrDifﬁcult mask ventilation\\nrHigh risk of gastric aspiration\\nrObese pts tend to spontaneously hypoventilate(hypoxia, hypercarbia, acidosis).\\nwake up and emergence\\nN/A\\nicu or pacu\\nN/A'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 341}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n328 Multiple Sclerosis\\nMULTIPLE SCLEROSIS\\nKARL WILLMANN, MD\\nscreening and evaluation\\n■Neurologic evaluation\\n➣ Dur ation of MS signs & symptoms\\n➣ Bulbar dysfunction\\n➣ Respiratory dysfunction (CXR ±PFTs, ABGs)\\n➣ Peripheral signs (particularly if considering regional anes-\\nthesia)\\n■Toxicity of pharmacotherapy\\n➣ Preop EKG, CBC & renal function tests\\n➣ IVIG, interferon beta 1-a (Avonex), interferon beta 1-b( B etaseron), glatiramer acetate (Copaxone) & mitox-\\nantrone (Novantrone) may cause marrow suppression,renal failure, arrhythmias, seizures & cardiac arrest.\\n■Anesthetic considerations\\n➣ Paraplegia/quadriplegia: risk of autonomic hyperreﬂexia\\n➣ Pharyngeal & laryngeal muscular impairment: risk of aspi-ration\\npreoperative preparation\\n■Aspiration precautions (esp. w/ pharyngeal/laryngeal dys-function)\\n➣ Metoclopramide (Reglan), H 2blocker, or\\n➣ Proton pump inhibitor, or\\n➣ Non-particulate antacids\\n■Continue MS meds until time of surgery.\\noperative preparation\\n■Arterial line\\n➣ Pulmonary dysfunction\\n➣ Paraplegia, quadriplegia\\n➣ History or risk of autonomic hyperreﬂexia\\n■Urinary catheter'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 342}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nMultiple Sclerosis 329\\n➣ Minimize autonomic responses to bladder distention\\n■Temperature monitoring\\n➣ Exacerbation of MS weakness is associated w/ hyper-\\nthermia.\\n➣ Avoid hyperthermia & treat aggressively if it develops.\\n■Positioning\\n➣ Carew/ sensory deﬁcits, spasticity, paraplegia, quadri-\\nplegia\\n➣ IV & line placement may be difﬁcult.\\nanesthesia\\n■Induction w/ aspiration precautions (pharyngeal, laryngeal\\ndysfunction)\\n➣ Rapid sequence induction\\n➣ Preoxygenation +cricothyroid pressure +head up\\n➣ Avoid succinylcholine (potential for exaggerated K\\nrelease).\\n■Maintenance\\n➣ Regional/neuraxial anesthesia\\nrMaycause exacerbation of MS (but no prospective\\nevidence)\\nrNoreported exacerbation of MS w/ epidural for labor\\npain\\nrNotcontraindicated if GA poses a greater risk than\\nregional\\nwake up and emergence\\n■Anticipate delayed emergence:\\n➣ Anesthetics (benzodiazepines potentiate)\\n➣ Non-depolarizing neuromuscular blockers\\nrBaclofen (Lioresal)\\nrDantrolene (Dantrium)\\nrPropantheline (Pro-Banthine)\\n■Anticipate pulmonary compromise:\\n➣ Ensure pts are awake, fully reversed from neuromuscularblockade'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 343}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n330 Multiple Sclerosis Muscular Dystrophy\\n➣ Able to maintain good oxygenation & ventilation\\n➣ Do not extubate if above criteria not met.\\n■Anticipate potential for pulmonary aspiration.\\nicu or pacu\\n■Consider a period of postop ventilation & ICU care:\\n➣ Severe pulmonary compromise\\n■Thoracic/abdominal procedures\\nMUSCULAR DYSTROPHY\\nJONATHAN T. KETZLER, MD\\nscreening and evaluation\\n■Necrotic & phagocytized muscle ﬁbers are seen on biopsy.\\n■Levels of serum enzymes derived from muscle tissue (crea-tinine kinase, lactate dehydrogenase, aspartate aminotrans-ferase, alanine aminotransferase) & myoglobin usually corre-late with severity of disease.\\n■Do a pulmonary evaluation on all pts with skeletal muscleweakness.\\n■Ptsw /signs of congestive heart failure should have a full car-\\ndiac workup.\\npreop evaluation\\nN/A\\noperative preparation\\nN/A\\nanesthesia\\n■Consider regional anesthesia to avoid the use of muscle relax-\\nants.\\n■General anesthesia'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 344}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nMuscular Dystrophy Myasthenia Gravis 331\\n➣ Ptsw/Duchenne’s muscular dystrophy are at higher risk of\\nmalignant hyperthermia, so avoid using triggering anes-thetics.\\n➣ Smooth muscle involvement may result in hypomotility\\nof the intestinal tract & delayed gastric emptying, so takeprecautions to prevent aspiration.\\n➣ There have been numerous reports of cardiac arrest w/induction, so monitor cardiac function carefully.\\n➣ Monitoring is aimed at early detection of malignant hyper-\\nthermia & congestive heart failure.\\n➣ Because of possible prolonged paralysis, avoid or limit use\\nof neuromuscular blocking agents.\\n➣ Marked respiratory & circulatory depression may be seen\\nwith the use of volatile anesthetics in pts w/ advanceddisease.\\n➣ Pts w /F V C <30% of predicted are at greatest risk of requir-\\ning postop ventilation.\\nwake up & emergence\\nN/A\\nicu and pacu\\n■Because of the potential for postop complications, observe\\npts overnight if more than a very minor procedure is perfor-med.\\n■Vigorous postop respiratory therapy can be helpful.\\nMYASTHENIA GRAVIS\\nKARL WILLMANN, MD AND D. B. COURSIN, MD\\nscreening and evaluation\\n■Duration & severity of symptoms, including bulbar dysfunc-\\ntion & respiratory dysfunction'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 345}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n332 Myasthenia Gravis\\n■Evaluate pts w/ dyspnea or orthopnea for anterior mediastinal\\nmass, including chest x-ray (CT), ﬂow loop diagrams.\\n■PFTs\\n■Discuss w/ pt possibility of postop intubation.\\n➣ Risks for prolonged intubation\\nrDur ation of disease >6 yrs\\nrHistory of other chronic lung disease\\nrPyridostigmine (Mestinon) dose >750 mg/day\\nrPreop vital capacity <2.9 L\\n■Discussion of postoperative analgesia (epidural, PCA, NSAID,\\netc.)\\n■Meds & doses, including steroids, immunosuppressive agents,\\nincluding cyclosporine, azathioprine & mycophenolate, anti-cholinesterases, recent plasmapheresis or immunoglobulin\\n■Labs: CBC, platelets, electrolytes, BUN, CR, LFTs\\n■Thorough history of pt’s symptoms & course of disease, look-ing for evidence of myasthenic or cholinergic crisis\\n■Myasthenic crisis, increased weakness & symptoms, is causedbytoo little acetylcholine & requires a higher dose of anti-\\ncholinesterase.\\n■Cholinergic crisis is heralded by increasing weakness & cholin-ergic symptoms because of too much acetylcholine at theNMJ.\\n■Often it is hard to distinguish btwn the two entities; they can bedelineated by giving a small dose of anticholinesterase (10 mgedrophonium); if the pt improves, myasthenic crisis is mostlikely.\\n■Neurology consult\\n■Optimize meds.\\n■MG symptoms should be at baseline.\\n■Evaluate pt for possible respiratory infections, which should\\nbe resolved before surgery.\\n■Ptmay require plasmapheresis or immunoglobin to improve\\nsymptoms; arrange prior to surgery.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 346}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nMyasthenia Gravis 333\\npreoperative preparation\\n■Forpts w/ bulbar dysfunction, pretreat w/ metoclopramide,\\nH2 blockers or proton pump inhibitor and/or non-particulateantacids.\\n■Avoid or minimize use of narcotics for preop anxiolysis; they\\ncan depress respiratory function in pts w/ compromised sta-tus in unmonitored situations.\\n■Ptsonsteroids may require stress-dose steroids.\\n■Maycontinue anticholinergic meds on day of surgery, espe-\\ncially pts who are dependent & awake w/ severe symptoms.Ptsw/more mild disease may skip the AM dose of anticholin-\\nergics if case is early in the morning.\\n■MicroMedex states there is a 1:30 ratio IV to oral conversion\\nof pyridostigmine (Mestinon).\\noperative preparation\\nN/A\\nanesthesia\\n■Induction\\n➣ Ifconcern about large anterior mediastinal mass w/ large\\nairway & vascular compression when pt supine, an awakeﬁberoptic intubation would be prudent.\\n➣ Ptsw/signiﬁcant respiratory function or pts undergoing\\nlarge abdominal or thoracic cases should have an arterialline.\\n➣ Rapid sequence induction w/ cricothyroid pressure for pts\\nw/ bulbar dysfunction, understanding the altered phar-macology of both nondepolarizing & depolarizing musclerelaxants\\n➣ Intubation of the trachea w/ no muscle relaxation is\\noptimal.\\n➣ MG pts are very sensitive to nondepolarizing agents, usu-ally requiring only 10% of the normal dose, if needed.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 347}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n334 Myasthenia Gravis\\n➣ Ptsareusually resistant to depolarizing agents & require\\n2–3 times the normal dose.\\n➣ Pts will have prolonged effect of depolarizing agents if\\nthey are treated w/ anticholinergic agents (inhibit pseu-docholinesterase).\\n➣ Avoid long-acting muscle relaxants.\\n➣ Volatile agents have muscle-relaxing properties that are\\nexaggerated in pts w/ MG & may be sufﬁcient to providethe desired level of muscular relaxation.\\n■Maintenance\\n➣ Regional anesthesia is acceptable, but techniques thatblock accessory muscles & rib cage muscles will increaserespiratory function in pts w/ already decreased respira-tory reserve.\\nwake up and emergence\\n■Extubation criteria must be met:\\n➣ Ptmust be fully awake w/ complete reversal of muscu-\\nlar blockade. Evaluate for cholinergic excess vs. muscularweakness.\\n➣ VC>15 mL/kg\\n➣ A-a gradient O 2>350 mm Hg on 100% FIO 2\\n➣ PaCO 2<50 mm Hg\\n➣ Negative inspiratory force >−20 cm H 2O\\n➣ Stable cardiac status\\n➣ Warm\\nicu or pacu\\n■Prolonged intubation & ventilation may be required.\\n■Neurology consult\\n■Continue steroids & anticholinesterases during the earlypostop period (if residual bulbar symptoms, pt may need gas-tric tube for medication administration).\\n■Possible plasmapheresis & immunoglobin therapy to improvestrength'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 348}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nNeuroleptic Malignant Syndrome 335\\nNEUROLEPTIC MALIGNANT SYNDROME\\nHUGH R. PLAYFORD, MD\\nscreening and evaluation\\n■Acute\\n➣ Assess & optimize intravascular volume & hemodynamics.\\n➣ Careful assessment of respiratory function, including\\nABGs\\n➣ Assess serum potassium & indices of renal function.\\n➣ Assess neurologic status.\\n■Chronic\\n➣ Usually little changed from normal\\npreoperative preparation\\n■Ifpossible, defer operative procedure until acute NMS has\\nresolved.\\n■Avoid neuroleptic drugs (including metoclopramide).\\noperative preparation\\n■Avoid neuroleptic drugs (including metoclopramide).\\n■Acute\\n➣ Usecare w/ positioning if signiﬁcant muscular rigidity\\nanesthesia\\n■Avoid neuroleptic drugs (including metoclopramide).\\nwake up and emergence\\nN/A\\nicu or pacu\\nN/A'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 349}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n336 Obstetric Patient\\nOBSTETRIC PATIENT HAVING INTERCURRENT SURGERY\\nJONATHAN T. KETZLER, MD\\nscreening and evaluation\\n■Ifnot emergent, consider delaying until second trimester.\\n➣ Delaying to second trimester decreases the incidence ofteratogenicity & spontaneous miscarriage.\\n➣ Risk of preterm labor is lower in second trimester than itis in third trimester.\\n■Discuss w/ pt risks & beneﬁts of anesthesia to fetus & preg-nancy.\\n■Educate pt about signs & symptoms of preterm labor.\\npreoperative preparation\\n■Pain & anxiety elevate maternal catecholamine levels & may\\ndecrease uterine blood ﬂow, so premedicate accordingly.\\n■Aspiration prophylaxis w/ H2-receptor antagonist, metoclo-pramide or antacid\\noperative preparation\\n■Discuss need for tocolysis w/ obstetrician.\\n➣ Indomethacin & magnesium sulfate are most commonlyused tocolytics.\\n➣ Magnesium sulfate may potentiate muscle relaxants &make hypovolemic shock more refractory.\\nanesthesia\\n■Avoid maternal hypoxemia & hypotension.\\n■Maintenance of uterine perfusion & maternal oxygenation topreserve fetal oxygenation are most important aspects. Leftlateral tilt if possible to avoid aortocaval compression.\\n■Becognizant of anesthetic effects on maternal cardiac output,\\noxygen delivery & uterine blood ﬂow.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 350}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nObstetric Patient 337\\n■Pregnancy outcome is not affected by type of anesthetic, type\\nof surgery, length of anesthetic or surgical blood loss.\\n■Monitoring\\n➣ BP\\n➣ Pulse oximetry\\n➣ End-tidal capnography\\n➣ Temperature\\n➣ After 24 wks gestation, intermittent or continuous fetalmonitoring if it will not interfere w/ the surgical procedure\\nrLoss of beat-to-beat variability is normal w/ anesthet-ics, but not decelerations.\\nrDecelerations may indicate need to increase maternal\\noxygenation, raise BP, increase uterine displacement,\\nchange site of surgical retraction or begin tocolytics.\\nrFetal monitoring has not been shown to improve fetal\\noutcome.\\n■General anesthesia\\n➣ Veryhigh likelihood of difﬁcult airway\\n➣ Full preoxygenation & denitrogenation\\n➣ Rapid sequence induction w/ cricoid pressure\\n➣ High concentration of oxygen\\n➣ Slowreversal of muscle relaxants to avoid rapid increases\\nin acetylcholine, which can induce uterine contraction\\n➣ Keep MAC <2.0 to prevent decreasing maternal cardiac\\noutput.\\n➣ Propofol reduces oxytocin-induced contractions of uter-\\nine smooth muscle.\\n■Regional anesthesia\\n➣ Minimizes drug exposure & changes in fetal heart rate\\n➣ Prevent hypotension w/ adequate hydration & uterine dis-\\nplacement.\\n➣ Treat hypotension aggressively w/ ephedrine.\\n➣ Decrease neuraxial dose by about one third.\\n■Principles for anesthesia <24 wks gestation'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 351}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n338 Obstetric Patient Parkinson’s Disease\\n➣ Delay surgery until second trimester if possible.\\n➣ Preop assessment by obstetrician\\n➣ Aspiration prophylaxis\\n➣ Monitor & maintain oxygenation, CO 2,B P&blood sugar.\\n➣ Useregional anesthesia when appropriate.\\n➣ Avoid high concentrations of nitrous oxide.\\n➣ Document fetal heart tones before & after anesthetic.\\n■Principles for anesthesia >24 wks gestation\\n➣ Discuss use of tocolytics w/ obstetrician.\\n➣ Aspiration prophylaxis\\n➣ Maintain left uterine displacement at ALL times.\\n➣ Monitor & maintain oxygenation, CO 2,B P&blood sugar.\\n➣ Fetal monitoring intraoperatively when feasible\\n➣ Monitor for uterine contractions postop.\\n➣ Document fetal heart tones before & after anesthetic.\\nwake up & emergence\\nN/A\\nicu or pacu\\nN/A\\nPARK INSON’S DIS EASE\\nROBERT N. SLADEN, MD\\nscreening and evaluation\\n■Severity of disease (very variable)\\n■Signs of general debility\\n➣ Muscle wasting\\n➣ Poor nutritional status\\n■Airway exam\\n➣ Limitation in mouth opening, neck mobility due to musclerigidity'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 352}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nParkinson’s Disease 339\\n➣ Excessive secretions\\n■Relevant lab studies\\n➣ Hct, CBC\\n➣ Electrolytes (total CO 2if ABG impracticable)\\n➣ Blood sugar\\n➣ BUN, creatinine\\n➣ LFTs\\n➣ ECG, chest x-ray\\npreoperative preparation\\n■Neurology consult\\n➣ Severe disease\\n➣ Recent change in status\\n➣ Assist w/ drug optimization\\n■Anticipate dehydration (severe disease)\\n➣ Establish venous access & provide judicious rehydration\\n■Anticipate difﬁcult airway\\n➣ Discuss w/ pt possible awake tracheal intubation.\\n➣ Prepare difﬁcult airway cart.\\noperative preparation\\n■Aspiration prophylaxis (anticipate difﬁcult tracheal intuba-tion)\\n➣ Anticholinergic agent (glycopyrrolate preferred)\\n➣ H2blocker (famotidine preferred)\\n➣ Metoclopramide\\n➣ Sodium bicitrate\\n■Anticipate difﬁcult access\\n➣ Peripheral IV, arterial line, IJ difﬁcult w/ severe rigidity\\n■Careful positioning\\n➣ Rigidity\\n➣ Support & protect all affected joints w/ soft material.\\n➣ Severe rigidity may render normal positioning impossible.\\n■Useactive warming devices to prevent hypothermia\\n➣ Forced-air convection blanket'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 353}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n340 Parkinson’s Disease\\nanesthesia\\n■Regional anesthesia\\n➣ Mayb eimpossible in presence of severe rigidity\\n➣ Anticipate hypotension (chronic dopaminergic vasodila-tion)\\n■General anesthesia\\n➣ Anticipate difﬁcult airway\\n➣ Anticipate aspiration (excessive secretions)\\n➣ Anticipate hyperreactive airways (excessive secretions)\\n➣ Anticipate hypotension (chronic dopaminergic vasodila-tion)\\nwake up and emergence\\n■Careful planning for anesthetic emergence\\n➣ Iftracheal intubation was difﬁcult, do not extubate until\\ncompletely awake.\\n➣ Ifin doubt, plan transient postop ventilation until airway\\nprotection is ensured.\\n■Potential complications on emergence\\n➣ Vomiting, aspiration\\n➣ Airway obstruction\\n➣ Respiratory depression\\n➣ Acute respiratory failure\\nicu and pacu\\n■Consider short period of postop mechanical ventilation (see\\nabove).\\n■Anticipate postop complications\\n➣ Airway obstruction\\n➣ Acute respiratory failure\\n➣ Sepsis, wound dehiscence\\n➣ Anemia\\n■Postop meds\\n➣ Defer antiplatelet agents until no further risk of bleeding.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 354}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nParkinson’s Disease Patient with a Transplant 341\\n➣ Provide GI prophylaxis (H 2blocker, proton pump\\ninhibitor).\\n➣ Resume preop meds as soon as possible.\\nPATIENT WITH A TRANSPLANT\\nARTHUR ATCHABAHIAN, MD\\nscreening and evaluation\\n■12-lead EKG\\n■Chest x-ray\\n■CBC, electrolytes, BUN, creatinine, glucose & liver functiontests\\nHeart Tx\\n■Reason for Tx: CAD, dilated CM, viral myocarditis\\n■Evaluate cardiac function clinically (exercise tolerance,\\nhypotension, JVD, pedal edema, signs of pulmonary edemaon chest auscultation, gallop).\\n■Obtain consult from cardiologist regarding function of thetransplant, coronary artery disease, current immunosuppres-sive therapy & history of rejection.\\n■Consider obtaining echocardiogram & noninvasive stress test\\nif information not available.\\nRenal Tx\\n■Reason for Tx: diabetes mellitus, vasculitis, glomerulonephri-\\ntis, uncontrolled hypertension, obstruction\\n■Evaluate renal function clinically (urine output & den-\\nsity) & biologically (BUN, creatinine, creatinine clearance ifneeded).\\n■Obtain consult from nephrologist regarding renal function &evolution, current immunosuppressive therapy & history ofrejection.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 355}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n342 Patient with a Transplant\\nLiver Tx\\n■Reason for transplant: cirrhosis w/ or w/out potential forrecurrence, biliary malformation, acute hepatic failure\\n■Evaluate liver function clinically (ascites, encephalopathy,\\njaundice) & biologically (PT, serum bilirubin, serum lactate).\\n■Obtain consult from hepatologist regarding liver function,current immunosuppressive therapy & history of rejection.\\nLung Tx\\n■Reason for Tx: cystic ﬁbrosis, end-stage emphysema, alpha-1antitrypsin deﬁciency, primary pulmonary hypertension\\n■Assess pulmonary function clinically (exercise tolerance, aus-cultation, cyanosis, pulse oximetry) & biologically (ABG, ortotal CO\\n2on electrolyte panel).\\n■Obtain consult from pulmonologist regarding pulmonaryfunction, current immunosuppressive therapy & history ofrejection.\\npreoperative preparation\\n■Take all immunosuppressive meds on the morning of surgery.\\noperative preparation\\n■Strict aseptic technique because of susceptibility to infection\\n■Consider rapid sequence intubation if renal or hepatic Tx.\\n■Consider stress-dose steroids unless very low-dose steroid\\nmaintenance & minor surgery.\\n■Careful positioning\\n➣ Fragile skin because of steroid treatment, renal or hepatic\\nfailure\\n➣ Ascites\\nanesthesia\\nHeart Tx\\n■Avoid right internal jugular central venous access, as this is\\nthe site used to perform myocardial biopsies.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 356}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nPatient with a Transplant 343\\n■Maintain adequate preload; avoid sudden vasodilation.\\n■Treat hypotension by ﬂuid administration & direct-acting\\nagents such as phenylephrine & norepinephrine.\\n■Risk of myocardial ischemia if signiﬁcant coronary artery dis-ease\\nRenal Tx\\n■Maintain adequate ﬂuid status to preserve renal perfusion.\\n■Closely monitor urine output; treat aggressively any oliguria.\\n■Avoid nephrotoxic meds (eg, radiologic contrast dye, amino-\\nglycosides, vancomycin, diuretics).\\n■Theoretical risk of nephrotoxicity w/ enﬂurane & sevoﬂurane\\nLiver Tx\\n■Avoid hypotension & hepatotoxic meds (halothane).\\n■Succinylcholine effect can be prolonged (decreased pseudo-\\ncholinesterase).\\n■Ifpoor graft function, considerations for hepatic insufﬁciency\\napply\\n➣ Decreased elimination of meds dependent on hepatic\\nfunction\\n➣ Hypoalbuminemia w/ decreased protein binding\\n➣ Propensity to hypoglycemia\\n➣ Coagulopathy, thrombocytopenia\\n➣ Esophageal varices: discuss need for gastric tube and/orTEE\\nLung Tx\\n■Ifpoor graft function or single-lung transplant, possible need\\nfor postop ventilation\\nwake up and emergence\\n■Delayed awakening or recovery from neuromuscular block-\\nade because of decreased elimination of drugs or metabolites\\n■Extubate when fully awake.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 357}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n344 Patient with a Transplant Pheochromocytoma\\nicu or pacu\\nInfections in the transplant recipient\\n■First month: nosocomial infections due to the same organisms(bacteria & fungi) as in immunocompetent surgical pts\\n■1–6 months: viral & opportunistic infections (eg, Pneumocystis\\ncarinii)\\n■After 6 months: pts on high-dose immunosuppressants areexposed to opportunistic infections\\n➣ Listeria monocytogenes (meningitis)\\n➣ Pneumocystis carinii (pneumonia)\\n➣ Cryptococcus neoformans (encephalitis)\\n➣ Aspergillus, Candida (pneumonia or disseminated dis-ease)\\n➣ CMV (hepatitis, pneumonitis, enterocolitis & glomeru-lonephritis)\\n■Blunted signs of infection; therefore, consider periodic routinecultures\\n■Meticulous attention to drug interactions (eg, cyclosporineabsorption decreased by sucralfate, allopurinol in combina-tion w/ azathioprine can trigger severe leukopenia)\\n■GI prophylaxis for pts on steroids, esp. if other risk factors (eg,mechanical ventilation, coagulation disorder)\\n■Continue immunosuppressive treatment.\\n■Risk of critical illness myopathy in pts necessitating prolongedneuromuscular blockade & receiving steroids\\nPHEOCHROMOCYTOMA\\nGIUDITTA ANGELINI, MD\\nscreening and evaluation\\n■The following are serum screening tests for pheochromo-cytoma:\\n➣ 2,000 pg/mL plasma catecholamines'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 358}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nPheochromocytoma 345\\n➣>1,200 mcg urine catecholamines\\n➣>100 mcg urine norepinephrine\\n➣>1mcg urine epinephrine\\n➣>2.5 mg urine metanephrines\\n➣>10 mg urine vanillylmandelic acid\\n➣ Notsuppressed by clonidine\\n➣ Metanephrines most sensitive\\n■MRI scan most helpful for extra-adrenal locations & pregnantpts\\n■CT w/ I-131-labeled metaiodobenzyl guanidine extremelyaccurate\\n■Arteriography can stimulate catecholamine release & shouldbe used w/ extreme care.\\npreoperative preparation\\n■Preop optimization w/ alpha blockers & intravascular volume\\nexpansion has reduced perioperative mortality from 45% to0–3%.\\n■Alpha blockers\\n➣ Phenoxybenzamine orally for up to 10–14 days before\\nsurgery\\n➣ Commence at 10–40 mg BID, but many need 80–200\\nmg/day.\\n➣ Increase dose to control BP & paroxysms.\\n➣ Irreversible binding of alpha receptors (presynaptic alpha-\\n2&postsynaptic alpha-1)\\n➣ Long-acting (24–48 hrs)\\n➣ Side effects: orthostatic hypotension, reﬂex tachycardia\\n➣ Prazosin 2–5 mg BID orally before surgery\\n➣ Competitive postsynaptic alpha-1 blocker\\n➣ Maybeused alone or in addition to phenoxybenzamine\\nfor hemodynamic stability\\n➣ Continue preoperative alpha blockers up to day of surgery.\\n➣ Phentolamine often used intraoperatively'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 359}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n346 Pheochromocytoma\\n■Beta blockers\\n➣ Used if tachycardia persists or arrhythmia develops w/\\nalpha blocker therapy\\n➣ Use only after alpha blockade has been initiated (to avoid\\nunopposed alpha agonism).\\n■Preoperative hypertensive crises\\n➣ Managed w/ additional phentolamine, nitroprusside orfenoldopam\\n■Alpha-methyl tyrosine (inhibits tyrosine hydroxylase) maybe used if surgery contraindicated or in the presence ofmetastatic disease.\\n➣ Used in combination w/ alpha blockade\\n■Magnesium\\n■ACE inhibitors\\n■Calcium channel blockers\\n■Preop hydration crucial to allow intravascular volume expan-\\nsion as the alpha blockade is introduced\\noperative preparation\\n■Avoid:\\n➣ Droperidol (due to inhibition of catecholamine reup-\\ntake)\\n➣ Atropine (exacerbates chronotropic effects of epine-\\nphrine)\\n➣ Morphine, curare, atracurium (associated w/ histaminerelease)\\n➣ Pancuronium, ketamine, ephedrine (indirectly stimulatecatecholamine)\\n➣ Halothane (myocardial irritability in the presence of highlevels of catecholamines)\\n■Monitoring\\n➣ V5 lead ECG, temperature, pulse oximetry, ETCO 2,a rterial\\nline, central line, urine catheter, PA catheter if myocardialdysfunction severe'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 360}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nPheochromocytoma 347\\nanesthesia\\n■Anesthetic\\n➣ Most agents not listed above to avoid can be used.\\n➣ Halothane may be avoided due to sensitization of\\nmyocardium to catecholamines.\\n➣ Desﬂurane has been shown to be safe despite increase in\\nsympathetic stimulation.\\n➣ Regional anesthesia can be used but will likely not control\\nepisodic hypertension.\\n■Controlling catecholamine release\\n➣ Nitroprusside 1–8 mcg/kg/min IV\\n➣ Phentolamine 1–5 mg IV q5min or 1 mg/min continuous\\ninfusion\\n➣ Labetalol 10–20 mg IV q10min to max 200 mg\\n➣ Esmolol 10–20 mg IV q10min or 50–300 mcg/kg/min con-tinuous\\n➣ Hydralazine 10 mg IV q30min to max 40 mg\\n➣ Magnesium sulfat e2gI Vu pt o6g w/out renal failure\\n■Hemodynamics after tumor removal\\n➣ Hypotension common\\n➣ Fluid hydration\\n➣ Norepinephrine infusion may be required.\\n■Pregnancy\\n➣ Magnesium particularly helpful in this group\\nwake up & emergence\\nN/A\\nicu or pacu\\n■Increased sensitivity to narcotics after tumor removal\\n■Hypoglycemia is possible & should be monitored.\\n■Catecholamine levels do not decrease for several days after\\nsurgery.\\n■Ifhypertension continues, there may be residual pheochro-\\nmocytoma.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 361}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n348 Platelet Disorders\\nPLATELET DISORDERS\\nKARL WILLMANN, MD\\nscreening and evaluation\\n■Hematology consult is necessary. Discontinue drugs & ther-apies that have a negative impact on platelet count & func-tion.\\n■Coagulation studies, including PTT, PT, ﬁbrinogen, plateletcount & thromoboelastogram\\npreoperative preparation\\n■Have platelets available if appropriate for treatment.\\n■Ifanticoagulation needed in the presence of HIT, use direct\\nthrombin inhibitor (eg, agatroban). Avoid all heparin prepa-rations.\\n■Inthe presence of uremia-induced platelet dysfunction, con-\\nsider DDAVP (0.3 mcg/kg IV) to improve platelet function.\\noperative preparation\\nN/A\\nanesthesia\\n■Induction\\n➣ Gentle laryngoscopy to avoid trauma & bleeding\\n➣ Avoid nasal intubation.\\n■Maintenance\\n➣ Regional anesthesia is relatively contraindicated in pts w/\\nbleeding diathesis.\\n➣ Minimize/avoid hypothermia (increases sequestration).\\nwake up and emergence\\n■Avoid coughing & bucking on endotracheal tube, leading to\\nbleeding.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 362}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nPlatelet Disorders Polycythemia 349\\nicu or pacu\\n■Continued monitoring of coagulation status; prompt treat-\\nment of platelet-related bleeding\\n■Rewarm to normothermia to aid platelet function.\\nPOLYCYTHEMIA\\nKARL WILLMANN, MD, AND DOUGLAS B. COURSIN, MD\\nscreening and evaluation\\n■Hct, Hgb, platelets, LFTs\\npreoperative preparation\\n■Control Hct for all elective surgery. Pts usually have been\\nundergoing phlebotomy to keep Hct values near normal.This should be continued. Hct near 46% is considered ade-quate.\\n■Have platelets available if bleeding is encountered.\\noperative preparation\\n■Take steps to reduce deep venous thrombosis during surgery,\\nsuch as applying sequential compression stockings or appro-priate anticoagulant prophylaxis.\\nanesthesia\\n■Nospeciﬁc concerns\\nwake up and emergence\\n■Nospeciﬁc concerns\\nicu or pacu\\n■Nospeciﬁc concerns other than the possibility of thrombosis\\n&bleeding issues'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 363}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n350 Psychiatric Disorders\\nPSYCHIATRIC DISORDERS\\nJONATHAN T. KETZLER, MD\\nscreening and evaluation\\n■Depression\\n➣ Investigate use of OTC meds such as St. John’s wort.\\n➣ Tricyclic antidepressants\\nrUsually continued through perioperative period\\n➣ MAOIs\\nrInthe past were discontinued 2 wks before surgery to\\nallow regeneration of enzymes irreversibly inhibited byMAO inhibitors\\nrBut because patients on MAOIs usually have severe\\nor refractory depression, continuing them through theperioperative period may be warranted on an individ-ualized basis; this is still controversial.\\nrIfMAOIs are continued, keep drug/drug interactions in\\nmind.\\n■Mania\\n➣ Lithium\\nrGreatest concern is perioperative toxicity.\\nrCheck serum lithium levels & electrolytes preopera-tively.\\nrLow serum sodium decreases renal excretion oflithium & can lead to toxicity.\\nrThere is no evidence that sodium loading is beneﬁcial.\\n■Schizophrenia\\n➣ Ptswell controlled on meds usually pose few problems.\\n➣ Continue meds through the perioperative period.\\npreop preparation\\nN/A'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 364}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nPsychiatric Disorders 351\\noperative preparation\\nN/A\\nanesthesia\\n■Depression\\n➣ Electroconvulsive therapy is being used more often forsevere or refractory depression, primarily due to the safetyadded with general anesthesia.\\nrTricyclic antidepressants\\nrMayincrease anesthetic requirements secondary to\\nenhanced brain catecholamine activity\\nrCentrally acting anticholinergic agents may be poten-\\ntiated, leading to postop confusion & delirium.\\nrResponse to both indirect-acting vasopressors & sym-\\npathomimetic agents may be enhanced.\\nrUsecaution when administering drugs such as pan-\\ncuronium, ketamine, meperidine & epinephrinecontaining local anesthetics.\\nrChronic use of tricyclic antidepressants may depletecardiac catecholamines, potentiating the myocardialdepressant effect of anesthetics.\\nrInthe face of hypotension, use small doses of direct-\\nacting vasopressors.\\nrMAOIs\\nrPhenelzine may decrease levels of plasma choli-\\nnesterase, prolonging the duration of succinylcho-line.\\nrUseofmeperidine in pts on MAOIs may result in\\nhyperthermia & seizures.\\nrMAOIs may exaggerate response to indirect-actingvasopressors & sympathomimetics.\\nrUsecaution when administering drugs such as pan-\\ncuronium, ketamine, meperidine & epinephrinecontaining local anesthetics.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 365}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n352 Psychiatric Disorders Restrictive Lung Disease\\nrInthe face of hypotension, use small doses of direct-\\nacting vasopressors.\\n■Mania\\n➣ Lithium\\nrLithium toxicity may cause confusion, sedation, muscleweakness, tremor & slurred speech.\\nrHigher concentrations may cause widening of theQRS complex, atrioventricular block, hypotension &seizures.\\nrFluid restriction & overdiuresis may lead to lithium tox-\\nicity.\\nrLithium may decrease minimum alveolar concentra-tion.\\nrLithium may prolong duration of neuromuscular block-ing agents.\\n■Schizophrenia\\n➣ Well-medicated pts may require less anesthetic.\\n➣ Antipsychotics may reduce the seizure threshold.\\nwake up & emergence\\nN/A\\nicu or pacu\\nN/A\\nRESTRICTIVE LUNG DISEASE\\nHUGH R. PLAYFORD, MBBS\\nscreening and evaluation\\n■Assess for severity of disease & any reversible components(esp. infection).\\n■Aside from the history & exam, consider chest x-ray, PFTs,ABGs, sputum culture & sensitivity.\\n■Identify & eradicate acute bacterial infection w/ antibiotics &physical therapy.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 366}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nRestrictive Lung Disease 353\\n■Optimize nutritional state for good muscular strength w/out\\noverfeeding-induced nutrition.\\n■Cease smoking.\\n■Most pts should have pneumococcal vaccine & yearly\\ninﬂuenza vaccines.\\n■Assess pt for chronic steroid usage (will need perioperativecoverage).\\n■Treat any cardiac dysfunction.\\n■Train pt in postop respiratory therapy techniques.\\npreoperative preparation\\n■Eradicate any pulmonary infection.\\n■Optimize pulmonary therapy.\\n■Consider physical therapy & nutrition.\\n■Ptsareat increased risk of developing acute respiratory failure\\nduring postop period.\\n■Plan intraoperative technique (regional, general, combined)\\n&postop analgesic regimen to have minimal pulmonary detri-\\nment.\\noperative preparation\\n■Antibiotics if needed\\n■Inﬂuenza vaccination\\n■Diuresis for cor pulmonale & right heart failure\\n■Supplemental oxygen titrated to pt’s needs\\n■Physical training programs\\nanesthesia\\n■Regional anesthesia\\n➣ Potentially avoids respiratory depressant effects of seda-\\ntive drugs\\n➣ Avoid regional techniques that provide sensory anesthe-\\nsia above T6 to T10 (may decrease expiratory reservevolume & impair effectiveness to cough & clear secre-tions).'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 367}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n354 Restrictive Lung Disease\\n■General anesthesia\\n➣ Volatile anesthesia allows humidiﬁcation, anesthesiadelivery w/ a relatively rapid onset & offset, blunting ofairway reﬂexes & reﬂex bronchospasm, & volatile-inducedbronchodilatation.\\n➣ Volatile anesthesia also attenuates regional hypoxic pul-monary vasoconstriction, leading to increased right-to-left intrapulmonary shunting.\\n➣ Nitrous oxide techniques limit the FiO2 that can be deliv-ered.\\n➣ Opioids may lead to prolonged respiratory depression; usejudiciously.\\n➣ Humidiﬁcation is used to prevent drying of secretions in\\nthe airways.\\n■Ifintubation is necessary, goals are:\\n➣ Adequate arterial oxygenation\\n➣ Avoiding ventilator-induced lung injury (barotrauma,\\nvolutrauma)\\nrVentilate w/ a similar technique to protective lung ven-\\ntilation for pts w/ ARDS.\\nrTidal volumes of 6–7 mL/kg, respiratory rate of 20–30\\nbreaths/min to achieve airway plateau pressures of <35\\ncm H 2O\\nrMay need modiﬁcation if hypercapnia of concern\\n(depresses myocardial function, increases intracranialpressure)\\nwake up and emergence\\n■Principles are to have the pt well analgesed w/ good effec-\\ntive cough & deep inspiration w/out any residual respiratorydepression.\\n■Extubation\\n➣ Ideally, extubate at the end of the surgical procedure(depends on procedure & duration of anesthesia).'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 368}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\nRestrictive Lung Disease 355\\n➣ Tracheal tube increases airway resistance & risk of reﬂex\\nbronchoconstriction, limits the pt’s ability to clear secre-tions effectively & increases the risk of iatrogenic infection.\\n■Analgesia\\n➣ Regional techniques using local anesthesia and/or neu-\\nraxial opioids may be able to avoid signiﬁcant respiratory\\ndepression.\\n➣ Neuraxial local anesthesia may lead to postural hypoten-\\nsion & interfere w/ postop ambulation & sputum clearance&incentive spirometry.\\n➣ Pt-controlled analgesia w/ systemic opioids may also min-\\nimize the risk of signiﬁcant respiratory depression.\\n➣ With any route of opioid, however, potent respiratory\\ndepression may develop; epidural opioids may depressventilation up to 12 hrs after administration.\\n➣ Consider other nonrespiratory depressing analgesics as\\nadjunctive agents (acetaminophen, alpha-2 agonists suchas clonidine and dexmedetomidine, NSAIDs).\\n■Chest physical therapy & incentive spirometry\\nicu or pacu\\n■Continued intubation & ventilation in the postop period may\\nbe necessary in pts after major upper abdominal or thoracicsurgery.\\n■Discontinuation of ventilation is based on the pt’s clinical\\ncondition (preexisting pulmonary impairment, surgical pro-cedure, duration of anesthesia) as well as indices of respiratoryfunction.\\n➣ The changes in pulmonary function that occur postop areprimarily restrictive; these changes added to preexistingrestrictive lung disease may be catastrophic in the indi-\\nvidual pt.\\n➣ Proportional decreases in all lung volumes; no change in\\nairway resistance'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 369}, page_content='P1: IBE0521759385P1secA3 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:56\\n356 Restrictive Lung Disease Rheumatoid Arthritis\\n➣ FRC decreases from decreased abdominal excursion (eg,from abdominal operations), abnormal postop respira-tory pattern (shallow, rapid breaths).\\n➣ Operative site is the most important factor.\\n➣ Non-laparoscopic upper abdominal operations decreaseFRC by 40–50% >lower abdominal & thoracic operations\\ndecrease FRC by 30% >other operative sites decrease FRC\\nby15–20%.\\nRHEUMATOID ARTHRITIS\\nROBERT N. SLADEN, MD\\nscreening and evaluation\\n■Signs of general debility\\n➣ Mild, moderate or severe (important impact on overall\\nplanning)\\n➣ Fixed deformities\\n➣ Major joint deformity (knees, hips, wrists)\\n➣ Poor nutritional status\\n■Airway exam\\n➣ Jaw opening (temporomandibular joint)\\n➣ Neck mobility (atlantoaxial joint, odontoid process)\\n➣ Fixed ﬂexion deformity of neck\\n■Signs of steroid therapy\\n➣ Muscle wasting, poor skin turgor, ecchymoses\\n➣ Cushing’s syndrome (includes hypertension, hyper-glycemia)\\n■Relevant lab studies\\n➣ Hct, CBC\\n➣ Electrolytes (total CO 2if ABG impracticable)\\n➣ Blood sugar\\n➣ BUN, creatinine\\n➣ LFTs'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 370}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nRheumatoid Arthritis 357\\n➣ ECG, chest x-ray\\n➣ PFTs & ABGs (if restrictive lung disease suspected)\\npreoperative preparation\\n■Discontinue aspirin & NSAIDs prior to major surgery\\n➣ Aspirin: 7 days prior to surgery\\n➣ NSAIDs: 24 hrs prior to surgery\\n➣ Evaluate risk-beneﬁt of analgesia vs. increased bleeding\\nrisk.\\n■Adrenal support for major surgery, stress\\n➣ Start hydrocortisone 100 mg IV q8h, taper over next 24–72\\nhrs.\\n■Anticipate dehydration (severe disease)\\n➣ Establish venous access & provide judicious rehydra-tion.\\n➣ Anticipate difﬁcult airway\\nrDiscuss possible awake tracheal intubation w/ pt.\\nrPrepare difﬁcult airway cart.\\noperative preparation\\n■Aspiration prophylaxis (anticipate difﬁcult tracheal intuba-tion)\\n➣ Anticholinergic agent (glycopyrrolate preferred)\\n➣ H2blocker (famotidine preferred)\\n➣ Metoclopramide\\n➣ Sodium bicitrate\\n■Useuniversal & aseptic precautions throughout (steroid,\\nimmunosuppressive therapy).\\n■Anticipate difﬁcult access\\n➣ Peripheral IV, arterial line, IJ difﬁcult w/ severe deformity\\n■Careful positioning\\n➣ Fragile skin, easy bruising\\n➣ Support & protect all affected joints w/ soft material.\\n➣ Severe deformity may render normal positioning impos-\\nsible.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 371}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n358 Rheumatoid Arthritis\\n■Use active warming devices to prevent hypothermia\\n➣ Forced-air convection blanket\\nanesthesia\\n■Regional anesthesia\\n➣ Notp recluded by aspirin, NSAIDs\\n➣ Mayb eimpossible in presence of severe deformity\\n➣ Difﬁcult airway is not a sole indication for regional anes-thesia.\\n➣ Mayb efaced w/ emergency intubation in total spinal\\n■General anesthesia\\n➣ Anticipate difﬁcult airway.\\n➣ Notify surgeon to be present, tracheotomy backup.\\n■Anesthetic induction for difﬁcult airway\\n➣ Awake ﬁberoptic intubation preferred\\n➣ Ifnot tolerated, consider inhalation induction w/ sponta-\\nneous breathing, then attempt ﬁberoptic intubation.\\n➣ Ifunsuccessful, place intubating LMA, then attempt tra-\\ncheal intubation via LMA.\\n➣ Ifunsuccessful, proceed w/ tracheotomy.\\n➣ Restrictive lung disease\\nrAvoid excessive tidal volumes.\\nrMayrequire rapid, shallow ventilation\\nwake up and emergence\\n■Careful planning for anesthetic emergence\\n➣ Iftracheal intubation was difﬁcult, do not extubate until\\npt is completely awake.\\n➣ Ifin doubt, plan transient postop ventilation until airway\\nprotection is ensured.\\n➣ Consider dexmedetomidine infusion (0.2–0.4 mcg/kg/hr)\\nrProvides endotracheal tube tolerance, analgesia &\\nanxiolysis w/out respiratory depression\\nrAllows careful assessment of airway & ability to meetextubation criteria'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 372}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nRheumatoid Arthritis Scleroderma 359\\n■Potential complications on emergence\\n➣ Vomiting, aspiration\\n➣ Airway obstruction\\n➣ Respiratory depression\\n➣ Acute respiratory failure\\nicu and pacu\\n■Consider short period of postop mechanical ventilation (see\\nabove).\\n➣ Anticipate postop complications\\nrAirway obstruction\\nrHyperglycemia, hypertension (Cushing’s syndrome)\\nrAcute respiratory failure\\nrSepsis, wound dehiscence\\nrAnemia\\n■Postop meds\\n➣ Defer antiplatelet agents until no further risk of bleeding.\\n➣ Provide GI prophylaxis (H 2blocker, proton pump\\ninhibitor).\\n➣ Steroid taper over 24–72 hrs to maintenance dose\\n➣ Resume preop meds as soon as possible.\\nSCLERODERMA\\nARTHUR ATCHABAHIAN, MD\\nscreening and evaluation\\n■Evaluate potential for difﬁcult intubation because of retrac-\\ntion of soft tissues around mouth & TMJ stiffness.\\n■BUN&c reatinine to assess renal function\\n■PFTs to determine severity of restrictive disease\\n■EKG to assess dysrhythmias or conduction abnormalities\\n■Consider echocardiography for assessment of ventricular\\nfunction, pericardial effusion & pulmonary artery pressures.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 373}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n360 Scleroderma\\n■PT (INR) to rule out coagulation disorder\\npreoperative preparation\\n■ACE inhibitors may improve renal insufﬁciency or slow pro-\\ngression.\\n■Broad-spectrum antibiotics & vitamin K to treat coagulation\\ndisorder due to malabsorption & bacterial overgrowth\\noperative preparation\\n■Consider anti-H 21–2 hrs preop.\\n■Administer non-particulate antacid (Bicitra) just before enter-ing OR.\\n■Keep operating temperature high to prevent vasoconstriction.\\nanesthesia\\n■Difﬁcult IV access because of skin thickening\\n➣ Central venous catheterization might be needed.\\n■Consider awake ﬁberoptic intubation, possibly nasal, if mouthopening is very limited.\\n■Oral or nasal telangiectasias\\n➣ Insert ETT & NGT w/ care.\\n■Vasoconstriction may interfere w/ pulse oximetry & NIBPmonitoring.\\n➣ Consider digital block to improve blood ﬂow.\\n➣ Use Doppler for BP.\\n➣ Arterial catheterization can induce severe spasm.\\n■Beta blockers & ergot alkaloids can precipitate severe Ray-\\nnaud’s phenomenon.\\n➣ Weigh beneﬁt & risks.\\n■Contracted intravascular compartment w/ severe hypoten-\\nsion on induction\\n■Pulmonary ﬁbrosis can make ventilation difﬁcult w/ high\\nairway pressures.\\n➣ Do not use spontaneous ventilation w/ general anesthesia.\\n■Avoid nitrous oxide if possible because of its pulmonary vaso-\\nconstrictive effect.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 374}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nScleroderma Sickle Cell Disease 361\\n■Limit opioid use because of effect on gut motility & respira-tions.\\n■Protect eyes.\\n■Consider renal function when choosing anesthetic agents.\\n■Prolonged effects of local anesthetics have been described.\\n➣ Regional anesthesia may be difﬁcult because of skin & joint\\nabnormalities.\\n■WarmIV ﬂuids & use warming blanket to prevent vasocon-\\nstriction.\\nwakeup and emergence\\n■Possible delayed emergence because of higher sensitivity to\\nopioids\\n■Postop ventilation may be indicated.\\nicu or pacu\\n■Consider postop ventilation because of pulmonary ﬁbrosis.\\n■Usedecreased doses of opioids because of effect on gut motil-\\nity & higher sensitivity.\\n■Prevent or treat hypothermia.\\n■Monitoring issues as above due to vasoconstriction\\n■Skin ulcerates easily, heals poorly & is at higher risk for infec-\\ntion because of poor blood ﬂow.\\n■Elevate head of bed by 30 degrees to prevent reﬂux & aspira-tion.\\n■Carefully follow renal function.\\nSICKLE CELL DISEASE\\nARTHUR ATCHABAHIAN, MD\\nscreening and evaluation\\n■Obtain CBC to assess anemia.\\n■Evaluate renal function (BUN, creatinine).\\n■Evaluate hepatic function (PT, bilirubin).'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 375}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n362 Sickle Cell Disease\\n■Consider echocardiogram to evaluate ventricular function.\\n■Chest x-ray & ABGs to assess pulmonary involvement\\npreoperative preparation\\n■Consider partial exchange transfusion\\n➣ Remove 15 mL/kg whole blood.\\n➣ Replace w/ 20 mL/kg RBCs to bring HbA to at least 40%.\\n➣ Depends on severity of anemia & type of surgery\\n➣ Risks of transfusion include bone marrow depression &hyperviscosity.\\n■Admit 1 day preop to ensure adequate IV hydration.\\noperative preparation\\n■Warmup operating room.\\n■Place warming blanket on pt as soon as possible.\\n■Warmall IV ﬂuid.\\nanesthesia\\n■CPB poses a special threat:\\n➣ Consider using high blood ﬂow & normothermia.\\n■Meticulous attention to avoiding hypothermia\\n➣ Warmup room.\\n➣ Uselowfresh gas ﬂows & heat/moisture exchanger.\\n➣ WarmIV ﬂuids\\n➣ Use warming blanket on pt.\\n■Meticulous attention to avoiding hypoxemia, acidosis & low\\nperipheral blood ﬂow\\n➣ Maintain hemodynamic stability.\\n➣ Maintain adequate hydration.\\n➣ Pay special attention to positioning.\\n➣ Consider using mixed venous oxygen saturation monitor-\\ning to guide therapy.\\n■Administration of bicarbonate is controversial & should notbe routine.\\n■Do not use orthopedic tourniquet.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 376}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nSickle Cell Disease Spinal Cord Injury 363\\n■Usep rudence w/ succinylcholine (reports of decreased\\nplasma cholinesterase activity).\\n■Central neuraxial blockade\\n➣ Compensatory vasoconstriction in nonblocked areas w/\\npossible sickling\\n➣ Maintains pulmonary function\\n➣ Decreases blood loss & incidence of thromboembolic\\nevents\\nwake up and emergence\\n■Treat pain aggressively.\\n■Meticulously prevent or treat hypoxemia & acidosis.\\nicu or pacu\\n■Treat pain aggressively w/ major analgesics.\\n■Chest physiotherapy to prevent pulmonary infections\\n■Early ambulation\\n■Administer supplemental oxygen for several days.\\n■Maintain intravascular ﬂuid status & body temperature.\\nSPINAL CORD INJURY\\nHUGH R. PLAYFORD, MBBS, AND GEBHARD WAGENER, MD\\nscreening and evaluation\\n■Neurologic\\n➣ Document neurologic deﬁcits.\\n■Cardiovascular\\n➣ Acute injury associated w/ hypotension, bradycardia,\\nhypovolemia related to other injuries\\n➣ Chronic injury related to risk of mass reﬂex\\n■Respiratory\\n➣ Poor respiratory reserve'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 377}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n364 Spinal Cord Injury\\n➣ Ptmay have a chronic respiratory acidosis related to\\nchronic hypoventilation.\\n➣ Hypoxia & widened arterial-alveolar gradient related to\\npulmonary collapse/atelectasis\\n➣ Consider PFTs, ABGs, chest x-ray.\\n■Electrolytes\\n➣ Hyponatremia, acutely\\n➣ Hypercalcemia, chronically\\n■Hematologic\\n➣ Acute injury: anemia usually related to other injuries\\n➣ Chronic injury: coagulopathy related to exogenous anti-coagulants\\npreoperative preparation\\n■Premeds (narcotics, sedatives) need to be titrated carefully in a\\nmonitored setting (OR) because of the risk of hypoventilation.\\n■Use care w/ premeds in acute injury that may impair neuro-\\nlogic exam.\\n■Atropine may counteract the vagal effects of some agents used\\nduring anesthesia.\\n■Ifar egional technique is considered, a rigorous neurologic\\nexam is needed to accurately deﬁne the neurologic deﬁcit.\\noperative preparation\\n■Monitoring\\n➣ Acute injury: Invasive hemodynamic monitoring may be\\nneeded, depending on the severity of the injury, otherinjuries & the invasiveness of the surgery. SSEP may beimportant for spinal stabilization & decompression pro-cedures.\\n➣ Chronic injury: Monitoring depends on the pt’s state & theinvasiveness of the surgery.\\n■Positioning & transportation\\n➣ Pay careful attention to these in both acute & chronic\\ninjury.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 378}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nSpinal Cord Injury 365\\n➣ Acute injury: Position pt awake to avoid exacerbating\\nspinal cord injury. Reverse Trendelenburg & similar posi-tions may have signiﬁcant adverse hemodynamic conse-quences.\\n➣ Chronic injury: Be aware of contractures, pressure points&existing pressure sores.\\n■Fasting\\n➣ Acute injury: Consider to be a “full stomach” secondary\\nto gastric atony, supine positioning, paralyzed abdominalmuscles & gastric tube.\\n■Attempt to have pt awake, able to be neurologically assessed,\\nwell analgesed & w/ minimal respiratory depression at con-\\nclusion of anesthesia.\\nanesthesia\\n■Succinylcholine is contraindicated in the presence of spinal\\ncord injury.\\n➣ Hyperkalemic response is related to the extrajunctional\\ncholinergic receptor proliferation of denervated muscle.\\n➣ Develops within 1 day & lasts up to 9 months after injury\\n➣ Degree of hyperkalemia is proportional to the amount of\\nmuscle involved (not the dose of succinylcholine).\\n■Cricoid pressure must be applied cautiously (but effectively)\\nin pts w/ unstable cervical & upper thoracic spinal cord injury.\\n■Longitudinal neck stabilization is required throughout intu-bation.\\n■Method of intubation\\n➣ Depends on pt’s condition, degree of neurologic injury,\\npreference & experience of anesthesiologist, & whetherthe injury is acute or chronic\\n■Temperature regulation\\n➣ Lesions above T1 may interfere w/ thermoregulation; esp.in the presence of anesthesia, pt may become poikilo-thermic.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 379}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n366 Spinal Cord Injury Stroke\\nwake up and emergence\\n■Extubate when pt meets extubation criteria, is awake & inter-active, is able to cough & has minimal pulmonary secretions.\\n■Careful monitoring of respiratory status\\n➣ Ptwill need intense physiotherapy to mobilize pulmonary\\nsecretions in the postop period.\\n■Careful neurologic assessment for operatively related neural\\ndeterioration\\nicu or pacu\\n■Respiratory support may need to be continued into the postopperiod.\\n■Avoid signiﬁcant postop respiratory depression w/ residual\\nanesthesia/sedation or analgesia.\\nSTROKE\\nGEBHARD WAGENER, MD\\nscreening and evaluation\\nPtsw /stroke:\\n■Avoid elective surgery at least 6 wks after stroke.\\n■Autoregulation, CO 2responsiveness & blood-brain barrier\\nabnormalities may persist for wks.\\n■Cardiac evaluation recommended for high-risk surgery:\\npotential for concomitant coronary artery disease\\n■Coagulation proﬁle, platelet count: hypercoagulable?\\n■BUN/creatinine, hematocrit: dehydration?\\n■Creatinine: renal vascular disease\\n■Glucose: avoid hyperglycemia\\n■pH, pCO 2: maintain moderate hypocarbia\\nToprevent perioperative stroke:\\n■Evaluate risk factors\\n■Ifhigh risk, pt will require:'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 380}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nStroke 367\\n➣ Cardiac evaluation: stress test, echocardiogram\\n■Assess:\\n➣ Baseline BP\\n➣ Degree of carotid stenosis\\npreoperative preparation\\nPtsw/stroke:\\n■Adequate hydration: start IV maintenance ﬂuid when NPO\\n■Assess & document neurologic deﬁcits.\\noperative preparation\\nN/A\\nanesthesia\\nForcarotid endarterectomy (CEA)\\n■Nobeneﬁt of awake CEA vs. general anesthesia w/ EEG mon-\\nitoring vs. SSEP vs. transcranial Doppler: stroke more likelyembolic than ischemic\\n■General placement of shunt or measurement of stump pres-sure alone not beneﬁcial\\n■Regional anesthesia:\\n➣ Advantage: more sensitive, no specialized knowledge nec-\\nessary\\n➣ Disadvantage: higher cerebral metabolic rate in awake\\nstate, pt cooperation essential\\n■IfEEG used:\\n➣ Get reliable baseline EEG.\\n➣ Maintain even levels of anesthesia to evaluate changes in\\nEEG.\\n➣ Maintain blood pressure 30–50% above baseline during\\nclamping of the carotid artery.\\n➣ Useshort-acting anesthetics allowing rapid postop\\nrecovery.\\n■Experience of anesthesiologist & center should determine\\ntechnique.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 381}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n368 Stroke\\n■Surgical manipulation of carotid sinus can cause bradycardia.\\nToprevent perioperative stroke:\\n■There is no evidence that regional anesthesia is beneﬁcial inpreventing perioperative stroke.\\n■Avoid manipulation of neck & extreme neck rotation/\\nﬂexion/extension w/ carotid disease.\\n■Settarget and acceptable BP range; treat any BP outside the\\nacceptable range.\\n■Maintain BP at least as high as baseline pressure in high-risk pts.\\n■Regional anesthesia may allow monitoring of mental status &detection of new strokes during surgery.\\nwake up and emergence\\nPtsw /stroke:\\nAfter general anesthesia:\\n■Wake up may be delayed\\n■Previously restored neurologic deﬁcits may reappear tem-\\nporarily in the immediate postop period.\\nToprevent perioperative stroke:\\n■Avoid hypotension & severe hypertension during emer-\\ngence.\\n■Hypertension may cause hemorrhagic conversion of an\\nischemic stroke.\\n➣ Ifanew stroke is suspected:\\nrKeep pt endotracheally intubated.\\nrElevate head 30 degrees to decrease intracranial pres-sure.\\nrIncrease BP to maintain CPP.\\nrObtain immediate head CT scan.\\nrConsider early (<3 hrs after stroke) angiogram & angio-plasty.\\nicu or pacu\\nPtsw /stroke:'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 382}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nStroke Subacute Bacterial Endocarditis Prophylaxis 369\\n■Admit to ICU.\\nAfter CEA:\\n■ICU preferable\\n■Observe for 24 hrs.\\n■Likely require invasive BP monitoring & aggressive control\\n■Rule out myocardial infarction.\\nSUBACUTE BACTERIAL ENDOCARDITIS PROPHYLAXIS\\nJONATHAN T. KETZLER, MD\\nscreening & evaluation\\nN/A\\npreoperative preparation\\nTreatment Recommendations for Common Invasive\\nProcedures\\nDental procedures\\n■Endocarditis prophylaxis recommended\\n➣ Dental extractions\\n➣ Periodontal procedures\\n➣ Dental implant placement & reimplantation of avulsed\\nteeth\\n➣ Root canal instrumentation\\n➣ Prophylactic cleaning of teeth or implants where bleeding\\nis anticipated\\n■Endocarditis prophylaxis not recommended\\n➣ Restorative dentistry\\n➣ Local anesthetic injections (non-intraligamentary)\\n➣ Intracanal endodontic treatment; postplacement &\\nbuildup\\n➣ Placement of rubber dams\\n➣ Postop suture removal'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 383}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n370 Subacute Bacterial Endocarditis Prophylaxis\\n➣ Placement of removal prosthodontic or orthodontic appli-ances\\n➣ Taking of oral impressions\\n➣ Fluoride treatments\\n➣ Taking of oral radiographs\\n➣ Orthodontic appliance adjustment\\n➣ Shedding of primary teeth\\nOral, respiratory, esophageal, other procedures\\n■Endocarditis prophylaxis recommended\\n➣ Tonsillectomy or adenoidectomy\\n➣ Surgical operations involving respiratory mucosa\\n➣ Rigid bronchoscopy\\n➣ Flexible bronchoscopy w/ biopsy\\n■Endocarditis prophylaxis not recommended\\n➣ Endotracheal intubation\\n➣ Flexible bronchoscopy (w/out biopsy)\\n➣ Tympanostomy tube insertion/removal\\n➣ Transesophageal echocardiography\\n➣ Cardiac catheterization including device placement\\n➣ Skin biopsy\\nGastrointestinal, genitourinary procedures\\n■Endocarditis prophylaxis recommended\\n➣ Biliary tract surgery\\n➣ Surgical operations involving intestinal mucosa\\n➣ Cystoscopy\\n➣ Urethral dilation\\n■Endocarditis prophylaxis not recommended\\n➣ GI endoscopy w/out biopsy\\n➣ Vaginal delivery\\n➣ Cesarean section\\n➣ Urinary catheterization w/out infection\\n➣ Circumcision'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 384}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nSubacute Bacterial Endocarditis Prophylaxis SLE 371\\noperative preparation\\nN/A\\nanesthesia\\nN/A\\nwake up & emergence\\nN/A\\nicu or pacu\\nN/A\\nSYSTEMIC LUPUS ERYTHEMATOSUS\\nARTHUR ATCHABAHIAN, MD\\nscreening and evaluation\\n■Assess renal function w/ BUN & creatinine; look for recentchange.\\n■Hct, white cell & platelet count to rule out anemia, leukopenia&thrombocytopenia\\n■Chest x-ray & EKG; consider echocardiogram, depending onclinical presentation\\npreoperative preparation\\n■Continue all meds until day of surgery.\\noperative preparation\\n■Unremarkable\\nanesthesia\\n■Noincreased risk of exacerbation, even w/ meds known to\\ninduce lupus\\n■Consider administering stress-dose steroids.\\n■Consider renal function in choice of anesthetic agents.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 385}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n372 SLE Thalassemia\\n■Nocorrelation between lab tests & risk of bleeding. Rely on\\nclinical exam (bruising, petechiae) to assess risk of centralneuraxial block.\\n■Possible difﬁcult mask ﬁt if prominent nasal & malar cuta-neous lesions\\n■Rare reports of cricoarytenoid arthritis w/ narrowed airway\\n■Ventilation can be difﬁcult if restrictive disease.\\n■Consider antibiotic prophylaxis for bacterial endocarditis.\\n■Consider DVT prophylaxis if prolonged procedure.\\nwake up and emergence\\n■Possible need for postop ventilation if severe restrictive dis-\\nease\\nicu or pacu\\n■Monitor EKG for arrhythmias.\\n■DVTp r ophylaxis because of hypercoagulable tendency\\n■Follow renal function.\\n➣ Acute renal failure possible following surgical stress\\n➣ Adjust medication dosing for renal function.\\n■Monitor CBC for anemia.\\n■Follow-up platelet count\\nTHALASSEMIA\\nARTHUR ATCHABAHIAN, MD\\nscreening and evaluation\\n■Diagnosis by electrophoresis of Hb\\n■Obtain CBC to assess anemia & platelet count.\\n■Obtain PT to rule out coagulation disorder.\\n■Obtain EKG to assess rhythm.\\n■Consider obtaining echocardiogram to evaluate ventricular\\nfunction.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 386}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nThalassemia Thyroid and Parathyroid Disease 373\\npreoperative preparation\\nTransfuse to Hb of 9 g/dL.\\noperative preparation\\nUnremarkable\\nanesthesia\\n■Deformity of the maxilla can render intubation difﬁcult.\\n■Careful positioning because of bone fragility & deformities\\n■Discuss risks & beneﬁts of regional anesthesia\\n➣ Coagulopathy, thrombocytopenia\\n➣ Noairway instrumentation, no cardiac depression\\n➣ Decreased blood loss & thromboembolic events\\n■Consider renal & hepatic function for anesthetic drug selec-\\ntion.\\n■Consider invasive monitoring if cardiac function is compro-\\nmised.\\nwake up and emergence\\nUnremarkable\\nicu or pacu\\nUnremarkable\\nTHYROID AND PARATHYROID DISEASE\\nGIUDITTA ANGELINI, MD\\nscreening and evaluation\\n■Indications for thyroidectomy\\n➣ Suspected malignancy\\n➣ Obstructive symptoms\\n➣ Retrosternal goiter\\n➣ Hyperthyroidism unresponsive to medical mgt\\n➣ Cosmetic reasons or patient anxiety'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 387}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n374 Thyroid and Parathyroid Disease\\n■Assess for abnormalities of thyroid function & symptoms ofthyroid disease.\\n■Cardiorespiratory assessment mandatory in pts w/ hyper- or\\nhypothyroidism\\n■Before surgery, obtain thyroid function tests, CBC, elec-trolytes, urea & calcium in pts w/ hyper- or hypothyroidism.\\n■Anticipate difﬁcult airway:\\n➣ Symptoms (dysphagia, positional dyspnea)\\n➣ Lingual thyroid\\n➣ ENT evaluation w/ indirect laryngoscopy: vocal cordassessment\\n➣ Chest x-ray: tracheal compression & deviation\\n➣ CT & MRI: associated abnormalities & ease of intubation(not routinely done)\\n➣ Respiratory ﬂow volume loops\\nrFixed obstruction: impaired inspiration/expiration\\nrVariable intrathoracic obstruction: impaired expiration\\nrVariable extrathoracic obstruction: impaired inspira-\\ntion\\n■Verylarge goiters\\n➣ Usually not as problematic as retrosternal goiter\\n➣ Potential difﬁcult intubation; lifting goiter anteriorly helps\\n➣ Prolonged surgical time, postop tracheomalacia\\n➣ Blood loss related to thyroid resection (rarely done today)\\n■Retrosternal goiter\\n➣ Superior vena cava syndrome w/ or w/out thrombosis\\n➣ Cerebral hypoperfusion from arterial compression\\n➣ Thyrocervical steal syndrome\\n➣ Phrenic & recurrent laryngeal nerve palsies\\n➣ Hor ner’s syndrome\\n➣ Pleural effusion, pericardial effusion, chylothorax\\n■Thyroid cancer\\n➣ Increased risk of recurrent laryngeal n. damage'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 388}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nThyroid and Parathyroid Disease 375\\n➣ Follicular cancer: lung & bone metastases release thyroxin\\n➣ Lymphoma & anaplastic thyroid cancer are treated w/\\nradiotherapy alone.\\n■Investigate for multiple endocrine neoplasia (MEN).\\n➣ MEN 1\\nrHyperparathyroidism, parathyroid tumors, pancreatic\\ntumors, pituitary adenomas\\n➣ MEN 2\\nrMedullary thyroid cancer, pheochromocytoma, hyper-\\nparathyroidism\\nrPositive genetic screen for proto-oncogene mutation\\nfor medullary thyroid cancer is an indication for pro-phylactic thyroidectomy.\\npreoperative preparation\\n■Reschedule elective surgery if pt is not clinically euthyroid.\\n■Consider stress-dose steroids in hypothyroid pts (high inci-\\ndence of concomitant adrenocortical deﬁciency).\\n■Symptomatic hypercalcemia & hyperparathyroidism\\n➣ Preop saline +diuresis (saliuresis)\\n➣ Bisphosphonates\\noperative preparation\\nN/A\\nanesthesia\\n■Anticipate postop nausea & vomiting; pain is less of an issueafter thyroidectomy.\\n■Hypothyroidism\\n➣ Verysensitive to anesthetics & sedatives\\n➣ Depressed response to hypoxemia, hypercarbia\\n■Regional anesthesia for thyroidectomy & parathyroidectomy\\n➣ Bilateral superﬁcial & deep cervical blocks'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 389}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n376 Thyroid and Parathyroid Disease\\n➣ Complications: vertebral artery puncture, epidural sub-\\narachnoid spread, bilateral phrenic n. block\\n■LMA\\n➣ Requires close cooperation btwn surgeon & anesthesiolo-gist as surgical manipulation can result in laryngospasm\\n➣ Contraindicated in pts w/ tracheal narrowing or deviation\\n➣ Allows assessment of vocal cord movement w/ ﬁberopticscope during stimulation of recurrent laryngeal nerve\\n➣ Intubating LMA is difﬁcult in pts w/ large goiter becauseof tracheal deviation.\\n■Anticipate difﬁcult intubation:\\n➣ 6% of tracheal intubations for thyroid surgery are likely tobe difﬁcult.\\n➣ No abnormality speciﬁc to thyroid disease reliably pre-\\ndicts difﬁculty.\\n➣ Consider using a small, reinforced tube in all pts, esp. ptsw/ any amount of tracheal compression.\\n➣ Have LMA, ﬁberoptic scope, transtracheal jet ventilation\\navailable.\\n➣ Tracheotomy with femoro-femoral bypass has been used\\nin severe airway obstruction.\\n■General anesthesia: method of choice for pts w/ exophthal-mos requiring eye surgery\\n■Thyroid storm\\n➣ Surgery, infection & trauma are all triggers.\\n➣ Supportive treatment: hydration, cooling & inotropes\\n➣ First-line treatment includes anti-thyroxine agents & betablockers.\\n➣ Magnesium decreases incidence & severity of catecho-\\nlamine-induced arrhythmias.\\n➣ Dantrolene (1 mg/kg) has been used successfully in ptsmistaken for MH\\n■Intraoperative evaluation for recurrent laryngeal nerve\\n➣ Use succinylcholine for intubation.'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 390}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nThyroid and Parathyroid Disease 377\\n➣ Place ETT w/ integrated EMG electrodes at level of vocal\\ncords.\\n➣ Spontaneous ventilation should resume by time of testing.\\n➣ Once recurrent laryngeal n. localized, stimulation w/0.1 mA is repeated w/ 0.05-mA increments until an evokedEMG is obtained.\\n■Medullary & papillary thyroid cancer\\n➣ Canspread to lymph nodes & may require block resection\\nin the neck\\n■Sternotomy: rarely required, even w/ retrosternal goiter\\n■10–20 seconds of sustained positive pressure before woundclosure is helpful to ensure hemostasis.\\n■Risks of parathyroid surgery\\n➣ 0.5%: injury to recurrent laryngeal nerve\\n➣ 0.5%: risk of damage to normal parathyroid glands\\n➣ 1%: risk of failure to identify adenoma\\n➣ Parathyroid cancer requires en bloc resection w/ regional\\nlymph node metastases.\\nwake up and emergence\\n■Extubation should be done w/ minimal coughing.\\n➣ Consider deep extubation or lidocaine suppression.\\n➣ Consider dexmedetomidine through emergence.\\n■Vocal cord injury\\n➣ Concern re recurrent laryngeal n:\\nrInspect vocal cords w/ ﬁberoptic scope before extuba-\\ntion.\\nrPlace LMA at the end of surgery while pt is sponta-\\nneously breathing.\\n➣ Unilateral vocal cord paralysis\\nrHoarseness, breathlessness, ineffective cough & aspira-\\ntion\\nrTemporary (3–4%)\\nrPermanent ( <1%)'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 391}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n378 Thyroid and Parathyroid Disease\\nrDuet oischemia, contusion, traction, entrapment, tran-\\nsection\\nrIntracordal injection, laryngeal reinnervation & surgi-cal corrective procedures can be done for permanentunilateral paralysis.\\n➣ Bilateral vocal cord paralysis\\nrStridor at extubation\\nrPtshould be reintubated.\\nrPermanent: consider tracheostomy\\n■Tracheomalacia\\n➣ Unlike deviation & compression of the trachea, whichresolve immediately, tracheomalacia persists.\\n➣ Develops in 5% of pts w/ tracheal compression\\n➣ Suggested by absence of cuff leak at the end of procedureor less air in cuff to create a seal\\n➣ Ptwill require tracheostomy & potentially some form of\\ntracheal support.\\nicu or pacu\\n■Monitor for respiratory obstruction:\\n➣ Myxedema: rarely, laryngeal edema in isolation w/outassociated hematoma\\n➣ Indirect laryngoscopy can also be used postop if vocal cord\\ndysfunction is suspected in the extubated pt.\\n➣ Cervical hematoma\\nrReoperation rate is 0.4% in 3,000 cases.\\nrCanp r oduce laryngeal or pharyngeal edema w/ poten-\\ntial for emergent & difﬁcult intubation\\n■Total thyroidectomy pts who were not on replacement shouldreceive thyroxine.\\n■Inadvertent parathyroidectomy\\n➣ Mayb er emoved in about 20% of total thyroidectomy cases\\n➣ Calcium evaluation & potential replacement may be nec-essary.\\n➣ Only about 3% remain permanently hypocalcemic'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 392}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nTransfusion Therapy 379\\nTRANSFUSION THERAPY\\nDOUGLAS B. COURSIN, MD, AND KARL WILLMANN, MD\\nscreening and evaluation\\n■Type & screen or cross-match, usually based on type of surgery,\\nlikelihood of blood loss & underlying health & Hgb of pt.\\n■Minimum safe blood order (MSBO) can guide need for trans-\\nfusion by the prior history of a surgeon performing the pro-posed elective procedure.\\npreoperative preparation\\nN/A\\noperative preparation\\nN/A\\nanesthesia\\nN/A\\nwake up and emergence\\nN/A\\nicu or pacu\\n■Over half of ICU pts are anemic by lab criteria within 72 hrs ofICU admission.\\n■1/7 ICU pts receive a transfusion per day.\\n■Over a third of all ICU pts receive a transfusion during theirICU course.\\n■Longer a pt stays in ICU, more transfusion therapy\\n■Transfusions are independently associated w/ increased\\nlength of ICU stay & increased morbidity & mortality.\\n■Usesimilar transfusion triggers for other settings, except tend\\nto transfuse earlier if CNS or cardiac ischemia or infarction.\\nIndications for platelet transfusion\\n■Prevention/treatment of nonsurgical bleeding due to throm-\\nbocytopenia'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 393}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n380 Transfusion Therapy von Willebrand’s Disease\\n■Ifpossible, prior to transfusion, establish the reason for throm-\\nbocytopenia. When thrombocytopenia is caused by mar-row failure, the following transfusion triggers are considered\\nappropriate:\\n■Ifplatelet count is <10,000 & no additional abnormalities exist\\n■Ifplatelet count is 10,000–20,000 & coagulation abnormalities\\nexist or there are extensive petechiae or ecchymoses\\n■Ifpts is bleeding at sites other than skin & platelet count is\\n<40–50,000\\n■Ptsw /accelerated platelet destruction w/ signiﬁcant bleeding\\n(eg, autoimmune thrombocytopenia or drug-induced throm-bocytopenia)\\n■The endpoint should be cessation of bleeding, since an incre-ment in platelet count is not likely to be achieved. Prophylactictransfusion is not indicated in these disorders.\\n■Prior to surgical & major invasive procedures when the platelet\\ncount is <50,000\\n■Do platelet count & coagulation studies prior to the transfu-sion to guide subsequent therapy. During surgery on pts w/quantitative or qualitative platelet defects, evaluate the ade-quacy of hemostasis by assessing microvascular bleeding.\\nPtsw /bleeding and/or urgent invasive procedures on warfarin\\ntherapy. Vitamin K will reverse the warfarin defect in about 12hrs.Do not transfuse plasma products for volume expansion, for pro-phylaxis following cardiopulmonary bypass or as a nutritionalsupplement.\\nVON WILLEBRAND’S DISEASE\\nKARL WILLMANN, MD, AND D. B. COURSIN, MD\\nscreening and evaluation\\n■Hematology consult'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 394}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\nvon Willebrand’s Disease 381\\n■Labs to determine subtype of vWD, as this will guide therapy.\\n■Baseline coagulation studies, including PTT, PT, platelet\\ncount (these may be normal), vWf antigen & ristocetin cofac-tor activity\\npreoperative preparation\\n■Consult w/ hematologist.\\n■Treatment w/ desmopressin (DDAVP) 1 hr prior to surgery to\\nstimulate vWf release & factor VIII (both 2- to 5-fold), which isindicated in typ eI&t r ansiently effective in IIa. It is absolutely\\ncontraindicated in type IIb (induces thrombocytopenia) & isof no help in type III or IV.\\n■Treatment for type IIb & III requires replacement of factors\\nfrom recombinant vWf, recombinant factor VIII that containsvWf, or factor VIII preparation, which also contain varyingamounts of vWf. Cryoprecipitate can also be used. The nonre-combinant preparations put the pt at risk for virally transmit-ted diseases & are not ﬁrst choices when recombinant therapyis available. Type IV requires platelet transfusion, as there is adefect in the binding site on platelets for vWf.\\n■Desmopressin is given as 0.3 ug/kg IV or 75 ug to each nos-\\ntril. Maximal effect in 30 min, duration 6–8 hrs. May need toredose btwn 8–12 hrs, as these are the half-lives of vWf & factor\\nVIII. There may be a decreased response to desmopressin w/repeated dosing, as it takes time to replete the stores of vWf &\\nfactor VIII.\\n■Antiﬁbrinolytics (aminocaproic acid, tranexamic acid) maybe helpful adjuncts for decreased destruction of ﬁbrin clot &decrease excessive hemorrhage.\\n■Regional anesthesia is relatively contraindicated.\\n■Avoid antiplatelet drugs.\\noperative preparation\\nN/A'),\n",
       " Document(metadata={'source': '../../dataset/pdfs/anesthesia/1.pdf', 'page': 395}, page_content='P1: IBE0521759385P1secA4 CUNY1088/Sladen 0 521 75938 5 June 8, 2007 15:57\\n382 von Willebrand’s Disease\\nanesthesia\\n■Induction\\n➣ Use care w/ laryngoscopy.\\n➣ Avoid nasal intubation.\\n■Maintenance\\n➣ Nospecial concerns\\n■Ifbleeding despite preparation & DDAVP, consider:\\n➣ Virus-inactivated factor VIII concentrates\\n➣ Cryoprecipitate (has vWF but carries infectious risk)\\n■Avoid antiplatelet drugs.\\nwake up and emergence\\n■Coughing w/ emergence & oral/tracheal suctioning maycause trauma & bleeding.\\nicu or pacu\\n■Continued monitoring of hemostasis & coagulation status.May need continued therapy for vWD.')]"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pages"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Semantic Chunking using semantic router"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "HuggingFaceEncoder(name='NeuML/pubmedbert-base-embeddings', score_threshold=0.5, type='huggingface', tokenizer_kwargs={}, model_kwargs={}, device='cuda')"
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from semantic_router.encoders import HuggingFaceEncoder\n",
    "\n",
    "encoder = HuggingFaceEncoder(\n",
    "    name = \"NeuML/pubmedbert-base-embeddings\"\n",
    ")\n",
    "\n",
    "encoder"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "from semantic_chunkers import StatisticalChunker\n",
    "\n",
    "chunker = StatisticalChunker(encoder=encoder)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [],
   "source": [
    "document_text = \"\\n\".join([page.page_content for page in pages])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\u001b[32m2024-10-15 15:01:17 INFO semantic_chunkers.utils.logger Single document exceeds the maximum token limit of 300. Splitting to sentences before semantically merging.\u001b[0m\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "00ab28ea28c84b978f33b46196ca3627",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "  0%|          | 0/252 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Asking to truncate to max_length but no maximum length is provided and the model has no predefined maximum length. Default to no truncation.\n",
      "c:\\Users\\Archit\\Desktop\\medic\\.venv\\Lib\\site-packages\\transformers\\models\\bert\\modeling_bert.py:439: UserWarning: 1Torch was not compiled with flash attention. (Triggered internally at C:\\actions-runner\\_work\\pytorch\\pytorch\\builder\\windows\\pytorch\\aten\\src\\ATen\\native\\transformers\\cuda\\sdp_utils.cpp:555.)\n",
      "  attn_output = torch.nn.functional.scaled_dot_product_attention(\n"
     ]
    }
   ],
   "source": [
    "chunks = chunker(docs=[document_text])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total documents: 839\n"
     ]
    }
   ],
   "source": [
    "from langchain.schema import Document\n",
    "\n",
    "doc = []\n",
    "\n",
    "for chunk in chunks[0]:  \n",
    "    combined_chunk = \" \".join(chunk.splits)  \n",
    "    doc.append(Document(page_content=combined_chunk))  \n",
    "\n",
    "print(f\"Total documents: {len(doc)}\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Custom Implementation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 115,
   "metadata": {},
   "outputs": [],
   "source": [
    "import networkx as nx\n",
    "\n",
    "G = nx.Graph()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 123,
   "metadata": {},
   "outputs": [],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "\n",
    "def view_Graph(G):\n",
    "    subax1 = plt.subplot(121)\n",
    "    nx.draw(G, with_labels=True, font_weight='bold')\n",
    "    subax2 = plt.subplot(122)\n",
    "    nx.draw_shell(G, nlist=[range(5, 10), range(5)], with_labels=True, font_weight='bold')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 131,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Nodes: [('A', {'role': 'admin'}), ('B', {}), ('C', {}), ('D', {})]\n",
      "Edges: [('A', 'B', {'relationship': 'friends'}), ('A', 'C', {}), ('B', 'D', {})]\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import networkx as nx\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "G = nx.Graph()\n",
    "\n",
    "G.add_node(\"A\", role=\"admin\")\n",
    "G.add_nodes_from([\"B\", \"C\", \"D\"])\n",
    "\n",
    "G.add_edge(\"A\", \"B\", relationship=\"friends\")\n",
    "G.add_edges_from([(\"A\", \"C\"), (\"B\", \"D\")])\n",
    "\n",
    "print(\"Nodes:\", G.nodes(data=True))  \n",
    "print(\"Edges:\", G.edges(data=True))  \n",
    "\n",
    "nx.draw(G, with_labels=True)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 133,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Nodes: [('Abc', {'role': 'user'}), ('efg', {}), ('hij', {}), ('kl', {})]\n",
      "Edges: [('Abc', 'efg', {'relationship': 'friends'}), ('Abc', 'hij', {}), ('efg', 'kl', {})]\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import networkx as nx\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "F = nx.Graph()\n",
    "\n",
    "F.add_node(\"Abc\", role=\"user\")\n",
    "F.add_nodes_from([\"efg\", \"hij\", \"kl\"])\n",
    "\n",
    "F.add_edge(\"Abc\", \"efg\", relationship=\"friends\")\n",
    "F.add_edges_from([(\"Abc\", \"hij\"), (\"efg\", \"kl\")])\n",
    "\n",
    "print(\"Nodes:\", F.nodes(data=True))  \n",
    "print(\"Edges:\", F.edges(data=True))  \n",
    "\n",
    "nx.draw(F, with_labels=True)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 135,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Nodes: [('A', {'role': 'admin'}), ('B', {}), ('C', {}), ('D', {}), ('Abc', {'role': 'user'}), ('efg', {}), ('hij', {}), ('kl', {})]\n",
      "Edges: [('A', 'B', {'relationship': 'friends'}), ('A', 'C', {}), ('B', 'D', {}), ('Abc', 'efg', {'relationship': 'friends'}), ('Abc', 'hij', {}), ('efg', 'kl', {})]\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "X= nx.union(G,F)\n",
    "\n",
    "print(\"Nodes:\", X.nodes(data=True))  \n",
    "print(\"Edges:\", X.edges(data=True))\n",
    "\n",
    "nx.draw(X, with_labels=True)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# LLMGraphTransformer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 95,
   "metadata": {},
   "outputs": [],
   "source": [
    "entity_extraction_prompt = '''\n",
    "\n",
    "Given a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities. Dont give me any code and dont mention 'json' at the top of the response.\n",
    "There should not be any extra output (even a single word) besides the output required\n",
    "\n",
    "-Steps-\n",
    "1. Identify all entities. For each identified entity, extract the following information:\n",
    "- entity_name: Name of the entity, capitalized\n",
    "- entity_type: Type of the entity, lowercased\n",
    "- entity_description: Comprehensive description of the entity's attributes and activities\n",
    "Format each entity as (\"entity\"{tuple_delimiter}<entity_name>{tuple_delimiter}<entity_type>{tuple_delimiter}<entity_description>\n",
    "\n",
    "2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\n",
    "For each pair of related entities, extract the following information:\n",
    "- source_entity: name of the source entity, as identified in step 1\n",
    "- target_entity: name of the target entity, as identified in step 1\n",
    "- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n",
    "- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n",
    " Format each relationship as (\"relationship\"{tuple_delimiter}<source_entity>{tuple_delimiter}<target_entity>{tuple_delimiter}<relationship_description>{tuple_delimiter}<relationship_strength>)\n",
    "\n",
    "3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **{record_delimiter}** as the list delimiter.\n",
    "\n",
    "4. When finished, output {completion_delimiter}\n",
    "\n",
    "######################\n",
    "-Examples-\n",
    "######################\n",
    "Example 1:\n",
    "\n",
    "Entity_types: [person, technology, mission, organization, location]\n",
    "Text:\n",
    "while Alex clenched his jaw, the buzz of frustration dull against the backdrop of Taylor's authoritarian certainty. It was this competitive undercurrent that kept him alert, the sense that his and Jordan's shared commitment to discovery was an unspoken rebellion against Cruz's narrowing vision of control and order.\n",
    "\n",
    "Then Taylor did something unexpected. They paused beside Jordan and, for a moment, observed the device with something akin to reverence. “If this tech can be understood...\" Taylor said, their voice quieter, \"It could change the game for us. For all of us.”\n",
    "\n",
    "The underlying dismissal earlier seemed to falter, replaced by a glimpse of reluctant respect for the gravity of what lay in their hands. Jordan looked up, and for a fleeting heartbeat, their eyes locked with Taylor's, a wordless clash of wills softening into an uneasy truce.\n",
    "\n",
    "It was a small transformation, barely perceptible, but one that Alex noted with an inward nod. They had all been brought here by different paths\n",
    "################\n",
    "Output:\n",
    "(\"entity\"{tuple_delimiter}\"Alex\"{tuple_delimiter}\"person\"{tuple_delimiter}\"Alex is a character who experiences frustration and is observant of the dynamics among other characters.\"){record_delimiter}\n",
    "(\"entity\"{tuple_delimiter}\"Taylor\"{tuple_delimiter}\"person\"{tuple_delimiter}\"Taylor is portrayed with authoritarian certainty and shows a moment of reverence towards a device, indicating a change in perspective.\"){record_delimiter}\n",
    "(\"entity\"{tuple_delimiter}\"Jordan\"{tuple_delimiter}\"person\"{tuple_delimiter}\"Jordan shares a commitment to discovery and has a significant interaction with Taylor regarding a device.\"){record_delimiter}\n",
    "(\"entity\"{tuple_delimiter}\"Cruz\"{tuple_delimiter}\"person\"{tuple_delimiter}\"Cruz is associated with a vision of control and order, influencing the dynamics among other characters.\"){record_delimiter}\n",
    "(\"entity\"{tuple_delimiter}\"The Device\"{tuple_delimiter}\"technology\"{tuple_delimiter}\"The Device is central to the story, with potential game-changing implications, and is revered by Taylor.\"){record_delimiter}\n",
    "(\"relationship\"{tuple_delimiter}\"Alex\"{tuple_delimiter}\"Taylor\"{tuple_delimiter}\"Alex is affected by Taylor's authoritarian certainty and observes changes in Taylor's attitude towards the device.\"{tuple_delimiter}7){record_delimiter}\n",
    "(\"relationship\"{tuple_delimiter}\"Alex\"{tuple_delimiter}\"Jordan\"{tuple_delimiter}\"Alex and Jordan share a commitment to discovery, which contrasts with Cruz's vision.\"{tuple_delimiter}6){record_delimiter}\n",
    "(\"relationship\"{tuple_delimiter}\"Taylor\"{tuple_delimiter}\"Jordan\"{tuple_delimiter}\"Taylor and Jordan interact directly regarding the device, leading to a moment of mutual respect and an uneasy truce.\"{tuple_delimiter}8){record_delimiter}\n",
    "(\"relationship\"{tuple_delimiter}\"Jordan\"{tuple_delimiter}\"Cruz\"{tuple_delimiter}\"Jordan's commitment to discovery is in rebellion against Cruz's vision of control and order.\"{tuple_delimiter}5){record_delimiter}\n",
    "(\"relationship\"{tuple_delimiter}\"Taylor\"{tuple_delimiter}\"The Device\"{tuple_delimiter}\"Taylor shows reverence towards the device, indicating its importance and potential impact.\"{tuple_delimiter}9){completion_delimiter}\n",
    "#############################\n",
    "Example 2:\n",
    "\n",
    "Entity_types: [person, technology, mission, organization, location]\n",
    "Text:\n",
    "They were no longer mere operatives; they had become guardians of a threshold, keepers of a message from a realm beyond stars and stripes. This elevation in their mission could not be shackled by regulations and established protocols—it demanded a new perspective, a new resolve.\n",
    "\n",
    "Tension threaded through the dialogue of beeps and static as communications with Washington buzzed in the background. The team stood, a portentous air enveloping them. It was clear that the decisions they made in the ensuing hours could redefine humanity's place in the cosmos or condemn them to ignorance and potential peril.\n",
    "\n",
    "Their connection to the stars solidified, the group moved to address the crystallizing warning, shifting from passive recipients to active participants. Mercer's latter instincts gained precedence— the team's mandate had evolved, no longer solely to observe and report but to interact and prepare. A metamorphosis had begun, and Operation: Dulce hummed with the newfound frequency of their daring, a tone set not by the earthly\n",
    "#############\n",
    "Output:\n",
    "(\"entity\"{tuple_delimiter}\"Washington\"{tuple_delimiter}\"location\"{tuple_delimiter}\"Washington is a location where communications are being received, indicating its importance in the decision-making process.\"){record_delimiter}\n",
    "(\"entity\"{tuple_delimiter}\"Operation: Dulce\"{tuple_delimiter}\"mission\"{tuple_delimiter}\"Operation: Dulce is described as a mission that has evolved to interact and prepare, indicating a significant shift in objectives and activities.\"){record_delimiter}\n",
    "(\"entity\"{tuple_delimiter}\"The team\"{tuple_delimiter}\"organization\"{tuple_delimiter}\"The team is portrayed as a group of individuals who have transitioned from passive observers to active participants in a mission, showing a dynamic change in their role.\"){record_delimiter}\n",
    "(\"relationship\"{tuple_delimiter}\"The team\"{tuple_delimiter}\"Washington\"{tuple_delimiter}\"The team receives communications from Washington, which influences their decision-making process.\"{tuple_delimiter}7){record_delimiter}\n",
    "(\"relationship\"{tuple_delimiter}\"The team\"{tuple_delimiter}\"Operation: Dulce\"{tuple_delimiter}\"The team is directly involved in Operation: Dulce, executing its evolved objectives and activities.\"{tuple_delimiter}9){completion_delimiter}\n",
    "#############################\n",
    "Example 3:\n",
    "\n",
    "Entity_types: [person, role, technology, organization, event, location, concept]\n",
    "Text:\n",
    "their voice slicing through the buzz of activity. \"Control may be an illusion when facing an intelligence that literally writes its own rules,\" they stated stoically, casting a watchful eye over the flurry of data.\n",
    "\n",
    "\"It's like it's learning to communicate,\" offered Sam Rivera from a nearby interface, their youthful energy boding a mix of awe and anxiety. \"This gives talking to strangers' a whole new meaning.\"\n",
    "\n",
    "Alex surveyed his team—each face a study in concentration, determination, and not a small measure of trepidation. \"This might well be our first contact,\" he acknowledged, \"And we need to be ready for whatever answers back.\"\n",
    "\n",
    "Together, they stood on the edge of the unknown, forging humanity's response to a message from the heavens. The ensuing silence was palpable—a collective introspection about their role in this grand cosmic play, one that could rewrite human history.\n",
    "\n",
    "The encrypted dialogue continued to unfold, its intricate patterns showing an almost uncanny anticipation\n",
    "#############\n",
    "Output:\n",
    "(\"entity\"{tuple_delimiter}\"Sam Rivera\"{tuple_delimiter}\"person\"{tuple_delimiter}\"Sam Rivera is a member of a team working on communicating with an unknown intelligence, showing a mix of awe and anxiety.\"){record_delimiter}\n",
    "(\"entity\"{tuple_delimiter}\"Alex\"{tuple_delimiter}\"person\"{tuple_delimiter}\"Alex is the leader of a team attempting first contact with an unknown intelligence, acknowledging the significance of their task.\"){record_delimiter}\n",
    "(\"entity\"{tuple_delimiter}\"Control\"{tuple_delimiter}\"concept\"{tuple_delimiter}\"Control refers to the ability to manage or govern, which is challenged by an intelligence that writes its own rules.\"){record_delimiter}\n",
    "(\"entity\"{tuple_delimiter}\"Intelligence\"{tuple_delimiter}\"concept\"{tuple_delimiter}\"Intelligence here refers to an unknown entity capable of writing its own rules and learning to communicate.\"){record_delimiter}\n",
    "(\"entity\"{tuple_delimiter}\"First Contact\"{tuple_delimiter}\"event\"{tuple_delimiter}\"First Contact is the potential initial communication between humanity and an unknown intelligence.\"){record_delimiter}\n",
    "(\"entity\"{tuple_delimiter}\"Humanity's Response\"{tuple_delimiter}\"event\"{tuple_delimiter}\"Humanity's Response is the collective action taken by Alex's team in response to a message from an unknown intelligence.\"){record_delimiter}\n",
    "(\"relationship\"{tuple_delimiter}\"Sam Rivera\"{tuple_delimiter}\"Intelligence\"{tuple_delimiter}\"Sam Rivera is directly involved in the process of learning to communicate with the unknown intelligence.\"{tuple_delimiter}9){record_delimiter}\n",
    "(\"relationship\"{tuple_delimiter}\"Alex\"{tuple_delimiter}\"First Contact\"{tuple_delimiter}\"Alex leads the team that might be making the First Contact with the unknown intelligence.\"{tuple_delimiter}10){record_delimiter}\n",
    "(\"relationship\"{tuple_delimiter}\"Alex\"{tuple_delimiter}\"Humanity's Response\"{tuple_delimiter}\"Alex and his team are the key figures in Humanity's Response to the unknown intelligence.\"{tuple_delimiter}8){record_delimiter}\n",
    "(\"relationship\"{tuple_delimiter}\"Control\"{tuple_delimiter}\"Intelligence\"{tuple_delimiter}\"The concept of Control is challenged by the Intelligence that writes its own rules.\"{tuple_delimiter}7){completion_delimiter}\n",
    "#############################\n",
    "\n",
    "When you give output dont mention anything like 'Here is the list of entities and relationships extracted from the text:'. Just give the response straight away\n",
    "\n",
    "\n",
    "-Real Data-\n",
    "######################\n",
    "Text: {input_text}\n",
    "######################\n",
    "Output:\n",
    "\n",
    "'''"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'entity_extraction_prompt' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[4], line 12\u001b[0m\n\u001b[0;32m      6\u001b[0m \u001b[38;5;28;01mfrom\u001b[39;00m \u001b[38;5;21;01mdotenv\u001b[39;00m \u001b[38;5;28;01mimport\u001b[39;00m load_dotenv\n\u001b[0;32m      8\u001b[0m load_dotenv()\n\u001b[0;32m     11\u001b[0m prompt \u001b[38;5;241m=\u001b[39m PromptTemplate(\n\u001b[1;32m---> 12\u001b[0m     template \u001b[38;5;241m=\u001b[39m \u001b[43mentity_extraction_prompt\u001b[49m\n\u001b[0;32m     13\u001b[0m     \n\u001b[0;32m     14\u001b[0m )\n\u001b[0;32m     16\u001b[0m llm_groq \u001b[38;5;241m=\u001b[39m ChatGroq(\n\u001b[0;32m     17\u001b[0m     groq_api_key \u001b[38;5;241m=\u001b[39m os\u001b[38;5;241m.\u001b[39mgetenv(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mgroq_api\u001b[39m\u001b[38;5;124m\"\u001b[39m),\n\u001b[0;32m     18\u001b[0m     model_name \u001b[38;5;241m=\u001b[39m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mgemma2-9b-it\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m     19\u001b[0m )\n\u001b[0;32m     21\u001b[0m llm_ollama \u001b[38;5;241m=\u001b[39m ChatOllama(\n\u001b[0;32m     22\u001b[0m     model \u001b[38;5;241m=\u001b[39m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mgemma2:9b\u001b[39m\u001b[38;5;124m\"\u001b[39m,  \u001b[38;5;66;03m#llama3.1:latest\u001b[39;00m\n\u001b[0;32m     23\u001b[0m )\n",
      "\u001b[1;31mNameError\u001b[0m: name 'entity_extraction_prompt' is not defined"
     ]
    }
   ],
   "source": [
    "from langchain_core.prompts import PromptTemplate\n",
    "from langchain.chains import LLMChain\n",
    "from langchain_ollama import ChatOllama\n",
    "import os\n",
    "from dotenv import load_dotenv\n",
    "\n",
    "load_dotenv()\n",
    "\n",
    "\n",
    "prompt = PromptTemplate(\n",
    "    template = entity_extraction_prompt\n",
    "    \n",
    ")\n",
    "\n",
    "llm_groq = ChatGroq(\n",
    "    groq_api_key = os.getenv(\"groq_api\"),\n",
    "    model_name = \"gemma2-9b-it\"\n",
    ")\n",
    "\n",
    "llm_ollama = ChatOllama(\n",
    "    model = \"gemma2:9b\",  #llama3.1:latest\n",
    ")\n",
    "\n",
    "query_chain = LLMChain(\n",
    "    llm = llm_ollama,\n",
    "    prompt = prompt\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'the best treatment for the patient. Therefore, the author(s), edi-tors, contributors, and the publisher make no warranty, expressor implied, and shall have no liability to any person or entity withregard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly, by the use of information contained in thispublication.Further, the author(s), editors, contributors, and the publisher are not responsible for misuse of any of the information pro-vided in this publication, for negligence by the user, or for anytypographical errors.'"
      ]
     },
     "execution_count": 97,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "doc[5].page_content"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 98,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'completion_delimiter': '<COMP>',\n",
       " 'tuple_delimiter': '|',\n",
       " 'record_delimiter': '<END>',\n",
       " 'input_text': 'the best treatment for the patient. Therefore, the author(s), edi-tors, contributors, and the publisher make no warranty, expressor implied, and shall have no liability to any person or entity withregard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly, by the use of information contained in thispublication.Further, the author(s), editors, contributors, and the publisher are not responsible for misuse of any of the information pro-vided in this publication, for negligence by the user, or for anytypographical errors.',\n",
       " 'text': '(\"entity\"|\"author(s)\"|\"person\"|\"The authors are responsible for the content of the publication.\")<END>\\n(\"entity\"|\"editors\"|\"person\"|\"Editors contribute to the review and refinement of the publication.\")<END>\\n(\"entity\"|\"contributors\"|\"person\"|\"Contributors provide additional content or expertise to the publication.\")<END>\\n(\"entity\"|\"publisher\"|\"organization\"|\"The publisher is responsible for distributing the publication.\")<END>\\n(\"entity\"|\"patient\"|\"person\"|\"The patient is the recipient of medical treatment discussed in the publication.\")<END>\\n(\"relationship\"|\"author(s)\"|\"publication\"|\"The authors are responsible for the content of the publication.\"|9)<END>\\n(\"relationship\"|\"editors\"|\"publication\"|\"Editors contribute to the review and refinement of the publication.\"|8)<END>\\n(\"relationship\"|\"contributors\"|\"publication\"|\"Contributors provide additional content or expertise to the publication.\"|7)<END>\\n(\"relationship\"|\"publisher\"|\"publication\"|\"The publisher is responsible for distributing the publication.\"|9)<END>\\n\\n\\n'}"
      ]
     },
     "execution_count": 98,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "query = doc[5].page_content \n",
    "\n",
    "response = query_chain.invoke({\n",
    "    'completion_delimiter': '<COMP>', \n",
    "    'tuple_delimiter': '|',\n",
    "    'record_delimiter': '<END>',\n",
    "    'input_text': query\n",
    "})\n",
    "\n",
    "response"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(\"entity\"|\"author(s)\"|\"person\"|\"The authors are responsible for the content of the publication.\")<END>\n",
      "(\"entity\"|\"editors\"|\"person\"|\"Editors contribute to the review and refinement of the publication.\")<END>\n",
      "(\"entity\"|\"contributors\"|\"person\"|\"Contributors provide additional content or expertise to the publication.\")<END>\n",
      "(\"entity\"|\"publisher\"|\"organization\"|\"The publisher is responsible for distributing the publication.\")<END>\n",
      "(\"entity\"|\"patient\"|\"person\"|\"The patient is the recipient of medical treatment discussed in the publication.\")<END>\n",
      "(\"relationship\"|\"author(s)\"|\"publication\"|\"The authors are responsible for the content of the publication.\"|9)<END>\n",
      "(\"relationship\"|\"editors\"|\"publication\"|\"Editors contribute to the review and refinement of the publication.\"|8)<END>\n",
      "(\"relationship\"|\"contributors\"|\"publication\"|\"Contributors provide additional content or expertise to the publication.\"|7)<END>\n",
      "(\"relationship\"|\"publisher\"|\"publication\"|\"The publisher is responsible for distributing the publication.\"|9)<END>\n",
      "\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "sam_text = response['text']\n",
    "\n",
    "print(sam_text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 152,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'id': 'chunk_1',\n",
       "  'entities': [{'entity_name': 'author(s)',\n",
       "    'entity_type': 'person',\n",
       "    'entity_desc': 'The authors are responsible for the content of the publication.'},\n",
       "   {'entity_name': 'editors',\n",
       "    'entity_type': 'person',\n",
       "    'entity_desc': 'Editors contribute to the review and refinement of the publication.'},\n",
       "   {'entity_name': 'contributors',\n",
       "    'entity_type': 'person',\n",
       "    'entity_desc': 'Contributors provide additional content or expertise to the publication.'},\n",
       "   {'entity_name': 'publisher',\n",
       "    'entity_type': 'organization',\n",
       "    'entity_desc': 'The publisher is responsible for distributing the publication.'},\n",
       "   {'entity_name': 'patient',\n",
       "    'entity_type': 'person',\n",
       "    'entity_desc': 'The patient is the recipient of medical treatment discussed in the publication.'}],\n",
       "  'relationships': [{'source_entity': 'author(s)',\n",
       "    'target_entity': 'publication',\n",
       "    'relationship_desc': 'The authors are responsible for the content of the publication.'},\n",
       "   {'source_entity': 'editors',\n",
       "    'target_entity': 'publication',\n",
       "    'relationship_desc': 'Editors contribute to the review and refinement of the publication.'},\n",
       "   {'source_entity': 'contributors',\n",
       "    'target_entity': 'publication',\n",
       "    'relationship_desc': 'Contributors provide additional content or expertise to the publication.'},\n",
       "   {'source_entity': 'publisher',\n",
       "    'target_entity': 'publication',\n",
       "    'relationship_desc': 'The publisher is responsible for distributing the publication.'}]}]"
      ]
     },
     "execution_count": 152,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "list_ = sam_text.split(\"\\n\")\n",
    "\n",
    "testing_data = []\n",
    "entities = []\n",
    "relationships = []\n",
    "\n",
    "\n",
    "for i,item in enumerate(list_):\n",
    "    \n",
    "    if len(item)>0:\n",
    "\n",
    "        if item[2:8] == \"entity\":\n",
    "            temp = item[10:-6].split(\"|\")\n",
    "\n",
    "            entity_name = temp[0][1:-1]\n",
    "            entity_type = temp[1][1:-1]\n",
    "            entity_desc = temp[2][1:-1]\n",
    "\n",
    "            entities.append({\n",
    "                'entity_name': entity_name,\n",
    "                'entity_type': entity_type,\n",
    "                'entity_desc': entity_desc\n",
    "            })\n",
    "        \n",
    "        elif item[2:14] == \"relationship\":\n",
    "            temp = item[16:-8].split(\"|\")\n",
    "\n",
    "            source_entity = temp[0][1:-1]\n",
    "            target_entity = temp[1][1:-1]\n",
    "            relationship_desc = temp[2][1:-1]\n",
    "\n",
    "            relationships.append({\n",
    "                'source_entity': source_entity,\n",
    "                'target_entity': target_entity,\n",
    "                'relationship_desc': relationship_desc\n",
    "            })\n",
    "    \n",
    "testing_data.append({\n",
    "    'id': 'chunk_1',\n",
    "    'entities': entities,\n",
    "    'relationships': relationships \n",
    "})\n",
    "\n",
    "testing_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_experimental.graph_transformers import LLMGraphTransformer\n",
    "\n",
    "\n",
    "llm_transformer = LLMGraphTransformer(\n",
    "    llm = llm_ollama\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [],
   "source": [
    "graph_documents = []"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from tqdm import tqdm\n",
    "\n",
    "for i, document in enumerate(tqdm(doc, desc=\"Converting pages to graph documents\")):\n",
    "    try:\n",
    "        temp = llm_transformer.convert_to_graph_documents([document])\n",
    "        graph_documents.append(temp)\n",
    "        \n",
    "    except Exception as e:\n",
    "        print(f\"Failed to generate graph for page {i} {e}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[[GraphDocument(nodes=[], relationships=[], source=Document(metadata={}, page_content='P1: SBT0521759385pre CUNY1088/Sladen 0 521 75938 5 June 23, 2007 13:27 Anesthesia andCo-Existing Disease Edited by ROBERT N. SLADEN, MD Professor and Vice-ChairDepartment of AnesthesiologyChief, Division of Critical CareDirector, Cardiothoracic and Surgical Intensive Care UnitsColumbia UniversityCollege of Physicians and SurgeonsNew York, NY DOUGLAS B. COURSIN, MD ProfessorDepartments of Anesthesiology and Internal MedicineUniversity of Wisconsin Medical SchoolMadison, WI JONATHAN T. KETZLER, MD Associate ProfessorDepartments of Anesthesiology and Critical Care ServicesUniversity of Wisconsin Medical SchoolMadison, WI HUGH PLAYFORD, MD Assistant ProfessorDepartment of AnesthesiologyAssociate Program DirectorCritical Care FellowshipColumbia UniversityCollege of Physicians and SurgeonsNew York, NY i P1: SBT0521759385pre CUNY1088/Sladen 0 521 75938 5 June 23, 2007 13:27 cambridge university press Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, S ˜ao Paulo, Delhi Cambridge University Press 32 Avenue of the Americas, New York, NY10013-2473, USA www.cambridge.orgInformation on this title: www.cambridge.org/9780521709385'))],\n",
       " [GraphDocument(nodes=[Node(id='Anesthesia And Co-Existing Disease', type='Publication', properties={}), Node(id='2007', type='Year', properties={}), Node(id='Pocketmedicine.Com, Inc.', type='Copyright', properties={}), Node(id='Robert N.', type='Person', properties={})], relationships=[], source=Document(metadata={}, page_content='C⃝2007, 2005, Anesthesia and Co-Existing Disease by PocketMedicine.com, Inc. This publication is in copyright. Subject to statutory exceptionand to the provisions of relevant collective licensing agreements,no reproduction of any part may take place withoutthe written permission of Cambridge University Press.First published 2007 Printed in the United States of America Acatalog record for this publication is available from the British Library. Library of Congress Cataloging in Publication DataAnesthesia and co-existing disease / Robert N.'))],\n",
       " [GraphDocument(nodes=[Node(id='Robert N Sladen', type='Person', properties={}), Node(id='Sladen Robert N', type='Person', properties={})], relationships=[], source=Document(metadata={}, page_content='Sladen . . .[et al.]. p. ;cm. ISBN-13: 978-0-521-70938-5 (pbk.)ISBN-10: 0-521-70938-5 (pbk.)1. Anesthesia. 2. Anesthetics – Side effects. I. Sladen, Robert N.[DNLM: 1. Anesthesia – methods. 2. Anesthesia – adverse effects.3. Perioperative Care – methods.'))],\n",
       " [GraphDocument(nodes=[Node(id='Wo 200 A5775', properties={}), Node(id='Rd82.A6594', properties={}), Node(id='978-0-521-70938-5', properties={})], relationships=[], source=Document(metadata={}, page_content='WO 200 A5775 2007]RD82.A6594 2007 617.9 ′6–dc22 2007016739 ISBN 978-0-521-70938-5 paperback Cambridge University Press has no responsibility for the persistence or accuracy of URL sfor external or third-party Internet Web sites referred to in this publicationand does not guarantee that any content on suchWebsites is, or will remain, accurate or appropriate. Every effort has been made in preparing this book to provide accurate and up-to-date information that is in accord with accepted standards and practice atthe time of publication. Nevertheless, the authors, editors, and publisher can makeno warranties that the information contained herein is totally free from error, notleast because clinical standards are constantly changing through research andregulation. The authors, editors, and publisher therefore disclaim all liability for'))]]"
      ]
     },
     "execution_count": 54,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "graph_documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [],
   "source": [
    "from neo4j import GraphDatabase\n",
    "\n",
    "local_user = 'neo4j'\n",
    "local_url = 'bolt://localhost:7687'\n",
    "local_password = 'qazplmg123456'\n",
    "\n",
    "driver = GraphDatabase.driver(\n",
    "    uri = local_url,\n",
    "    auth = (local_user, local_password)\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.graphs import Neo4jGraph\n",
    "from dotenv import load_dotenv\n",
    "import os \n",
    "\n",
    "load_dotenv()\n",
    "\n",
    "graph = Neo4jGraph(\n",
    "    url = 'neo4j+s://2e177e83.databases.neo4j.io',\n",
    "    username = os.getenv('NEO4J_USERNAME'),\n",
    "    password = os.getenv('NEO4J_PASSWORD'),\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[]"
      ]
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "clear_graph_query = \"MATCH (n) DETACH DELETE n\"\n",
    "graph.query(clear_graph_query)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "\n",
    "with open('graph_doc_1.json', 'r') as file:\n",
    "\n",
    "    data = json.load(file)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.graphs.graph_document import GraphDocument, Node, Relationship\n",
    "from langchain.schema import Document\n",
    "\n",
    "graph_docs = []\n",
    "\n",
    "for i, chunk in enumerate(data):\n",
    "\n",
    "    node_list = []\n",
    "\n",
    "    for node in chunk['nodes']:\n",
    "        node = Node(id=node['id'], type=node['type'], properties = node['properties'])\n",
    "        node_list.append(node)\n",
    "\n",
    "\n",
    "    relationship_list  = []\n",
    "\n",
    "    source_doc = Document(page_content = doc[i].page_content, metadata = doc[i].metadata)\n",
    "\n",
    "\n",
    "    temp_doc = GraphDocument(\n",
    "        nodes =  node_list,\n",
    "        relationships = relationship_list,\n",
    "        source = source_doc\n",
    "        \n",
    "    )\n",
    "\n",
    "    graph_docs.append(temp_doc)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "metadata": {},
   "outputs": [],
   "source": [
    "graph.add_graph_documents(\n",
    "    graph_docs,\n",
    "    baseEntityLabel=True,\n",
    "    include_source=True\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "c:\\Users\\Archit\\Desktop\\medic\\.venv\\Lib\\site-packages\\sentence_transformers\\cross_encoder\\CrossEncoder.py:13: TqdmExperimentalWarning: Using `tqdm.autonotebook.tqdm` in notebook mode. Use `tqdm.tqdm` instead to force console mode (e.g. in jupyter console)\n",
      "  from tqdm.autonotebook import tqdm, trange\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "WARNING:tensorflow:From c:\\Users\\Archit\\Desktop\\medic\\.venv\\Lib\\site-packages\\tf_keras\\src\\losses.py:2976: The name tf.losses.sparse_softmax_cross_entropy is deprecated. Please use tf.compat.v1.losses.sparse_softmax_cross_entropy instead.\n",
      "\n"
     ]
    }
   ],
   "source": [
    "from langchain_huggingface import HuggingFaceEmbeddings\n",
    "\n",
    "embedding_model = HuggingFaceEmbeddings(\n",
    "    model_name = 'NeuML/pubmedbert-base-embeddings'\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_groq import ChatGroq\n",
    "import os\n",
    "\n",
    "llm_groq = ChatGroq(\n",
    "    groq_api_key = os.getenv(\"groq_api\"),\n",
    "    model_name = \"gemma2-9b-it\",\n",
    "    \n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_community.vectorstores import Neo4jVector\n",
    "from langchain.chains import RetrievalQA\n",
    "from langchain import PromptTemplate\n",
    "\n",
    "db_store = Neo4jVector.from_existing_graph(\n",
    "    embedding_model,\n",
    "    search_type = 'hybrid',\n",
    "    node_label = 'Document',\n",
    "    text_node_properties=['text'],\n",
    "    embedding_node_property='embedding'\n",
    ")\n",
    "\n",
    "\n",
    "chain = RetrievalQA.from_chain_type(\n",
    "    llm = llm_groq,\n",
    "    chain_type = 'stuff',\n",
    "    retriever = db_store.as_retriever(),\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Received notification from DBMS server: {severity: WARNING} {code: Neo.ClientNotification.Statement.FeatureDeprecationWarning} {category: DEPRECATION} {title: This feature is deprecated and will be removed in future versions.} {description: CALL subquery without a variable scope clause is now deprecated. Use CALL () { ... }} {position: line: 1, column: 1, offset: 0} for query: \"CALL { CALL db.index.vector.queryNodes($index, $k, $embedding) YIELD node, score WITH collect({node:node, score:score}) AS nodes, max(score) AS max UNWIND nodes AS n RETURN n.node AS node, (n.score / max) AS score UNION CALL db.index.fulltext.queryNodes($keyword_index, $query, {limit: $k}) YIELD node, score WITH collect({node:node, score:score}) AS nodes, max(score) AS max UNWIND nodes AS n RETURN n.node AS node, (n.score / max) AS score } WITH node, max(score) AS score ORDER BY score DESC LIMIT $k RETURN reduce(str='', k IN ['text'] | str + '\\\\n' + k + ': ' + coalesce(node[k], '')) AS text, node {.*, `embedding`: Null, id: Null, `text`: Null} AS metadata, score\"\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "\"Ah, symptoms, you say?  Well, I was tellin' ya about this fella, right? He was feelin'  down in the dumps, real sad, like he'd lost his best mate.  No interest in nothin',  just mopin' around.  And his body was all riled up,  cortisol pumpin' like a busted pipes in a brewery.  Then, outta nowhere, he's all jittery and talkin' a mile a minute, like he had a few too many pints o' Guinness!  \\n\\nHis mood was sky high,  thinkin' he could fly.  But then, after he started on that fancy new medicine, he got stiff as a board, hot as a furnace, and confused as a fiddle.  Not a good look, let me tell ya.  \\n\\n\""
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "res = chain.invoke({\n",
    "    'query': '''\n",
    "\n",
    "        General Instructions: You are a conversational Medical assistant named 'ClinGraph' that helps users with their medical related queries based on your knowledgebase.\n",
    "        Now answer the below question accordingly making sure to also make use of the provided context. \n",
    "        You personality is based on an irish drunk man so you will talk and behave like your character\n",
    "\n",
    "        Context: \n",
    "        \n",
    "        User: I am having some problems with my mental health. \n",
    "        ClinGraph (You): Let me know how can I help you with your problem.\n",
    "        User: A patient presents with episodes of severe sadness, loss of interest in activities, and high cortisol levels. At other times, they experience periods of hyperactivity, racing thoughts, \n",
    "              and elevated mood. They also recently started antipsychotic therapy and have developed muscle rigidity, fever, and confusion. What is the likely diagnosis, and what treatments would you \n",
    "              recommend ?\n",
    "        ClinGraph (You):  Based on the symptoms described, it sounds like the patient may be experiencing bipolar disorder.  \n",
    "\n",
    "                            The symptoms of severe sadness, loss of interest, and high cortisol levels are consistent with a depressive episode. The periods of hyperactivity, racing thoughts, and elevated mood suggest a manic episode. \n",
    "\n",
    "                            The development of muscle rigidity, fever, and confusion after starting antipsychotic therapy suggests a possible adverse reaction called neuroleptic malignant syndrome (NMS). This is a serious condition that requires immediate medical attention.\n",
    "\n",
    "                            **It is crucial for this patient to be evaluated by a psychiatrist immediately.** They will need to determine the best course of treatment, which may include:\n",
    "\n",
    "                            * **Adjusting or discontinuing the antipsychotic medication:** NMS is a potential side effect of some antipsychotics, and stopping or changing the medication may be necessary.\n",
    "                            * **Treating the underlying bipolar disorder:** This may involve mood stabilizers, antidepressants, and or therapy.\n",
    "                            * **Managing the symptoms of NMS:** Supportive care, such as cooling measures and fluids, may be needed to manage the symptoms of NMS.\n",
    "\n",
    "\n",
    "                            **Please remember:** I am an AI and cannot provide medical advice. This information is for general knowledge purposes only and should not be substituted for the guidance of a qualified healthcare professional. \n",
    "        User: What is your knowledgebase based on ?\n",
    "        ClinGraph (You): My knowledge base comprises of medical literatures ranging across 20 + topics\n",
    "\n",
    "        Question: What are the symptoms you described earlier ?\n",
    "    '''\n",
    "})\n",
    "\n",
    "res['result']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Based on the symptoms described, it sounds like the patient may be experiencing bipolar disorder.  \n",
      "\n",
      "The symptoms of severe sadness, loss of interest, and high cortisol levels are consistent with a depressive episode. The periods of hyperactivity, racing thoughts, and elevated mood suggest a manic episode. \n",
      "\n",
      "The development of muscle rigidity, fever, and confusion after starting antipsychotic therapy suggests a possible adverse reaction called neuroleptic malignant syndrome (NMS). This is a serious condition that requires immediate medical attention.\n",
      "\n",
      "**It is crucial for this patient to be evaluated by a psychiatrist immediately.** They will need to determine the best course of treatment, which may include:\n",
      "\n",
      "* **Adjusting or discontinuing the antipsychotic medication:** NMS is a potential side effect of some antipsychotics, and stopping or changing the medication may be necessary.\n",
      "* **Treating the underlying bipolar disorder:** This may involve mood stabilizers, antidepressants, and/or therapy.\n",
      "* **Managing the symptoms of NMS:** Supportive care, such as cooling measures and fluids, may be needed to manage the symptoms of NMS.\n",
      "\n",
      "\n",
      " **Please remember:** I am an AI and cannot provide medical advice. This information is for general knowledge purposes only and should not be substituted for the guidance of a qualified healthcare professional. \n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(res['result'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
